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ABSTRACT 
The antimicrobial resistance data among zoonotic and indicator bacteria in 2012, submitted by 26 European Union 
Member  States,  were  jointly  analysed  by  the  EFSA  and  the  ECDC.  Resistance  in  zoonotic  Salmonella  and 
Campylobacter isolates from humans, animals and food and resistance in indicator Escherichia coli, as well as data on 
methicillin-resistant Staphylococcus aureus, in animals and food were addressed. Resistance in human isolates was 
mainly interpreted using clinical breakpoints, while microbiological resistance in animal and food isolates was assessed 
using epidemiological cut-off values. Resistance was commonly found in isolates from humans, animals and food, 
although  marked  disparities  in  resistance  were  frequently  observed  between  Member  States.  In  Salmonella  from 
humans, high resistance levels were recorded to ampicillin, sulfonamides and tetracyclines, while resistance to third-
generation cephalosporins and fluoroquinolones remained low. In Salmonella and Escherichia coli isolates from fowl, 
pigs, cattle and meat thereof, microbiological resistance to ampicillin, tetracyclines and sulfonamides was commonly 
detected, while microbiological resistance to third-generation cephalosporins was generally low. High to very high 
microbiological resistance to (fluoro)quinolones was observed in Salmonella isolates from turkeys, fowl and broiler 
meat. In Campylobacter from humans, resistance to ampicillin, ciprofloxacin, nalidixic acid and tetracyclines was high, 
while  resistance  to  erythromycin  was  low  to  moderate.  High  to  extremely  high  microbiological  resistance  to 
ciprofloxacin, nalidixic acid and tetracyclines was observed in Campylobacter isolates from fowl, broiler meat, pigs and 
cattle, whereas much lower levels were observed for erythromycin and gentamicin. Increasing trends for ciprofloxacin 
resistance was observed in Campylobacter isolates from humans, broilers and/or pigs in several Member States. Multi-
resistance and co-resistance to critically important antimicrobials in both human and animal isolates were presented, 
and for the first time, multi-resistance patterns in Salmonella serovars. Very few isolates from animals were co-resistant 
to critically important antimicrobials. A minority of isolates from animals belonging to a few Salmonella serovars 
(notably Kentucky and Infantis) were resistant to high levels of ciprofloxacin. 
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About EFSA 
The European Food Safety Authority (EFSA), located in Parma, Italy, was established and funded by the 
European Union (EU) as an independent agency in 2002 following a series of food scares that caused the 
European  public  to  voice  concerns  about  food  safety  and  the  ability  of  regulatory  authorities  to  protect 
consumers.  EFSA  provides  objective  scientific  advice  on  all matters,  in  close  collaboration  with  national 
authorities and in open consultation with its stakeholders, with a direct or indirect impact on food and feed 
safety,  including  animal  health  and  welfare  and  plant  protection.  EFSA  is  also  consulted  on  nutrition  in 
relation to EU legislation. EFSA’s work falls into two areas: risk assessment and risk communication. In 
particular, EFSA’s risk assessments provide risk managers (EU institutions with political accountability, i.e. 
the  European  Commission,  the  European  Parliament  and  the  Council)  with  a  sound  scientific  basis  for 
defining  policy-driven  legislative  or  regulatory  measures  required  to  ensure  a  high  level  of  consumer 
protection with regard to food and feed safety. EFSA communicates to the public in an open and transparent 
way on all matters within its remit. Collection and analysis of scientific data, identification of emerging risks 
and scientific support to the European Commission, particularly in the case of a food crisis, are also part of 
EFSA’s mandate, as laid down in the founding Regulation (EC) No 178/2002
4 of 28 January 2002. 
About ECDC 
The  European  Centre  for  Disease  Prevention  and  Control  (ECDC),  an  EU  agency  based  in  Stockholm, 
Sweden,  was  established  in  2005.  The  objective  of  ECDC  is  to  strengthen  Europe’s  defences  against 
infectious diseases. According to Article 3 of the founding Regulation (EC) No 851/2004
5 of 21 April 2004, 
ECDC’s  mission  is  to  identify,  assess  and  communicate  current  and  emerging  threats  to  human  health 
posed by infectious diseases. In order to achieve this mission, ECDC works in partnership with national 
public  health  bodies  across  Europe  to  strengthen  and  develop  EU-wide  disease  surveillance  and  early 
warning systems. By working with experts throughout Europe, ECDC pools Europe’s knowledge in health so 
as  to  develop  authoritative  scientific  opinions  about  the  risks  posed  by  current  and  emerging  infectious 
diseases. 
About the report 
Based on Article 33 in the Regulation (EC) 178/2002, EFSA’s Zoonoses Unit is responsible for examining 
data on zoonoses, antimicrobial resistance and food-borne outbreaks collected from the Member States in 
accordance with Directive 2003/99/EC
6 and for preparing the European Union Summary Report from the 
results.  Regarding  antimicrobial  resistance  data  from  2012,  this  European  Union  Summary  Report  was 
produced in collaboration with ECDC and the Animal Health and Veterinary Laboratories Agency (AHVLA), 
the United Kingdom and the University of Hasselt in Belgium, contracted by EFSA. 
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Summary 
Zoonoses are infections and diseases that are transmissible between animals and humans. Infection can be 
acquired directly from animals, or through the ingestion of contaminated foodstuffs. The severity of these 
diseases in humans can vary from mild symptoms to life-threatening conditions. The zoonotic bacteria that 
are resistant to antimicrobials are of special concern, since they might compromise the effective treatment of 
infections  in  humans.  In  order  to  follow  the  occurrence  of  antimicrobial  resistance  in  zoonotic  bacteria 
isolated from humans, animals and food in the European Union, information is collected and analysed from 
the European Union Member States. 
In 2012, 26 Member States reported data on antimicrobial resistance in zoonotic bacteria to the European 
Commission  and  the  European  Food  Safety  Authority,  and  19  Member  States  submitted  data  to  the 
European Centre for Disease Prevention and Control. In addition, three other European countries provided 
information. Assisted by its contractors, the Animal Health and Veterinary Laboratories Agency in the United 
Kingdom and the University of Hasselt in Belgium, the European Food Safety Authority and the European 
Centre for Disease Prevention and Control analysed the data, the results of which are  published in this 
European  Union  Summary  Report  on  antimicrobial  resistance.  Information  on  resistance  was  reported 
regarding Salmonella and Campylobacter isolates from human cases, food and animals, whereas data on 
indicator Escherichia coli and indicator enterococci isolates related only to animals and food. Information was 
reported  by  some  Member  States  on  the  occurrence  of  methicillin-resistant  Staphylococcus aureus  in 
animals and food; the antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus isolates was 
additionally reported by two countries.  
Data  on  antimicrobial  resistance  in  isolates  from  human cases  were  mainly  interpreted  by  using  clinical 
breakpoints, while the quantitative data on antimicrobial resistance in isolates from food and animals were 
assessed  using  harmonised  epidemiological  cut-off  values  that  detect  microbiological  resistance,  i.e. 
reduced susceptibility to the antimicrobials tested, as well as using clinical breakpoints where considered 
appropriate. Direct comparisons should  only  be made between isolates from different sources using  the 
same measure of determining resistance (i.e. by applying the same breakpoint). 
The  reporting  of  antimicrobial  resistance  data  at  isolate-based  level  by  a  significant  number  of  Member 
States  allowed  the  second  analysis  at  the  European  Union  level  of  multi-resistance  and  co-resistance 
patterns to critically important antimicrobials in both human and animal isolates. Detailed analyses of multi-
drug resistance in certain Salmonella serovars, including analysis of high-level resistance to ciprofloxacin 
and pentavalent resistance, were possible for Member States reporting isolate-based data and included for 
the first time in the report. In addition, for certain bacterial species, antimicrobial resistance data could be 
analysed at the production-type level, such as broilers, laying hens and breeders of Gallus gallus, which 
allows the analysis of the data to be fine-tuned. 
Antimicrobial resistance was commonly detected in isolates of Salmonella and Campylobacter from human 
cases as well as from food-producing animals and food in the European Union. This was also the case for 
indicator (commensal) Escherichia coli isolated from animals and food. For many of the antimicrobials, the 
levels of resistance varied greatly between different Member States.  
In the European Union, the occurrence of resistance in Salmonella isolates from cases of salmonellosis in 
humans was high for ampicillin, streptomycin, sulfonamides and tetracyclines and moderate for nalidixic acid, 
with high levels of multi-drug resistance observed in some countries. Resistance to the critically important 
antimicrobials  for  human  medicine,  cefotaxime  (a  third-generation  cephalosporin)  and  ciprofloxacin  (a 
fluoroquinolone), was relatively low, although the resistance levels for ciprofloxacin were generally higher in 
countries using more sensitive interpretive criteria, such as epidemiological cut-off values. Co-resistance to 
ciprofloxacin and cefotaxime among Salmonella isolates was very low. The resistance levels also differed 
substantially between the three most commonly reported serovars, with higher resistance to ciprofloxacin, 
gentamicin  and  nalidixic  acid  observed  in  Salmonella  Enteritidis  than  in  Salmonella  Typhimurium  and 
monophasic Salmonella Typhimurium and the opposite for the other antimicrobials.  
There  was  a  high  level  of  resistance  to  ampicillin,  ciprofloxacin,  nalidixic  acid  and  tetracyclines  among 
Campylobacter isolates from human cases, with high and very high levels of multi-drug resistance observed 
in some countries. The levels of resistance to erythromycin in human  Campylobacter jejuni isolates was 
overall low, but moderately high in Campylobacter coli. Very high resistance levels to ciprofloxacin were 
reported  in  human  Campylobacter  isolates,  with  increasing  trends  observed  in  several  Member  States. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food 2012 
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Almost  one  in  six  human  Campylobacter  coli  isolates  were  also  resistant  to  both  erythromycin  and 
ciprofloxacin, which is worrying as these two antimicrobials are the clinically most important for treatment of 
campylobacteriosis in humans. 
The  high  proportions  of  Salmonella,  Campylobacter  and  indicator  Escherichia  coli  isolates  exhibiting 
‘microbiological resistance’ or reduced susceptibility to fluoroquinolones (ciprofloxacin) remain of concern. In 
Salmonella spp. isolates of food and animal origin, the highest occurrence of resistance to ciprofloxacin was 
noted in fattening turkeys, broiler meat, turkeys and broilers of Gallus gallus, where the proportion of such 
isolates varied between 46.0 % and 86.2 % in the reporting Member State group. Ciprofloxacin resistance 
was recorded more often in broilers than in breeders and laying hens. Two Member States demonstrated a 
significant increasing trend for ciprofloxacin and nalidixic acid resistance and one a decreasing trend for both 
antimicrobials in Salmonella species from Gallus gallus over the period from 2006 to 2012. Considering the 
indicator Escherichia coli isolates, the levels of ciprofloxacin resistance observed in isolates from broilers and 
pigs  were  52.7 %  and  7.5 %,  respectively.  Furthermore,  high  to  extremely  high  resistance  to 
fluoroquinolones was commonly observed in Campylobacter isolates from Gallus gallus and broiler meat, as 
well  as  from  pigs  and  cattle,  at  levels  ranging  from  32.0 %  (Campylobacter  coli  from  pigs)  to  82.7 % 
(Campylobacter coli from meat from broilers).  
Resistance to the third-generation cephalosporin cefotaxime was observed in Salmonella spp. isolates from 
Gallus gallus, turkeys, pigs, cattle and meat derived from broilers, pigs and bovine at very low or low levels 
varying between 0.4 % and 4.5 %, as well as in indicator Escherichia coli isolates from Gallus gallus, pigs 
and cattle at low or moderate levels ranging from 1.4 % to 10.2 %. Resistance to erythromycin was detected 
in Campylobacter isolates from Gallus gallus, pigs, cattle and broiler meat at levels of 0.4 % (Campylobacter 
jejuni from Gallus gallus) to 23.9 % (Campylobacter coli from pigs). 
Among Salmonella isolates from meat and animals, microbiological resistance to tetracyclines, ampicillin and 
sulfonamides was reported at levels of 9.5 % to 66.7 % and it was higher in isolates from pigs and turkeys 
than in those from broilers, laying hens, breeding hens and cattle. Resistance to ciprofloxacin and nalidixic 
acid  was  higher  in  Salmonella  isolates  from  fattening  turkeys  and  broilers  (41.5-86.2 %)  than  it  was  in 
isolates from breeding hens, laying hens, pigs or cattle (5.8-25.5 %). In isolates of Campylobacter from meat 
and animals, resistance was commonly detected to tetracyclines at levels up to 76.8 %, whereas much lower 
resistance was reported to gentamicin (levels lower than 4.1 %).  
Among indicator Escherichia coli from broilers and pigs, microbiological resistance to tetracyclines, ampicillin 
and sulfonamides was commonly reported at levels of 29.5 % to 54.7 %, resistance levels being lower in 
laying hens (18.3 % to 25.2 %). In the case of cattle, levels of resistance to these antimicrobials fell within 
the range 34.7 % to 46.7 % in younger age groups, mainly fattening veal calves, but values were lower in 
older cattle, mainly adult  cows. In general, resistance levels  were  lower among isolates  from cattle and 
layers than in isolates from broilers and pigs. 
Multi-resistance (reduced susceptibility to at least three antimicrobial classes according to epidemiological 
cut-off values) was generally high in Salmonella isolates from broilers, pigs and cattle in those countries 
reporting  isolate-based  data.  However,  co-resistance/reduced  susceptibility  to  the  clinically  important 
antimicrobials  ciprofloxacin  and  cefotaxime  in  the  same  isolate  was  detected  in  very  few  isolates  of 
Salmonella  species.  Multi-resistance  was  either  not  detected  or  reported  at  very  low  or  low  levels  in 
Campylobacter jejuni isolates from broilers, and co-resistance to ciprofloxacin and erythromycin at the same 
time was reported at low levels. High-level ciprofloxacin resistance was observed in a limited number of 
Salmonella isolates, notably belonging to the serovars Kentucky and Infantis, from broilers, laying hens and 
turkeys, but not in isolates from pigs or cattle, although it was detected in isolates from pig meat. A small 
number  of  serovars,  including  notably  the  serovar  Infantis,  displayed  pentavalent  resistance,  which  is 
potentially significant because certain Salmonella serovars which have shown epidemic spread have shown 
such pentavalent resistance in the past. 
Several statistically significant national trends in resistance levels in isolates from animals were observed. 
Among Salmonella isolates, more decreasing than increasing trends were found, whereas in the case of 
Campylobacter, the statistically significant national trends were mostly increasing.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
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1. INTRODUCTION 
The antimicrobial agents used in food-producing animals in Europe are frequently the same, or belong to the 
same classes, as those used in human medicine. Antimicrobial resistance is the main undesirable side effect 
of  antimicrobial  use  in  both  humans  and  animals  and  results  from  the  continuous  positive  selection  of 
resistant bacterial clones, whether these are pathogenic, commensal or even environmental bacteria. This 
will modify the population structure of microbial communities, leading to accelerated evolutionary trends with 
unpredictable consequences for human health. The use of antimicrobials can differ in humans and food-
producing animals, in terms of both the methods of administration and the quantities administered; there are 
important variations between and within food-producing animal species, as well as between countries. 
Bacterial resistance to antimicrobials occurring in food-producing animals can spread to people not only via 
food-borne routes, but also by routes such as water or environmental contamination as well as through direct 
animal contact. Campylobacter, Salmonella and some strains of Escherichia coli are examples of zoonotic 
bacteria  which can infect people  by the food-borne  route. Infections  with bacteria  which are resistant to 
antimicrobials  may  result  in  treatment  failures  or  necessitate  the  use  of  second-line  antimicrobials  for 
therapy. The commensal bacterial flora can also form a reservoir of resistance genes which may transfer 
between bacterial species, including transference to organisms capable of causing disease in both humans 
and animals (EFSA, 2008).  
The monitoring of antimicrobial resistance in zoonotic and commensal bacteria in food-producing animals 
and food thereof is a prerequisite for understanding the development and diffusion of resistance, providing 
relevant risk assessment data, and evaluating targeted interventions. Resistance monitoring entails specific 
and  continuous  data  collection,  analysis  and  reporting  that  quantitatively  follow  temporal  trends  in  the 
occurrence  and  distribution  of  resistance  to  antimicrobials,  and  should  also  allow  the  identification  of 
emerging or specific patterns of resistance. 
1.1. Antimicrobial resistance monitoring and reporting at the European Union level 
According  to  Directive  2003/99/EC  on  the  monitoring  of  zoonoses  and  zoonotic  agents,  Member  States 
(MSs) are obliged to monitor and report antimicrobial resistance in Salmonella and Campylobacter isolates 
obtained  from  healthy  food-producing  animals  and  from  food.  In  addition,  Commission  Decision 
2007/407/EC
7 lays down detailed requirements on the harmonised monitoring and reporting of antimicrobial 
resistance  of  Salmonella  isolates  from  various  poultry  populations  and  pigs,  sampled  under  the 
corresponding national control and monitoring programmes of Salmonella. The monitoring and reporting of 
antimicrobial resistance data from the indicator organisms Escherichia coli and enterococci is voluntary. 
Decision 1082/2013
8 on serious cross-border threats to health and repealing Decision No 2119/98/EC, as 
complemented by Decision 2000/96/EC
9 with amendment Decision 2003/542/EC
10 on the diseases to be 
progressively covered by the network, provides the basis for data collection on human diseases in MSs and 
reporting to the European Centre for Disease Prevention and Control (ECDC). ECDC has provided data on 
zoonotic infections in humans, as well as their analyses, for the Community Summary Reports since 2005. 
Starting  in  2007,  data  on  human  cases  have  been  reported  from  The  European  Surveillance  System 
(TESSy), maintained by ECDC. 
This EU Summary Report 2012 includes data related to the occurrence of antimicrobial resistance both in 
isolates from animals and foodstuffs, collected in the framework of Directive 2003/99/EC, and in isolates from 
human cases, derived from the networks under Decision 2119/98/EC.  This report is a joint collaboration 
between the European Food Safety Authority (EFSA) and ECDC with the assistance of EFSA’s contractors, 
the Animal Health and Veterinary Laboratories Agency (AHVLA) in the United Kingdom and the University of 
                                                 
7  Commission Decision 2007/407/EC of 12 June 2007 on a harmonised monitoring of antimicrobial resistance in Salmonella in poultry 
and pigs. OJ L 153, 14.6.2007, p. 26–29. 
8 Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to 
health and repealing Decision No 2119/98/EC. OJ L 293, 5.11.2013, p. 1–15. 
9  Commission Decision 2009/539/EC of 10 July 2009 amending Decision 2000/96/EC on communicable diseases to be progressively 
covered  by  the  Community  network  under  Decision  No 2119/98/EC  of  the  European  Parliament and  of  the  Council.  OJ  L  180, 
11.7.2009, p. 22–23. 
10 Commission  Decision  2003/542/EC  of  17  July  2003  amending  Decision  2000/96/EC  as  regards  the  operation  of  dedicated 
surveillance networks. OJ L 185, 24.7.2003, p. 55–58. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food 2012 
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Hasselt  in  Belgium.  MSs,  other  reporting  countries,  the  European  Commission  (EC)  and  the  relevant 
European Union Reference Laboratories  (EU-RL)  were consulted  while  preparing  the report. The efforts 
made by MSs, the reporting non-MSs and the EC in the reporting of zoonoses data and in the preparation of 
this report are gratefully acknowledged. 
The main issues when comparing antimicrobial resistance data originating from different countries are the 
use of different laboratory methods and different interpretive criteria of resistance. These issues have been 
addressed by the development of EFSA’s guidelines for harmonised monitoring and reporting of resistance 
in food-producing animals and food thereof. The resistance monitoring performed under these guidelines 
utilises epidemiological cut-off values (ECOFFs) which separate the naïve, susceptible wild-type bacterial 
populations  from  isolates  that  have  developed  reduced  susceptibility  to  a  given  antimicrobial  agent 
(Kahlmeter et al., 2003). The ECOFFs may differ from breakpoints used for clinical purposes, which are 
defined against a background of clinically relevant data, including therapeutic indication, clinical response 
data,  dosing  schedules,  pharmacokinetics  and  pharmacodynamics.  In  the  EU  Summary  Reports  on 
antimicrobial resistance from 2004 to 2011, ECOFFs were applied to minimum inhibitory concentration (MIC) 
data to define resistant Salmonella, Campylobacter, indicator E. coli and indicator enterococci isolates from 
animals and food. The use of harmonised methods and ECOFFs ensured the comparability of data over time 
at the country level and also facilitated the comparison of the occurrence of resistance between MSs. The 
same methods and principles have been applied in this 2012 Summary Report on antimicrobial resistance. 
The antimicrobial susceptibility data reported to EFSA for the year 2012 for Campylobacter, Salmonella and 
indicator E. coli isolates from animals and food were analysed and all quantitative data were interpreted 
using ECOFFs. This report also includes results of phenotypic monitoring of resistance caused by extended-
spectrum  beta-lactamases  (ESBLs)  in  Salmonella  and  indicator  E. coli,  conferring  resistance  to  third-
generation cephalosporins, as well as the second investigation at the EU level of the occurrence of complete 
susceptibility and multi-resistance in data reported at the isolate level. A list of the antimicrobials included in 
this  evaluation  of  multi-resistance  can  be  found  in  Chapter  8  ‘Materials  and  methods’.  The  majority  of 
antimicrobial resistance data reported to EFSA by MSs comprised data collected in accordance with EFSA’s 
monitoring guidelines; quantitative disc diffusion data constituted only a small percentage of the total data 
and were analysed in the report as qualitative data only. This has circumvented the problem that ECOFFs 
are not available for the different disc diffusion methods used by MSs. 
The report also encompasses resistance in Salmonella and Campylobacter isolates from human cases of 
salmonellosis and campylobacteriosis, respectively. These data were reported as qualitative data (with one 
exception), mostly interpreted using clinical breakpoints (CBPs), by MSs to TESSy. An important general 
feature  of  this  report  is  that  human  data  are  largely  based  on  susceptibility  testing  of  clinical  isolates, 
whereas animal data are based mainly on the testing of isolates from healthy animals, where testing has 
been performed in accordance with EFSA’s recommendations. The data on zoonotic bacteria from humans 
have  largely  been  collated  and  collected  using  CBPs.  Such  data  are  therefore  not  always  directly 
comparable with data from food-producing animals and food, which have been analysed using ECOFFs. 
Indeed, the use of ECOFFs in animal and food isolates generally conveys the picture of  ‘microbiological 
resistance’ levels in these isolates higher than ‘clinical resistance’ levels recorded in human isolates, where 
CBPs  have  been  used.  These  issues  are  discussed  further  in  the  chapters  on  Campylobacter  and 
Salmonella.  Universal  adoption  and  understanding  of  the  distinction  between  CBPs  and  ECOFFs  would 
enable clinicians to choose the appropriate treatment based on information relevant to the individual patient, 
yet would recognise that epidemiologists need to be aware of small changes in bacterial susceptibility, which 
may indicate emerging resistance and allow for appropriate control measures to be considered. ECOFFs, 
CBPs and related concepts regarding antimicrobial resistance/susceptibility are presented in detail hereafter. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food 2012 
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1.2. Epidemiological cut-off values and clinical breakpoints 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has defined clinical breakpoints 
(CBPs) and epidemiological cut-off values (ECOFFs). A microorganism is defined as clinically resistant when 
the degree of resistance shown is associated with a high likelihood of therapeutic failure. The microorganism 
is categorised as resistant by applying the appropriate CBP in a defined phenotypic test system, and this 
breakpoint may alter with legitimate changes in circumstances (for example alterations in dosing regime, 
drug formulation, patient factors). 
A microorganism is defined as wild-type for a bacterial species when no acquired or mutational resistance 
mechanisms are present to the antimicrobial in question. A microorganism is categorised as wild-type for a 
given bacterial species presenting a lower minimum inhibitory concentration (MIC) to the antimicrobial in 
question than the appropriate ECOFF in a defined phenotypic test system. This cut-off value will not be 
altered by changing circumstances (such as alterations in frequency of antimicrobial administration). Wild-
type  microorganisms  may  or  may  not  respond  clinically  to  antimicrobial  treatment.  A  microorganism  is 
defined  as  non-wild-type  for  a  given  bacterial  species  by  the  presence  of  an  acquired  or  mutational 
resistance mechanism to the antimicrobial in question. A microorganism is categorised as non-wild-type for a 
given bacterial species by applying the appropriate ECOFF value in a defined phenotypic test system; non-
wild-type organisms are considered to show ‘microbiological resistance’ (as opposed to ‘clinical resistance’). 
CBPs and ECOFFs may be the same, although it is often the case that the ECOFF is lower than the CBP. 
Comparative advantages and disadvantages of the use of CBPs versus ECOFFs (see box hereafter) have 
been taken into account in the detailed specifications for harmonised monitoring schemes on antimicrobial 
resistance  in  animals  and  food  devised  by  EFSA.  These  guidelines  have  been  published  (EFSA,  2007, 
2008) and the terminology used is that devised by EUCAST (Kahlmeter et al., 2003). As far as possible, 
ECOFFs  have  been  used  in  this  report,  as  recommended  in  the  guidelines,  to  determine  non-wild-type 
organisms also termed ‘microbiologically resistant’ organisms, and to ensure that results from different MSs 
are comparable. Hereafter in this report, ‘microbiologically antimicrobial-resistant’ organisms are referred to 
as ‘resistant’ for brevity. 
 
CLINICAL BREAKPOINTS (CLINICAL RESISTANCE) 
The clinician, or veterinarian, choosing an antimicrobial agent to treat humans or animals with a bacterial 
infection requires information that the antimicrobial selected is effective against the bacterial pathogen. 
Such information will be used, together with clinical details such as the site of infection, ability of the 
antimicrobial to reach the site of infection, formulations available and dosage regimes, when determining 
an appropriate therapeutic course of action. The in vitro susceptibility of the bacterial pathogen can be 
determined  and  clinical  breakpoints  used  to  ascertain  whether  the  organism  is  likely  to  respond  to 
treatment. Clinical breakpoints (CBPs) will take into account the clinical behaviour of the drug following 
administration and assume that a clinical response will be obtained if the drug is given as recommended 
and  there  are  no  other  adverse  factors  which  affect  the  outcome.  Conversely,  if  the  CBP  indicates 
resistance, then it is likely that treatment will be unsuccessful. Frequency of dosing is one factor that can 
affect  the  antimicrobial  concentration  achieved  at  the  site  of  infection.  Therefore,  different  dosing 
regimes  can  lead  to  the  development  of  different  CBPs,  as  occurs  in  some  countries  for  certain 
antimicrobials where different therapeutic regimes are in place. Although the rationale for the selection of 
different CBPs may be clear, their use makes the interpretation of results from different countries in 
reports  of  this  type  problematic,  as  the  results  are  not  directly  comparable  between  those  different 
countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food 2012 
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The  EUCAST  ECOFFs  which  should  be  applied  to  interpret  the  results  obtained  by  MSs  are  quoted  in 
Commission  Decision  2007/407/EC.  However,  since  this  Decision  was  adopted,  there  have  been  some 
minor changes to a few of the ECOFFs for some antimicrobials. This occurs because, as more data are 
collected relating to more bacterial isolates, the normal distribution of the wild-type population can in some 
cases  be  better  defined.  This  2012  EU  Summary  Report  interprets  the  antimicrobial  resistance  data  in 
accordance with the current Decision. The Decision is currently undergoing review by the EC, notably on the 
basis  of  the  technical  specifications  proposed  for  harmonised  monitoring  of  antimicrobial  resistance  in 
animals and food recently issued by EFSA (EFSA, 2012a, b, c), and the expected revision in the future will 
update a number of the ECOFFs to be used. 
 
REVISION OF EPIDEMIOLOGICAL CUT-OFF VALUES 
The epidemiological cut-off value (ECOFF) for E. coli versus ciprofloxacin has been recently revised by 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Wild-type isolates are now 
considered to have a ciprofloxacin minimum inhibitory concentration lower than or equal to  0.06 mg/L 
(which is a change from the original tentative ECOFF of 0.03 mg/L and which now corresponds to the 
ECOFF for Salmonella spp.). The proportion of isolates showing microbiological resistance according to 
this breakpoint will alter when the new breakpoint is adopted and in fact will be reduced. For reasons of 
continuity and to comply with the current legislation where applicable, the ECOFFs used in this report 
have been those adopted in EFSA’s recommendations (EFSA, 2007, 2008) and quoted in Commission 
Decision  2007/407/EC.  For  these  reasons,  the  most  recent  revisions  by  EUCAST  have  not  been 
included in this report. The report for 2013 will incorporate all of these changes in a comprehensive 
revision, which will also re-evaluate the historical data using the revised ECOFFs, as well as taking into 
account revised EU legislation in this area, which will include the revised ECOFFs. 
EPIDEMIOLOGICAL CUT-OFF VALUES (MICROBIOLOGICAL RESISTANCE) 
For a given bacterial species, the pattern of the minimum inhibitory concentration (MIC) distribution or the 
inhibition zone diameter distribution (i.e. the frequency of occurrence of each given MIC or zone diameter 
plotted against the MIC value or zone diameter obtained) can enable the separation of the wild-type 
population of microorganisms from those populations which show a degree of resistance. The wild-type 
susceptible population is assumed to have no acquired or mutational resistance and commonly shows a 
normal distribution. 
When  bacteria  acquire  resistance  by  a  clearly  defined  and  efficacious  mechanism,  such  as  the 
acquisition  of  a  plasmid  bearing  a  gene  which  produces  an  enzyme  capable  of  destroying  the 
antimicrobial, then the MIC or zone diameter distribution commonly shows two major sub-populations, 
one a fully susceptible normal distribution of isolates and the other a fully resistant population which has 
acquired the resistance mechanism. Resistance may be achieved by a series of small steps, such as 
changes in the permeability of the bacterial cell wall to the antimicrobial or other mechanisms which 
confer a degree of resistance. In this case, there may be populations of organisms which occur lying 
between  the  fully  susceptible  population  and  more  resistant  populations.  The  epidemiological  cut-off 
value (ECOFF) indicates the MIC or  zone diameter above which the pathogen has some detectable 
reduction in susceptibility. ECOFFs are derived by testing an adequate number of isolates to ensure that 
the wild-type population can be confidently identified for a given antimicrobial. The clinical breakpoint, 
which is set to determine the therapeutic effectiveness of the antimicrobial, may fail to detect emergent 
resistance. Conversely, the ECOFF detects any deviation in susceptibility from the wild-type population, 
although  it  may  not  be  appropriate  for  determining  the  likelihood  of  success  or  failure  for  clinical 
treatment. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria from 
humans, animals and food 2012 
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1.3. Developments in the harmonised monitoring of antimicrobial resistance 
The ECDC  has, during 2012 and  2013, arranged several expert  workshops together  with its Food-  and 
Waterborne Diseases and Zoonoses (FWD) network in order to develop an EU protocol  for harmonised 
monitoring  of  antimicrobial  resistance  in  human  Salmonella  and  Campylobacter  isolates  (ECDC,  2014). 
Consultation  was  also  sought  from  EFSA,  EUCAST  and  the  EU  Reference  Laboratory  for  Antimicrobial 
Resistance  to  facilitate  comparison  of  data  between  countries  and  with  results  from  the  antimicrobial 
resistance monitoring performed in isolates from animals and food products. The protocol is effective from 
2014 and supports the implementation of the Commission Action Plan on antimicrobial resistance.  
In 2012, EFSA, at the request of the EC, reviewed and revised the detailed specifications for the harmonised 
monitoring of antimicrobial resistance in food-producing animals (EFSA, 2007, 2008). Three reports have 
been produced describing proposals to improve (1) the harmonisation, analysis and reporting of data on 
antimicrobial resistance in animals and food collected from the MSs (EFSA, 2012a), (2) the harmonised 
monitoring and reporting of antimicrobial resistance in Salmonella, Campylobacter and indicator E. coli and 
Enterococcus spp. bacteria transmitted through food (EFSA, 2012b) and (3) the harmonised monitoring and 
reporting of antimicrobial resistance in methicillin-resistant Staphylococcus aureus (EFSA, 2012c). 
 
A NEW LEGISLATION ON HARMONISED MONITORING OF ANTIMICROBIAL RESISTANCE IN ANIMALS AND 
FOOD 
In 2013, based on the proposals issued by EFSA, the European Commission put forward and discussed 
with the MSs a new legislation on the harmonised monitoring of antimicrobial resistance in Salmonella, 
Campylobacter and  indicator bacteria  in food-producing animals and food. The Commission Decision 
2013/652/EU
11  of  12  November  2013  establishes  a  list  of  combinations  of  bacterial  species,  food-
producing animal populations and food products and sets up priorities for the monitoring of antimicrobial 
resistance from a public health perspective. 
Monitoring of antimicrobial resistance in E. coli become mandatory, as it is for Salmonella and C. jejuni in 
the major food producing animal population and their derived meat. Sampling should be performed at the 
level of domestically produced animal populations, corresponding to different production types, and not at 
the animal species level, with the aim of collecting data that, in the future, could be combined with those 
on exposure to antimicrobials. The concept of a threshold is introduced for some animal populations and 
their  derived  meat  to  determine  whether  monitoring  of  antimicrobial  resistance  should  be  mandatory. 
Provisions  have  been  taken  where  possible  to  exploit  samples  that  would  be  collected  under  other 
existing control programmes.  
Microdilution methods for testing are confirmed and this should be accompanied by the application of 
European Committee on Antimicrobial Susceptibility Testing epidemiological cut-off values (ECOFFs) for 
the  interpretation  of  microbiological  resistance.  The  harmonised  panel  of  antimicrobials  used  for 
Salmonella, Campylobacter, E. coli and Enterococcus spp. is broadened with the inclusion of substances 
that either are important for human health or can provide clearer insight into the resistance mechanisms 
involved. The concentration ranges to be used ensure that both the ECOFF and the clinical breakpoint 
are included so that comparability of results with human data is made possible.  
The specific monitoring of extended-spectrum beta-lactamase-, AmpC- and carbapenemase-producing 
Salmonella and indicator commensal E. coli is also foreseen. The collection and reporting of data is to be 
performed at the isolate level, in order to enable more in-depth analyses to be conducted, in particular on 
the occurrence of multi-resistance. The Commission Implementing Decision 2013/652/EU will enter into 
force in 2014, as well as the Commission Implementing Decision 2013/653/EU
12 of 12 November 2013
 as 
regards a Union financial aid towards a coordinated control plan for antimicrobial resistance monitoring in 
zoonotic agents in 2014. 
                                                 
11 Commission Implementing Decision 2013/652/EU of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in 
zoonotic and commensal bacteria. OJ L 303, 14.11.2013, p. 26–39. 
12 Commission Implementing Decision 2013/653/EU of 12 November 2013 as regards a Union financial aid towards a coordinated 
control plan for antimicrobial resistance monitoring in zoonotic agents in 2014. OJ L 303, 14.11.2013, p. 40–47. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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2. MAIN FINDINGS 
2.1. Main findings of the European Union Summary Report on antimicrobial resistance 2012 
 
•  In 2012, MSs reported qualitative data (and one non-MS reported quantitative data) on antimicrobial 
resistance in Salmonella and Campylobacter isolates from human cases mostly interpreted by using 
clinical breakpoints (CBPs) to define the resistant isolates. In contrast, quantitative data (minimum 
inhibitory concentrations (MICs) and/or inhibition zone diameter (IZD) results) on antimicrobial 
resistance, reported for isolates from food and animals, were interpreted by using epidemiological cut-
off values (ECOFFs). ECOFFs are often lower than CBPs, and this can result in more isolates being 
classified as resistant, although that is dependent on the distribution of MICs obtained. 
•  Antimicrobial resistance was regularly observed in isolates of Salmonella and Campylobacter  from 
human cases as well as from food-producing animals and food in the EU. For many of the 
antimicrobials, the levels of resistance varied greatly between different MSs and animal production 
types.  
•  Fluoroquinolones, such as ciprofloxacin, and third-generation cephalosporins, such as cefotaxime, are 
considered critically important antimicrobials in the treatment of severe or invasive salmonellosis in 
humans. Likewise, fluoroquinolones and macrolides, such as erythromycin, are considered critically 
important for treating severe Campylobacter infections. Therefore, special attention was paid to 
resistance against these substances in the analyses of the data. 
•  ‘Clinical resistance’ at the EU level in Salmonella spp. isolates from human cases was high (between 
23.6 % and 30.0 %) to ampicillin, streptomycin, sulfonamides and tetracyclines. In contrast, resistance 
to ciprofloxacin and cefotaxime was relatively low (on average <6 % and <2 %, respectively); however, 
even low levels of resistance to these critically important antimicrobials are important. The determined 
resistance levels to ciprofloxacin were influenced by the interpretive criteria used in each country, 
resulting in higher resistance levels in countries using more sensitive criteria. The introduction of 
harmonised EUCAST methods and interpretive criteria in more and more MSs is therefore much 
welcomed and supported by ECDC.  
•  Multi-drug resistance (MDR, defined as reduced susceptibility to at least three antimicrobial classes) 
was high to very high in human Salmonella isolates in eight out of 12 reporting countries; however, 
there were very low levels of co-resistance to ciprofloxacin and cefotaxime. Furthermore, more than half 
of all Salmonella isolates were susceptible to the complete range of antimicrobials tested. 
•  In food and animal isolates, the highest occurrence of ‘microbiological resistance’ to ciprofloxacin was 
noted in Salmonella spp. isolates from fattening turkeys, broiler meat and fowl (Gallus gallus) (from 
37.3 % to 86.2 % at the MS group level). The further sub-division of the Gallus gallus species into 
production types revealed higher overall resistance to ciprofloxacin in Salmonella spp. isolates from 
CLINICAL RESISTANCE AND MICROBIOLOGICAL RESISTANCE: USE OF CLINICAL BREAKPOINTS AND 
EPIDEMIOLOGICAL CUT-OFF VALUES 
Development of resistance in bacteria is a major threat to public health. It is therefore important to detect 
any occurrence of resistance and increases in resistance levels as early as possible. In this report, 
acquired resistance in bacteria is denoted ‘microbiological resistance’ and harmonised epidemiological 
cut-off values (ECOFFs) are used to interpret the results of susceptibility testing in isolates from animals 
and food. In contrast, results of susceptibility testing of clinical isolates from humans are interpreted using 
clinical breakpoints (CBPs) to guide medical treatment of the patient. The CBP is in many cases less 
sensitive than the ECOFF for a specific bacteria–drug combination, resulting in that isolates interpreted 
with ECOFFs more often will be classified as (microbiologically) resistant than isolates interpreted with 
CBPs. Direct comparisons between isolates from different sources should therefore only be made when 
the criteria for interpretation is at the same level (see breakpoint figures SA1 and CA1). The 
harmonisation efforts on antimicrobial resistance monitoring in humans led by ECDC include introduction 
of quantitative reporting. This will enable use of ECOFFs for interpretation of susceptibility testing results 
from human isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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broilers (46.0 %) than in those from breeding hens (25.5 %) or laying hens (19.4 %). In cattle, pigs and 
pig meat, low resistance levels were observed (7.6 %–9.1 %).  
• ‘Microbiological resistance’ to cefotaxime (a third-generation cephalosporin) was observed in 
Salmonella spp. isolates from Gallus gallus, turkeys, pigs and cattle and in meat derived from broilers, 
pigs and cattle, but at low or very low levels (0.4 %–4.5 %), when all reporting MSs were considered. 
However, even low levels of resistance to this critically important antimicrobial are important. Resistance 
to cefotaxime was not detected in Salmonella strains isolated from cattle in reporting countries in 2011, 
but was detected in a single MS in 2012. 
•  ‘Microbiological resistance’ to tetracyclines, ampicillin and sulfonamides was frequently reported among 
Salmonella spp. isolates from meat and animals (9.5 %–66.7 % at MS group level). Resistance to these 
antimicrobials was higher in isolates from pigs, turkeys and cattle (34.5 %–66.7 %) than in isolates from 
Gallus gallus (21.2 %–28.3 %). 
•  Multi-drug resistance (MDR, reduced susceptibility to at least three antimicrobial classes according to 
ECOFFs) was high in Salmonella spp. isolates from animals in some countries reporting isolate-based 
data; however,  co-resistance/reduced susceptibility to the clinically important antimicrobials, 
ciprofloxacin and cefotaxime, was at very low to low levels.  
•  Detailed analyses of MDR in certain Salmonella serovars, including analysis of high-level resistance to 
ciprofloxacin and pentavalent resistance, was possible for MSs reporting isolate-based data from 
animals and food. High-level ciprofloxacin resistance was observed in a limited number of Salmonella 
isolates, notably belonging to the serovars Kentucky and Infantis, from broilers, laying hens and turkeys, 
but not in isolates from pigs or cattle, although it was detected in isolates from pig meat. A small number 
of serovars, in particular S. Infantis, displayed pentavalent resistance, which is potentially significant 
because certain Salmonella serovars which have shown epidemic spread have shown such pentavalent 
resistance in the past. 
•  MDR data on Salmonella isolates from animals and meat also provided evidence relating to (1) the non-
detection of a serovar (S. Enteritidis) with a particular resistance pattern which has shown increased 
virulence for humans and (2) the spread of particular strains of Salmonella  which have a typical 
antimicrobial resistance pattern (well-illustrated by monophasic S. Typhimurium isolates, where 
examination of the antimicrobial resistance patterns shown allows presumptive identification of the main 
clones which have been described). 
•  The ‘clinical resistance’ among Campylobacter spp. isolates from human cases was high (between 
32.4 % and 48.8 %) for ampicillin, ciprofloxacin, nalidixic acid and tetracyclines. Low resistance levels 
(average 3.1 %) were observed to the clinically important antimicrobial erythromycin. Multi-resistance in 
human Campylobacter isolates was moderate or high in some countries. Levels of co-resistance to the 
clinically important antimicrobials, ciprofloxacin and erythromycin, were on average low among 
Campylobacter jejuni ( C. jejuni) isolates and moderate among Campylobacter coli ( C. coli) isolates. 
However, even low levels of co-resistance to both of these critically important antimicrobials are of 
significance. 
•  Extremely high ‘microbiological resistance’ levels to ciprofloxacin (a fluoroquinolone) was commonly 
observed in C. coli isolates from broiler meat and broilers (Gallus gallus) (82.7  % and 78.4  %, 
respectively), with somewhat lower levels in C. jejuni (59.5 % and 44.1 %, respectively). High levels 
were also reported for isolates from pigs and cattle (32.0 % to 32.9 %). Important differences were 
observed between animal species and MSs. 
• ‘Microbiological resistance’ to erythromycin was detected at very low to moderate levels in 
Campylobacter isolates from broilers (Gallus gallus) and broiler meat (0.4 %–16.5 %). The highest level 
of resistance to erythromycin at the reporting MS group level was observed in C. coli isolates from pigs 
(23.9 %), while the level of erythromycin resistance in isolates of C. jejuni from cattle across reporting 
MSs was very low (0.6 %).  
•  Considering all reporting MSs, ‘microbiological resistance’ to nalidixic acid and tetracyclines was 
common among Campylobacter isolates from meat and animals (31.6 %–81.0 %), whereas resistance EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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to gentamicin was low (0.2 %–4.1 %). As for Salmonella, levels of resistance to nalidixic acid followed 
closely those observed for ciprofloxacin. 
• Multi-resistance  (reduced susceptibility to at least three antimicrobial classes according to ECOFFs) 
was generally low in C. jejuni isolates from broilers and co-resistance to the clinically important 
antimicrobials, ciprofloxacin and erythromycin, was, in the same isolates, either not detected or 
recorded at low levels. Multi-resistance and co-resistance levels were generally higher in C. coli isolates 
from broilers and fattening pigs. 
•  Analysis of MDR data for Campylobacter  can also provide indications of certain mechanisms of 
resistance. Resistance to ciprofloxacin and erythromycin in Campylobacter  is usually the result of 
mutation with or without the additional action of efflux pumps. Additionally, the efflux pump CmeABC 
has been shown to confer a degree of resistance to erythromycin, ciprofloxacin and tetracyclines. 
Isolates of both C. coli and C. jejuni, from animals and humans were detected which showed resistance 
to erythromycin, ciprofloxacin and tetracyclines, raising the possibility that CmeABC may have been 
responsible for, or contributed to, the observed pattern of ‘microbiological resistance’. 
•  Several statistically significant national trends in resistance levels in isolates from animals were 
observed. Among Salmonella spp. isolates, more decreasing than increasing trends were found, 
whereas in Campylobacter isolates the statistically significant national trends were mostly increasing. 
Increasing (decreasing) trends in resistance to (fluoro)quinolones in C. jejuni,  C. coli and E. coli in 
broilers and pigs were observed in a number of countries having consistently reported AMR data 
through active monitoring programmes over the last years. 
• Among  indicator (commensal) E. coli isolates from animals, ‘microbiological resistance’ to ampicillin, 
streptomycin sulfonamides and tetracyclines, was commonly reported in Gallus gallus and pigs 
(29.5 %–54.7 %), lower levels being reported in cattle (24.5 %–30.6 %). Resistance to ciprofloxacin and 
nalidixic acid was highest among E. coli isolates from Gallus gallus (57.6 % and 47.4 %, respectively), 
while levels were lower in pigs and cattle (4.9 %–12.2 %). Cefotaxime resistance was low in pigs and 
cattle (1.4 % and 2.4 %, respectively), and moderate in isolates from Gallus gallus (10.2 %), considering 
all reporting MSs. At the MS level, resistance to cefotaxime in indicator E. coli showed wider variation in 
some species or production types, for example ranging between 0 % and 13.5 % in broilers. 
• Indicator  E. coli  from meat from Gallus gallus, pigs and cattle showed moderate or high levels of 
resistance to ampicillin, sulfonamides and tetracyclines, considering all reporting MSs. Resistance to 
cefotaxime was 3 % or less in E. coli from meat from all three animal species and for all reporting MSs.  
•  In general, resistance to third-generation cephalosporins in E. coli was higher than that observed in 
Salmonella spp. (in which resistance was sometimes not detected) for the same species of animals, 
which is consistent with the hypothesis that E. coli may provide a reservoir of cephalosporin resistance 
genes for organisms such as Salmonella. 
•  Multi-resistance was high in indicator (commensal) E. coli isolates from animals in some countries 
reporting isolate-based data; however,  co-resistance to the clinically important antimicrobials, 
ciprofloxacin and cefotaxime, was generally reported at very low to low levels. Considering the E. coli 
for which isolate-based data was available, ciprofloxacin ‘microbiological resistance’ was a frequent 
component of MDR patterns in E. coli from broilers occurring in 72.3 % of isolates, whereas it occurred 
in 16.0 % of MDR patterns in isolates from pigs. 
2.2. Zoonotic and indicator agent-specific summaries 
2.2.1. Salmonella 
The  Salmonella  spp. data presented in this report comprise results for all reported Salmonella  serovars 
which have been amalgamated to represent the overall occurrence of antimicrobial resistance in Salmonella 
within humans and the various animal and food categories. The differences in the distribution and 
prevalence of particular serovars and phage types of Salmonella in different countries and in different animal 
species, and their associated patterns of resistance, may explain some of the differences in the levels of EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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antimicrobial resistance observed as well as in those of multi-resistance. The spread of particularly resistant 
clones, and the occurrence of resistance genes within these clones, can be exacerbated by the use of 
antimicrobials in the human and animal populations and the selective pressure this exerts. Other factors, 
such as foreign travel by humans, international food trade, animal movements, farming systems, animal 
husbandry and the pyramidal structure of some types of animal primary production can also influence the 
spread of resistant clones. 
In addition to the amalgamated data for Salmonella spp., resistance data for the most numerous Salmonella 
serovars in humans, S. Enteritidis,  S.  Typhimurium and monophasic S. Typhimurium,  were  analysed 
separately. 
2.2.1.1. In humans 
In 2012, 19 MSs and two non-MSs provided information on antimicrobial resistance in Salmonella isolates 
from cases of salmonellosis in humans. 
The reported data represented 25.6 % of the confirmed salmonellosis cases reported in the EU/European 
Economic Area (EEA) in 2012. ‘Clinical resistance’ in human Salmonella isolates was high for ampicillin 
(27.6  %), streptomycin (23.6  %), sulfonamides (28.9  %) and tetracyclines (30.0  %), and moderate for 
nalidixic acid (14.4 %), and high levels of multi-resistance were observed in some countries (28.9 % overall). 
For these first four antimicrobials this was largely a result of the high to extremely high resistance levels 
observed among S. Typhimurium and monophasic S. Typhimurium isolates. However, more than half of all 
isolates tested were susceptible to the complete range of antimicrobials in the human data collection. In 
addition, the resistance to the clinically important antimicrobials, ciprofloxacin and cefotaxime, was on 
average relatively low (5.1 % and 1.1 %, respectively), although in the case of ciprofloxacin, markedly higher 
in countries using more sensitive interpretive criteria such as EUCAST ECOFFs. Co-resistance to 
ciprofloxacin and cefotaxime among isolates was very low (0.2 %). Resistance to quinolones (ciprofloxacin 
and nalidixic acid) was generally higher in S. Enteritidis isolates than in S. Typhimurium isolates.  
When assessed by geographical region, Salmonella spp. isolates acquired within the EU/EEA countries 
exhibited greater resistance to ampicillin, sulfonamides, streptomycin and tetracyclines, while the highest 
levels of resistance to ciprofloxacin were observed in isolates from cases that had travelled in Asia, Africa or 
European countries outside of the EU/EEA.  
2.2.1.2. In animals and food 
In 2012, information on antimicrobial resistance in Salmonella isolates from animals and food was reported 
by 19 MSs and two non-MSs. 
Among  Salmonella spp. isolates from Gallus gallus, the resistance level to tetracyclines, ampicillin and 
sulfonamides in all reporting MSs was at a high level, 25.9 %, 21.2 % and 28.3 %, respectively. Resistance 
to ciprofloxacin and nalidixic acid was higher (37.3 % and 34.3 %, respectively), for all reporting MSs. In 
general, there were large variations in the levels of resistance to these antimicrobials between different 
reporting MSs. The occurrence of resistance to cefotaxime in all reporting MSs was low, at 4.5 %. 
For the second year, data were presented at the production-type level, where possible, throughout the 
report. In 2012, 13 MSs reported quantitative data from broilers, and 12 MSs reported quantitative data from 
laying hens. In general, the levels of resistance in this production type were slightly higher in isolates from 
broilers than those reported when all Gallus gallus production types were considered for isolates from layers 
or breeding flocks. Twelve MSs reported quantitative data from laying hens in 2012, and in contrast to the 
data from broilers, the levels of resistance in this production type were lower than those reported when all 
Gallus gallus were considered. Quantitative data on isolates of Salmonella  spp. from breeding flocks of 
Gallus gallus were reported by four MSs in 2012 and the levels of resistance among isolates from breeding 
flocks of Gallus gallus were generally higher than those observed in laying hens but lower than in isolates 
from broilers. 
Multi-resistance levels (reduced susceptibility to at least three different antimicrobial classes using ECOFFs) 
were generally high in Salmonella spp. isolates from broilers and moderate in those from laying hens. In 
general, co-resistance to ciprofloxacin and cefotaxime was low, and not detected when using CBPs. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Some MSs showed statistically significant increasing trends in resistance among Salmonella spp. isolates 
from Gallus gallus over the years 2006 to 2012, whereas other MSs exhibited decreasing trends. Statistically 
significant decreasing trends were more frequently observed than significant increasing trends. Two MSs 
demonstrated a significant increasing trend for ciprofloxacin and nalidixic acid ‘microbiological resistance’ 
and one a decreasing trend for both antimicrobials. In particular, resistance to cefotaxime remained generally 
low, very low or absent in reporting MSs between 2006 and 2012. 
Resistance in S. Enteritidis was lower than in Salmonella spp. isolates from Gallus gallus. In S. Enteritidis, 
the occurrence of resistance for all reporting MSs was 3.3 % for tetracyclines, 5.5 % for ampicillin and 4.3 % 
for sulfonamides, whereas the level of ‘microbiological resistance’ to ciprofloxacin and nalidixic acid was 
23.9 % and 22.2 %, respectively. 
In Salmonella spp. isolates from broiler meat, resistance levels for all reporting MSs for tetracyclines and 
sulfonamides were high and very high at 48.9 % and 53.0 %, respectively. ‘Microbiological resistance’ to 
ciprofloxacin and nalidixic acid resistance was also very high, with overall resistance levels of 63.1 % and 
57.3 %, respectively. The resistance level for cefotaxime was low, at 4.3 %. 
Among  Salmonella  spp. isolates from turkeys, the level of resistance to tetracyclines, ampicillin and 
sulfonamides in all reporting MSs was very high at 66.7 %, 56.5 % and 58.9 %, respectively. The levels of 
resistance to ciprofloxacin and nalidixic acid were also very high and high, at 59.9  % and 42.0  %, 
respectively, for all reporting MSs. Often, there were large variations in the levels of resistance to these 
antimicrobials among the different reporting MSs. The occurrence of resistance to cefotaxime in all reporting 
MSs was very low, at 0.8 %. Five MSs reported quantitative data from fattening turkeys and, in general, the 
levels of resistance in this production type were slightly higher than those reported when all turkey 
production types were considered. Multi-resistance was generally very high in Salmonella spp. isolates from 
turkeys; however, co-resistance to ciprofloxacin and cefotaxime (interpreted using CBPs) was not detected. 
For Salmonella spp.  isolates from pigs, resistance levels in the reporting group of MSs were very high: 
63.3  % for tetracyclines and sulfonamides, and 60.2  % for ampicillin. Ciprofloxacin and nalidixic acid 
‘microbiological resistance’ levels remained low, at 7.6 % and 5.8 %, respectively, and the level of resistance 
to cefotaxime was also low, at 2.3 % overall. Five MSs reported quantitative data from fattening pigs and the 
levels of resistance in this production type were lower than those reported when all pig production types 
were considered. Resistance to tetracyclines, ampicillin and sulfonamides was common in Salmonella spp. 
from pig meat, 49.2  %, 47.5  % and 53.5  %, respectively, considering all reporting MSs. ‘Microbiological 
resistance’ to ciprofloxacin and nalidixic acid was at a low level (7.6  % and 4.2  %, respectively) and 
cefotaxime resistance was very low, at 0.9 %. The trends in resistance observed in Salmonella spp. isolates 
from pigs over the years 2006 to 2012 remained stable in some countries, while fluctuation was observed in 
others. Among the few statistically significant national trends, slightly more decreasing trends were observed 
than increasing ones. However, it is noteworthy that ‘microbiological resistance’ to cefotaxime remained 
generally low, very low or absent in reporting MSs over the period 2006 to 2012. Multi-resistance was 
generally very high in Salmonella spp. isolates from fattening pigs; however, co-resistance to ciprofloxacin 
and cefotaxime was not detected when using CBPs. 
Among Salmonella spp. isolates from cattle, the occurrence of resistance to tetracyclines, ampicillin and 
sulfonamides in all reporting MSs was high, at 36.0  %, 34.5  % and 42.4  %, respectively. The level of 
resistance to ciprofloxacin and nalidixic acid was low, 9.1 % for both, for all reporting MSs, while cefotaxime 
resistance was observed among the reporting MSs at a very low level (0.4  %). Although variation was 
observed between MSs in the level of resistance to some antimicrobials, overall trends in resistance 
between 2006 and 2012 were mainly decreasing ones among Salmonella  spp. from cattle. Variability 
between MSs was observed in multi-resistance levels in Salmonella spp. isolates from cattle; however, co-
resistance to ciprofloxacin and cefotaxime was not detected when using CBPs. The few statistically 
significant trends observed in resistance levels among Salmonella isolates from cattle were all decreasing 
ones. 
With respect to detailed analyses of MDR in Salmonella serovars, high-level resistance to ciprofloxacin in S. 
Kentucky was identified in isolates from broilers, laying hens and turkeys. S. Kentucky with high-level 
ciprofloxacin resistance was also detected in meat from turkeys and in meat from broilers. S. Kentucky 
isolates showing high-level resistance to ciprofloxacin are likely to belong to the clone of S. Kentucky 
sequence type 198, which recently emerged in North Africa and the Middle East exhibiting such resistance 
and which has subsequently been detected in poultry in some European countries. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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S. Infantis showing high-level ciprofloxacin resistance, together with resistance to a core antimicrobial pairing 
of sulfonamides and tetracyclines (but with other resistances which were not invariably present in all high-
level ciprofloxacin S.  Infantis isolates) was detected in meat from broilers, pig meat and broilers. The 
occurrence of S. Infantis with this resistance pattern in several MSs and in different types of animal or meat 
probably indicates that either a clone of S. Infantis showing such resistance has spread within Europe or that 
several clones have gained such high-level ciprofloxacin resistance independently. In addition to showing 
high-level ciprofloxacin resistance, S. Infantis also featured as a serovar displaying ‘pentavalent’ resistance 
that is resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracyclines. A small 
number of serovars displayed this resistance phenotype which is potentially significant because certain 
Salmonella serovars which have shown epidemic spread have shown such pentavalent resistance in the 
past. Although a relatively low number of serovars were detected showing such pentavalent resistance, 
these included several important serovars relevant to public health, including, for example, S. Saintpaul, as 
well as S. Typhimurium. 
Resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides, tetracyclines and trimethoprim was 
not detected in isolates of S. Enteritidis from animals or meat for which isolate-based data was available. 
This pattern of resistance has previously been reported in human S. Enteritidis isolates which possess a 
combined virulence-resistance plasmid; such strains cause human infections of increased severity. The 
absence of certain resistance phenotypes can therefore be just as significant as the detection of resistance 
in evaluating the current situation in Europe. 
Considering monophasic S. Typhimurium, the MDR results assist in tracking the increasing spread of this 
Salmonella serovar. Different clones have been identified and using the MDR information it is possible to 
presumptively identify each clone. The so-called ‘Spanish clone’ is resistant to ampicillin, chloramphenicol, 
gentamicin, streptomycin, sulfonamides, tetracyclines and trimethoprim, whereas the ‘US clone’ is fully 
susceptible and the ‘European clone’ is resistant to ampicillin, streptomycin, sulfonamides and tetracyclines. 
The pattern associated with the Spanish clone was only seen in 1.8 % (5 out of 279) isolates from fattening 
pigs, where the pattern associated with the European clone was much more frequently detected. 
2.2.2. Campylobacter 
2.2.2.1. In humans 
Overall, 14 MSs and one non-MS provided information on antimicrobial resistance in isolates from 
campylobacteriosis cases in humans for the year 2012. 
Data from antimicrobial susceptibility testing represented 17.9 % of the total confirmed campylobacteriosis 
cases reported in the EU/EEA in 2012. Fewer countries reported results for Campylobacter than for 
Salmonella.  The variety of methods and interpretive criteria used by MSs in antimicrobial susceptibility 
testing for Campylobacter was still large, even though some harmonisation towards the use of EUCAST 
CBPs could be observed. The launch of CBPs for disc diffusion by EUCAST in 2012 will most likely facilitate 
this harmonisation further, as many countries use disc diffusion for testing of human isolates.  
The ‘clinical resistance’ levels in human Campylobacter isolates were highest for nalidixic acid (48.8 %) and 
ciprofloxacin (47.4 %) followed by ampicillin (36.4 %) and tetracyclines (32.4 %), with high levels of multi-
resistance observed in some countries. Resistance to the clinically important antimicrobial erythromycin was 
low overall (3.1 %), but moderately high in C. coli (15.1 %), although the number of isolates of this species 
tested was small. 
Sufficient data were available for levels of resistance to be compared by geographical region for 
ciprofloxacin, erythromycin, nalidixic acid and tetracyclines. Isolates acquired in EU/EEA countries had the 
lowest frequency of resistance to all these antimicrobials, with resistance to both ciprofloxacin and 
erythromycin notably lower than in isolates acquired in Asia and Africa. However, the number of isolates 
tested that originated from infections acquired outside of the EU/EEA was very low.  
2.2.2.2. In animals and food 
In 2012, 15 MSs and one non-MS reported quantitative MIC data for Campylobacter isolates from food and 
animals. Five MSs additionally reported qualitative data where the method of testing was not specified; 
however, these data are not presented in the report. When considering all host species, the highest levels of 
resistance were seen for the (fluoro)quinolones (ciprofloxacin and nalidixic acid) and tetracyclines. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Resistance to erythromycin and gentamicin was comparatively low among Campylobacter isolates from food 
and animals. Resistance was generally higher in C. coli than in C. jejuni from the same host species 
(Gallus gallus). 
For  C. jejuni isolates from Gallus gallus, resistance was high for ciprofloxacin (44.1  %), nalidixic acid 
(41.4 %) and tetracyclines (34.1 %), while levels of resistance to erythromycin and gentamicin were very low, 
at 0.4 % and 0.7 %, respectively. A similar pattern was seen for C. coli isolates from Gallus gallus; however, 
levels of resistance were higher overall. Levels of resistance to ciprofloxacin, nalidixic acid and tetracyclines 
were extremely high at 78.4 %, 75.7 % and 73.1 %, respectively, while levels of resistance to erythromycin 
and gentamicin were moderate (11.2 %) and low (4.1 %), respectively.  
Multi-resistance (reduced susceptibility to at least three antimicrobial classes according to ECOFFs) was 
very low, low or not detected in C. jejuni isolates from broilers, and co-resistance to the clinically important 
antimicrobials ciprofloxacin and erythromycin in the same isolates was either not detected or recorded at low 
levels in the reporting MSs. The situation was different for C. coli from broilers where multi-resistance as a 
percentage of all isolates received by the individual MSs ranged from 3.0 % to 55.6 % and co-resistance to 
ciprofloxacin and erythromycin ranged from 0 % to 22.2 %.  
Although resistance to ciprofloxacin and nalidixic acid in Gallus gallus varied greatly among reporting MSs 
over the period 2006 to 2012, some statistically increasing trends in resistance to these antimicrobials were 
observed for several MSs, both for C. jejuni and C. coli.  
For C. jejuni isolates from broiler meat, resistance, considering all reporting MSs, ranged from high to very 
high for ciprofloxacin (59.5 %), nalidixic acid (57.9 %) and tetracyclines (47.5 %), while levels of resistance to 
erythromycin and gentamicin ranged from low to very low at 1.8 % and 0.7 %, respectively. A similar pattern 
was seen for C. coli isolates from broiler meat; however, levels of resistance were higher overall. Levels of 
resistance to ciprofloxacin and nalidixic acid were extremely high at 82.7 % and 81.0 %, respectively, very 
high for tetracyclines at 57.3 %, moderate for erythromycin at 16.5 % and low for gentamicin at 1.7 %. 
C. coli isolates from pigs were derived from fattening pigs (one MS did not specify the production level). 
Resistance to ciprofloxacin, nalidixic acid and tetracyclines ranged from high to extremely high at 32.0 %, 
31.6  % and 76.8  %, respectively. Resistance was high to erythromycin (23.9  %) and low to gentamicin 
(2.9 %). Resistance to ciprofloxacin and/or nalidixic acid in C. coli from pigs showed a significantly increasing 
trend in three reporting MSs over the period 2006 to 2012.  
Multi-resistance (reduced susceptibility to at least three antimicrobial classes according to ECOFFs) varied 
greatly in occurrence with C. coli isolates from pigs from the different MSs, ranging from 3.9 % to 97.3 %. 
Co-resistance to the clinically important antimicrobials, ciprofloxacin and erythromycin, was low for three 
reporting countries, ranging from 2.9 % to 9.4 %, but extremely high in one MS at 76.7 %. 
C. jejuni isolates from cattle were also considered. Overall, resistance was high for ciprofloxacin (32.9 %), 
nalidixic acid (32.5 %) and tetracyclines (43.5 %), while resistance to erythromycin and gentamicin was very 
low at 0.6 % and 0.2 %, respectively. No statistically significant trends in ciprofloxacin and nalidixic acid 
resistance were observed in any of the reporting countries, but erythromycin resistance significantly 
decreased statistically in the Netherlands over the period 2006 to 2012. 
Multi-resistance (reduced susceptibility to at least three antimicrobial classes according to ECOFFs) ranged 
from 0 % to 12.3 % in C. jejuni isolates from cattle from the reporting MSs. Co-resistance to the clinically 
important antimicrobials, ciprofloxacin and erythromycin, was low or not detected. 
2.2.3. Indicator (commensal) Escherichia coli 
Eleven MSs and two non-MSs reported quantitative data on antimicrobial resistance in indicator E. coli 
isolates from animals and food in 2012. Most of the data related to isolates from Gallus gallus, pigs and 
cattle; four MSs reported results for meat derived from each of those species.  
Indicator  E. coli  from meat from Gallus gallus, pigs and cattle showed high or very high levels of 
‘microbiological resistance’ to ampicillin, sulfonamides and tetracyclines, considering all reporting MSs. 
Resistance was less than 4  % to gentamicin, less than 3  % to cefotaxime and less than 7  % to EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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chloramphenicol for all reporting MSs and for meat from all three animal species. The levels of resistance 
were therefore broadly similar for meat from broilers, pigs and bovine animals for all reporting MSs for these 
antimicrobials. The situation was different for ciprofloxacin and nalidixic acid, where ‘microbiological 
resistance’ was high in meat from broilers considering all reporting MSs at 29.1 % and 24.1 %, respectively, 
but low in meat from pigs and cattle at less than 7 %. 
Most data on Gallus gallus referred to broilers, although two MSs provided data on E. coli from laying hens. 
Resistance levels were in general higher among E. coli from broilers than from laying hens. Regarding 
broilers, the highest overall ‘microbiological resistance’ levels observed at the reporting MS group level were 
to ciprofloxacin (52.7 %), ampicillin (50.4 %), sulfonamides (45.4 %), tetracyclines (43.3 %), nalidixic acid 
(43.2 %) and streptomycin (38.4 %). The isolates from laying hens also most commonly showed reduced 
susceptibility to these antimicrobials, but resistance levels were lower, ranging between 10.1 % and 43.3 %. 
Resistance to cefotaxime was low in both broilers (6.2 %) and layers (6.0 %). There was substantial variation 
in the level of resistance to these antimicrobials between reporting MSs. Countries mostly reported relatively 
stable resistance in E. coli isolates from Gallus gallus between 2006 and 2012. However, statistically 
significant trends in resistance to all of these antimicrobials, except tetracyclines, have been identified: these 
trends have more commonly been increasing ones than decreasing ones.  
Concerning indicator E. coli isolates from pigs, the highest overall ‘microbiological resistance’ levels in the 
reporting group of MSs were observed for tetracyclines (54.7  %), streptomycin (50.3  %), sulfonamides 
(41.7 %) and ampicillin (29.5 %). Resistance to both ciprofloxacin and nalidixic acid was low at 7.5 % and 
4.9 %, respectively. Overall, only 1.4 % of isolates were resistant to cefotaxime. There were large differences 
in the occurrence of resistance between MSs. There were fewer statistically significant trends than in isolates 
from Gallus gallus. No significant trends were observed for cefotaxime. 
Multi-resistance levels (reduced susceptibility to at least three antimicrobial classes according to ECOFFs) 
were generally high in indicator E. coli isolates from broilers and pigs, and in a number of reporting countries. 
Co-resistance/reduced susceptibility to the clinically important antimicrobials, ciprofloxacin and cefotaxime, 
was also detected in very few isolates from these species. 
In the reporting group of MSs, resistance levels in indicator E. coli isolates from cattle were generally lower 
than among isolates from Gallus galllus and pigs. The highest resistance levels observed were to 
tetracyclines (30.6  %), sulfonamides (28.3  %), streptomycin (25.1  %) and ampicillin (24.5  %). 
‘Microbiological resistance’ to ciprofloxacin was moderate, at 12.2 %, and resistance to nalidixic acid was 
low, at 8.6 %. Overall, only a few isolates (2.4 %) expressed resistance to cefotaxime. The occurrence of 
resistance was variable between MSs for most of the antimicrobials. As for Salmonella, some MSs 
presented data at the production-type level for cattle, although only three MSs did so. One of these MSs 
reported much higher resistance among younger animals, mainly fattening veal calves, compared with older 
cattle, mainly adult cows, but this was not observed in the other countries. There have been numerous 
statistically significant trends in resistance since 2006, mainly of a decreasing nature.  
Strains of E. coli are not separated on phenotypic characteristics (e.g. serotype) in the current monitoring 
programme and a less detailed analysis is therefore possible than for Salmonella where isolates can be sub-
divided by serovar. The common core patterns of ‘microbiological resistance’ to ampicillin, streptomycin, 
sulfonamides, tetracyclines and trimethoprim (and combinations thereof) frequently observed in the 
monitoring of E. coli isolates are probably related to the presence of class 1 or class 2 integrons, which 
generally carry genes conferring resistance to these antimicrobials. A common core of ‘microbiological 
resistance’ to ampicillin, sulfonamides and tetracyclines, generally with ‘microbiological resistance’ to 
ciprofloxacin and frequently with such resistance to streptomycin and trimethoprim, was discernible in 
broilers. However, no single pattern or patterns of ‘microbiological resistance’ occurred at a high frequency in 
broilers. In fattening pigs, two MDR patterns were predominant (streptomycin, sulfonamides, tetracyclines 
and streptomycin, sulfonamides, tetracyclines, ampicillin and trimethoprim) and each accounted for more 
than 5  % of the total number of E. coli  isolates from fattening pigs for which isolate-based data were 
available. Ciprofloxacin resistance (microbiological) frequently occurred as a component of MDR in E. coli 
from broilers and was observed in 72.3  % of MDR isolates (120 out of 166), whereas ‘microbiological 
resistance’ to ciprofloxacin occurred infrequently as a component of MDR in pigs and was present in 16.0 % 
(32 out of 200) of porcine MDR in E. coli isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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2.2.4. Methicillin-resistant Staphylococcus aureus 
A low number of MSs reported the results of monitoring food for methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA was detected in meat from broilers, turkeys, pigs and bovine animals. Some MSs also 
examined products such as fish and fruit and detected MRSA in a low number of such products. The 
occurrence of MRSA in meat and products derived from animals may reflect colonisation of those animals 
with MRSA; however, the occurrence of MRSA in products such as fish and fruit may also reflect 
contamination from human personnel who may be colonised with MRSA involved in the preparation of such 
foods. Strain typing would probably assist in elucidating the likely origin of MRSA isolates in these samples. 
Some MSs undertook comprehensive monitoring at various stages along the food chain revealing interesting 
differences in the occurrence of MRSA at different stages of food production. 
In relation to healthy food-producing animals, MRSA was detected in meat-producing turkey flocks, but not in 
breeding flocks in one MS. There was a large degree of variation between MSs in the occurrence of MRSA 
in pigs, with one MS not detecting MRSA in a farm-based national survey, whilst another MS reported that 
99 % of animals were positive in slaughterhouse monitoring. Three MSs examined cattle for MRSA; the 
number of animals which were positive in sampling on farms for one MS was considerably lower than when 
calves were sampled at slaughter. The occurrence of MRSA in dairy cows in this MS (9.9 %) was similar to 
the occurrence in calves under one year old (10.2 %), both types of animals being sampled on farms. In 
calves under one year old monitored at slaughterhouse through sampling of nasal swabs, the occurrence of 
MRSA ranged from 45.0 % to 47.1 %. Sheep and goats were investigated by one MS and no MRSA was 
detected. Molecular typing data was reported by one MS in relation to isolates from cattle; the majority of 
isolates were spa-type t011 belonging to MRSA clonal complex (CC) 398, the common livestock-associated 
type of MRSA occurring in Europe.  
Several MSs reported results of clinical investigations which yielded MRSA in food-producing animals and 
companion animals. MRSA was detected in cats, dogs and horses in one MS as well as in clinical diagnostic 
samples from pigs. 
Temporal trends in the occurrence of MRSA in animals could be assessed for two MSs and one non-MS. 
Monitoring of sheep and goats on farms in 2011 and 2012 in one MS did not reveal the presence of MRSA in 
these animals in either year. A further MS monitored calves under one year old on the farms in 2010 and 
2012 and reported similar numbers of animals positive for MRSA in each year (19.6  % and 19.2  %, 
respectively). The same MS also reported results on the occurrence of MRSA in meat production turkeys, at 
the farm in 2010 and 2012. The prevalence reported was moderate in both years (19.6 % in 2010 and 
12.8  % in 2012). One non-MS reported data on the occurrence of MRSA in fattening pigs at slaughter 
through the monitoring of nasal swabs in consecutive years from 2009 to 2012. The numbers of animals 
positive for MRSA showed a slow increase over this period from 2.2 % in 2009 to 18.1 % in 2012. Molecular 
typing data were also available for these MRSA isolates, the majority of which belonged to spa-type t034, 
CC398, while much lower numbers of MRSA sequence type ST 49 were reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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3. ANTIMICROBIAL RESISTANCE IN SALMONELLA 
3.1. Introduction 
Salmonella is an important zoonotic pathogen of economic significance in both humans and animals. The 
genus  Salmonella  is divided into two species: S. enterica and S. bongori. There are six sub-species of 
S. enterica  and most Salmonella  belong to the sub-species S. enterica  subsp.  enterica.  Salmonella  are 
further sub-divided into serovars based on the serological reactions of their somatic O-antigens and flagellar 
H-antigens. Different serovars have often been named based on the location where the serovar was first 
isolated. In this report, the organisms are identified by genus followed by serovar, e.g. S. Typhimurium. 
There are more than 2,500 serovars of zoonotic Salmonella which have been recognised, and the 
prevalence of these different serovars can change over time. 
Human salmonellosis is usually characterised by the acute onset of fever, abdominal pain, nausea and 
sometimes vomiting. The majority of Salmonella infections result in mild, self-limiting, gastrointestinal illness 
and usually do not require antimicrobial treatment. In some patients the infection may be more serious and 
the associated dehydration can be life threatening. Invasive disease, such as Salmonella bacteraemia or 
meningitis, can occur in a smaller sub-set of patients, with a higher risk in patients who are immuno-
compromised. In cases of severe enteric disease, or when Salmonella invades and causes a bloodstream 
infection, effective antimicrobials are essential for treatment and can be life saving. The treatment of choice 
for  Salmonella  infection is fluoroquinolones for adults and third-generation cephalosporins for children. 
Resistance in Salmonella  to these first-line treatments, resulting in infections with antimicrobial-resistant 
strains, may cause treatment failure, which in turn can lead to more severe outcomes in patients. 
Salmonellosis has also been associated with long-term or chronic sequelae, e.g. reactive arthritis. 
The common reservoir of non-typhoidal Salmonella strains is the intestinal tract of a wide range of domestic 
and wild animals. A wide variety of food stuffs of both animal and plant origin can be contaminated with 
Salmonella, which may cause infection in humans. Transmission usually occurs when the bacteria are 
introduced during food preparation or are allowed to multiply in food (for example because of inadequate 
storage temperature, inadequate cooking or cross-contamination of ready-to-eat food and uncooked food). 
Salmonella may also be transmitted through direct contact with infected animals or humans, or by contact 
with contaminated environments. 
Overall, considering all Salmonella infections in the EU, S. Enteritidis and S. Typhimurium are the serovars 
most frequently associated with human illness. S. Enteritidis cases in humans are most commonly 
associated with the consumption of contaminated eggs and poultry meat, while S. Typhimurium cases are 
mostly associated with the consumption of contaminated pig, bovine and poultry meat.  
In animals, particularly in certain species, sub-clinical infections or healthy carriage can be common. The 
organism may spread rapidly and easily between animals in a herd or flock without the animals showing any 
clinical signs in some cases and animals may become intermittent or persistent carriers. In other species, 
clinical disease may occur following Salmonella infection and, in particular, cattle may succumb to fever, 
diarrhoea and abortion following infection, particularly with some serovars such as S. Dublin.  In  calves, 
Salmonella can cause outbreaks of diarrhoea with high mortality. Fever and diarrhoea are less common in 
pigs than in cattle and sheep and poultry may also show no signs of infection. 
Salmonella spp. comprise the amalgamated results for all Salmonella serovars reported by a MS. In the case 
of sampling in animals performed in accordance with EFSA’s recommendations (EFSA, 2007) and related to 
National Salmonella Control Programmes (NCP), there is a defined method of selecting isolates for inclusion 
in the monitoring. The relative contribution of different serovars possessing a particular resistance should 
ideally be considered when interpreting the results, in order to evaluate the influence of clonal dissemination 
of serovars. If a MS has reported the susceptibility of particular serovars and excluded others, then this 
would introduce a source of bias in the susceptibility figures relating to Salmonella spp. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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3.2. Overview of reported resistance data in Salmonella from humans, animals and food 
Nineteen MSs, as well as Iceland and Norway, provided data for 2012 on human Salmonella isolates. 
Countries reported qualitative data (i.e. interpreted antibiotic susceptibility testing (AST) results for tested 
isolates; susceptible (S), intermediate (I) or resistant (R)) with the exception of Norway, which used the 
isolate-based reporting under piloting at ECDC to report measured IZDs. Twenty MSs and two non-MSs 
(Norway and Switzerland) reported quantitative MIC and disc inhibition zones data on the antimicrobial 
resistance of Salmonella isolates recovered from animals and food in 2012. Table SA1 presents an overview 
of the MSs reporting on antimicrobial resistance, either MIC or IZD data, on Salmonella spp. from humans 
and various animal and food categories in 2012. 
Table  SA1.    Overview of countries reporting antimicrobial resistance data using MICs and disc 
diffusion inhibition zones on Salmonella spp. (all serovars) from humans and various animal and 
food categories in 2012 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Human 
12  MSs: AT, EE, ES, FR, GR, HU, IT, LU, LT, RO, SI, SK 
2  Non-MSs: IS, NO 
Gallus gallus (fowl)  1  MS: GR 
Meat from broilers  
(Gallus gallus)  1  MS: GR 
Meat from pigs  1  MS: GR 
Dilution 
Human  10  MSs: DE, DK, FR, HU, IE, MT, NL, RO, SK, UK 
Gallus gallus (fowl)  18 
MSs: AT, BE, CZ, DE, DK, ES, FI, HU, IE, IT, LV, NL, 
PL, PT, RO, SK, SE, UK 
Non-MS: CH 
Turkeys  13  MSs: AT, BE, CZ, DE, ES, FI, HU, IE, IT ,PL, PT, SK, 
UK 
Pigs  16 
MSs: BE, CZ, DE, DK, EE, ES, FI, HU, IE, IT, LV, NL, 
PL, RO, SK, SE 
Non-MS: CH 
Cattle (bovine animals)  12 
MSs: BE, CZ, DK, EE, ES, FI, DE, IE, IT, LV, NL, SE 
Non-MSs: NO, CH 
Meat from broilers  
(Gallus gallus)  14  MSs: BE, CZ, DE, EE, ES, HU, IE, IT, LV, NL, PL, PT, 
RO, SK 
Meat from turkeys  10  MSs: CZ, DE, EE, HU, IE, IT, LV, PL, PT, SK 
Meat from pigs  14  MSs: BE, CZ, DE, DK, EE, ES, HU, IE, IT, LV, NL, PL, 
RO, SK 
Meat from bovine animals  9  MSs: CZ, DE, EE, ES, FI, HU, IE, IT, NL 
MIC:  minimum inhibitory concentration. 
Note: for abbreviations of Member States (MS) and other reporting countries see Appendix 7.  
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3.3.1. Antimicrobial resistance in Salmonella spp. in humans 
In total, 23,625 Salmonella spp. isolates were tested by the 19 reporting MSs, as well as Iceland and 
Norway, for resistance to one or more antimicrobials, representing 25.6  % (N=92,443) of all confirmed 
human salmonellosis cases reported in the EU/EEA in 2012. Levels of resistance are only shown when at 
least 20 isolates are tested. The number of antimicrobials tested per isolate varied by country. Ampicillin and 
ciprofloxacin were tested by all 19 MSs and 2 non-MSs, while sulfonamides were only tested by 15 MSs and 
1 non-MS. Please note that the Danish data were excluded from Table SA2 since Denmark only reported 
data for S. Typhimurium and monophasic S. Typhimurium and inclusion of these data would have skewed 
the EU average for Salmonella spp.  
 
In order to better assess the impact from food consumed within each reporting country on the antimicrobial 
resistance levels found in human Salmonella isolates, the analysis focused on domestically-acquired cases. 
Several countries, however, did not provide information on travel (or non-travel) of their cases. Cases with 
unknown travel status were therefore also included in the analysis. A separate analysis was made on travel-
associated cases by geographical regions. 
3.3.1.1. Resistance levels in Salmonella spp. isolates from human cases 
The highest average levels of resistance in human Salmonella spp. isolates  in 2012 were reported for 
tetracyclines (30.0  %; N=15,233), sulfonamides (28.9  %; N=14,582), ampicillin (27.6  %, N=18,972) and 
streptomycin (23.6 %; N=16,643) (Table SA2). However, as in previous years, wide variability in frequencies 
of resistance to different antimicrobials was observed among the reporting countries. The variability may 
reflect the differences in the Salmonella population that people are exposed to in different countries, but may 
also arise due to differences in testing or sampling methods applied by individual countries as well as the 
use of different interpretive criteria. Sampling bias could also arise by only including isolates from 
hospitalised cases. This may explain some of the extreme observations.  
Resistance levels can also differ substantially between Salmonella  serovars and therefore an in-depth 
analysis is presented separately below for the three most common serovars, S. Enteritidis, S. Typhimurium 
and monophasic S. Typhimurium 1,4,[5],12:i:-,.   
3.3.1.2. Comparison of resistance levels in Salmonella spp. isolates acquired within EU/EEA 
and in other geographical regions 
To compare resistance levels in isolates acquired across the world, isolates from travel-associated cases 
were classified into seven different geographical regions
13 EU/EEA, non-EU/EEA, Africa, Asia, North and 
Central America, South America and Oceania, based on the probable country of infection. Isolates from non-
travel-associated cases were combined with those from cases infected in another EU/EEA country. Please 
note that the number of isolates tested per region does not necessarily reflect the number of travels to that 
region. Moreover, only 13 isolates were tested for infections acquired in Oceania and the results for this 
region should therefore be interpreted with caution.  
Varying levels of resistance were observed among Salmonella  spp. infections acquired in the different 
geographical regions (Table SA3). Isolates acquired within EU/EEA countries had the highest level of 
resistance to ampicillin (27.8  %; N=20,124), streptomycin (23.9  %; N=17,759), sulfonamides (29.2  %; 
N=15,686) and tetracyclines (30.2  %; N=16,340) of all regions. Resistance levels to ciprofloxacin was 
however higher in isolates from all other regions and particularly high in isolates originating in Asia (22.7 %; 
N=1,160), Africa (20.5 %; N=774) and Europe (non-EU/EEA countries) (19.5 %, N=41). Resistance levels to 
cefotaxime was also higher in isolates acquired in South America (4.8 %; N=21), Africa (2.1 %; N=767) and 
Asia (1.5 %; N=1,145) compared to the EU/EEA (1.1 %; N=18,949), though only a few isolates were tested 
from South America (Table SA3).  
 
                                                           
13 Regional classification from United Nations Statistical Division. Available online http://unstats.un.org/unsd/methods/m49/m49regin.htm EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA2.  Antimicrobial resistance in Salmonella spp. (all non-typhoidal serovars) from humans per country in 2012, using clinical breakpoints
1  
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N %  Res N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria 1,815  17.4  1,815  0.6 1,815  3.5 1,815  1.1 1,815  2.0 1,815  0.9 
Denmark
2  – – – – – – – – – – – – 
Estonia 218  15.1  216  0.9  175  0 214  3.3 175  4.0 171  0.6 
France 1,278  28.2  1,278  2.6 1,278  6.3 1,278  12.8 1,278  9.4 1,278  3.8 
Germany 1,994  36.4  1,994  0.9  –  –  1,994 1.5  1,994 2.4 1,994  1.5 
Greece 106  20.8  34  5.9  72  5.6  106  0 34  100 72  4.2 
Hungary 588  55.1  588  2.4  588  12.9 588  0.3 588  2.6 588  1.0 
Ireland 217  39.2  217  0.9  217  13.8 217  1.4 217  0.9 217  0.9 
Italy  133  61.7 133  0 133  6.8 133  1.5 133  2.3 131  1.5 
Latvia  54  11.1  17  NA  -  -  48 0 3  NA – – 
Lithuania 1,734  13.7  1,478  0.7  812 2.0  1,362 0.3  673 0.3  624  0 
Luxembourg 135  40.7  135  0  135  8.1 135  3.0 135  1.5 135  0.7 
Malta  88  21.6 – – – –  88  18.2  88  84.1 – – 
Netherlands
3  1,028 35.6  1,028  0.7  1,028  5.4 1,028  6.3 1,028  1.5  –  – 
Romania 137  41.6  137  1.5  137  7.3 137  1.5 137  1.5 137  0 
Slovakia  965 14.1  338 10.4  67 7.5  356 1.7  341  96.2  1 NA 
Slovenia 392  15.3  392  0  392  8.2 392  0.8 392  6.9 392  5.6 
Spain 1,874  47.9  1,875  1.5 1,873  8.1 1,874  0.9 1,874  2.3 1,874  2.1 
United Kingdom  6,216  23.5  6,161  0.6  6,177 4.9  6,233 9.1  6,186 1.6  6,158 1.5 
Total (18 MSs)  18,972  27.6  17,836  1.1  14,899  5.7  17,998  5.1  17,091  5.0  15,587  1.7 
Iceland  22  0.1 – –  22  0.1  22 0 – – – – 
Norway  359  20.1 – –  359  7.2  359  0.3 – – – – 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see Table MM2.  
2.   Data from Denmark not included in this table as only available for S. Typhimurium (see Table SA6) and monophasic S. Typhimurium (see Table SA7). 
3.  Epidemiological cut-off values were used for interpretation. 
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Table SA2 (continued).  Antimicrobial resistance in Salmonella  spp. (all non-typhoidal serovars) from humans per country in 2012, using clinical 
breakpoints
1 
Country  Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria 1,815  16.4  1,815  18.5  1,815 17.9  1,815  19.4  1,815  3.3 
Denmark
2 –  –  –  –  –  –  –  –  –  – 
Estonia 174  21.3  169  10.7  171 9.9  172  11.0  214  1.4 
France 1,278  23.5  1,278  33.2  1,278 36.0  1,278  37.7  1,278  6.6 
Germany 1,993  9.9  1,994  43.5 –  –  –  –  1,994  8.4 
Greece 73  6.8  72  18.1  –  –  72  22.2  30  6.7 
Hungary 588  33.0  588  46.9  588 57.1  588  55.3  588  8.0 
Ireland 217  7.4  217  39.2  217 43.3  217  42.9  217  8.3 
Italy 133  5.3  133  62.4  133  61.7  132  64.4  133  6.0 
Latvia –  –  –  –  –  –  –  –  53  0 
Lithuania 643  11.7  623  6.6  622 6.4  621  9.0 1,736  2.2 
Luxembourg 135  10.4  135  39.3  135 40.0  135  36.3  135  4.4 
Malta –  –  –  –  –  –  –  –  88  46.6 
Netherlands
3 1,028  5.5  1,028  35.3  1,028 34.8  1,028  37.6  –  – 
Romania 137  23.4  136  27.2  136 62.5  137  27.7  137  15.3 
Slovakia 7  NA  11  NA  38  5.3  613  11.9  –  – 
Slovenia 392  8.9  392  15.6  390 16.9  392  19.9  392  2.6 
Spain 1,875  22.6  1,874  39.2  1,873 44.2  1,875  47.0  1,874  6.4 
United Kingdom  6,201  11.5  6,178  8.7 6,158  23.9  6,158 26.6 6,228 8.8 
Total (18 MSs)  16,689  14.4  16,643  23.6  14,582  28.9  15,233  30.0  16,912  6.9 
Iceland 3  NA  –  –  –  –  –  –  22  0 
Norway 359  10.3  47  91.5  47 95.7  359  21.4  359  3.9 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2.  
2.  Data from Denmark not included in this table as only available for S. Typhimurium (see Table SA6) and monophasic S. Typhimurium (see Table SA7). 
3.  Epidemiological cut-off values were used for interpretation. 
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Table  SA3.    Antimicrobial resistance in Salmonella  spp. (all non-typhoidal serovars) from humans acquired in the EU/EEA and other geographical 
regions in 2012, using clinical breakpoints
1  
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA Countries)  20,124  27.8  18,949  1.1 16,038  5.7 19,157  5.4 18,209 4.8  16,671 1.7 
Europe (non-EU/EEA Countries)  41  4.9  40  0 36  2.8 41  19.5 40  7.5 38  2.6 
Africa  773  20.2 767  2.1 756  7.8 774 20.5 770  7.1 734  2.7 
Asia 1,158  24.3  1,145  1.5 1,132  6.9 1,160  22.7 1,147  4.6 1,075  4.0 
Northern and Central America  178  3.4  175  0 176  2.3 181  10.5 178 2.8 173 0.6 
South  America  21 9.5  21 4.8  19  10.5 21 9.5 21  4.8 18  11.1 
Oceania  13  15.4 13  0 13  15.4 13  15.4 13  7.7 13  0 
 
Country  Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA Countries)  17,814  14.2  17,759 23.9  15,686 29.2  16,340 30.2  18,041  6.8 
Europe (non-EU/EEA Countries)  38  26.3  38 5.3  35 5.7 35 11.4 40  5.0 
Africa  769 22.9  768 10.7  754 21.6 755  26.2 739  14.3 
Asia  1,147 22.9  1,146 10.9  1,126 24.6  1,128  25.7  1,086  10.7 
Northern and Central America  177  10.2 177  5.1 174  10.9  174 11.5  177  5.6 
South  America  21 19.0  21 14.3 19  15.8  19  10.5  18  11.1 
Oceania  13  15.4 13  7.7 13 15.4  13  15.4  13  7.7 
N: number of isolates tested; % Res: percentage of resistant isolates; NA: not applicable - if less than 10 isolates were tested resistance was not calculated. 
1.   Epidemiological cut-off values were used for interpretation in the Netherlands and Denmark. 
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3.3.1.3. Multi-drug resistance among Salmonella spp. isolates from human cases 
Thirteen MSs tested isolates for the full range of antimicrobials included in the human data collection for 
Salmonella spp., however as Denmark only provided data for serovars Salmonella  Typhimurium and 
monophasic S. Typhimurium, which are known to be multi-drug resistant, the Danish data were excluded 
from the analysis to avoid bias.  
About half of the human Salmonella spp. isolates in the 12 MSs were susceptible to all 10 antimicrobials 
(51.3 %; N=13,496), varying from 13.2 % (N=136) in Romania to 74.8 % (N=612) in Lithuania (Table SA4). 
Multi-drug resistance was high (28.9 %; N=13,496; country average 33.5 %) at the EU level, with the highest 
levels reported from Italy (63.1  %; N=130) and Hungary (55.8  %; N=588). The proportions of isolates 
susceptible to all and resistant (or non-susceptible) to any one up to 10 antimicrobials are presented by MSs 
in Figure SA2. The proportions differed substantially between countries. Isolates resistant to five 
antimicrobials were reported from all 12 MSs, and seven MSs (Austria, France, Hungary, Ireland, Lithuania, 
Spain and the United Kingdom) even reported a few isolates resistant to 9 or all 10 antimicrobials. The 
serotypes of those isolates resistant to 9 or 10 antimicrobials included monophasic S.  Typhimurium 
1,4,[5],12:i:- (six isolates), S. Brandenburg (four), S. Typhimurium (four), S. Infantis (three), S. Montevideo 
(three), S. Agona (one), S. Albany (one), S. Concord (one), S. Derby (one), S. Haifa (one), S. Havana (one), 
S. Kentucky (one), and S. Panama (one).  
Few isolates exhibited co-resistance to both ciprofloxacin and cefotaxime at the EU level (0.2 %; N=13,496) 
(Table SA4).  
Table SA4.  Complete susceptibility, multi-resistance and co-resistance (non-susceptibility) to 
ciprofloxacin and cefotaxime as determined by clinical breakpoints in Salmonella spp. from humans 
by MS, 2012
1 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
Cip and Ctx (%) 
Austria (N=1,815)  57.6  19.0  0.1 
Estonia (N=167)  64.1  11.4  0 
France (N=1,278)  49.1  37.0  0.4 
Hungary (N=588)  16.5  55.8  0.2 
Ireland (N=217)  52.5  41.9  0 
Italy (N=130)  33.1  63.1  0 
Lithuania (N=612)  74.8  7.2  0 
Luxembourg (N=135)  43.7  40.7  0 
Romania (N=136)  13.2  38.2  0 
Slovenia (N=390)  64.4  16.4  0 
Spain (N=1,870)  18.7  47.4  0.1 
United Kingdom (N=6,158)  60.9  23.7  0.3 
Total (12 MSs) (N=13,496)  51.3  28.9  0.2 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; Cip: ciprofloxacin; 
Ctx: cefotaxime; MS: Member State. 
Susceptible to all:  proportion of isolates clinically susceptible to all antimicrobial substances of the European Centre for Disease 
Prevention and Control (ECDC) common set for Salmonella. 
Multi-resistant:  proportion of isolates clinically non-susceptible (resistant and intermediate) to at least three different antimicrobial 
substances belonging to any three antimicrobial families from the ECDC common antimicrobial set for Salmonella. 
Co-resistant to Cip and Ctx: proportion of isolates clinically non-susceptible to both ciprofloxacin and cefotaxime. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM2.  
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Figure SA2.  Frequency distribution of Salmonella spp. isolates from humans completely susceptible 
or resistant to 1 to 10 antimicrobials, as determined by clinical breakpoints, 2012
1  
 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella  
Susceptible: total number of isolates susceptible to all antimicrobial substances of the common set for Salmonella. 
res1-res10: total number of isolates non-susceptible (resistant and intermediate) to between 1 and 10 antimicrobial substances of the 
common set for Salmonella. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this graph. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM2.  
 
3.3.2. Antimicrobial resistance in Salmonella Enteritidis in humans 
As in previous years, S. Enteritidis was the most common Salmonella  serovar identified in 2012, with 
34,019 cases reported in the EU/EEA. Seventeen MSs and Norway reported data on antimicrobial resistance 
in S. Enteritidis isolates for ≥20 isolates (ranging from 13 MSs for sulfonamides to all 17 MSs and Norway for 
ciprofloxacin and ampicillin (Table SA5)). 
3.3.2.1. Resistance levels in Salmonella Enteritidis isolates from human cases 
The highest level of resistance among S. Enteritidis isolates in 2012 was observed for nalidixic acid (18.8 %; 
N=4,628). By country, the highest level was observed in Spain (60.3  %; N=527), followed by Romania 
(37.0 %; N=46), France (31.7 %; N=101) and Estonia (26.3 %; N=137) (Table SA5). 
Compared with the data presented in this report for 2011 (EFSA and ECDC, 2013), the average level of 
resistance to ciprofloxacin was significantly lower in 2012 (4.9 %; N=5,598 in 2012 vs 12.7 %; N=7,965 in 
2011). This can be explained by the exclusion in 2012 of isolates acquired during travelling as ciprofloxacin 
resistance levels were markedly higher in all other parts of the world than in the EU/EEA (see further Table 
SA3). Another reason for the lower resistance level is also that the countries reporting the highest 
ciprofloxacin resistance levels in 2011 (Denmark and Italy) did not test or only tested very few isolates of 
S. Enteritidis in 2012, thus having less effect on the total average than in 2011. By country, the highest 
resistance to ciprofloxacin in 2012 was reported in the United Kingdom (14.2 %; N=1,636), followed by the 
Netherlands (9.6 %; N=281) and Malta (7.4 %; N=27), all three of which used sensitive interpretive criteria for 
this antimicrobial. 
As in previous years, resistance to cefotaxime was generally not detected or very low in the reporting MSs in 
2012, total average 0.7  % (N=5,588), with the exception of Slovakia (11.3  %; N=240) (Table SA5). In 
Slovakia, cefotaxime resistance is not tested at the National Public Health Reference Laboratory and the 
methods and breakpoints applied in the testing laboratories are not known. Other noteworthy observations 
were the extremely high resistance levels to gentamicin among S. Enteritidis in Slovakia (97.1 %; N=244) 
and Malta (96.3 %; N=27), and the high resistance level to sulfonamides in Romania (41.3 %; N=46) and to 
trimethoprim/sulfamethoxazole in Malta (33.3 %; N=27) (Table SA5).  
0 % 20 % 40 % 60 % 80 % 100 %
United Kingdom (N=6,158)
Spain (N=1,870)
Slovenia (N=390)
Romania (N=136)
Luxembourg (N=135)
Lithuania (N=612)
Italy (N=130)
Ireland (N=217)
Hungary (N=588)
France (N=1,278)
Estonia (N=167)
Austria (N=1,815)
Susceptible
res1
res2
res3
res4
res5
res6
res7
res8
res9
res10EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  32
Table SA5.  Antimicrobial resistance in S. Enteritidis from humans per country in 2012, using clinical breakpoints
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  890  2.4 890  0.1 890  0 890  0 890  0 890  0 
Estonia  172  7.6 170  0.6 138  0 169  3.6 139  0 135  0 
France  101  3.0 101  0 101  1.0 101  0 101  0 101  0 
Germany  207  1.4  207  0.5 – –  207 0  207 0  207 0 
Greece  30  6.7  5  NA 25  0 30  0  5  NA 25  4.0 
Hungary  43  27.9 43  0 43  0 43  0 43  0 43  0 
Ireland  30  3.3 30  0 30  0 30  0 30  0 30  0 
Italy  7  NA 7  NA 7  NA 7  NA 7  NA 7  NA 
Latvia  40 0  13  NA – –  39 0 – – – – 
Lithuania 1,405  8.5  1,200  0.3  659 0.2  1,106 0.2  531  0  499  0 
Luxembourg  34  8.8 34  0 34  0 34  0 34  0 34  0 
Malta  27  7.4 – – – –  27  7.4  27  96.3 – – 
Netherlands
2  281  2.8 281  0.4 281  0.4 281  9.6 281  0  –  – 
Romania  46  2.2 46  0 46  0 46  0 46  0 46  0 
Slovakia 752  4.0  240  11.3  40 5.0  256 1.6  244  97.1  1 NA 
Slovenia  169  2.4 169  0 169  0.6 169  0 169  0 169  0 
Spain  527  12.9 527  0.4 526  0.6 527  0.4 527  0 527  0.2 
United  Kingdom  1,634  4.7 1,625  0.1 1,627 0.5  1,636  14.2  1,628 0.1  1,624 0.1 
Total (18 MSs)  6,395  5.7  5,588  0.7  4,616  0.4  5,598  4.9  4,909  5.5  4,338  0.1 
Iceland  3  NA – – 3  NA 3  NA – – – – 
Norway  79  6.3 – –  79  2.5  79 0 – – – – 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2. 
2.  Epidemiological cut-off values were used for interpretation. 
 
Table continued overleaf. 
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Table SA5 (continued). Antimicrobial resistance in S. Enteritidis from humans per country in 2012, using clinical breakpoints
1  
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim
3
N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria  890 5.5  890 0.6  890 0.4  890 1.3  890 0.2 
Estonia 137  26.3  134  1.5  135 1.5  136 2.2  169 0.6 
France  101  31.7 101  1.0 101 2.0  101 3.0  101 1.0 
Germany  207 1.0  207 0.5  –  –  –  –  207 0.5 
Greece  25 0  25  4.0 – –  25  4.0 5  NA 
Hungary  43 2.3  43 4.7  43 2.3  43 4.7  43  0 
Ireland  30  16.7 30  3.3 30  3.3 30  3.3 30  0 
Italy  7 NA  7 NA  7 NA  7 NA  7 NA 
Latvia  – – – – – – – –  42 0 
Lithuania  499 9.8  498 0.2  498  0  496 3.6  1,405 1.1 
Luxembourg  34  14.7 34  2.9 34  2.9 34  0 34  0 
Malta  – – – – – – – –  27  33.3 
Netherlands
2  281 9.3  281 0.4  281 0.7  281 1.4  -  - 
Romania  46  37.0 46  4.3 46  41.3 46  2.2 46  0 
Slovakia  2 NA  –  –  31 6.5  468 1.9  –  – 
Slovenia  169 4.1  169 1.2  167 3.0  169 3.6  169 0.6 
Spain  527  60.3 527  1.9 527 2.8  527 2.7  527 1.1 
United Kingdom  1,630  19.8  1,627  0.6 1,624  1.8 1,624 3.0  1,636 2.8 
Total (18 MSs)  4,628  18.8  4,619  0.9  4,414  1.9  4,877  2.5  5,338  1.5 
Iceland  – – – – – – – – 3  NA 
Norway  79  13.9 – – – –  79  3.8  79  1.3 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2. 
2.  Epidemiological cut-off values were used for interpretation. 
3.  For at least the following countries, the results are for the combination trimethoprim/sulfamethoxazole: France, Germany, Hungary, Luxembourg, Malta, Spain and Norway. 
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3.3.3. Antimicrobial resistance in Salmonella Typhimurium in humans 
As in previous years, S. Typhimurium was the second most common Salmonella serovar identified in 2012, 
with 18,248 cases reported in the EU/EEA. Sixteen MSs and Norway reported data on antimicrobial 
resistance in S. Typhimurium isolates for ≥20 isolates (ranging from 13 MSs for kanamycin and sulfonamides 
to all 16 MSs and Norway for ciprofloxacin and ampicillin) (Table SA6). 
3.3.3.1. Resistance levels in Salmonella Typhimurium isolates from human cases 
The highest level of resistance in S.  Typhimurium was observed for ampicillin (66.6  %; N=4,183), 
tetracyclines (63.7  %; N=3,272), sulfonamides (62.4  %; N=3,182) and streptomycin (46.2  %; N=3,951) 
(Table SA6). The levels of resistance to these antimicrobials were high to extremely high in the reporting 
MSs. Resistance levels observed in S.  Typhimurium isolates to the two clinically most important 
antimicrobials were 2.2  % (N=4,114) for ciprofloxacin and 0.9  % (N=4,057) for cefotaxime. The highest 
resistance levels to ciprofloxacin were observed in the United Kingdom (4.3 %; N=1,686), the Netherlands 
(4.0 %; N=224) and Denmark (2.6 %; N=117), all three of which used more sensitive interpretive criteria than 
other countries. The highest level of resistance to cefotaxime was observed in France (3.6 %; N=110) (Table 
SA6). 
Other noteworthy observations were the extremely high resistance in S. Typhimurium to gentamicin in 
Slovakia (92.9 %; N=56) and to streptomycin in Germany (82.3 %; N=744) (Table SA6).  
3.3.3.2. Trends in resistance levels in Salmonella Typhimurium isolates from human cases 
Country-specific trends in S. Typhimurium resistance to ciprofloxacin and cefotaxime over the years 2008 to 
2012 are presented in Figures SA5 and SA6, respectively. Only countries reporting data for at least three 
consecutive years and 10 isolates per year were included. 
The five-year trend (2008–2012) in resistance to ciprofloxacin by country showed that the countries using 
more sensitive interpretive criteria throughout the period (Denmark, the Netherlands and the United 
Kingdom) reported consistently higher levels of resistance compared with other countries (Figure SA5). A 
slight increasing trend over the period was observed in Denmark and decreasing trends were observed in 
Luxembourg and the Netherlands. A peak (smaller or larger) in resistance levels could be noted in 2010 in 
Denmark, Estonia, Lithuania, Luxembourg, the Netherlands and the United Kingdom, while in Italy, Malta 
and Slovakia, a peak was observed in 2011. Austria, France, Greece and Slovenia did not report any 
resistant isolates during the period. 
There were few common trends between countries regarding cefotaxime resistance in S. Typhimurium 
during the period 2008 to 2012 (Figure SA6). An exception was a proportionally large increase in resistance 
levels observed in 2012 compared with previous years in Denmark, Hungary, Ireland and the Netherlands, 
and compared with 2011 in Lithuania, Romania and Spain. Please note, however, that the number of 
cefotaxime resistant isolates overall was very low and therefore even minor increases or decreases in the 
number of resistant isolates may influence the proportion of resistant isolates. A peak (smaller or larger) in 
resistance levels could also be noted in 2010 in Germany, Italy, Lithuania, the Netherlands and Spain, while 
in Austria, Slovakia and the United Kingdom, a peak was observed in 2011. Luxembourg did not report any 
resistant isolates during the period. 
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Table SA6.  Antimicrobial resistance in S. Typhimurium from humans per country in 2012, using clinical breakpoints
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria 236  56.8  236  0.4  236  21.2 236  0 236  1.3 236  1.7 
Denmark
2  117 48.7  117  1.7  117 13.7  117 2.6  117 2.6  117 2.6 
Estonia  19 NA  19 NA  10 NA  19 NA  10 NA  10 NA 
France  110  60.9 110  3.6 110  43.6 110  0 110  0 110  0.9 
Germany  744  81.2 744  0.9  –  – 744  0 744  0.9 744  1.9 
Greece  29  37.9 15  NA 14  NA 29  0 15  NA 14  NA 
Hungary 240  72.1  240  2.1  240  26.7 240  0 240  0.8 240  0.8 
Ireland 59  59.3  59  1.7  59  45.8 59  1.7 59  1.7 59  1.7 
Italy  33  69.7 33  0 33  12.1 33  0 33  0 33  0 
Latvia  11 NA  4 NA  -  -  6 NA  3 NA  –  – 
Lithuania  132  59.8  116  0.9 87  16.1  119  0 70  0 66  0 
Luxembourg  27  70.4 27  0 27  25.9 27  0 27  0 27  0 
Malta  7  NA – – – – 7  NA 7  NA – – 
Netherlands
2  224 60.7  224  0.9  224 18.3 224  4.0 224  0.9  –  – 
Romania  54  75.9 54  1.9 54  18.5 54  1.9 54  1.9 54  0 
Slovakia  114  71.1 56  1.8 20  15.0 56  0 56  92.9  -  - 
Slovenia  32  28.1 32  0 32  12.5 32  0 32  0 32  0 
Spain 316  76.9  316  1.3  316  30.1 316  0 316  0.9 316  3.2 
United Kingdom  1,679  63.0  1,655  0.4  1,662  12.3 1,686  4.3 1,666 1.6  1,654 1.6 
Total (19 MSs)  4,183  66.6  4,057  0.9  3,241  18.3  4,114  2.2  4,019  3.0  3,712  1.7 
Iceland  8  NA – – 8  NA 8  NA – – – – 
Norway  76  28.9 – –  76  21.1  76 0 – – – – 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2. 
2.  Epidemiological cut-off values were used for interpretation. 
 
Table continued overleaf. 
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Table SA6 (continued). Antimicrobial resistance in S. Typhimurium from humans per country in 2012, using clinical breakpoints
1 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim
3 
N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria 236  2.5  236  55.9  236 54.2  236 58.5  236  4.7 
Denmark
2  117  1.7 117  52.1 117  53.0 117  31.6 117  7.7 
Estonia  10 NA  9 NA  10 NA  10 NA  19 NA 
France  110  6.4 110  61.8 110 66.4  110 64.5  110  5.5 
Germany  744  9.9  744  82.3 – – – –  744  10.2 
Greece  14 NA  14 NA  –  –  14 NA  12 NA 
Hungary 240  2.9  240  57.1  240 64.2  240 59.6  240 12.1 
Ireland 59  8.5  59  55.9  59 61.0  59 61.0  59 16.9 
Italy  33  3.0 33  69.7 33  72.7 33  72.7 33  12.1 
Latvia  – – – – – – – – 8  NA 
Lithuania  66 12.1  66 48.5  66 48.5  66 43.9  135  5.9 
Luxembourg  27  3.7 27  55.6 27  63.0 27  59.3 27  0 
Malta  – – – – – – – – 7  NA 
Netherlands
2  224  3.6 224  50.0 224  55.8 224  57.1  –  – 
Romania  54  3.7 54  51.9 54  83.3 54  51.9 54  27.8 
Slovakia  3 NA  8 NA  4 NA  80  53.8  –  – 
Slovenia 32  9.4  32  31.3  32 28.1  32 31.3  32  6.3 
Spain  316 15.2  316 57.6  316 74.1  316 76.3  316 12.0 
United Kingdom  1,671  4.5  1,662  22.6 1,654  63.1 1,654 68.5  1,685 14.7 
Total (19 MSs)  3,956  6.4  3,951  46.2  3,182  62.4  3,272  63.7  3,834  12.0 
Iceland  2  NA – – – – – – 8  NA 
Norway  76  7.9 14  NA 14  NA 76  27.6 76  1.3 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2. 
2.  Epidemiological cut-off values were used for interpretation. 
3.  For at least the following countries, the results are for the combination trimethoprim/sulfamethoxazole: France, Germany, Hungary, Luxembourg, Malta, Spain and Norway. 
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3.3.4.  Antimicrobial resistance in monophasic Salmonella Typhimurium 1,4,[5],12:i:- in 
humans 
Since the introduction of a separate serovar code in the reporting in 2010, monophasic S. Typhimurium 
1,4,[5],12:i:- has become the third most common Salmonella serovar in humans. In 2012, 5,932 cases were 
reported by the EU/EEA countries. Eight MSs reported data on antimicrobial resistance in monophasic 
S. Typhimurium 1,4,[5],12:i:-  isolates for ≥20 isolates for all 11 antimicrobials except for kanamycin and 
trimethoprim which seven MSs reported data for (Table SA7). 
3.3.4.1.  Resistance levels in monophasic Salmonella Typhimurium 1,4,[5],12:i:- isolates 
human cases 
Extremely high levels of resistance were observed for tetracyclines (92.7 %; N=1,263), ampicillin (89.5 %; 
N=1,263), sulfonamides (89.1  %; N=1,262) and streptomycin (86.9  %; N=1,263) in monophasic 
S. Typhimurium  1,4,[5],12:i:- (Table SA7). This resistance pattern, ASSuT, is a well-known character for 
monophasic S. Typhimurium 1,4,[5],12:i:- and was observed at similar levels in all nine reporting MSs. 
Resistance levels to the two clinically most important antimicrobials were 0.7 % (N=1,263) for ciprofloxacin 
and 2.1 % (N=1,263) for cefotaxime, which regarding ciprofloxacin was lower than in other S. Typhimurium 
but regarding cefotaxime was higher. The highest resistance levels to ciprofloxacin was observed in Italy 
(3.2  %; N=62) and Denmark (1.9  %; N=107). It should be noted that Denmark used ECOFFs for 
interpretation which are more sensitive than the clinical breakpoints for ciprofloxacin. The highest levels of 
resistance to cefotaxime were observed in France (5.2 %; N=115), Spain (2.8 %; N=571) and Austria (2.1 %; 
N=95) (Table SA7). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA7.  Antimicrobial resistance in monophasic S. Typhimurium 1,4,[5],12:i:- from humans per country in 2012, using clinical breakpoints
1 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
N %  Res N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria  95  93.7 95  2.1 95  5.3 95  0 95  3.2 95  2.1 
Denmark
2  107  83.2 107  0 107  0 107  1.9 107  0.9 107  0 
Estonia  12 NA  12 NA  12 NA  12 NA  12 NA  12 NA 
France  115  90.4 115  5.2 115  2.6 115  0 115  0 115  0 
Ireland  45  86.7 45  0 45  0 45  0 45  0 45  0 
Italy  62  91.9 62  0 62  6.5 62  3.2 62  3.2 60  0 
Luxembourg  30  96.7 30  0 30  6.7 30  0 30  3.3 30  3.3 
Netherlands
2  226  85.4 226  0.9 226  2.7 226  0.9 226  2.2  -  - 
Spain  571  90.9 571  2.8 571  5.3 571  0.5 571  3.7 571  3.2 
Total (9 MSs)  1,263  89.5  1,263  2.1  1,263  4.0  1,263  0.7  1,263  3.2  1,035  2.0 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines  Trimethoprim 
N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria  95  0 95  92.6 95  93.7 95  91.6 95  6.3 
Denmark
2  107  0 107  87.9 107  89.7 107  96.3 107  0 
Estonia  12 NA  12 NA  12 NA  12 NA  12 NA 
France  115  2.6 115  89.6 115 92.2  115 93.0  115  6.1 
Ireland  45  2.2 45  97.8 45  97.8 45  97.8 45  0 
Italy  62  3.2 62  90.3 62  90.3 62  90.3 62  3.2 
Luxembourg 30  3.3  30  90.0  30 93.3  30 80.0  30 10.0 
Netherlands
2  226  0.4 226  88.1 226  85.4 226  94.2  -  - 
Spain  571  1.8 571  83.0 570 87.7  571 91.9  571  6.8 
Total (9 MSs)  1,263  1.4  1,263  86.9  1,262  89.1  1,263  92.7  1,037  5.5 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated; MS: Member States. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM2. 
2.  Epidemiological cut-off values were used for interpretation. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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3.4. Antimicrobial resistance in Salmonella isolates from animals and food 
Nineteen MSs and two non-MSs (Norway and Switzerland) reported quantitative MIC data and one MS 
reported IZD data on antimicrobial resistance in Salmonella isolates recovered from animals and food in 
2012. The MSs reporting either MIC or IZD data, for each animal or food category, are listed in Tables SA1, 
SA8 and SA9. As quantitative IZD data constitute a relatively small percentage of the total data available, 
these data have, therefore, been analysed as qualitative data only. The susceptibility test results for 
Salmonella isolates reported as qualitative data are presented in Appendix 2. 
In this report, antimicrobial resistance data for all reported Salmonella isolates were collated to generate a 
figure for Salmonella spp. (covering all reported serovars) for each country, year and animal/food category. 
In addition, the Salmonella serovars which are most prevalent and significant for public health, S. Enteritidis, 
S. Typhimurium and monophasic S.  Typhimurium, were reported separately where sufficient quantitative 
data were available from the various animal/food categories. Frequency distributions of serovars per animal 
and meat categories are presented in Appendix 1. 
Table SA8.  Overview of countries reporting quantitative antimicrobial resistance data using MIC and 
disc inhibition zones on S. Typhimurium from various animal and food categories in 2012 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Gallus gallus (fowl)  1  MS: GR 
Meat from pig  1  MS: GR 
Dilution 
Gallus gallus (fowl)  12 
MSs: AT, BE, DE, DK, ES, FI, HU, IT, PL, RO, SE, UK 
Non-MS: CH 
Turkeys  7  MSs: AT, BE, DE, ES, FI, IT, UK 
Pigs  14 
MSs: BE, CZ, DE, DK, EE, ES, FI, HU, IE, LV, NL, RO, 
SE, SK 
Non-MS: CH 
Cattle (bovine animals)  11 
MSs: BE, CZ, DE, DK, EE, ES, FI, IE, IT, NL, SE 
Non-MS: CH 
Meat from broilers  
(Gallus gallus)  3  MSs: IE, IT, LV 
Meat from turkeys  4  MSs: DE, HU, IT, PT 
Meat from pigs  12  MSs: BE, CZ, DE, DK, EE, HU, IE, IT, LV, NL, PL, RO 
Meat from bovine animals  7  MSs: CZ, DE, EE, FI, IE, IT, NL 
Note: For abbreviations of Member States (MS) and other reporting countries, see Appendix 7; MIC: minimum inhibitory concentration. 
Table SA9.  Overview of countries reporting quantitative antimicrobial resistance data using MIC and 
disc inhibition zones on S. Enteritidis from various animal and food categories in 2012 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion  Gallus gallus (fowl)  1  MS: GR 
Dilution 
Gallus gallus (fowl)  15 
MSs: AT, BE, CZ, DE, DK, ES, HU, IT, LV, NL, PL, PT, 
RO, SK, UK 
Non-MS: CH 
Turkeys  5  MSs: AT, CZ, DE, HU, SK 
Pigs  5  MSs: BE, DE, DK, EE, HU 
Cattle (bovine animals)  4 
MSs: BE, CZ, DK, EE 
Non-MS: CH 
Meat from broilers  
(Gallus gallus)  7  MSs: BE, CZ, DE, LV, NL, PL, SK 
Meat from pigs  2  MSs: CZ, RO 
Meat from turkeys  3  MSs: CZ, DE, HU 
Note: For abbreviations of Member States (MS) and other reporting countries, see Appendix 7; MIC: minimum inhibitory concentration. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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In this chapter, resistance to ampicillin, cefotaxime, ciprofloxacin, chloramphenicol, gentamicin, nalidixic acid, 
sulfonamides and tetracyclines has been analysed in detail in line with the antimicrobials listed in the EFSA 
monitoring and reporting specifications for antimicrobial resistance in Salmonella  (EFSA, 2007). The 
occurrence of resistance to these substances was tabulated, temporal trends and spatial distribution of 
resistance was drawn and the multi-resistance and a specific co-resistance pattern was analysed. The 
results of these analyses are displayed in this report according to the following inclusion criteria: whenever a 
country subjected more than 10 isolates to susceptibility testing for a given animal or food category then 
these data were not included in any further analyses. In addition, tables were generated and analysis was 
performed only if four or more countries tested and reported quantitative data for a given Salmonella 
category and sampling origin. 
•  Temporal trend graphs of resistance were generated showing resistance to ampicillin, cefotaxime, 
ciprofloxacin and nalidixic acid for Salmonella isolates from animals and food over the 2006–2012 
period. Only countries which had reported data for four or more years during 2006–2012 were 
included. Data from 2004 and 2005 were excluded from the temporal trends graphs because of the 
relative scarcity of data compared with the 2006–2012 period. Statistical analysis of the trend within 
individual countries was performed using logistic regression when data were available for five or more 
years.  
•  The spatial distributions of ampicillin and nalidixic acid resistance rates in Salmonella spp. from Gallus 
gallus, turkeys, pigs and cattle were presented. For countries where resistance level figures for 2012 
were not available, 2011 figures were used instead.  
•   Multi-resistance was analysed in isolate-based data on Salmonella isolates tested for the full 
harmonised set of antimicrobials (nine substances) belonging to different classes. Multi-resistance was 
defined as the non-susceptibility to at least three different antimicrobial classes. The proportions of 
isolates susceptible to all antimicrobials and resistant (non-susceptible) from one to nine antimicrobials 
are presented. Co-resistance to cefotaxime (Ctx) and ciprofloxacin (Cip) was estimated as these two 
antimicrobials are of particular interest in human medicine in the case of treatment of severe 
salmonellosis. Co-resistance was addressed using both ECOFFs (Ctx>0.5 mg/L and Cip>0.06 mg/L) 
and clinical breakpoints (Ctx>2 mg/L and Cip>1 mg/L). Complete susceptibility and multi-resistance 
were analysed for isolate-based resistance data reported by the MSs and the results are shown at 
Appendix 4. 
The antimicrobials selected by the different MSs and non-MSs for susceptibility testing of Salmonella are 
shown in Chapter 8 Materials and methods, Table MM6. For further information on reported MIC distributions 
and number of resistant isolates for apramycin, ceftazidime, ceftiofur, colistin, florfenicol, kanamycin, 
neomycin, spectinomycin, streptomycin and trimethoprim, refer to the Level 3 tables published on the EFSA 
website. 
3.4.1. Antimicrobial resistance in Salmonella isolates from food 
This section describes the MIC data for isolates of Salmonella  spp. and S. Enteritidis from meat from 
broilers,  Salmonella  spp.,  S. Typhimurium and monophasic S. Typhimurium from meat from pigs and 
Salmonella spp. from meat from bovine animals.  
3.4.1.1. Meat from broilers and spent hens (Gallus gallus) 
Quantitative MIC susceptibility data for isolates of Salmonella spp. from broiler meat from 12 MSs in 2012 
are included in the following analysis. Data for S. Typhimurium isolates are not presented separately for 
meat from broilers as no MS tested more than 10 isolates. 
Representative sampling and monitoring 
In reporting MSs, data on antimicrobial resistance in Salmonella isolates from meat from Gallus gallus 
derived from active monitoring carried out within the framework of either official sampling or Hazard Analysis 
and Critical Point Control (HACCP) and own-check programmes. Samples of meat from broilers and spent 
hens were collected randomly at either the slaughterhouse, the cutting/processing plant, or at retail outlets. 
In Belgium, the Czech Republic, Ireland and Romania, representative random sampling of meat from EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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broilers, whether carcase swabs or samples of neck skin, fresh meat, minced meat, meat products or meat 
preparations, was carried out entirely or primarily at the slaughterhouse or at the processing plant. In 
Portugal and Romania, sampling of fresh meat and meat preparations from broilers was also performed at 
retail. Moreover, Belgium was the only reporting MS to monitor resistance in Salmonella isolates derived 
from swabbing of both carcases of spent hens and chilled broilers at the slaughterhouse. Germany, Hungary, 
the Netherlands, Poland and Spain did not provide any details on the sampling scheme used. 
Resistance levels in Salmonella spp. isolates from meat from broilers and spent hens 
Table SA10 describes the occurrence of resistance to selected antimicrobials in Salmonella spp. isolated 
mostly from broiler meat in MSs in 2012. 
In 2012, resistance to ampicillin, sulfonamides and tetracyclines was generally high to extremely high in the 
reporting MSs, although levels of resistance were highly variable across countries, ranging from 0  % to 
48.6 % for ampicillin and from 0 % to 87.3 % for both sulfonamides and tetracyclines. Resistance levels to 
chloramphenicol and gentamicin were typically lower, a number of MSs observing no resistance to one or 
both of these antimicrobials. Variation in the resistance recorded was important, between 0 % and 18.1 % for 
chloramphenicol and from 0 % to 45.5 % for gentamicin.  
As in previous years, the occurrence of resistance to ciprofloxacin and nalidixic acid was typically similar 
within MSs, while, between countries, resistance levels ranged from 0  % to 100  %. The overall level of 
resistance to cefotaxime across the reporting MSs remained low in 2012 at 4.3 %, as generally resistance 
was either not detected or observed at low levels. The Netherlands reported a high level of resistance to 
cefotaxime of 31.1 %, which was similar to that (31.9 %) reported in 2011. 
Considering the figures at reporting MS group level for Salmonella spp. isolated from broiler meat, there 
were increases in the levels of resistance to sulfonamides and tetracyclines which stood at 44.8 % and 
43.7 % in 2011 and were 53.0 % and 48.9 % in 2012. However, there are a number of factors which can 
influence changes in the occurrence of resistance in Salmonella spp. in different years: (1) differences in the 
contributing MSs and their relative contribution to the total, since levels of resistance vary greatly between 
MSs, (2) differences in the relative contribution of different serovars (which can vary greatly in the 
resistances shown), (3) changes in the level of resistance. 
Salmonella spp. comprise the amalgamated results for all Salmonella serovars reported by a reporting MS 
for a different animal or food category. The relative contribution of different serovars possessing a particular 
resistance should ideally be considered when interpreting the results, in order to evaluate the influence of 
clonal dissemination of serovars. The chapter has also presented data at the individual serovar level for a 
number of Salmonella serovars. 
Resistance levels in Salmonella Enteritidis isolates from meat from broilers and spent hens 
Resistance among S. Enteritidis isolates from broiler meat in reporting MSs was generally lower than that 
reported in Salmonella spp. As low numbers of isolates of S. Enteritidis (fewer than 10) were recovered from 
meat from broilers in the Czech Republic, Germany, the Netherlands and Slovakia, these countries have 
been excluded from the detailed analysis, leaving only Belgium, Latvia and Poland contributing to the 
analysis; thus, there are insufficient data to present a specific table. 
Data from Belgium showed marked differences in the occurrence of ciprofloxacin resistance in Salmonella 
spp. from meat from broilers and spent hens. While no resistance was detected in isolates from spent hens 
there was 39.5 % ciprofloxacin resistance in isolates from broilers.  
One isolate (4.3 %) was resistant to ampicillin, sulfonamides and tetracyclines in Latvia, while four isolates 
(15.4 %) were resistant to ampicillin and sulfonamides and one isolate (3.8 %) was resistant to tetracyclines 
in Poland. 
In both Latvia and Poland, no resistance was detected to cefotaxime, chloramphenicol and gentamicin, while 
resistance to ciprofloxacin and nalidixic acid was recorded in both countries. In Latvia, 16 isolates (69.6 %) 
were resistant to both antimicrobials, while 14 isolates and 13 isolates (53.8 % and 50.0 %) were resistant to 
ciprofloxacin and nalidixic acid, respectively.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA10.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. from meat from broilers and spent hens in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium
1  43  34.9  43  0  43  0  43  39.5  43  0  43  39.5  43  11.6  43  0 
Belgium
2  66  0  66  0  66  0  66  0  66  0  66  0  66  0  66  0 
Czech Republic  47  4.3  47  0  47  0  47  34.0  47  0  47  34.0  47  34.0  –  – 
Germany  94  39.4  94  12.8  94  18.1  94  70.2  94  3.2  94  58.5  94  58.5  94  48.9 
Hungary  164  4.3  168  0.6  168  1.8  168  97.6  168  1.2  168  95.8  168  79.8  168  76.8 
Ireland  70  22.9  70  2.9  70  7.1  70  11.4  70  4.3  70  11.4  70  21.4  70  7.1 
Latvia  32  9.4  32  0  32  3.1  32  53.1  32  0  32  53.1  32  9.4  32  6.3 
Netherlands  74  48.6  74  31.1  74  9.5  74  51.4  72  1.4  74  47.3  74  52.7  74  36.5 
Poland  93  23.7  93  0  93  2.2  93  67.7  93  1.1  93  52.7  93  35.5  93  31.2 
Portugal  37  24.3  37  0  37  5.4  37  13.5  37  13.5  37  13.5  37  43.2  37  56.8 
Romania  189  18.0  189  1.1  189  10.1  189  89.4  189  5.3  189  89.9  189  87.3  189  87.3 
Slovakia  14  0  14  0  14  0  14  71.4  14  0  14  71.4  14  71.4  14  71.4 
Spain  33  27.3  –  –  15  0  33  100  33  45.5  33  21.2  –  –  15  26.7 
Total (12 MSs)  956  19.9  927  4.3  942  5.9  960  63.1  958  4.2  960  57.3  927  53.0  895  48.9 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested, % Res: percentage of resistant isolates; –: no data reported. 
1. Broilers   
2. Spent  hens 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Multi-resistance among Salmonella isolates from meat from broilers 
In 2012, four MSs provided isolate-based data concerning resistance in Salmonella spp. in meat from 
broilers. Important variability was observed in both rates of complete susceptibility and multi-resistance of the 
isolates tested in the reporting MSs (Table SA11). The frequency distributions (Figure SA7) showed that 
reduced susceptibility to six or up to eight different substances might be observed in some tested isolates, 
while the Czech Republic recorded multi-resistance to three classes at a maximum. Very few isolates were 
resistant to both ciprofloxacin and cefotaxime (Table SA11). 
Table SA11.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
meat from broilers in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Czech Republic (N=47)  30  63.8  16  34.0  0.289  0 (0)  0 (0) 
Germany (N=94)  23  24.5  61  64.9  0.582  9 (1)  9.6 (1.1) 
Ireland (N=70)  51  72.9  16  22.9  0.395  2 (0)  2.9 (0) 
Romania (N=188)  13  6.9  163  86.7  0.542  2 (0)  1.1 (0) 
MS:Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility (EUCAST) clinical breakpoints 
(Ctx:>2 mg/L and Cip:>1 mg/L). 
Figure SA7.  Frequency distribution of Salmonella spp. in meat from broilers completely susceptible 
or resistant to one or up to nine antimicrobials, in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
0 % 10 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 %
Romania (N=188)
Ireland (N=70)
Germany (N=94)
Czech Republic (N=47)
sus
res1
res2
res3
res4
res5
res6
res7
res8
res9EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  48
3.4.1.2. Meat from pigs 
Twelve MSs reported quantitative MIC data for Salmonella spp. from pig meat in 2012. Data for S. Enteritidis 
isolates are not presented separately for meat from pigs as none of the MSs reporting data tested more than 
10 isolates. Tables SA12 and SA13 present the level of resistance to selected antimicrobials for 
Salmonella spp. and S. Typhimurium. 
Representative sampling and monitoring 
Pig meat sample types collected at the slaughterhouse by Belgium, Estonia, Ireland and Poland consisted 
mainly of carcase swabs, while different kinds of meat samples (fresh meat, minced meat and meat 
preparations) were collected by the Czech Republic, Denmark, Estonia, Ireland, Italy and Romania either at 
meat cutting/processing plants, at retail outlets or at catering outlets. Whether based on official sampling or 
HACCP and own-check programmes, objective sampling was primarily carried out in MSs reporting 
information on sampling design. Conversely, Germany, Hungary, Poland and Spain did not report detailed 
information on the sampling design of meat from pigs used.  
Resistance levels in Salmonella spp. isolates from meat from pigs 
Salmonella spp. isolated from pig meat mostly displayed high to extremely high occurrence of resistance to 
ampicillin, tetracyclines and sulfonamides, although resistance varied from not detected (in Latvia on 13 
isolates) to very/extremely high levels across the reporting MSs, varying from 0  % to nearly 70  % for 
ampicillin and sulfonamides and to more than 90 % for tetracyclines. Chloramphenicol resistance remained 
moderate, at 12.6 %, at MS group level, and ranged from 0 % to 44.4 % among the reporting MSs. Overall, 
gentamicin resistance was 2.4 % in the reporting group of MSs; it was not detected in seven MSs and 
ranged between 0.4 % and 31.3 % in the remaining five reporting MSs. The proportion of Salmonella spp. 
isolates resistant to ciprofloxacin and nalidixic acid was generally low to moderate among the reporting MSs. 
Once more in 2012, Denmark and Estonia did not detect resistance to either ciprofloxacin or nalidixic acid, 
and neither did Latvia on the limited number of 13 isolates tested. Resistance to cefotaxime in reporting MSs 
was either not detected (in eight MSs) or reported at low levels, ranging from 0.6 % to 3.0 %, between the 
four MSs reporting resistance. 
Resistance levels in Salmonella Typhimurium isolates from meat from pigs 
Ten MSs reported quantitative MIC data for S. Typhimurium isolates from pig meat in 2012. Although the 
features of the resistance in S. Typhimurium parallel those observed in Salmonella spp., resistance levels to 
most of the antimicrobials in S.  Typhimurium isolates were typically higher than the levels reported in 
Salmonella spp. isolates in the vast majority of reporting MSs. Contrastingly, in Denmark, S. Typhimurium 
isolates presented lower levels of resistance to ampicillin, sulfonamides and tetracyclines than the overall 
group of Salmonella spp. isolates. The 13 S. Typhimurium isolates tested in Latvia did not exhibit resistance 
to any of the antimicrobials tested. 
Resistance levels in monophasic Salmonella Typhimurium isolates from meat from pigs 
As low numbers of isolates of monophasic S. Typhimurium (fewer than 10) were recovered from meat from 
pigs in the Czech Republic, Greece, Hungary, Italy, the Netherlands and Slovakia, these countries have 
been excluded from the detailed analysis, leaving only Denmark, Germany and Ireland contributing to the 
analysis; thus, there are insufficient data to present a specific table. 
Denmark detected no resistance to cefotaxime, gentamicin, ciprofloxacin and nalidixic acid. In both Germany 
and Ireland, no resistance was detected to cefotaxime. Resistance was detected against ampicillin, 
sulfonamides and tetracyclines at extremely high levels ranging from 73.9 % to 100 %. One isolate (2.7 %) 
was resistant to both ciprofloxacin and nalidixic acid in Germany, whilst Ireland reported no resistance for 
these antimicrobials. One isolate (4.5 %) was resistant to chloramphenicol in Denmark, nine (24.3 %) in 
Germany and two (8.7 %) in Ireland. Denmark detected no resistance to gentamicin whilst one isolate and 
two isolates (2.7  % and 8.7  %, respectively) were resistant to gentamicin in Germany and Ireland, 
respectively. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA12.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from meat from pigs in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  262  60.7  262  1.5  262  11.5  262  1.1  262  0.4  262  1.1  262  60.3  262  45.4 
Czech Republic  33  42.4  33  3.0  33  12.1  33  6.1  33  0  33  6.1  33  51.5  –  – 
Denmark
1  41  56.1  41  0  41  2.4  41  0  41  0  41  0  41  61.0  41  51.2 
Estonia  22  4.5  22  0  22  4.5  22  0  22  0  22  0  22  13.6  22  9.1 
Germany  163  49.1  163  0.6  163  14.1  163  6.1  163  0.6  163  5.5  163  50.3  163  49.1 
Hungary  16  68.8  16  0  16  31.3  16  12.5  16  0  16  12.5  16  56.3  16  93.8 
Ireland  69  53.6  69  0  69  17.4  69  1.4  69  4.3  69  1.4  69  69.6  69  66.7 
Italy  85  41.2  85  0  85  10.6  85  1.2  85  2.4  85  1.2  85  50.6  85  58.8 
Latvia  13  0  13  0  13  0  13  0  13  0  13  0  13  0  13  0 
Netherlands  52  28.8  52  0  52  1.9  52  3.8  51  0  52  3.8  52  42.3  52  34.6 
Poland  31  22.6  22  0  31  9.7  31  16.1  31  0  11  9.1  31  16.1  31  32.3 
Romania  125  37.6  125  1.6  125  16.0  125  10.4  125  4.8  125  11.2  125  60.8  125  54.4 
Spain  34  58.8  –  –  18  44.4  34  97.1  32  31.3  34  11.8  –  –  18  66.7 
Total (13 MSs)  946  47.5  903  0.9  930  12.6  946  7.6  943  2.4  926  4.2  912  53.5  897  49.2 
MS: Member State; MIC: minimum inhibitory concentration; N: total number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
1.  Denmark reported only monophasic S. Typhimurium and S. Typhimurium isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA13.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Typhimurium isolates from meat from pigs in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Belgium  105  73.3  105  1.0  105  13.3  105  1.0  105  0  105  1.0  105  69.5  105  52.4 
Denmark  18  27.8  18  0  18  0  18  0  18  0  18  0  18  38.9  18  11.1 
Germany  58  51.7  58  0  58  19.0  58  8.6  58  0  58  8.6  58  56.9  58  56.9 
Hungary  10  80.0  10  0  10  40.0  10  10.0  10  0  10  10.0  10  60.0  10  100 
Ireland  22  63.6  22  0  22  36.4  22  4.5  22  0  22  4.5  22  72.7  22  63.6 
Italy  18  100  18  0  18  27.8  18  0  18  0  18  0  18  100  18  100 
Latvia  13  0  13  0  13  0  13  0  13  0  13  0  13  0  13  0 
Netherlands  16  50.0  16  0  16  6.3  16  6.3  16  0  16  6.3  16  50.0  16  50.0 
Poland  11  45.5  11  0  11  18.2  11  9.1  11  0  11  9.1  11  45.5  11  63.6 
Romania  43  62.8  43  2.3  43  34.9  43  18.6  43  2.3  43  14.0  42  66.7  42  71.4 
Total (10 MSs)  314  61.1  314  0.6  314  19.1  314  5.7  314  0.3  314  5.1  313  62.0  313  56.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Multi-resistance among Salmonella spp. isolates from meat from pigs 
In 2012, seven MSs provided isolate-based data concerning resistance in Salmonella spp. in meat from pigs. 
In most cases, complete susceptibility in the isolates tested ranged between 20 % and 40 % and multi-
resistance was typically high to very high. Contrastingly, complete susceptibility reached above 85 % and 
multiresistance was lower than 15 % in Estonia, although these figures were assessed on an isolate sample 
of small size (Table SA14). The frequency distributions (Figure SA8) showed similarities among the multi-
resistance recorded in three reporting MSs, with some isolates showing reduced susceptibility to up to six or 
seven different substances, while Estonia recorded multi-resistance to four classes at a maximum. Very few 
isolates were resistant to both ciprofloxacin and cefotaxime in a single MS (Table SA14). 
Table SA14.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
meat from pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Czech Republic (N=33)  12  36.4  14  42.4  0.464  0 (0)  0 (0) 
Denmark
1 (N=41)  12  29.3  24  58.5  0.315  0 (0)  0 (0) 
Estonia (N=22)  19  86.4  3  13.6  0.189  0 (0)  0 (0) 
Germany (N=163)  62  38.0  79  48.5  0.46  0 (0)  0 (0) 
Ireland (N=69)  15  21.7  41  59.4  0.545  0 (0)  0 (0) 
Italy (N=85)  32  37.6  43  50.6  0.5  0 (0)  0 (0) 
Romania (N=125)  30  24.0  70  56.0  0.427  1 (0)  0.8 (0) 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility (EUCAST) clinical breakpoints 
(Ctx:>2 mg/L and Cip:>1 mg/L). 
1. Denmark reported only monophasic S. Typhimurium and S. Typhimurium isolates. 
Figure SA8.  Frequency distribution of Salmonella spp. in meat from pigs completely susceptible or 
resistant to one or up to nine antimicrobials, in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
Note: Denmark reported only monophasic S. Typhimurium and S. Typhimurium isolates. 
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3.4.1.3. Meat from bovine animals 
Five MSs reported quantitative MIC data for Salmonella spp. from bovine meat in 2012. Table SA15 presents 
the level of resistance to selected antimicrobials for Salmonella spp. isolates. 
Representative sampling and monitoring 
Monitoring and surveillance programmes for Salmonella spp. in meat from bovine animals are in place in 
Germany, Ireland, Italy, the Netherlands and Spain, while surveillance of HACCP and own checks 
submissions takes place in Ireland. Sample types collected by MSs at slaughterhouses consisted of carcase 
swabs. Germany, Ireland, the Netherlands and Spain tested meat, without details about sampling stage. Italy 
tested meat preparations at retail outlets.  
Resistance levels in Salmonella spp. isolates from meat from bovine animals 
Among the five reporting MSs, Salmonella spp. isolated from meat from bovine animals generally displayed 
high levels of resistance to ampicillin, sulfonamides and tetracyclines, varying from 20.8 % to 78.6 % for 
ampicillin, 25.0  % to 55.6  % for sulfonamides and 10.0  % to 61.5  % for tetracyclines. Chloramphenicol 
resistance was low, at 9.9 %, at MS group level, and ranged from 0 % to 25.0 % across the reporting MSs, 
with the Netherlands and Spain detecting no resistance. Gentamicin resistance was only detected in Spain 
(57.1 %). Resistance to either ciprofloxacin or nalidixic acid was generally similar among the reporting MSs, 
ranging from no resistance detected to low/moderate levels, with the notable exception of Spain reporting 
high resistance to nalidixic acid (28.6  %) and extremely high resistance to ciprofloxacin (100  %). The 
occurrence of resistance to cefotaxime was generally not detected in reporting MSs, as only the Netherlands 
reported 5.6 % resistance. 
Multi-resistance among Salmonella spp. isolates from meat from bovine animals 
As only three MSs reported resistance for isolate-based data on 10 or more isolates of Salmonella spp. from 
meat from bovine animals, the corresponding multi-resistance analysis is not presented in this report. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Table SA15.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from meat from bovine animals in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Germany  16  50.0  16  0  16  25.0  16  0  16  0  16  0  16  50.0  16  43.8 
Ireland  24  20.8  24  0  24  12.5  24  0  24  0  24  0  24  25.0  24  33.3 
Italy  13  30.8  13  0  13  7.7  13  7.7  13  0  13  7.7  13  38.5  13  61.5 
Netherlands  18  33.3  18  5.6  18  0  18  11.1  18  0  18  11.1  18  55.6  18  44.4 
Spain  14  78.6  –  –  10  0  14  100  14  57.1  14  28.6  –  –  10  10.0 
Total (5 MSs)  85  40.0  71  1.4  81  9.9  85  20.0  85  9.4  85  8.2  71  40.8  81  39.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
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3.4.2. Antimicrobial resistance in Salmonella isolates from animals 
3.4.2.1. Domestic fowl (Gallus gallus) 
In 2012, 16 MSs submitted quantitative antimicrobial susceptibility data for Salmonella spp. from Gallus 
gallus. As in previous years, an overview of all data relating to Gallus gallus including breeding and laying 
hens and broiler flocks, as well as unspecified flocks of Gallus gallus, is presented. However, as in 2011, 
data from flocks of broilers, laying hens and breeders are also presented separately.  
Representative sampling and monitoring 
In the vast majority of MSs, isolates for antimicrobial resistance testing are obtained from national 
surveillance and control programmes carried out according to the EU legislation. In Latvia, isolates were 
obtained from faecal samples from broilers before slaughter and from laying hens on the farm. 
Resistance levels in Salmonella spp. isolates from Gallus gallus 
Table SA16 shows the level of resistance to antimicrobials among isolates of Salmonella spp. from 
Gallus gallus in 2012. There was generally high resistance reported to ampicillin, sulfonamides and 
tetracyclines in the reporting MS group, although the levels of resistance varied between 0 % and 44.4 % for 
ampicillin, between 0 % and 57.5 % for sulfonamides and between 6.3 % and 55.9 % for tetracyclines across 
the 16 reporting countries. Resistance to chloramphenicol and gentamicin was mostly either not detected or 
reported at low levels among the reporting MSs. The levels of resistance to ciprofloxacin and nalidixic acid 
were mostly moderate to very high within individual MSs, although four MSs did not detect resistance or 
reported low resistance to these compounds. This considerable disparity in resistance to ciprofloxacin and 
nalidixic acid among Salmonella isolates, from different MSs, may reflect the variability of serovars of 
Salmonella spp. included in the analyses of the different MSs. Cefotaxime resistance was reported by 11 of 
the 16 reporting MSs at low levels, with the exception of Belgium which reported for the first time in 2012 
susceptibility results at a level of 18.1 %.  
Resistance levels in Salmonella spp. isolates from broilers 
Thirteen MSs reported quantitative data on resistance among isolates of Salmonella spp. from broiler flocks 
in 2012 (Table SA17). Resistance to ampicillin and tetracyclines varied from low to high levels among the 
reporting MSs, while resistance to sulfonamides was moderate to high in all reporting MSs. For 
chloramphenicol and gentamicin, absence or low levels of resistance were mostly reported, as only Romania 
reported moderate resistance to these substances. Resistance to ciprofloxacin and nalidixic acid was 
generally high in the reporting MSs, although Denmark, Ireland and the United Kingdom reported either no 
resistance or low levels of resistance to both compounds. Cefotaxime resistance was either not detected or 
observed at very low and low levels, with the exception of Italy which reported a moderate resistance at 
13.3 %. In general, the levels of resistance in broiler flocks were slightly higher than those reported when all 
Gallus gallus were considered, as this category includes data from broilers, laying hens and breeders. 
Resistance levels in Salmonella spp. isolates from laying hens 
Twelve MSs reported quantitative data on resistance among isolates of Salmonella spp. from laying hens in 
2012 (Table SA18). Resistance to ampicillin, sulfonamides and tetracyclines was generally reported at low to 
moderate levels across the reporting MSs, with the exception of Romania reporting high resistance to these 
substances. Resistance to chloramphenicol and gentamicin was either not detected or recorded at low 
levels, ranging from 0 % to 3.7 % and from 0 % to 6.2 %, respectively. Portugal reported resistance only to 
ciprofloxacin (9.4 %) and nalidixic acid (12.5 %). Resistance to ciprofloxacin and nalidixic acid was generally 
reported at moderate to high levels, while Germany, the Netherlands and the United Kingdom recorded low 
resistance to these substances. Latvia observed no resistance to both compounds. Cefotaxime resistance 
was observed only by Austria and Italy at low levels of 1.6 % and 1.2 %. Generally, resistance in laying hens 
was similar to or lower than that reported in broilers. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Resistance levels in Salmonella spp. isolates from breeding flocks 
Quantitative data on isolates of Salmonella spp. from breeding flocks of Gallus gallus were reported by four 
MSs in 2012 (Table SA19). The breeder categories reported were: unspecified breeding flocks, unspecified 
grandparent breeding flocks, parent breeding flocks for the broiler production line and elite breeding flocks 
for egg production line. The levels of resistance among isolates from breeding flocks of Gallus gallus were 
generally higher than those observed in laying hens. The occurrence of resistance to ampicillin, 
sulfonamides and tetracyclines was high across the reporting MSs (22.7  %, 20.9  % and 32.5  %, 
respectively). High levels of resistance to ciprofloxacin and nalidixic acid were observed at the MS group 
level (25.5 % and 22.7 % respectively), but these levels were at almost half of the level reported for broilers. 
For these antimicrobials, reported resistance levels ranged from 7.4 % to 53.1 %. The Czech Republic and 
Poland reported no resistance to cefotaxime, chloramphenicol and gentamicin. The overall occurrence of 
gentamicin resistance, considering all reporting MSs, was 5.5 %. Cefotaxime resistance was reported by two 
MSs with an overall resistance at MS group level of 1.8 %. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA16.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  176  4.0  176  0.6  176  1.1  176  18.2  176  0.6  176  16.5  176  17.0  176  22.7 
Belgium  664  44.4  664  18.1  664  7.1  664  39.0  664  3.5  664  37.0  664  37.0  664  24.4 
Czech Republic  386  4.7  386  0.3  386  0  386  19.4  386  1.3  386  19.2  386  18.1  –  – 
Denmark  28  32.1  28  0  28  0  28  0  28  0  28  0  28  28.6  28  32.1 
Germany  238  6.7  238  0.8  238  2.1  238  14.3  238  0  238  22.7  238  15.5  238  13.0 
Hungary  261  9.2  261  0.4  261  1.1  261  69.0  261  1.9  261  67.4  261  57.5  261  55.9 
Ireland  38  10.5  38  0  38  0  38  2.6  38  0  38  2.6  38  10.5  38  7.9 
Italy  328  21.3  328  5.2  328  4.0  328  23.8  328  2.4  328  23.5  328  18.0  328  25.3 
Latvia  14  7.1  14  0  14  0  14  0  14  0  14  0  14  0  14  7.1 
Netherlands  192  22.9  192  4.2  192  3.1  192  18.2  192  5.2  192  16.1  192  15.1  192  9.4 
Poland  739  7.8  739  0.7  739  2.2  738  39.2  739  0  739  35.0  734  12.1  739  8.4 
Portugal  79  6.3  174  2.3  174  2.9  174  23.6  174  0  174  21.8  174  10.9  174  6.3 
Romania  964  41.2  964  5.3  964  10.9  964  68.4  964  15.7  964  58.6  964  52.9  964  47.4 
Slovakia  85  0  85  0  85  0  85  30.6  85  0  85  30.6  85  25.9  85  25.9 
Spain  179  9.5  179  0.6  179  1.1  179  22.3  179  3.4  179  19.0  179  8.4  179  12.3 
United Kingdom  236  4.7  236  0  236  2.1  236  2.1  236  4.2  236  2.1  236  17.4  236  21.6 
Total (16 MSs)  4,607  21.2  4,702  4.5  4,702  4.4  4,701  37.3  4,702  4.7  4,702  34.3  4,697  28.3  4,316  25.9 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA17.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from broilers in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  113  3.5  113  0  113  0  113  22.1  113  0  113  22.1  113  18.6  113  23.9 
Czech Republic  351  4.0  351  0.3  351  0  351  20.8  351  1.4  351  20.5  351  19.4  –  – 
Denmark  24  29.2  24  0  24  0  24  0  24  0  24  0  24  29.2  24  29.2 
Hungary  175  6.9  175  0.6  175  1.1  175  90.3  175  1.1  175  90.3  175  77.7  175  73.7 
Ireland  38  10.5  38  0  38  0  38  2.6  38  0  38  2.6  38  10.5  38  7.9 
Italy  105  37.1  105  13.3  105  4.8  105  32.4  105  6.7  105  30.5  105  31.4  105  38.1 
Netherlands  130  27.7  130  6.2  130  3.1  130  24.6  130  7.7  130  21.5  130  16.9  130  6.2 
Poland  189  6.3  189  0.5  189  0.5  189  40.7  189  0  189  36.5  189  14.8  189  10.1 
Portugal  27  18.5  122  3.3  122  4.1  122  27.9  122  0  122  26.2  122  15.6  122  9.0 
Romania  784  43.9  784  6.4  784  12.2  784  73.0  784  17.5  784  62.0  784  57.4  784  48.7 
Slovakia  55  0  55  0  55  0  55  41.8  55  0  55  41.8  55  34.5  55  34.5 
Spain  29  34.5  29  3.4  29  3.4  29  65.5  29  13.8  29  62.1  29  20.7  29  31.0 
United Kingdom  170  5.3  170  0  170  2.9  170  2.4  170  5.9  170  2.4  170  21.8  170  25.3 
Total (13 MSs)  2,190  22.6  2,285  3.5  2,285  5.2  2,285  46.0  2,285  7.7  2,285  41.5  2,285  37.2  1,934  36.0 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA18.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from laying hens in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  63  4.8  63  1.6  63  3.2  63  11.1  63  1.6  63  6.3  63  14.3  63  20.6 
Germany  51  3.9  51  0  51  2.0  51  2.0  51  0  51  2.0  51  9.8  51  2.0 
Hungary  86  14.0  86  0  86  1.2  86  25.6  86  3.5  86  20.9  86  16.3  86  19.8 
Italy  161  15.5  161  1.2  161  3.1  161  18.0  161  0  161  18.0  161  10.6  161  16.8 
Latvia  14  7.1  14  0  14  0  14  0  14  0  14  0  14  0  14  7.1 
Netherlands  54  3.7  54  0  54  3.7  54  5.6  54  0  54  5.6  54  1.9  54  5.6 
Poland  132  5.3  132  0  132  0  132  25.8  132  0  132  22.0  132  5.3  132  0.8 
Portugal  32  0  32  0  32  0  32  9.4  32  0  32  12.5  32  0  32  0 
Romania  145  22.1  145  0  145  2.8  145  46.2  145  6.2  145  43.4  145  30.3  145  37.2 
Slovakia  29  0  29  0  29  0  29  10.3  29  0  29  10.3  29  10.3  29  10.3 
Spain  150  4.7  150  0  150  0.7  150  14.0  150  1.3  150  10.7  150  6.0  150  8.7 
United Kingdom  66  3.0  66  0  66  0  66  1.5  66  0  66  1.5  66  6.1  66  12.1 
Total (12 MSs)  983  9.5  983  0.3  983  1.6  983  19.4  983  1.5  983  17.4  983  11.5  983  14.3 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 
Table SA19.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from breeders of Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Czech Republic  27  11.1  27  0  27  0  27  7.4  27  0  27  7.4  27  7.4  –  – 
Italy  36  8.3  36  2.8  36  2.8  36  16.7  36  2.8  36  19.4  36  13.9  36  22.2 
Poland  15  0  15  0  15  0  15  20.0  15  0  15  20.0  15  0  15  0 
Romania  32  59.4  32  3.1  32  15.6  32  53.1  32  15.6  32  40.6  32  50.0  32  59.4 
Total (4 MSs)  110  22.7  110  1.8  110  5.5  110  25.5  110  5.5  110  22.7  110  20.9  83  32.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Resistance levels in Salmonella Enteritidis isolates from Gallus gallus 
Susceptibility data on S.  Enteritidis isolates from Gallus gallus were reported by 13 MSs in 2012 
(Table SA20).  Resistance to ampicillin, sulfonamides and tetracyclines was generally not detected or 
recorded at low levels in most MSs, with the exceptions of Belgium and Romania which reported moderate 
to high levels of resistance to these substances. Chloramphenicol and gentamicin resistance was often 
rarely detected or recorded at low levels; resistance to these substances in the reporting MS group equalled 
0.8 % and 0.4 %, respectively. In contrast to the other antimicrobials tested, the occurrence of ciprofloxacin 
and nalidixic acid resistance varied substantially, from 0 % to 88.9 % for ciprofloxacin, and, from 0 % to 
92.6 % for nalidixic acid, among three distinct groups of reporting MSs. While seven MSs either did not 
detect any resistance or recorded low resistance, two MSs reported moderate resistance and the four 
remaining MSs, high to extremely high resistance. Once more, the levels of ciprofloxacin and nalidixic acid 
resistance, within each MS, were generally very similar, as would be expected. Resistance to cefotaxime in 
S. Enteritidis was reported only by Belgium, Poland and Portugal in 2012, making the overall resistance at 
MS group level low at 1.3 %. Interestingly, Germany did not observe any resistance to the substances tested 
in the S. Enteritidis isolates from Gallus gallus. 
Resistance levels in Salmonella Enteritidis isolates from broilers 
Six MSs reported quantitative data on isolates of S. Enteritidis from broiler flocks in 2012 (Table SA20). 
Among the six reporting MSs, the overall resistance to ampicillin was low, at 3.2 %, and no resistance was 
reported by the Czech Republic and Slovakia. The overall levels of resistance to sulfonamides and 
tetracyclines were 2.7 % and 3.0 %, respectively. Austria was the only country to report no resistance to 
ciprofloxacin and nalidixic acid among isolates of S. Enteritidis from broiler flocks. Portugal was the only 
country to observe resistance to cefotaxime, at the low level of 5.3 %.  
Resistance levels in Salmonella Enteritidis isolates from laying hens 
Quantitative data on isolates of S. Enteritidis from laying hens were reported by 10 MSs in 2012 
(Table  SA20). The levels of resistance among isolates from laying hens were generally either similar 
(Poland, Slovakia) or higher (Romania) than those observed in broiler flocks, when considering the MSs 
reporting for both populations. Austria, Germany and Slovakia did not observe resistance to any of the 
antimicrobials tested. The occurrence of resistance to ampicillin, sulfonamides and tetracyclines was low 
across the reporting MSs (4.1 %, 4.7 % and 3.6 %, respectively). Only four MSs observed resistance to 
sulfonamides and tetracyclines with values varying from 2.3  % to 18.2  % and from 2.3  % to 15.2  %, 
respectively. Moderate levels of resistance to ciprofloxacin and nalidixic acid were observed at the MSs 
group level (18.5 % and 17.1 %, respectively). For these antimicrobials, reported resistance levels reported 
ranged from 0 % to 36.3 %. No resistance was observed to cefotaxime and chloramphenicol. Hungary and 
Romania were the only countries to report resistance to gentamicin at low levels of 4.0  % and 1.5  %, 
respectively. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA20.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Enteritidis isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus                                               
Austria  36  2.8  36  0  36  0  36  0  36  0  36  0  36  0  36  0 
Belgium  81  23.5  81  14.8  81  6.2  81  17.3  81  2.5  81  16.0  81  16.0  81  11.1 
Czech Republic  251  0  251  0  251  0  251  1.2  251  0  251  0.8  251  0.4  –  – 
Germany  80  0  80  0  80  0  80  0  80  0  80  0  80  0  80  0 
Hungary  26  3.8  26  0  26  0  26  0  26  3.8  26  0  26  3.8  26  0 
Italy  31  3.2  31  0  31  0  31  12.9  31  0  31  12.9  31  3.2  31  6.5 
Latvia  11  9.1  11  0  11  0  11  0  11  0  11  0  11  0  11  9.1 
Netherlands  38  2.6  38  0  38  0  38  7.9  38  0  38  7.9  38  0  38  0 
Poland  496  6.9  496  0.6  496  0.4  496  43.3  496  0  496  39.3  496  3.8  496  0.8 
Portugal  27  7.4  27  3.7  27  3.7  27  88.9  27  0  27  92.6  27  3.7  27  7.4 
Romania  76  7.9  76  0  76  2.6  76  27.6  76  2.6  76  27.6  76  22.4  76  18.4 
Slovakia  47  0  47  0  47  0  47  2.1  47  0  47  2.1  47  0  47  0 
Spain  45  4.4  45  0  45  0  45  28.9  45  0  45  28.9  45  2.2  45  2.2 
Total (13 MSs)  1,245  5.5  1,245  1.3  1,245  0.8  1,245  23.9  1,245  0.4  1,245  22.2  1,245  4.3  994  3.3 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Note: Data reported under 'All Gallus gallus' include data which have been reported by production level. 
 
Table continued overleaf. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  61
Table SA20 (continued.) Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and 
tetracyclines among S. Enteritidis isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Broiler flocks                                                 
Austria  21  4.8  21  0  21  0  21  0  21  0  21  0  21  0  21  0 
Czech Republic  236  0  236  0  236  0  236  1.3  236  0  236  0.8  236  0.4  –  – 
Poland  131  6.1  131  0  131  0  131  39.7  131  0  131  35.9  131  3.8  131  0 
Portugal  19  10.5  19  5.3  19  5.3  19  100  19  0  19  100  19  5.3  19  10.5 
Romania  10  30.0  10  0  10  20.0  10  50.0  10  10.0  10  50.0  10  50.0  10  40.0 
Slovakia  21  0  21  0  21  0  21  4.8  21  0  21  4.8  21  0  21  0 
Total (6 MSs)  438  3.2  438  0.2  438  0.7  438  18.3  438  0.2  438  16.9  438  2.7  202  3.0 
Laying hen flocks                                                 
Austria  15  0  15  0  15  0  15  0  15  0  15  0  15  0  15  0 
Germany  21  0  21  0  21  0  21  0  21  0  21  0  21  0  21  0 
Hungary  25  4.0  25  0  25  0  25  0  25  4.0  25  0  25  4.0  25  0 
Italy  28  3.6  28  0  28  0  28  14.3  28  0  28  14.3  28  0  28  3.6 
Latvia  11  9.1  11  0  11  0  11  0  11  0  11  0  11  0  11  9.1 
Netherlands  38  2.6  38  0  38  0  38  7.9  38  0  38  7.9  38  0  38  0 
Poland  91  6.6  91  0  91  0  91  36.3  91  0  91  30.8  91  3.3  91  0 
Romania  66  4.5  66  0  66  0  66  24.2  66  1.5  66  24.2  66  18.2  66  15.2 
Slovakia  25  0  25  0  25  0  25  0  25  0  25  0  25  0  25  0 
Spain  43  4.7  43  0  43  0  43  25.6  43  0  43  25.6  43  2.3  43  2.3 
Total (10 MSs)  363  4.1  363  0  363  0  363  18.5  363  0.6  363  17.1  363  4.7  363  3.6 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Note: Data reported under 'All Gallus gallus' include data which have been reported by production level. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Resistance levels in Salmonella Typhimurium isolates from Gallus gallus 
Five MSs reported quantitative MIC antimicrobial susceptibility data for S. Typhimurium isolates from 
Gallus gallus in 2012 (Table SA21). Only three MSs provided production level information with these data: in 
Austria and Hungary, two isolates of S. Typhimurium were from broiler flocks and eight were from laying 
hens. Germany reported 13 isolates from broiler flocks. 
The overall level of resistance to ampicillin, sulfonamides and tetracyclines, in the reporting MS group, was 
higher among S. Typhimurium isolates from Gallus gallus (39.5 %, 46.0 % and 35.5 %, respectively), than in 
S. Enteritidis isolates and all Salmonella spp. isolates as a whole. All MSs detected resistance to ampicillin, 
sulfonamides and tetracyclines generally at high levels, and the occurrence of resistance ranged from 7.1 % 
to 86.7  %, 10.0  % to 86.7  % and 7.1  % to 80.0  %, respectively. Among individual MSs, the level of 
ciprofloxacin resistance varied from 0 % in Austria, Germany and Hungary, to 66.7 % in Poland. Similarly, 
the level of resistance to nalidixic acid among individual MSs varied from 0 % in Austria and Hungary, to 
60.0 % in Poland. Austria and Belgium reported resistance to gentamicin at low levels of 10.0 % and 2.1 %, 
respectively. Cefotaxime resistance was observed only by Belgium (10.6 %). 
Resistance levels in Salmonella Infantis isolates from Gallus gallus 
Nine MSs reported quantitative MIC antimicrobial susceptibility data for S. Infantis isolates from Gallus gallus 
in 2012 (Table SA22). Only Belgium did not provide production level information with these data.  
The resistance to sulfonamides and tetracyclines varied markedly and were generally high to extremely high 
among the reporting MSs. A similar situation occurred regarding the resistance to ciprofloxacin and nalidixic 
acid. When reported, resistance to ampicillin varied between low, moderate and high levels. Cefotaxime 
resistance was not detected or recorded at very low levels by most reporting MSs and was observed at a 
high level by Italy (27.6 %), at a moderate level by Belgium (14.3 %) and at a low level by Romania (7.6 %). 
Resistance levels in Salmonella Kentucky isolates from Gallus gallus 
Five MSs reported quantitative MIC antimicrobial susceptibility data for S. Kentucky isolates from 
Gallus gallus in 2012 (Table SA23). All MSs provided production level information with these data.  
Generally, MSs reported resistance to ampicillin, sulfonamides and tetracyclines at high to extremely high 
levels. Conversely, Ireland recorded low to moderate resistance to these substances. The occurrence of 
resistance to ciprofloxacin and nalidixic acid was generally extremely high in the reporting MSs, with the 
exception of Ireland detecting 3 % resistance. Resistance to chloramphenicol was low to moderate. Ireland 
and Italy were the only MSs not reporting resistance to gentamicin, while the three remaining MSs reported 
high to extremely high levels of resistance. Cefotaxime resistance was observed only in Italy and Romania at 
around the 10 % level, making the overall resistance at MS group level 6.3 %. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Table SA21.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Typhimurium isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria  10  20.0  10  0  10  20.0  10  0  10  10.0  10  0  10  30.0  10  30.0 
Belgium  47  63.8  47  10.6  47  14.9  47  25.5  47  2.1  47  23.4  47  68.1  47  53.2 
Germany  42  7.1  42  0  42  7.1  42  0  42  0  42  47.6  42  19.0  42  7.1 
Hungary  10  10.0  10  0  10  10.0  10  0  10  0  10  0  10  10.0  10  10.0 
Poland  15  86.7  15  0  15  80.0  15  66.7  15  0  15  60.0  15  86.7  15  80.0 
Total (5 MSs)  124  39.5  124  4.0  124  20.2  124  17.7  124  1.6  124  32.3  124  46.0  124  35.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 
Table SA22.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Infantis isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Austria  25  0  25  0  25  0  25  96.0  25  0  25  96.0  25  96.0  25  96.0 
Belgium  28  21.4  28  14.3  28  0  28  17.9  28  10.7  28  17.9  28  21.4  28  7.1 
Czech Republic  52  15.4  52  0  52  0  52  96.2  52  0  52  96.2  52  96.2  –  – 
Hungary  172  4.7  172  0.6  172  1.2  172  94.2  172  0.6  172  95.3  172  83.7  172  79.1 
Italy  29  41.4  29  27.6  29  0  29  62.1  29  3.4  29  65.5  29  55.2  29  55.2 
Poland  118  3.4  118  0  118  0  118  44.1  118  0  118  44.1  118  44.1  118  39.0 
Romania  303  23.4  303  7.6  303  9.2  303  98.3  303  6.3  303  97.0  303  82.8  303  82.8 
Slovakia  25  0  25  0  25  0  25  88.0  25  0  25  88.0  25  88.0  25  88.0 
Spain  13  0  13  0  13  0  13  7.7  13  0  13  7.7  13  7.7  13  0 
Total (9 MSs)  765  14.2  765  4.7  765  3.9  765  82.6  765  3.1  765  82.5  765  74.0  713  69.7 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA23.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Kentucky isolates from Gallus gallus in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Czech Republic  11  63.6  11  0  11  0  11  54.5  11  45.5  11  54.5  11  54.5  –  – 
Ireland  33  12.1  33  0  33  3.0  33  3.0  33  0  33  3.0  33  9.1  33  3.0 
Italy  30  56.7  30  10.0  30  6.7  30  93.3  30  0  30  93.3  30  16.7  30  40.0 
Romania  74  97.3  74  9.5  74  5.4  74  100  74  94.6  74  95.9  74  95.9  74  94.6 
Spain  10  40.0  10  0  10  10.0  10  60.0  10  50.0  10  60.0  10  50.0  10  40.0 
Total (5 MSs)  158  65.8  158  6.3  158  5.1  158  72.8  158  50.6  158  70.9  158  57.0  147  59.2 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among Salmonella spp. isolates from Gallus gallus 
Figures SA9 to SA11 indicate how the level of resistance to selected antimicrobials in Salmonella spp. 
isolates from Gallus gallus has changed over the period 2006–2012 in the MSs. It is important to note that 
because some antimicrobial resistance is associated with particular serovars or clones within serovars, 
fluctuations in the occurrence of resistance in Salmonella spp. isolates within a country may result from 
changes in the proportions of different Salmonella serovars which contribute to the total numbers of 
Salmonella spp. isolates tested.  
For the majority of MSs, resistance to ampicillin decreased slightly between 2011 and 2012, although the 
slight increase observed in Denmark between 2010 and 2011 was continued in 2012. Across the seven 
years of data, levels of resistance to ampicillin remained broadly constant for most of the reporting MSs, 
while decreasing trends were observed in Italy and the Netherlands (Figure SA9). The level of resistance to 
cefotaxime in Salmonella spp. was generally low, very low or absent in reporting MSs between 2006 and 
2012. A statistically significant decreasing trend, for five or more years, was observed in Italy and Spain 
(Figure SA10). Statistically significant increasing trends in resistance to ciprofloxacin and nalidixic acid were 
registered in three MSs for five or more years over the 2006–2012 period. Spain observed a statistically 
significant decreasing trend in resistance to both antimicrobials, while Italy and the Netherlands observed a 
significant decrease in resistance to ciprofloxacin only.  
Figure SA9.  Trends in ampicillin resistance in tested Salmonella spp. isolates from Gallus gallus in 
reporting MSs, 2006-2012, quantitative data 
 
MS: Member State. 
Note: Statistically significant increasing or decreasing trends for five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Germany (↑), Italy (↓), the Netherlands (↓) and Poland (↑).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA10.  Trends in cefotaxime resistance in tested Salmonella spp. isolates from Gallus gallus 
in reporting MSs, 2006-2012, quantitative data 
 
MS: Member State. 
Note: A statistically significant decreasing trend for five or more years, as tested by logistic regression model (p  ≤0.05), was observed 
for Italy (↓) and Spain (↓).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA11.  Trends in ciprofloxacin and nalidixic acid resistance in tested Salmonella spp. isolates 
from Gallus gallus in reporting MSs, 2006-2012, quantitative data 
 
MS: Member State. 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Austria (↑), and Slovakia (↑) for both ciprofloxacin and nalidixic acid and in Poland (↑) for ciprofloxacin. A statistically significant 
decreasing trend was observed for ciprofloxacin in Italy (↓) and the Netherlands (↓), and for both ciprofloxacin and nalidixic acid in 
Spain (↓).  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among S. Enteritidis isolates from Gallus gallus 
Figure SA12 indicates how the level of resistance to selected antimicrobials in S. Enteritidis isolates from 
Gallus gallus has changed over the period 2006–2012 in the MSs. Most of the reporting MSs observed a 
similarity in their trends in resistance to ciprofloxacin and nalidixic acid among isolates of S. Enteritidis from 
Gallus gallus over the 2006-2012 period. However, statistically significant decreasing trends were observed 
in Germany, the Netherlands and Spain for both substances, while a significant increasing trend was 
observed in Poland, also for both substances. 
Figure SA12.  Trends in ciprofloxacin and nalidixic acid resistance in tested S. Enteritidis isolates 
from Gallus gallus in reporting MSs, 2006-2012, quantitative data 
 
MS:  Member State. 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤ 0.05), was observed 
in the Czech Republic (↓), Germany (↓), the Netherlands (↓) and Spain (↓) for both ciprofloxacin and nalidixic acid. A statistically 
significant increasing trend was observed in Poland (↑) and Portugal (↑) for both ciprofloxacin and nalidixic acid.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among Salmonella isolates from Gallus gallus 
Figures SA13 to SA14 show the spatial distributions of ampicillin and nalidixic acid resistance in 
Salmonella spp. isolated from Gallus gallus in 2012. Figure SA13 illustrates important variability in levels of 
ampicillin resistance in Salmonella spp. across the EU and the absence of a clear spatial distribution. Figure 
SA14 illustrates either the continued absence or the low prevalence of resistance to nalidixic acid in 
Salmonella spp. in Northern and Western Europe, but high levels of resistance in Southern and Eastern 
Europe. 
Figure SA13.  Spatial distribution of ampicillin resistance among Salmonella spp. from Gallus gallus 
in countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note:Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either inhibition zone diameter data, MIC data for fewer than 10 isolates, or purely qualitative data (as 
proportion of resistant isolates).  
1.  For France, 2011 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure  SA14.    Spatial distribution of nalidixic acid resistance among Salmonella spp.  from 
Gallus gallus in countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note:Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either inhibition zone diameter data, MIC data for fewer than 10 isolates, or purely qualitative data (as 
proportion of resistant isolates).  
1.  For France, 2011 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Multi-resistance among Salmonella spp. isolates from broilers and laying hens of Gallus gallus 
In 2012, 10 MSs reported isolate-based data on resistance in Salmonella spp. from broiler flocks, which 
represents 2 more reporting countries compared with 2011, while isolate-based data concerning resistance 
in Salmonella spp. from laying hen flocks were reported by 9 MSs in 2012, which accounts for 3 additional 
reporting countries compared with the previous year.  
Complete susceptibility was typically very high (≥ 50 %) in tested isolates from laying hens and generally 
similar or higher than those observed in tested isolates from broilers, which varied substantially among 
reporting MSs from 7.4 % in Hungary to up to 81.6 % in Ireland (Tables SA24 and SA25). Similarly, multi-
resistance rates in laying hens were mostly low to moderate (≤  20  %) among reporting MSs, except in 
Romania, where 37.9 % of tested isolates exhibited reduced susceptibility to three or more substances, 
while, in broilers, multi-resistance rates were generally moderate to high, with the exception of Ireland, which 
reported a low level of multi-resistance, and Hungary and Romania, which recorded very high levels of multi-
resistance.  
Considering the multi-resistance distributions of Salmonella spp. isolates in broilers and laying hens (Figures 
SA15 and SA16), higher proportions of isolates exhibiting reduced susceptibility to an important number of 
different substances were generally observed in broilers compared with laying hens. While in Italy and 
Romania, some isolates showed reduced susceptibility to a maximum of eight and nine different substances 
in broilers, which were higher numbers than in certain isolates from laying hens in the same country. The 
opposite was true in Austria, Hungary and Spain, where the maximum numbers of substances to which a 
number of isolates were multi-resistant were higher in laying hens than in broilers. 
Very few isolates were resistant to both ciprofloxacin and cefotaxime in Salmonella spp. isolates from laying 
hens and broilers (Tables SA24 and SA25).  
Multi-resistance among S. Enteritidis isolates from broilers and laying hens of Gallus gallus 
In 2012, three MSs provided isolate-based data concerning resistance in S. Enteritidis in broilers and six 
MSs provided isolate-based data concerning resistance in S. Enteritidis in laying hens. 
Levels of complete susceptibility were commonly very high in S. Enteritidis isolates from broilers and laying 
hens and multi-resistance was either not detected or observed at low levels (Tables SA26 and SA27). An 
exception to this is Romania where rates of both complete susceptibility and multi-resistance were high in 
isolates from broilers (although assessed on a small sample of 10 isolates only) and multi-resistance was 
moderate in isolates from laying hens. One S. Enteritidis isolate from broilers exhibited multi-resistance to 
eight different classes. 
Co-resistance to both ciprofloxacin and cefotaxime, in S. Enteritidis isolates, from laying hens and broilers 
was not observed in the reporting MSs (Tables SA26 and SA27). 
 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA24.  Complete  susceptibility, multi-resistance and index of 
diversity in Salmonella spp. from broilers in MSs reporting isolate-based 
data, 2012 
Table SA25.  Complete  susceptibility, multi-resistance and index of 
diversity in Salmonella spp. from laying hens in MSs reporting isolate-
based data, 2012 
Country 
Susceptible 
to all 
Multi-
resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=113)  82  72.6  23  20.4  0.243  0 (0)  0 (0) 
Czech Republic (N=351) 271  77.2  67  19.1  0.385  0 (0)  0 (0) 
Denmark (N=24)  17  70.8  7  29.2  0  0 (0)  0 (0) 
Hungary (N=175)  13  7.4  128  73.1  0.279  0 (0)  0 (0) 
Ireland (N=38)  31  81.6  3  7.9  0.264  0 (0)  0 (0) 
Italy (N=105)  55  52.4  43  41.0  0.67  13 (0)  12.4 (0) 
Romania (N=781)  135  17.3  474  60.7  0.648  41 (2)  5.2 (0.3) 
Spain (N=29)  6  20.7  10  34.5  0.394  1 (0)  3.4 (0) 
United Kingdom (N=17)  5  29.4  2  11.8  0.162  0 (0)  0 (0) 
 
Country 
Susceptible 
to all 
Multi-
resistant  Index of 
diversity
Co-resistant to 
Cip and Ctx 
n % n % n % 
Austria (N=63)  47  74.6  9  14.3  0.361  0 (0)  0 (0) 
Germany (N=51)  44  86.3  1  2.0  0.221  0 (0)  0 (0) 
Hungary (N=86)  59  68.6  16  18.6  0.38  0 (0)  0 (0) 
Italy (N=161)  111  68.9  23  14.3  0.372  2 (0)  1.2 (0) 
Romania (N=145)  72  49.7  55  37.9  0.450  0 (0)  0 (0) 
Spain (N=150)  119  79.3  8  5.3  0.321  0 (0)  0 (0) 
United Kingdom (N=11)  10  90.9  1  9.1  0  0 (0)  0 (0) 
 
MS:Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx):  the frequencies and percentages of Salmonella isolates not susceptible to concentrations greater than epidemiological cut-off values 
(Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip: >1mg/L). 
 
  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA15.  Frequency distribution of Salmonella spp. isolates from 
broilers completely susceptible or resistant to one to nine 
antimicrobials in MSs reporting isolate-based data, 2012 
Figure SA16.  Frequency distribution of Salmonella spp. isolates from laying 
hens completely susceptible or resistant to one to nine antimicrobials in 
MSs reporting isolate-based data, 2012 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; sus: susceptible to all antimicrobial substances of the EFSA common 
set for Salmonella; res1–res9: resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
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Table SA26.  Complete  susceptibility, multi-resistance and index of 
diversity in S. Enteriditis from broilers in MSs reporting isolate-based 
data, 2012 
Table SA27.  Complete  susceptibility, multi-resistance and index of 
diversity in S. Enteriditis from laying hens in MSs reporting isolate-based 
data, 2012 
Country 
Susceptible 
to all 
Multi-
resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=21)  20  95.2  0  0  0  0 (0)  0 (0) 
Czech Republic (N=236)  231  97.9  0  0  0.068  0 (0)  0 (0) 
Romania (N=10)  4  40.0  5  50.0  0.315  0 (0)  0 (0) 
 
Country 
Susceptible 
to all  Multi-resistant  Index of 
diversity 
Co-resistant to 
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=15)  15  100  0  0  NA  0 (0)  0 (0) 
Germany (N=21)  21  100  0  0  NA  0 (0)  0 (0) 
Hungary (N=25)  23  92.0  0  0  0.086  0 (0)  0 (0) 
Italy (N=28)  22  78.6  0  0  0  0 (0)  0 (0) 
Romania (N=66)  49  74.2  11  16.7  0.336  0 (0)  0 (0) 
Spain (N=43)  32  74.4  1  2.3  0.14  0 (0)  0 (0) 
MS:Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx):  the frequencies and percentages of Salmonella isolates not susceptible to concentrations greater than epidemiological cut-off values 
(Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip: >1 mg/L). 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA17.  Frequency distribution of S. Enteritidis isolates from broilers 
completely susceptible or resistant to one to nine antimicrobials in MSs 
reporting isolate-based data, 2012 
Figure SA18.  Frequency  distribution  of  S. Enteritidis isolates from 
laying hens completely susceptible or resistant to one to nine 
antimicrobials in MSs reporting isolate-based data, 2012 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; sus: susceptible to all antimicrobial substances of the EFSA common 
set for Salmonella; res1–res9: resistance to one antimicrobial substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
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3.4.2.2. Turkeys 
In 2012, nine MSs submitted quantitative antimicrobial susceptibility data for Salmonella spp. from turkeys, in 
accordance with the EU legislation. This section includes data from fattening flocks and unspecified flocks of 
turkeys. Seven MSs reported data on S. Typhimurium in turkeys and five MSs reported data on monophasic 
S. Typhimurium in turkeys; however, no country submitted sufficient data to warrant inclusion in the report.  
Representative sampling and monitoring 
In the reporting MSs, Austria, the Czech Republic, Germany, Hungary, Ireland, Italy, Poland, Spain and the 
United Kingdom, antimicrobial resistance monitoring in Salmonella spp. isolates from turkeys relied primarily 
on the national control and eradication programme of Salmonella based on census sampling of fattening 
flocks  in accordance with EU regulations. Only one representative Salmonella isolate per positive 
epidemiological unit (flock), derived from environmental samples of faeces or dust, was gathered to account 
for clustering. In some reporting countries, representative subsets of Salmonella isolates were randomly 
selected at the laboratory for susceptibility testing, whereas, in some others, all the Salmonella isolates 
recovered were tested for susceptibility. Either no or incomplete information on antimicrobial resistance 
monitoring in turkeys was provided by Hungary, Italy, Poland and the United Kingdom. 
Resistance levels in Salmonella spp. isolates from turkeys 
Data on antimicrobial resistance among Salmonella spp. in turkeys were reported by nine MSs in 2012 
(Table SA28). The occurrence of resistance to ampicillin, sulfonamides and tetracyclines was generally high 
to extremely high across the reporting MSs. An exception to this is Austria which reported low resistance to 
tetracyclines. For chloramphenicol and gentamicin, contrasting levels of resistance were observed. As for 
chloramphenicol, two-thirds of the reporting MSs did not record resistance or observed low resistance, while 
one-third reported moderate to high resistance, and for gentamicin, high resistance were reported by two-
thirds of the reporting MSs, while the remaining MSs observed low resistance. Resistance levels to 
ciprofloxacin and nalidixic acid were high to extremely high among the reporting MSs, except in the United 
Kingdom which reported low resistance. Cefotaxime resistance was very low in the reporting group of nine 
MSs at 0.8  %, with only Italy, Poland and Spain reporting any cefotaxime-resistant isolates at low 
proportions of 4.2 %, 3.6 % and 1.2 %, respectively. In contrast to the general feature, Ireland detected 
resistance only to sulfonamides and tetracyclines at low levels in a small sample of 11 Salmonella spp. 
isolates. 
The feature of the resistance observed in the sub-set of Salmonella spp. isolates obtained from fattening 
turkey flocks in five MSs generally paralleled that described above in Salmonella spp. in turkeys with high to 
extremely high resistance to ampicillin, ciprofloxacin, nalidixic acid, sulfonamides and tetracyclines, low to 
moderate resistance to gentamicin and an absence of or low resistance to cefotaxime and chloramphenicol.  
Eight MSs reported resistance among Salmonella spp. isolates from both broilers (Gallus gallus) and turkeys 
in 2012. As previously observed in 2010 and 2011, resistance was much higher in turkeys than in broilers, in 
particular for ampicillin, ciprofloxacin, chloramphenicol, gentamicin, nalidixic acid, sulfonamides and 
tetracyclines. More reporting MSs did not detect resistance to cefotaxime in isolates from turkeys than in 
isolates from Gallus gallus and thus, overall, resistance was lower (0.8 %) in turkeys than in Gallus gallus 
(4.8 %). The difference in resistance levels between the two species needs to be interpreted with caution 
because, except for Spain, resistance levels in Salmonella spp. isolates from turkeys are estimated on lower 
numbers of isolates compared with Gallus gallus. 
Resistance levels in Salmonella Kentucky isolates from turkeys 
Hungary and Poland reported quantitative MIC antimicrobial susceptibility data for S. Kentucky isolates from 
turkeys in 2012 and the results are presented in Table SA29. High levels of resistance to ampicillin, 
ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines were recorded by both MSs, while 
resistance was not detected in cefotaxime and chloramphenicol. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Table SA28.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from turkeys in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Turkeys                                                 
Austria  38  23.7  38  0  38  0  38  78.9  38  7.9  38  78.9  38  26.3  38  5.3 
Czech Republic  27  55.6  27  0  27  0  27  81.5  27  29.6  27  81.5  27  29.6  –  – 
Germany  87  55.2  87  0  87  2.3  87  32.2  87  21.8  87  28.7  87  57.5  87  48.3 
Hungary  174  51.1  174  0  174  0.6  174  91.4  174  20.7  174  84.5  174  33.9  174  55.2 
Ireland  14  0  14  0  14  0  14  0  14  0  14  0  14  14.3  14  14.3 
Italy  48  62.5  48  4.2  48  12.5  48  37.5  48  25.0  48  37.5  48  58.3  48  97.9 
Poland  55  50.9  55  3.6  55  21.8  55  52.7  55  25.5  55  45.5  55  54.5  55  58.2 
Spain  169  95.9  169  1.2  169  56.8  169  89.9  169  3.0  169  21.3  169  85.2  169  91.7 
United Kingdom  142  31.7  142  0  142  0.7  142  9.9  142  0.7  142  9.9  142  79.6  142  76.8 
Total (9 MSs)  754  56.5  754  0.8  754  15.6  754  59.9  754  13.0  754  42.0  754  58.9  727  66.7 
Fattening turkeys                                               
Austria  38  23.7  38  0  38  0  38  78.9  38  7.9  38  78.9  38  26.3  38  5.3 
Czech Republic  20  40.0  20  0  20  0  20  75.0  20  10.0  20  75.0  20  10.0  –  – 
Germany  12  50.0  12  0  12  0  12  0  12  8.3  12  0  12  58.3  12  66.7 
Hungary  174  51.1  174  0  174  0.6  174  91.4  174  20.7  174  84.5  174  33.9  174  55.2 
Spain  169  95.9  169  1.2  169  56.8  169  89.9  169  3.0  169  21.3  169  85.2  169  91.7 
Total (5 MSs)  413  66.3  413  0.5  413  23.5  413  86.2  413  11.4  413  55.2  413  53.8  393  66.4 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Table SA29.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Kentucky isolates from turkeys in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Hungary  35  100  35  0  35  0  35  100  35  97.1  35  100  35  97.1  35  97.1 
Poland  11  90.9  11  0  11  0  11  100  11  100  11  100  11  100  11  100 
Total (2 MSs)  46  97.8  46  0  46  0  46  100  46  97.8  46  100  46  97.8  46  97.8 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among Salmonella isolates from turkeys 
Figures SA19 and SA20 show the spatial distributions of ampicillin and nalidixic acid resistance in 
Salmonella spp. isolated from turkeys in 2012. These illustrate great variation in levels of ampicillin and 
nalidixic acid resistance in Salmonella spp. across the EU. Higher resistance to ampicillin was recorded in 
Southern Europe and to a lesser extent in Central and Eastern Europe compared with Western and Northern 
Europe. Regarding nalidixic resistance, a number of Central European MSs reported much higher levels of 
resistance. 
Spatial distribution of ampicillin resistance among Salmonella spp. from turkeys in countries 
reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note:Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either inhibition zone diameter data, MIC data for fewer than 10 isolates, or purely qualitative data (as 
proportion of resistant isolates).  
1.  For France, 2011 data were used. 
 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA19.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from turkeys in 
countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note:Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting either inhibition zone diameter data, MIC data for fewer than 10 isolates, or purely qualitative data (as 
proportion of resistant isolates).  
1.  For France, 2011 data were used. 
Multi-resistance among Salmonella spp. isolates from turkeys 
In 2012, seven MSs provided isolate-based data concerning resistance in Salmonella spp. from turkeys; one 
more than in 2011. Complete susceptibility was exhibited by less than one-quarter of the isolates tested in 
most of the reporting MSs with, in particular, Italy and Spain reporting low to very low levels of susceptibility. 
Contrastingly, Ireland reported 85.7 % of complete susceptibility, although, in this case, it was assessed on 
an isolate sample of small size. Multi-resistance was high to extremely high in most reporting MSs ranging 
from 26.3 % in Austria to 95.3 % in Spain (Table SA30), while moderate multi-resistance was reported in 
Ireland. The frequency distributions (Figure SA21) showed similarities among multi-resistance recorded in 
Austria, the Czech Republic, Germany and Hungary with some isolates showing reduced susceptibility to as 
many as five and six different substances, while Italy and Spain reported isolates showing reduced 
susceptibility to up to seven and nine antimicrobials. Ireland recorded multi-resistance to no more than three 
classes of antimicrobials at a maximum.  
Very few isolates were resistant to both ciprofloxacin and cefotaxime (Table SA30). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA30.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
turkeys in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=38)  7  18.4  10  26.3  0.231  0 (0)  0 (0) 
Czech Republic (N=27)  2  7.4  11  40.7  0.427  0 (0)  0 (0) 
Germany (N=87)  20  23.0  51  58.6  0.365  0 (0)  0 (0) 
Hungary (N=174)  11  6.3  96  55.2  0.426  0 (0)  0 (0) 
Ireland (N=14)  12  85.7  2  14.3  0  0 (0)  0 (0) 
Italy (N=48)  0  0  39  81.2  0.554  1 (0)  2.1 (0) 
Spain (N=169)  3  1.8  161  95.3  0.601  2 (0)  1.2 (0) 
MS:  Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip:>1 mg/L). 
Figure SA20.  Frequency  distribution  of  Salmonella spp. in turkeys completely susceptible or 
resistant to one to nine antimicrobials, in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
Multi-resistance among S. Enteritidis and S. Typhimurium isolates from turkeys 
Generally, the S. Enteritidis, S. Typhimurium and monophasic S. Typhimurium isolates from turkey flocks 
were very rare in the isolate-based dataset of the reporting MSs. Data on multi-resistance in these serovars 
from turkeys are therefore not presented in this report, as the inclusion criteria (more than three reporting 
countries providing data on more than 10 isolates per production type) were not met.  
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3.4.2.3. Pigs 
Quantitative MIC data for Salmonella spp. isolated from pigs from 10 MSs in 2012 are included in the 
following analyses. 
Representative sampling and monitoring 
Isolates from Spain and some of the isolates from Estonia were collected as part of monitoring plans, 
whereas Germany and Italy and also Estonia tested isolates obtained through passive surveillance via 
diagnostic submissions. Denmark collected isolates from sub-clinical infections detected via the serological 
surveillance programme, from healthy pigs at slaughter. Sample types collected by MSs were generally 
faecal, while Estonia and Spain also tested ileocaecal lymph nodes at slaughter. 
Resistance levels in Salmonella spp. isolates from pigs 
Data describing the occurrence of resistance to selected antimicrobials in isolates of Salmonella spp. from 
pigs are presented in Table SA31. Isolates tested by Denmark, Germany and the Netherlands made up over 
77 % of the total isolates tested in 2012, so the results from these three countries will have influenced the 
overall levels reported at MS group level. 
Resistance to ampicillin, sulfonamides and tetracyclines was generally high to extremely high, ranging from 
more than 30 % to about 90 % among the reporting MSs. The only exception to this was Estonia which 
reported an ampicillin resistance of 18.8 %. Although lower, resistance to chloramphenicol varied between 
0 % and 33.3 % among the reporting MSs, while gentamicin resistance was typically low in the reporting 
MSs ranging from 0 % to 10.4 %.  
Three MSs detected no resistance or reported very low resistance to either ciprofloxacin or nalidixic acid in 
Salmonella spp. isolates from pigs. Among the MSs which did detect resistance, the occurrence of 
ciprofloxacin and nalidixic acid resistance mostly ranged from about 5 % to 25 %, with the exception of 
Poland which recorded a ciprofloxacin resistance of 60.0 %. Resistance to cefotaxime was generally not 
detected or reported at low levels in Salmonella spp. in pigs, with only three MSs reporting cefotaxime 
resistance ranging from 2.1 % to 11.2 %. 
Five MSs reported quantitative data on isolates of Salmonella spp. from fattening pigs in 2012 (Table SA31). 
At the reporting MS group level, the overall resistance to ampicillin, sulfonamides and tetracyclines were 
high, at 35.2 %, 40.1 % and 45.6 %, respectively. Low levels of resistance to ciprofloxacin and to nalidixic 
acid were observed at the MS group level (4.1 % and 3.7 %, respectively), with values varying from 0 % to 
23.7 %. As usually observed, the levels of resistance within each MS were generally very similar for the two 
compounds. In Salmonella spp. from fattening pigs, Denmark and Spain were the only countries to report 
resistance to gentamicin at levels of 2.9 % and 10.4 %, respectively. Cefotaxime resistance was observed 
only by Spain at a low level of 6.3 %. 
Quantitative data on isolates of Salmonella spp. from breeding pigs were reported by one MS in 2012 
(Table SA31).  
Resistance levels in Salmonella Typhimurium isolates from pigs 
Quantitative MIC antimicrobial susceptibility results for S. Typhimurium isolates from pigs were reported by 
five MSs in 2012 (Table SA32). More than half of isolates tested (52.6 %) were from Germany, so the results 
from Germany will have more bearing on the overall levels. The occurrence of resistance to ampicillin, 
chloramphenicol, sulfonamides and tetracyclines among S. Typhimurium isolates from pigs was higher than 
that reported in Salmonella spp., with the overall level of resistance in the reporting MS group being 76.7 % 
for ampicillin, 30.1 % for chloramphenicol, 77.5 % for sulfonamides and 71.7 % for tetracyclines. Among the 
individual reporting MSs, resistance to ampicillin ranged from 41.3  % to 85.5  %, resistance to 
chloramphenicol ranged from 14.5 % to 53.3 %, resistance to sulfonamides ranged from 46.0 % to 86.1 % 
and resistance to tetracyclines ranged from 36.5 % to 93.3 %. Resistance to ciprofloxacin and gentamicin 
was fairly similar in S. Typhimurium and Salmonella spp. (7.5 % vs. 7.6 % and 3.7 % vs 3.4 %, respectively). 
Resistance to cefotaxime and nalidixic acid was similar in S. Typhimurium and Salmonella spp. (2.3 % and EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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5.8  %, respectively). In the reporting MS group, cefotaxime resistance was detected in S. Typhimurium 
isolates from Belgium at a moderate level (10.7 %), and from Germany at a low level (1.1 %). 
Resistance levels in monophasic Salmonella Typhimurium isolates from pigs 
Table SA33 describes the resistance among isolates of monophasic S. Typhimurium from pigs. Six MSs 
reported quantitative data from pigs. As for S. Typhimurium, more than half of isolates tested (55.2 %) were 
from Germany, so the results from Germany will have more bearing on the overall levels. The levels of 
resistance to ampicillin, sulfonamides and tetracyclines reported in monophasic S. Typhimurium were much 
higher than the levels reported in Salmonella spp. from pigs (91.3 % vs. 60.2 %, 91.0 % vs. 63.3 % and 
93.5 % vs 63.3 %, respectively).  
Extremely high resistance to ampicillin, sulfonamides and tetracyclines was observed across all reporting 
MSs (91.3 %, 91.0 % and 93.5 %, respectively), and this ranged from 84.0 % to 94.3 % for ampicillin, from 
84.0 % to 93.9 % for sulfonamides and from 80.0 % to 100 % for tetracyclines. Low levels of resistance to 
chloramphenicol (9.4 %) and gentamicin (5.1 %) were reported at the MS group level, and ranged from 
2.5  % to 30.0  % and from 0  % to 21.4  %, respectively. In addition, low resistance to ciprofloxacin and 
nalidixic acid was reported at the MS group level (8.7  % and 5.6  %, respectively). Denmark and the 
Netherlands observed no resistance to both compounds, while in the remaining four MSs, resistance ranged 
from 3.9 % to 60.0 %. Cefotaxime resistance was observed by Belgium, Germany and Spain making the 
overall resistance, at MS group level, 2.7 %. 
Resistance levels in Salmonella Derby isolates from pigs 
Table SA34 describes the resistance among isolates of S. Derby from pig. Four MSs reported quantitative 
data from pigs. The levels of resistance to ampicillin, sulfonamides and tetracyclines reported in S. Derby 
were lower than the levels reported in Salmonella spp. from pigs (12.4 % vs. 60.3 %, 22.8 % vs. 63.4 % and 
31.3 % vs. 63.4 %, respectively). Low levels of resistance to chloramphenicol, ciprofloxacin and gentamicin 
(1.2 %) were reported at the MS group level. The levels of resistance to nalidixic acid and cefotaxime were 
low at the MS group level. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA31.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from pigs in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
All pigs                                                 
Belgium  187  65.2  187  11.2  187  13.9  187  22.5  187  3.2  187  18.2  187  63.1  187  57.8 
Denmark  374  31.3  374  0  374  4.5  374  0  374  2.9  374  0  374  36.4  374  40.6 
Estonia  32  18.8  32  0  32  0  32  0  32  0  32  0  32  43.8  32  31.3 
Germany  627  77.4  627  2.1  627  22.2  627  7.5  627  4.1  627  4.9  627  79.6  627  75.6 
Hungary  38  57.9  38  0  38  10.5  38  23.7  38  0  38  23.7  38  68.4  38  60.5 
Ireland  24  50.0  24  0  24  33.3  24  16.7  24  4.2  24  16.7  24  66.7  24  83.3 
Italy  25  36.0  25  0  25  12.0  25  12.0  25  8.0  25  12.0  25  48.0  25  48.0 
Netherlands  263  64.6  263  0  263  9.1  263  0.8  263  1.5  263  0.8  263  66.5  263  68.8 
Poland  10  90.0  10  0  10  30.0  10  60.0  10  0  10  30.0  10  90.0  10  80.0 
Spain  48  58.3  48  6.3  48  14.6  48  20.8  48  10.4  48  16.7  48  54.2  48  89.6 
Total (10 MSs)  1,628  60.2  1,628  2.3  1,628  14.2  1,628  7.6  1,628  3.4  1,628  5.8  1,628  63.3  1,628  63.3 
Fattening pigs                                                 
Denmark  374  31.3  374  0  374  4.5  374  0  374  2.9  374  0  374  36.4  374  40.6 
Estonia  14  28.6  14  0  14  0  14  0  14  0  14  0  14  35.7  14  14.3 
Hungary  38  57.9  38  0  38  10.5  38  23.7  38  0  38  23.7  38  68.4  38  60.5 
Netherlands  17  11.8  17  0  17  5.9  17  5.9  17  0  17  5.9  17  23.5  17  23.5 
Spain  48  58.3  48  6.3  48  14.6  48  20.8  48  10.4  48  16.7  48  54.2  48  89.6 
Total (5 MSs)  491  35.2  491  0.6  491  5.9  491  4.1  491  3.3  491  3.7  491  40.1  491  45.6 
Breeding pigs                                                 
Belgium  187  65.2  187  11.2  187  13.9  187  22.5  187  3.2  187  18.2  187  63.1  187  57.8 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table SA32.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Typhimurium isolates from pigs in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All pigs                                                 
Belgium  75  81.3  75  10.7  75  20.0  75  20.0  75  2.7  75  13.3  75  74.7  75  66.7 
Denmark  63  41.3  63  0  63  17.5  63  0  63  1.6  63  0  63  46.0  63  36.5 
Germany  273  82.8  273  1.1  273  37.7  273  6.6  273  5.1  273  5.5  273  86.1  273  79.5 
Ireland  15  60.0  15  0  15  53.3  15  20.0  15  6.7  15  20.0  15  73.3  15  93.3 
Netherlands  55  85.5  55  0  55  14.5  55  0  55  0  55  0  55  76.4  55  74.5 
Total (5 MSs)  481  76.7  481  2.3  481  30.1  481  7.5  481  3.7  481  5.8  481  77.5  481  71.7 
Fattening pigs                                                 
Denmark  63  41.3  63  0  63  17.5  63  0  63  1.6  63  0  63  46.0  63  36.5 
Breeding pigs                                                 
Belgium  75  81.3  75  10.7  75  20.0  75  20.0  75  2.7  75  13.3  75  74.7  75  66.7 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Table SA33.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
monophasic S. Typhimurium isolates from pigs in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  41  90.2  41  19.5  41  14.6  41  26.8  41  7.3  41  24.4  41  87.8  41  87.8 
Denmark  81  84.0  81  0  81  2.5  81  0  81  7.4  81  0  81  84.0  81  87.7 
Germany  228  94.3  228  0.9  228  9.6  228  7.5  228  3.1  228  3.9  228  93.9  228  96.5 
Netherlands  39  92.3  39  0  39  7.7  39  0  39  5.1  39  0  39  92.3  39  94.9 
Poland  10  90.0  10  0  10  30.0  10  60.0  10  0  10  30.0  10  90.0  10  80.0 
Spain  14  85.7  14  7.1  14  21.4  14  14.3  14  21.4  14  7.1  14  92.9  14  100 
Total (6 MSs)  413  91.3  413  2.7  413  9.4  413  8.7  413  5.1  413  5.6  413  91.0  413  93.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
Table SA34.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
S. Derby isolates from pigs in 2012, using harmonised epidemiological cut-off values 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 
 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Belgium  14  21.4  14  7.1  14  7.1  14  7.1  14  0  14  14.3  14  50.0  14  28.6 
Denmark  176  9.7  176  0  176  2.3  176  0  176  1.1  176  0  176  16.5  176  31.3 
Germany  42  28.6  42  11.9  42  2.4  42  9.5  42  2.4  42  9.5  42  38.1  42  23.8 
Netherlands  28  0  28  0  28  0  28  0  28  0  28  0  28  25.0  28  42.9 
Total (4 MSs)  260  12.3  260  2.3  260  2.3  260  1.9  260  1.2  260  2.3  260  22.7  260  31.2 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among Salmonella isolates from pigs 
The temporal variation in the level of resistance to selected antimicrobials in Salmonella spp., isolated from 
pigs between 2006 and 2012, is presented in Figures SA22 to SA24. The figures demonstrate that, in some 
MSs, resistance levels have continued to fluctuate; however, in other countries, such as in Germany and 
Sweden, the occurrence of resistance has remained fairly stable in recent years. Over the seven reporting 
years, significantly decreasing trends in resistance were reported by the Netherlands for ampicillin, while 
Ireland, Italy and Spain reported statistically significant increasing trends in resistance to the same 
substance (Figure SA22). Considering resistance to (fluoro) quinolones, ciprofloxacin and nalidixic acid, 
Estonia and Germany reported statistically decreasing trends in resistance to both compounds over the 
2006–2012 period. In contrast, Spain showed increasing trends in resistance to these two substances. 
Additionally, Ireland registered an increasing trend in resistance to ciprofloxacin (Figure SA24). Cefotaxime 
resistance among Salmonella spp. isolates from pigs remained either low, very low or absent in the reporting 
MSs between 2006 and 2012; and no significant trends were detected for MSs reporting five or more years 
of data (Figure SA23). 
Figure SA21.  Trends in ampicillin resistance in Salmonella spp. from pigs in reporting MSs, 2006-
2012, quantitative data 
 
MS: Member State. 
Note: Statistically significant increasing or decreasing trends for five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Ireland (↑), Italy (↑), the Netherlands (↓) and Spain (↑).  
Danish data are not comparable between years: data from 2006-2010 contained only S. Typhimurium isolates while all the isolates were 
reported in 2011 and 2012. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Figure SA22.  Trends in cefotaxime resistance in Salmonella spp. from pigs in reporting MSs, 2006-
2012, quantitative data 
 
MS: Member State. 
Note: No statistically significant trend for five or more years, as tested by a logistic regression model (p  ≤0.05), was observed in any of 
the reporting countries.  
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA23.  Trends in ciprofloxacin and nalidixic acid resistance in Salmonella spp. from pigs in 
reporting MSs, 2006-2012, quantitative data 
 
MS: Member State. 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Estonia (↓) and Germany (↓) for both ciprofloxacin and nalidixic acid. A statistically significant increasing trend was observed in 
Spain (↑) for both ciprofloxacin and nalidixic acid and in Ireland (↑) for ciprofloxacin.  
Danish data are not comparable between years: data from 2006-2010 contained only S. Typhimurium isolates while all the isolates were 
reported in 2011 and 2012. 
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Spatial distribution of resistance among Salmonella isolates from pigs 
The spatial distribution of ampicillin and nalidixic acid resistance in Salmonella spp. from pigs in 2012 is 
shown in Figures SA25 and SA26. Figure SA25 emphasises the large differences in ampicillin resistance 
rates in different MSs, although no clear spatial distributions were observed. In most countries, nalidixic acid 
resistance in Salmonella spp. isolated from pigs was reported to be low, with no clear spatial distribution 
apparent (Figure SA26). 
Figure SA24.  Spatial  distribution of ampicillin resistance among Salmonella spp. from pigs in 
countries reporting MIC data in 2012 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note: Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting inhibition zone diameter data, MIC data for fewer than 10 isolates or purely qualitative data (as proportion 
of resistant isolates).  
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Figure SA25.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from pigs in 
countries reporting MIC data in 2012 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note: Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting inhibition zone diameter data, MIC data for fewer than 10 isolates or purely qualitative data (as proportion 
of resistant isolates).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Multi-resistance among Salmonella spp. isolates from fattening pigs 
In 2012, seven MSs provided isolate-based data concerning resistance in Salmonella spp. from pigs. The 
levels of complete susceptibility varied between the reporting MSs, from 6.2 % in Spain to 64.3 % in Estonia. 
The multi-resistance levels were high to very high in all reporting MSs, ranging from 34.0 % in Denmark to 
76.9 % in Germany (Table SA35). The frequency distributions (Figure SA27) showed discrepancies among 
the multi-resistance recorded in the reporting MSs with some isolates showing reduced susceptibility to up to 
eight different substances in Italy and Spain, while Estonia recorded multi-resistance to three classes at a 
maximum. Very few isolates were resistant to both antimicrobials ciprofloxacin and cefotaxime (Table SA35). 
Table SA35.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
fattening pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Denmark (N=374)  179  47.9  127  34.0  0.388  0 (0)  0 (0) 
Estonia (N=14)  9  64.3  5  35.7  0.151  0 (0)  0 (0) 
Germany (N=627)  89  14.2  482  76.9  0.544  5 (0)  0.8 (0) 
Hungary (N=38)  9  23.7  27  71.1  0.414  0 (0)  0 (0) 
Ireland (N=24)  2  8.3  15  62.5  0.586  0 (0)  0 (0) 
Italy (N=25)  10  40.0  12  48.0  0.586  0 (0)  0 (0) 
Spain (N=48)  3  6.2  28  58.3  0.562  2 (0)  4.2 (0) 
MS:  Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip:>1 mg/L). 
Figure SA26.  Frequency  distribution  of  Salmonella spp. from fattening pigs isolates completely 
susceptible or resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella.   
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Multi-resistance among S. Typhimurium isolates from fattening pigs 
In 2012, three MSs provided isolate-based resistance data on S. Typhimurium from pigs concerning more 
than 10 isolates. Rates of full susceptibility and multi-resistance are respectively lower and higher than those 
assessed in Salmonella spp. for the three MSs reporting for both groups. Resistance to both ciprofloxacin 
and cefotaxime in S. Typhimurium isolates from pigs was not observed in the three reporting MSs (Table 
SA36). 
Table SA36.  Complete susceptibility, multi-resistance and index of diversity in S. Typhimurium from 
fattening pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Denmark (N=63)  31  49.2  27  42.9  0.458  0 (0)  0 (0) 
Germany (N=273)  24  8.8  221  81.0  0.519  0 (0)  0 (0) 
Ireland (N=15)  0  0  10  66.7  0.593  0 (0)  0 (0) 
MS:  Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx: >0.5 mg/L and Cip: >0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx: >2 mg/L and Cip: >1 mg/L). 
Figure SA27.  Frequency  distribution  of  S. Typhimurium from fattening pigs isolates completely 
susceptible or resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella.  
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3.4.2.4. Cattle (bovine animals) 
In this report, calves, dairy cattle, beef cows and heifers are included under the term ‘cattle’. Quantitative 
MIC data for Salmonella spp. isolated from cattle in seven MSs in 2012 are included in the following analysis 
of antimicrobial resistance levels. 
Representative sampling and monitoring 
Isolates tested by Belgium, Finland, Germany, Ireland and Sweden were obtained through national 
monitoring programmes and generally consisted of faecal samples. Finland also tested lymph nodes at 
slaughter. Italy obtained isolates through passive surveillance. 
Resistance levels in Salmonella spp. isolates from cattle 
The levels of resistance to selected antimicrobials in isolates of Salmonella spp. from cattle reported by MSs 
in 2012 are presented in Table SA37. Isolates tested by Belgium, Germany and the Netherlands made up 
over 68 % of the total isolates tested in 2012, so the results from these countries will have influenced the 
overall levels reported at MS group level. High levels of resistance to ampicillin, sulfonamides and 
tetracyclines were commonly reported in Salmonella spp. from cattle in 2012; considering all reporting MSs, 
the levels of resistance were 34.5 %, 42.4 % and 36.0 %, respectively. Ampicillin resistance ranged from 
13.2 % to 61.1 % across reporting MSs, the range for sulfonamides was 17.6 % to 66.7 %, while the range 
for tetracyclines was 5.3 % to 58.3 %. As in the previous year, only Germany and Italy reported resistance to 
gentamicin, making the overall resistance 1.1 %. 
At MS group level, the overall occurrence of resistance to both ciprofloxacin and nalidixic acid was 9.1 %. 
Finland and Sweden were the only MSs to report no resistance to ciprofloxacin or nalidixic acid in 
Salmonella spp. isolates from cattle. Cefotaxime resistance was only reported by Belgium (2.4 %). 
Resistance levels in Salmonella Typhimurium isolates from cattle 
Table SA38 shows the level of resistance reported on S. Typhimurium isolates from cattle in 2012. Across 
the six reporting MSs, the level of resistance to ampicillin and tetracyclines was high, at 43.4 % and 44.9 %, 
respectively. The resistance levels reported by individual MSs varied from 11.4 % to 84.0 % for ampicillin 
and from 6.3  % to 83.3  % for tetracyclines. There were very high levels of resistance to sulfonamides 
(50.0%), ranging from 11.4 % to 91.7 %. The overall resistance to chloramphenicol was high (21.3 %) at MS 
group level, which varied from 0  % to 66.7  %. As in the previous year, resistance to gentamicin in 
S. Typhimurium isolates from cattle was detected only in Germany at the low level of 2.9 %. 
The occurrence of resistance to both ciprofloxacin and nalidixic acid in the reporting MS group as a whole 
was low (2.2 % for ciprofloxacin and 2.9 % for nalidixic acid) as Belgium was the only country to report 
resistance (12.0 % for ciprofloxacin and 16.0 % for nalidixic acid). Cefotaxime resistance in S. Typhimurium 
isolates from cattle in 2012, as in 2011, was not reported by any MS. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Table SA37.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella spp. isolates from cattle in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Belgium  42  59.5  42  2.4  42  28.6  42  28.6  42  0  42  31.0  42  66.7  42  31.0 
Finland  19  21.1  19  0  19  0  19  0  19  0  19  0  19  21.1  19  5.3 
Germany  68  13.2  68  0  68  5.9  68  8.8  68  1.5  68  8.8  68  19.1  68  26.5 
Ireland  36  61.1  36  0  36  44.4  36  5.6  36  0  36  5.6  36  61.1  36  58.3 
Italy  14  35.7  14  0  14  21.4  14  14.3  14  14.3  14  7.1  14  35.7  14  42.9 
Netherlands  68  33.8  68  0  68  5.9  68  2.9  68  0  68  2.9  68  54.4  68  50.0 
Sweden  17  17.6  17  0  17  11.8  17  0  17  0  17  0  17  17.6  17  11.8 
Total (7 MSs)  264  34.5  264  0.4  264  15.5  264  9.1  264  1.1  264  9.1  264  42.4  264  36.0 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
Table SA38.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines among 
Salmonella Typhimurium from cattle in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N %  Res N %  Res  N  %  Res  N %  Res N %  Res N %  Res N %  Res N %  Res 
Belgium  25  84.0  25  0  25  20.0  25  12.0  25  0  25  16.0  25  72.0  25  48.0 
Finland  16  25.0  16  0  16  0  16  0  16  0  16  0  16  25.0  16  6.3 
Germany  35  11.4  35  0  35  8.6  35  0  35  2.9  35  0  35  11.4  35  28.6 
Ireland  24  70.8  24  0  24  66.7  24  0  24  0  24  0  24  70.8  24  66.7 
Netherlands  24  41.7  24  0  24  12.5  24  0  24  0  24  0  24  91.7  24  83.3 
Sweden  12  25.0  12  0  12  16.7  12  0  12  0  12  0  12  25.0  12  16.7 
Total (6 MSs)  136  43.4  136  0  136  21.3  136  2.2  136  0.7  136  2.9  136  50.0  136  44.9 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among Salmonella isolates from cattle 
It is evident from Figures SA29 and SA30 that large variations exist between MSs in the level of resistance 
to some antimicrobials, particularly ampicillin. The figures illustrate the trends in resistance to ampicillin 
ciprofloxacin and nalidixic acid among Salmonella isolates from cattle from 2006 to 2012. As in 2011, trends 
in resistance over time were mainly decreasing among Salmonella spp. from cattle. Germany experienced 
statistically significant decreasing trends in resistance to ampicillin (Figure SA29), and Germany also 
reported statistically significant decreasing trends in resistance to tetracyclines (data were not presented). 
No significant trends were observed in the reported resistance to ciprofloxacin and nalidixic acid between 
2006 and 2012 (Figure SA30). 
Figure SA28.  Trends in ampicillin resistance in Salmonella spp. from cattle in reporting MSs, 2006-
2012, quantitative data 
 
MS: Member State. 
Note: A statistically significant decreasing trend for five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Germany (↓).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure SA29.  Trends in ciprofloxacin and nalidixic acid resistance in Salmonella spp. from cattle in 
reporting MSs, 2006-2012, quantitative data 
 
MS: Member State. 
Note: For both ciprofloxacin and nalidixic acid, no statistically significant trend for five or more years, as tested by a logistic regression 
model (p ≤0.05), was observed in any of the reporting countries.  
  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among Salmonella isolates from cattle 
Figures SA31 and SA32 show the spatial distributions of ampicillin and nalidixic acid resistance in 
Salmonella spp. isolated from cattle in 2012. Figure SA31 illustrates the absence of a clear spatial 
distribution. Figure SA32 illustrates the continued absence, or low prevalence, of resistance to nalidixic acid 
in Salmonella spp. isolated from cattle in Europe. 
Figure SA30.  Spatial  distribution of ampicillin resistance among Salmonella  spp. from cattle in 
countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note: Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting inhibition zone diameter data, MIC data for less than 10 isolates, or purely qualitative data (as proportion 
of resistant isolates).  
1.  For Norway, 2011 data were used. 
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Figure SA31.  Spatial distribution of nalidixic acid resistance among Salmonella spp. from cattle in 
countries reporting MIC data in 2012
1 
 
Note: Percentages shown in this map refer to countries which reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data have been used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting inhibition zone diameter data, MIC data for less than 10 isolates, or purely qualitative data (as proportion 
of resistant isolates). MIC: minimum inhibitory concentration; MS: Member State. 
1.  For Norway, 2011 data were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Multi-resistance among Salmonella spp. isolates from cattle 
In 2012, six MSs reported isolate-based data concerning resistance in Salmonella spp. from cattle. The 
proportions of complete susceptible isolates were generally high to extremely high and varied between the 
reporting MSs, from 19.0 % in Belgium to 82.4 % in Sweden. Two reporting MSs (Finland and Sweden) 
reported moderate levels of multi-resistance in isolates tested from cattle, while the remaining MSs reported 
high levels of multi-resistance ranging between 20.6  % and 58.3  % (Table SA39). The frequency 
distributions (Figure SA33) showed that Belgium, Germany, Ireland and Italy detected isolates exhibiting 
reduced susceptibility to higher numbers of different substances (six to seven classes) than the two other 
MSs (five classes). Few isolates were resistant to both antimicrobials ciprofloxacin and cefotaxime (Table 
SA39). 
Table SA39.  Complete susceptibility, multi-resistance and index of diversity in Salmonella spp. from 
cattle in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  n  % 
Belgium (N=42)  8  19.0  21  50.0  0.551  1 (0)  2.4 (0) 
Finland (N=19)  15  78.9  2  10.5  0.317  0 (0)  0 (0) 
Germany (N=68)  45  66.2  14  20.6  0.409  0 (0)  0 (0) 
Ireland (N=36)  12  33.3  21  58.3  0.336  0 (0)  0 (0) 
Italy (N=14)  8  57.1  6  42.9  0.414  0 (0)  0 (0) 
Sweden (N=17)  14  82.4  3  17.6  0.203  0 (0)  0 (0) 
MS:  Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates.  
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip:>1 mg/L). 
Figure SA32.  Frequency  distribution  of  Salmonella spp. from cattle completely susceptible or 
resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella.  
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Multi-resistance among S. Typhimurium isolates from cattle 
In 2012, five MSs reported isolate-based data concerning resistance in S. Typhimurium from cattle (Table 
SA40). These are the same as those reporting in Salmonella spp., except Italy which did not report any 
resistance data in S. Typhimurium in cattle. Generally, complete susceptibility and multi-resistance rates in 
S. Typhimurium isolates were similar to or lower than those in Salmonella spp. in the remaining MSs, with 
the exception of Sweden which reported higher multi-resistance in S. Typhimurium than in Salmonella spp. 
(Table SA39). The maximum numbers of substances to which some S. Typhimurium are multi-resistant are 
the same as those in Salmonella spp. (Figure SA34) No isolates were resistant to both antimicrobials 
ciprofloxacin and cefotaxime (Table SA40). 
Table SA40.  Complete susceptibility, multi-resistance and index of diversity in S. Typhimurium from 
cattle in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ctx 
n  %  n  %  N  % 
Belgium (N=25)  1  4.0  12  48.0  0.496  0 (0)  0 (0) 
Finland (N=16)  12  75.0  2  12.5  0.317  0 (0)  0 (0) 
Germany (N=35)  24  68.6  3  8.6  0.315  0 (0)  0 (0) 
Ireland (N=24)  7  29.2  16  66.7  0.157  0 (0)  0 (0) 
Sweden (N=12)  9  75.0  3  25.0  0.203  0 (0)  0 (0) 
MS:  Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Salmonella. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three classes from the common set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to ciprofloxacin (Cip) and cefotaxime (Ctx): the frequencies and percentages of Salmonella isolates not susceptible to 
concentrations greater than epidemiological cut-off values (Ctx:>0.5 mg/L and Cip:>0.06 mg/L). Figures in parentheses indicate the 
occurrence of resistance determined using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints (Ctx:>2 mg/L and Cip:>1 mg/L). 
Figure SA33.  Frequency  distribution  of  S. Typhimurium from cattle completely susceptible or 
resistant to one to nine antimicrobials in MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Salmonella; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for Salmonella. 
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3.4.3. Comparison of ‘clinical’ and ‘microbiological resistance’ to ciprofloxacin 
Fluoroquinolones, including ciprofloxacin, are recognised as being critically important in human medicine 
and often constitute the first-line treatment for invasive salmonellosis. Therefore, the high levels of 
ciprofloxacin resistance observed among Salmonella spp., from some animal species that were discussed 
earlier in this chapter, are of concern. Resistance levels were particularly high among Gallus gallus and 
turkeys when interpreted using the EUCAST ECOFFs. 
When the data were re-analysed using the CLSI breakpoints, the resistance levels were considerably lower 
(Table SA41). Four countries reported very high or extremely high resistance to ciprofloxacin among 
Salmonella spp. from turkeys when using the EUCAST ECOFFS. One of the nine countries reporting more 
than 10 isolates detected no resistance. However, when the CLSI breakpoints were applied to analyse these 
data, high resistance was detected only in the Czech Republic (33.3  %), Poland (21.8  %) and Hungary 
(20.1 %).  Among  Salmonella spp. from Gallus gallus, resistance levels reached up to 69.0  % using the 
EUCAST ECOFFs and only three of the 17 countries reporting more than 10 isolates detected no resistance. 
However, using the CLSI breakpoints, resistance was only found in six countries, at low levels in Romania 
(8.9 %), Belgium (1.7 %), the Czech Republic (1.6 %), Hungary (1.9 %) and Spain (3.4 %) and at a very low 
level in Poland (0.3 %). Regarding Salmonella spp. from pigs, when using the EUCAST ECOFFS, one of the 
eight countries reporting more than 10 isolates detected no resistance. However, when the CLSI breakpoints 
were applied to analyse these data, low resistance was detected only in Belgium (2.7 %). Several countries 
reported low, moderate or high resistance among Salmonella spp. from cattle when EUCAST ECOFFS were 
used. None of these countries were found to have any resistant isolates when using the CLSI breakpoints.  
The geographical distribution of the occurrence of resistance to ciprofloxacin in turkeys and the fact that this 
parallels the occurrence of S.  Kentucky in farm animal species indicates how the clonal spread of one 
serovar can influence the overall picture. 
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Table SA41.  Resistance  (%)  to  ciprofloxacin  among  Salmonella  spp. from Gallus gallus, turkeys, pigs and cattle in 2012, using harmonised 
epidemiological cut-off values or CLSI breakpoints 
Country 
Gallus gallus
1  Turkeys
2  Pigs
3  Cattle
4 
N  EUCAST % Res  CLSI % Res  N  EUCAST % Res  CLSI % Res  N  EUCAST % Res  CLSI % Res  N  EUCAST % Res  CLSI % Res 
Austria  176  18.2  0  38  78.9  0  –  –  –  –  –  – 
Belgium  664  39.0  1.7  –  –  –  187  22.5  2.7  42  28.6  0 
Czech Republic  386  19.4  1.6  27  81.5  33.3  –  –  –  –  –  – 
Denmark  28  0  0  –  –  –  374  0  0  –  –  – 
Estonia  –  –  –  –  –  –  32  0  0  –  –  – 
Finland  –  –  –  –  –  –  –  –  –  19  0  0 
Germany  238  14.3  0  87  32.2  1.1  627  7.5  0  68  8.8  0 
Hungary  261  69.0  1.9  174  91.4  20.1  38  23.7  0  –  –  – 
Ireland  38  2.6  0  14  0  0  24  16.7  0  36  5.6  0 
Italy  328  23.8  0  48  37.5  0  25  12.0  0  14  14.3  0 
Latvia  14  0  0  –  –  –  –  –  –  –  –  – 
Netherlands  192  18.2  0  –  –  –  263  0.8  0  68  2.9  0 
Poland  738  39.2  0.3  55  52.7  21.8  10  60.0  0  –  –  – 
Portugal  174  23.6  0  –  –  –  –  –  –  –  –  – 
Romania  964  68.4  8.9  –  –  –  –  –  –  –  –  – 
Slovakia  85  30.6  0  –  –  –  –  –  –  –  –  – 
Spain  179  22.3  3.4  169  89.9  1.2  48  20.8  0  –  –  – 
Sweden  –  –  –  –  –  –  –  –  –  17  0  0 
United Kingdom  236  2.1  0  142  9.9  0  –  –  –  –  –  – 
CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; –: no data reported. 
1.  Gallus gallus: in Finland and Sweden, five and eight isolates were respectively sensitive to ciprofloxacin (minimum inhibitory concentration (MIC) below the epidemiological cut-off value (ECOFF)). 
2.  Turkeys: in Slovakia, two isolates (N=4) displayed reduced susceptibility to ciprofloxacin (MIC above both the EUCAST and CLSI thresholds), while, in Belgium, Finland and Portugal, two, one and nine 
isolates, respectively, were sensitive to ciprofloxacin (MIC below the EUCAST ECOFF). 
3.  Pigs: in Finland, Latvia and Sweden, five, three and four isolates, respectively were sensitive to ciprofloxacin (MIC below the EUCAST ECOFF).  
4.  Cattle: in Estonia, one isolate (N=7) displayed reduced susceptibility to ciprofloxacin (MIC above both the EUCAST and CLSI thresholds), while, in Latvia and Spain, two and nine isolates, respectively,  
were sensitive to ciprofloxacin (MIC below the EUCAST ECOFF). 
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3.4.4. Further analysis of multi-drug resistance in certain Salmonella serovars 
In the paragraphs above, the ‘summary indicators’ of multi-drug resistance (MDR)
14 have been tabulated 
showing notably the proportion of isolates which are fully susceptible, multi-drug resistant and co-resistant to 
ciprofloxacin and cefotaxime. Graphs also show the proportions of isolates resistant to different numbers of 
antimicrobials; corresponding data are also set out in Appendix 3. The information relating to Salmonella 
spp. from a MS often covers a variety of different serovars, each of which may have a different propensity to 
exhibit antimicrobial resistance and because the serovars which are prevalent in different MSs may vary, this 
will account for some of the pronounced variation in the recorded MDR parameters for Salmonella spp. 
which is evident in different MSs. S. Enteritidis in general exhibited much lower MDR than S. Typhimurium; 
however, there were marked differences between MSs in the occurrence of MDR for each of these serovars. 
The analysis of such patterns is most useful when applied at the serovar level, therefore MDR is considered 
briefly for Salmonella spp. and then several serovars of current importance are examined individually. 
3.4.4.1. Multi-drug resistance patterns 
Salmonella spp. 
The patterns of resistance exhibited by all reported Salmonella serovars comprise aggregated data from a 
variety of different serovars and are presented in Appendix 4 (Appendix Tables MDRP1 to MDRP7). A range 
of different resistance genes, occurring in different combinations and associated with different genetic 
elements occurs in Salmonella and consequently the range of patterns obtained is large. Detailed analysis of 
the specific patterns of resistance detected is the most useful when it is performed at the serovar level. 
However, the overall data from all Salmonella spp. have also been examined to determine which serovars 
demonstrate pentavalent resistance to ampicillin, chloramphenicol, sulfonamides, streptomycin and 
tetracyclines. This pattern of resistance (which may occur with additional resistance) has been demonstrated 
by a number of Salmonella serovars which have spread epidemically in animals, such as S. Typhimurium 
definitive phage types 104 and 204c, as well as S. Newport. See Section 3.4.4.4 Analysis of pentavalent 
resistance. 
Salmonella Enteritidis 
Information on MDR was available for S. Enteritidis isolates from broilers and laying hens. MDR was 
uncommon in S. Enteritidis isolates, occurring in only 1.9 % of 270 isolates from broilers and 5.8 % of 206 
isolates from laying hens (Appendix Tables MDRP8 and MDRP9). All MDR isolates from laying hens and the 
majority (4 out of 5) of MDR isolates from broilers were resistant to ciprofloxacin. Ampicillin, sulfonamide and 
tetracycline resistance was commonly observed as components of the MDR patterns. S. Enteritidis phage 
type 1 (PT1) from broilers commonly shows resistance to nalidixic acid and ciprofloxacin; however, other 
phage types (for example PT4, 7 and 21) may also demonstrate resistance to this antimicrobial, although 
usually less frequently (EFSA, 2007). Phage type 8 commonly showed susceptibility to the antimicrobials 
tested in EFSA’s baseline survey of broilers in the EU in 2005-2006. Otherwise, S. Enteritidis showed a 
greatly reduced propensity to display MDR than S. Typhimurium did. 
Salmonella Typhimurium 
S. Typhimurium showed a wide diversity of MDR patterns, especially evident in fattening pigs and cattle, 
species from which the largest numbers of isolates were available. It is noteworthy that the commonest 
pattern of MDR was resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracyclines 
in all types of animals except broilers, where it was the second most commonly observed pattern (Appendix 
Tables MDRP10 to MDRP13). This pattern has commonly been associated with S. Typhimurium definitive 
phage type 104 in recent years, although it can also be seen as part of the pattern in other phage types, 
such as DT193 and U288 (these latter types also frequently display trimethoprim resistance). Resistance to 
cefotaxime was not detected as part of the MDR profiles in cattle and ciprofloxacin resistance was usually 
uncommon in S.  Typhimurium MDR isolates, although it was most frequent in pigs, where gentamicin 
resistance was also more frequently detected.  
                                                       
14 Multi-drug resistance is defined as resistance to any three antimicrobials in the panel recommended by EFSA – and considering 
resistance to nalidixic acid and ciprofloxacin as a single resistance. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Monophasic Salmonella Typhimurium 
The patterns of multi-drug resistance for monophasic S. Typhimurium isolates from broilers, layers, turkeys, 
fattening pigs and cattle as well as meat from turkeys, pigs and cattle are shown in Appendix Tables 
MDRP14 to MDRP21. The most frequent pattern of resistance observed was resistance to ampicillin, 
streptomycin, sulfonamides and tetracyclines in all categories, except meat from turkeys, where this pattern 
with additional resistance to ciprofloxacin was predominant. Germany was the only MS providing data for 
meat from turkeys and contributed most of the isolates from turkeys; although resistance to ampicillin, 
streptomycin, sulfonamides and tetracyclines predominated in isolates from turkeys from this MS, this 
pattern with additional ciprofloxacin resistance was most commonly observed in isolates from turkey meat. 
More than 86 % of isolates exhibited MDR from all categories, except turkeys, where more than 70 % were 
MDR. The numbers of isolates received from categories other than pigs and meat from pigs were less than 
20 and only two to four different resistance patterns were detected; these frequently involved acquisition of 
resistance to one or more of chloramphenicol, gentamicin, ciprofloxacin and trimethoprim, with or without 
loss of resistance to sulfonamide, ampicillin and tetracyclines. Streptomycin resistance was invariably 
present in the MDR isolates in all categories except from pigs and meat from pigs, where it was only absent 
from 5 out of 377 isolates. Among the reporting countries of isolate-based data, Germany contributed the 
majority of isolates for all categories, except broilers and laying hens, and the diversity of MDR patterns 
observed for this MS may be a reflection of the greater number of isolates examined.  
Salmonella Kentucky 
The patterns of MDR for S. Kentucky isolates from broilers, laying hens and meat from broilers are shown in 
Appendix Tables MDRP22 to MDRP24. More than 80 % of isolates from broilers had the core resistance 
pattern to ampicillin, ciprofloxacin, gentamicin, sulfonamides and tetracyclines, often with resistance to 
streptomycin. The core pattern with additional streptomycin resistance was also the most commonly 
observed pattern in meat from broilers. Although in laying hens the commonest pattern was resistance to 
ampicillin, ciprofloxacin and tetracyclines, the pattern of resistance to ampicillin, ciprofloxacin, gentamicin, 
sulfonamides and tetracyclines (in some cases with additional resistance) was also observed.  
Salmonella Derby 
There were very few S. Derby isolates reported from broilers, cattle and meat from cattle (ten or less) 
(Appendix Tables MDRP25 to MDRP30). S. Derby isolates from turkeys were 99.2 % MDR, whereas the 
situation for isolates from pigs and meat from pigs was markedly different with 17.4  % and 25.3  % 
respectively, exhibiting MDR. Resistance to streptomycin, sulfonamides and tetracyclines was the most 
frequently observed MDR pattern in isolates from both pigs and pig meat. Ciprofloxacin resistance was 
uncommon in S. Derby isolates from pigs occurring in only 2.4 % of the isolates for which isolate-based data 
was available. This contrasts with the situation in turkeys, where the most common resistance pattern was 
resistance to ampicillin, chloramphenicol, ciprofloxacin, sulfonamides, tetracyclines and trimethoprim, 
occurring in 49.6 % of isolates. Ciprofloxacin resistance was present in more than 90 % of S. Derby isolates 
from turkeys (Appendix Tables MDRP28). 
Salmonella Infantis 
Information on MDR was available for 529 S. Infantis isolates from broilers and 162 from broiler meat 
(Appendix Tables MDRP33 and MDRP31). Lower numbers of isolates were available from laying hens (36), 
turkeys (27), fattening pigs (18) and meat from pigs (23). The number of different MDR patterns obtained 
was approximately in proportion to the number of available isolates from each animal and food category. A 
very diverse range of 43 different MDR patterns was reported for 529 S. Infantis from broilers. Resistance to 
ciprofloxacin was invariably present as a component of the MDR patterns in broilers and turkeys and 
occurred in almost all isolates from broiler meat and laying hens; it was less common in MDR isolates from 
pigs and pig meat. Resistance to a common core antimicrobial pattern of ciprofloxacin, sulfonamides and 
tetracyclines occurred in 97.5 % (158 out of 162) of S. Infantis isolates from broiler meat and 82.4 % (436 out 
of 529) of isolates from broilers, 77.8 % (28 out of 36) from laying hens, 92.6 % (25 out of 27) from turkeys, 
39.0 % (7 out of 18) of isolates from pigs and 13.0 % (3 out of 23) of isolates from pig meat. Resistance to 
ciprofloxacin, streptomycin, sulfonamides and tetracyclines (a pattern associated with S. Infantis definitive 
phage type 213) occurred in 29.9  % (158 out of 529) of S.  Infantis isolates from broilers alone or with 
additional resistances, while 19.4 % (7 out of 36) of isolates from laying hens, 18.5 % (5 out of 27) of isolates EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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from turkeys and 27.2 % (44 out of 162) of isolates from broiler meat showed this core pattern of resistance. 
Ciprofloxacin, streptomycin, sulfonamide and tetracycline resistance was uncommon in pigs and meat from 
pigs occurring in 5.6 % (1 out of 18) and 8.7 % (2 out of 23) of S. Infantis isolates, respectively. 
3.4.4.2. Co-resistance to cefotaxime and ciprofloxacin 
Table SA42 describes those Salmonella  serovars which were co-resistant to both cefotaxime and 
ciprofloxacin using EUCAST clinical breakpoints. In this table, data derived from the testing of fewer than 10 
isolates and from fewer than four reporting countries have been included. The table also describes the 
resistance patterns for such isolates (applying ECOFFs for the other antimicrobials). Co-resistance to 
cefotaxime and ciprofloxacin has relevance for public health, since these are frequently the two main 
antimicrobials used for first-line treatment of human patients with salmonellosis. 
Table SA42.  Co-resistance to cefotaxime and ciprofloxacin (applying EUCAST clinical breakpoints) 
Source 
Total number 
isolates for which 
relevant data 
available  
Number of isolates 
resistant to 
cefotaxime and 
ciprofloxacin
1 (%) 
Serovar (number of isolates) and resistance 
pattern(s) of isolates of this serovar co-
resistant to cefotaxime and ciprofloxacin
2 
Meat from 
broilers  
(Gallus gallus) 
410  7 (1.7 %) 
Other serovars (5) AmpCtxCipNalSuTet 
S.  Infantis (1) AmpCtxChlCipNalSuTetTmp 
S. Rissen (1) AmpCtxChlCipNalSuTetTmp 
Broilers  1,641  28 (1.7 %) 
S. Agona (1) 
AmpCtxChlCipGenNalStrSuTetTmp 
S. Hadar (6) AmpCtxChlCipNalStrSuTmp and 
AmpCtxCipNalSuTetTmp 
S. Infantis (14) AmpCtxCipNalSuTetTmp 
AmpCtxCipNalSuTet AmpCtxCipNal  
AmpCtxCipGenNalSuTetTmp 
AmpCtxCipGenNalStrSuTet and 
AmpCtxChlCipGenNalStrSuTetTmp 
S. Kentucky (1) AmpCtxCipNal 
S. Livingstone (2) AmpCtxCipGenNalStrSu and 
AmpCtxChlCipNalSuTetTmp 
S. Mbandaka (1) AmpCtxCipNalSuTetTmp 
S. Senftenberg (2) AmpCtxChlCipGenNalSu 
S. Thompson (1) AmpCtxCipNalSuTetTmp 
Laying hens  686  2 (0.3 %)  S. Kentucky (2) AmpCtxCipNal 
Turkeys  567  1 (0.2 %)  S. Derby (1) AmpCtxChlCipNalStrSuTetTmp 
Fattening pigs 
and unspecified  1,155  5 (0.4 %) 
S. Derby (4) AmpCtxCipNalStrSuTmp 
S. Typhimurium, monophasic (1) 
AmpCtxCipNalStrSuTetTmp 
Cattle  
(bovine animals)  212  1 (0.5 %)  S. Livingstone (1) AmpCtxCipNalStrSuTetTmp 
1.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints were applied for cefotaxime 
(R>2 mg/L) and ciprofloxacin (R>1 mg/L). 
2.  EUCAST epidemiological cut-off values were applied for antimicrobials other than cefotaxime and ciprofloxacin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Considering the Salmonella  serovars showing co-resistance to cefotaxime and ciprofloxacin, multi-drug 
resistant S. Infantis with co-resistance to cefotaxime and ciprofloxacin was infrequent among Salmonella 
isolates on broiler meat, comprising 0.2 % (1 out of 410) of the total available; however, it was the most 
common serovar which exhibited co-resistance at the clinical breakpoint for cefotaxime and ciprofloxacin in 
broilers, where it accounted for 0.8 % (14 out of 1,641) of the total isolates from broilers. Other serovars 
exhibiting co-resistance generally occurred at a low frequency and were detected as one or two MDR 
isolates, apart from S.  Hadar in broilers (6 out of 1,641 isolates) and S. Derby in pigs (4 out of 1,155 
isolates). The same co-resistant serovar (S. Infantis) was therefore detected in broilers and broiler meat. Co-
resistance to cefotaxime and ciprofloxacin was most frequently observed in Salmonella  serovars from 
broilers, affecting 1.7 % of isolates and involving eight different serovars. Co-resistance affected less than 
1 % of Salmonella isolates from other categories of livestock. Isolate-based data were available for fewer 
isolates from cattle (212) than for the other species and a single MDR isolate of S. Livingstone was detected 
from cattle exhibiting co-resistance to cefotaxime and ciprofloxacin. Interestingly, the resistance pattern 
observed (AmpCtxCipNalStrSuTetTmp), but without trimethoprim resistance was also observed in an isolate 
of  S.  Livingstone from broilers, suggesting possible transmission of this MDR serovar between these 
livestock sectors.  
3.4.4.3. Analysis of high-level ciprofloxacin resistance 
High-level resistance to ciprofloxacin in Salmonella of animal and food origin, as well as the serovars 
displaying such resistance, are shown in Appendix 5. A variety of serovars displayed high-level ciprofloxacin 
resistance and were frequently resistant to other antimicrobials. 
Considering those serovars occurring most frequently and in a number of different MSs and types, 
S.  Kentucky was represented in isolates from Romania, the Czech Republic, Spain and Hungary from 
broilers from Romania, Spain and Hungary from laying hens and from the Czech Republic, Spain and 
Hungary from turkeys. It was also detected in single isolates from meat from turkeys in the Czech Republic 
and from meat from broilers in Ireland. S. Infantis was the second most frequently encountered in a number 
of different MSs. A single isolate of S. Typhimurium showing high-level ciprofloxacin resistance was reported 
from meat from pigs. 
A particular clone of S.  Kentucky sequence type 198 with high-level ciprofloxacin resistance has been 
detected in Africa and the middle East (Le Hello et al., 2011) and has been subsequently detected in poultry 
in some European countries (Wasyl and Hoszowski, 2012). S. Kentucky showing such high-level resistance 
to ciprofloxacin was detected in several MSs in 2012 and from a number of different sources. The 
occurrence of this serovar/phenotype is only evident in MSs reporting isolate-based data. The MSs detecting 
such isolates in broilers include Romania (8.2 %; 64 out of 781), the Czech Republic (1.4 %; 5 out of 351), 
Spain (13.8 %; 4 out of 29) and Hungary (0.6 %; 1 out of 175). In laying hens, it was detected in Romania 
(2.7 %; 4 out of 146), Spain (1.3 %; 2 out of 150) and Hungary (2.3 %; 2 out of 86) and in turkeys in the 
Czech Republic (33.3 %; 9 out of 27), Spain (1.2 %; 2 out of 169) and Hungary (19.0 %; 33 out of 174). The 
Czech Republic detected S. Kentucky with high-level ciprofloxacin resistance in meat from turkeys (1 out of 
10; 10.0 %), while Ireland detected it in meat from broilers (1.4 %; 1 out of 70). S. Kentucky with high-level 
ciprofloxacin resistance has therefore been reported from a larger number of MSs in 2012 than was the case 
in 2011 and is now being detected in all three types of poultry, which are monitored (broilers, laying hens 
and turkeys), as well as in broiler and turkey meat. Its occurrence may be under-estimated because not all 
MSs report isolate-based data and some MSs have reported the occurrence of unspecified serovars which 
possess this phenotype. Genotypic typing data were not available; therefore, the isolates with this phenotype 
cannot be definitively assigned to the ST198 clone of S. Kentucky. 
Salmonella serovars displaying high-level ciprofloxacin resistance were reported in poultry only and were not 
detected in fattening pigs or cattle in the reporting MSs. However, single isolates of S. Typhimurium and 
S. Infantis displaying such resistance were recovered from pig meat in two MSs and these MSs did not 
examine isolates from fattening pigs. The diversity of serovars displaying high-level ciprofloxacin resistance 
in poultry differed between MSs and was greatest in Romania which detected it in the serovars Agona, 
Infantis, Kentucky, Liverpool, Livingstone, Rissen and Tennessee in broilers and in the serovars Albany, 
Corvallis, Hadar, Kentucky and Thompson from laying hens. Hungary also detected high-level resistance to 
ciprofloxacin in serovars other than Kentucky; namely in S. Stanley from turkeys, S. Saintpaul from laying 
hens and S. Infantis from broilers. High-level resistance to fluoroquinolones in Salmonella generally involves 
multiple mutations of the DNA gyrase genes which are chromosomally located and therefore not transferable 
between bacteria in bacterial conjugation. The results suggest that clonal spread of S. Kentucky with high-
level ciprofloxacin resistance may be occurring in EU MSs; however, genetic confirmation would be required EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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to substantiate this observation. Moreover, a range of different serovars showing high-level resistance to 
ciprofloxacin is emerging in some MSs and this may be the result of the selective pressure of usage of 
fluoroquinolones. 
S. Infantis with high-level ciprofloxacin resistance was detected in several MSs, raising the possibility that 
this serovar is also spreading clonally in poultry and possibly other species in Europe. In total, 14 isolates 
were recovered from Romania (broilers and broiler meat), Hungary (broilers) and the Czech Republic (pig 
meat). In addition to high-level ciprofloxacin resistance, all isolates were also resistant to sulfonamides and 
tetracyclines, with some possessing a range of additional resistances. Genetic examination would be 
required to investigate whether this represents clonal expansion of a high-level ciprofloxacin-resistant strain 
or multiple independent evolutions of several different strains. S.  Infantis resistant to nalidixic acid, 
streptomycin, sulfonamides and tetracyclines belonging to definitive phage type 213 has been reported from 
several European countries (Nógrády et al., 2012). This pattern of resistance has also been noted in 
S. Infantis isolates from broilers in Iran (Rahmani et al., 2013), while resistance to nalidixic acid, tetracyclines 
and nitrofurantoin has been reported in Israel (Gal-Mor et al., 2010). 
3.4.4.4. Analysis of pentavalent resistance 
The occurrence of such pentavalent resistance in different serovars is shown in Table SA43. Some such 
serovars were detected sporadically with only one reported instance (e.g. S. Wisbech, S. Kapemba) while 
others were detected at higher frequencies (e.g. S. Infantis) and sometimes in several different types of 
livestock (S. Infantis). In view of the observation that pentavalent resistance has been shown by many of the 
serovars which have become highly prevalent over the last few decades; describing these serovars in this 
way may provide an early indication of newly emerging epidemic strains. 
Table SA43.  Salmonella  serovars detected with pentavalent resistance amongst those for which 
isolate-based data is available 
Origin  Serovars detected with pentavalent
1 resistance 
Meat from broilers  S. Java (2), S. Infantis (1), S. Typhimurium (3) 
Meat from pigs  S. enterica subsp. enterica (2), S. Typhimurium (33), S. 1,4,[5],12:i:- (3), S. Kapemba (1), 
S. 4,12:i:- (1), S. Infantis (1), S. Typhimurium, monophasic (1), other serovars (1) 
Meat from turkeys  Other serovars (1) 
Broilers  S. Agona  (1),  S. Infantis  (10),  S. Liverpool  (5),  S. Tennessee  (2),  S. Senftenberg  (2), 
S. Kentucky (4), S. Typhimurium (3), S. Saintpaul (1) 
Laying hens  S. Typhimurium (4), S. Kentucky (1), S. Infantis (1) 
Turkeys  S. 1,4,[5],12:i:-  (1),  S. Agona  (1),  S. Derby  (13),  S. Hadar  (1),  S. Typhimurium  (1), 
S. Wisbech (1), S. London (3), S. Anatum (1) 
Fattening pigs  S. Typhimurium (112), S. 1,4,[5],12:i:- (20), Other serovars (7), S. enterica subsp. enterica 
(2), S. 4,12:i:- (1), S. Typhimurium, monophasic (2), S. Choleraesuis (1), not typeable (1) 
Cattle  S. Typhimurium (28), S. Rissen (1) 
1. Resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracyclines. 
S. Infantis features as a serovar displaying pentavalent resistance, occurring at a relatively higher frequency 
in some animal categories (and in more than one different type of animal), as well as showing high-level 
ciprofloxacin resistance. It has also been detected in more than one MS. The detection of high-level 
ciprofloxacin resistance, associated with sulfonamide and tetracycline or pentavalent resistance in S. Infantis 
warrants further investigation to determine the relationship between those isolates currently occurring in 
animals and human as well as the relation to isolates detected in previous years. 
Pentavalent resistance in Salmonella serovars can be related to the presence of the genetic structure 
known as Salmonella genomic island 1 (SGI1), which has been detected in a number of different serovars 
including Agona, Java, Albany and Newport in addition to S. Typhimurium (Velge et al., 2005). Recent 
genetic analysis (Beutlich et al., 2011) has shown the occurrence of several variations of the basic pattern of 
pentavalent resistance associated with SGI1 in European Salmonella isolates, related to the deletion and 
acquisition of different resistance genes. Thus, the ‘classical’ resistance pattern associated with SGI1 is 
conferred by the resistance genes blaPSE-1,  floR,  sul1, tet(G) and aadA2, whereas the variant SGI-1A 
occurring in S. Derby, has these genes together with dfrA10, conferring trimethoprim resistance. SGI-1C EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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(also detected in S. Derby) has a deletion such that only aadA2 and sul1 remain, conferring resistance to 
streptomycin and sulfonamides. SGI-1M was a variant detected in S. Typhimurium with blaPSE-1, floR, sul1, 
tet(G) and aadB, the latter gene conferring gentamicin resistance. SGI1-K1 is a variant of SGI-1 described in 
S. Kentucky ST198 (Le Hello et al., 2011) showing high-level ciprofloxacin resistance, which also carries 
gentamicin resistance (conferred by aacA5), as well as genes conferring resistance to ampicillin, 
sulfonamides, streptomycin and tetracyclines. This MDR pattern (with additional resistance to ciprofloxacin) 
was that most frequently observed in S. Kentucky isolates from broilers and was also observed in isolates 
from laying hens and meat from broilers. Another pattern detected in S.  Kentucky with high-level 
ciprofloxacin resistance was also evident; namely ampicillin, sulfonamide and tetracycline resistance, which 
has been associated with the Salmonella genomic island variant SGI1-K2. 
MDR was uncommon in S. Enteritidis isolates, occurring in only 1.9 % of 270 isolates from broilers and 
5.8  % of 206 isolates from laying hens, a marked contrast to the position in S. Typhimurium. All MDR 
isolates from laying hens and the majority (4 out of 5) MDR isolates from broilers were resistant to 
ciprofloxacin; resistance to ampicillin, sulfonamides and tetracyclines was also generally observed in MDR 
isolates. There were no S.  Enteritidis isolates recovered from animals which were resistant to the 
antimicrobials ampicillin, chloramphenicol, sulfonamides, streptomycin, tetracyclines and trimethoprim. This 
resistance phenotype has been associated with a combined virulence–resistance plasmid in S. Enteritidis (a 
hybrid plasmid carrying both virulence and resistance determinants) and allows increased intra-cellular 
proliferation resulting in more severe human infections; an African origin was suspected in a European study 
of several isolates from humans (Rodriguez et al., 2012). This resistance phenotype might occur through 
other genetic configurations and cannot be used to confirm the presence of the combined virulence–
resistance plasmid. However, it serves to illustrate how the data may be used to assess the possible 
incursion of such strains into the EU and to flag isolates for possible further investigation. 
S. Typhimurium displayed a diverse range of resistance patterns, including patterns which can be 
associated with particular definitive phage types, such as ampicillin, chloramphenicol, streptomycin, 
sulfonamide and tetracycline resistance (associated with DT104) and this core pattern plus additional 
resistance to trimethoprim (which can be associated with phage types such as DT193 and U288). 
Resistance to ampicillin, chloramphenicol, gentamicin, sulfonamides and tetracyclines (the ‘SGI-1M pattern’, 
see above), albeit with additional resistances, was observed in 3.2 % (11 out of 341) of S. Typhimurium 
isolates from pigs. Cefotaxime resistance was not observed as part of MDR patterns in S. Typhimurium and 
resistance to ciprofloxacin was relatively uncommon. The wide range of resistance patterns detected may 
reflect the considerable diversity of strain types exhibited by this serovar (which may be a very old serovar) 
and consequently differences in the acquisition or ability to acquire resistance genes (Lan et al., 2009). 
Some of the definitive phage types of S. Typhimurium have been considered to have complex origins (Lan et 
al., 2009) and therefore might also differ in their propensity to develop or acquire resistance.  
The majority of monophasic S. Typhimurium demonstrated the typical pattern of ‘tetravalent’ resistance to 
ampicillin, streptomycin, sulfonamides and tetracyclines, with this pattern plus resistance to ciprofloxacin 
prominent in isolates from turkey meat. The core pattern with additional resistance to trimethoprim was the 
second most commonly observed pattern in isolates from fattening pigs. The relative frequency of 
occurrence of the different patterns is likely to be biased by the relative contributions from individual MSs, 
because different MSs have reported variations in the patterns of resistance in this serovar. Monophasic 
S. Typhimurium with chromosomally encoded resistance to ampicillin, streptomycin, sulfonamides and 
tetracyclines have become particularly common in numerous EU countries since 2000, while Spanish U302-
based monophasic strains have also been found to be multi-resistant, most frequently to ampicillin, 
chloramphenicol, gentamicin, streptomycin, sulfonamides, tetracyclines and trimethoprim (EFSA BIOHAZ 
Panel, 2010b). Strains showing resistance to ampicillin, streptomycin, sulfonamides and tetracyclines 
carrying the resistance genes blaTEM, strA-strB, sul2 and tet(B) (generally belonging to phage definitive types 
120 or 193) have been considered the ‘European’ clone and carry Salmonella genomic island 2. Two other 
lineages have been described, the ‘Spanish’ clone referred to above and the ‘US’ clone, which is generally 
susceptible (Bugarel et al., 2013). A recent study of isolates from diverse sources in France ascribed 71 % of 
isolates to the Spanish clone and 2 % to the US clone (Bugarel et al., 2013). The pattern of resistance to 
ampicillin, chloramphenicol, gentamicin, streptomycin, sulfonamides, tetracyclines and trimethoprim was only 
described in 1.8  % (5 out of 279) of isolates from fattening pigs, whilst the pattern associated with the 
European clone was much more frequently detected. Resistance to cefotaxime as part of MDR was 
observed in 1.1  % of isolates from fattening pigs (3 out of 279) and one of these monophasic 
S. Typhimurium isolates was resistant to all antimicrobials in the test panel. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Ten isolates were detected which were resistant to all nine antimicrobials in the test panel, including the 
single monophasic S. Typhimurium isolate from fattening pigs (0.1 %; 1 out of 983) and a single isolate of 
S. Agona from turkeys (0.2 %; 1 out of 567). In broilers, 0.5 % (8 out of 1 659) of Salmonella isolates were 
resistant to all of the antimicrobials in the test panel, comprising the serovars Infantis (two), Kentucky (two), 
Agona, Liverpool, Senftenberg and Tennessee. The two S. Kentucky isolates, one of the Infantis isolates 
and the Agona isolate demonstrated high-level ciprofloxacin resistance with MICs >4 mg/L. 
There were only very few S. Derby isolates from broilers, cattle and meat from cattle (10 or less). MDR to 
streptomycin, sulfonamides and tetracyclines which was observed in both of only two S. Derby isolates from 
cattle was the commonest pattern observed in S. Derby isolates from fattening pigs. Different MSs were 
involved, but, where a MDR pattern and serovar are common in one species and the same pattern but at a 
lower frequency is observed in another species, spill over from a major reservoir host to a minor one is a 
possible explanation. The findings at EU level relating to pigs are therefore broadly consistent with a French 
study of isolates from pigs, pig meat and humans which found that 69.2 % were simultaneously resistant to 
streptomycin, sulfonamides and tetracyclines (Kerouanton et al., 2013). In Spain, 85.7 % of porcine S. Derby 
isolates were resistant to tetracyclines, 85.7  % to streptomycin, 71.4  % to sulfonamides and 50  % to 
ampicillin, whilst 42.8 % showed trimethoprim/sulfonamide resistance and 7.1 % were resistant to nalidixic 
acid (Valdezate et al., 2005). These prevalences of resistance are consistent with the MDR patterns 
observed. Isolates of S. Derby from pigs were markedly different from those in turkeys in relation to their 
tendency to display MDR (99.2 % in turkeys; 17.4 % in pigs) and the extent to which ciprofloxacin is a 
component of MDR patterns (2.3  % in MDR isolates from pigs; more than 90  % in MDR isolates from 
turkeys). SGI1-A has been described in S. Derby and comprised resistance to ampicillin, chloramphenicol, 
streptomycin, sulfonamides and tetracyclines (‘pentavalent’ resistance) with additional resistance to 
trimethoprim. This pattern was observed in isolates from turkeys and - with additional resistance to 
ciprofloxacin - was the most commonly observed MDR pattern in that animal species.  
3.5.  Overview of the findings of antimicrobial resistance in Salmonella at Member State 
reporting group level, 2012 
Figures SA35 and SA36 illustrate the resistance levels for the groups of MSs reporting quantitative MIC data 
in 2012. These data were not all derived from the same group of MSs, which needs to be considered when 
interpreting these figures. Resistance levels to ampicillin, chloramphenicol, sulfonamides and tetracyclines in 
S. Typhimurium from Gallus gallus were higher than in S. Enteritidis from Gallus gallus. However, resistance 
to ciprofloxacin and nalidixic acid was higher in S. Enteritidis than in S. Typhimurium. In terms of all 
Salmonella spp., resistance levels in isolates from broiler meat were higher than those in isolates from 
Gallus gallus. This represents a return to the pattern observed in 2009 with an increase in resistance in 
isolates from broiler meat compared with the levels reported in 2010. 
In a very similar pattern to that observed in 2010, resistance levels to tetracyclines, sulfonamides and 
ampicillin were higher in Salmonella isolated from turkeys, pigs and cattle than in isolates from Gallus gallus, 
whereas, for ciprofloxacin and nalidixic acid, the highest resistance was observed in turkeys and in Gallus 
gallus. The levels of resistance to sulfonamides and tetracyclines in isolates from turkeys decreased in 2012, 
whereas the levels of resistance to these antimicrobials in isolates from pigs increased compared with 2010. 
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Figure SA34.  Resistance  to  ampicillin,  cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines in 
Salmonella spp., S. Enteritidis and S. Typhimurium from Gallus gallus and Salmonella spp. from meat from broilers at reporting MS group level in 2012 
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Figure SA35.  Resistance  to  ampicillin,  cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines in 
Salmonella spp. from Gallus gallus, turkey, pigs and cattle at reporting MS group level in 2012 
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3.6. Discussion 
Salmonellosis continues to be the second most commonly reported zoonotic disease in humans in the EU, 
exceeded only by campylobacteriosis, although there has been a significant decline in human salmonellosis 
cases over the period 2007 to 2012. This decrease is assumed to be mainly the result of a reduction in 
Salmonella prevalence in flocks of laying hens, broilers and turkeys, probably as a result of the national 
control and monitoring programmes implemented by the MSs in the corresponding production sectors (EFSA 
and ECDC, 2014). 
In 2012, information on antimicrobial resistance in Salmonella isolates from human cases was reported by 
19 MSs and two non-MS. The number of isolates submitted by these countries corresponded to one-quarter 
of the salmonellosis cases reported within the EU in 2012 and is considered a representative sample. MSs 
not reporting antimicrobial resistance data are, however, still encouraged to do so, in order to achieve the 
best possible assessment of the levels of antimicrobial resistance in human Salmonella isolates in the EU. A 
novelty in this year’s report was that isolates from cases notified as having been acquired during travelling 
outside of the reporting country were excluded from all analyses except the analysis of resistance in 
difference geographical regions. This was done to better assess the impact on Salmonella isolates from food 
consumed within each reporting country on the antimicrobial resistance levels found in human isolates in that 
country. Please note, however, that imported food, which can constitute a large proportion of the food 
available in some countries, is not covered by this report.   
Resistance in human Salmonella isolates was high for ampicillin, sulfonamides, streptomycin and 
tetracyclines and moderate for nalidixic acid. These first four compounds are antimicrobials that are or have 
been commonly used for treatment of animals and formerly were commonly used in humans. For these four 
antimicrobials, the important resistance observed was largely the result of the high to extremely high 
resistance levels observed among S.  Typhimurium and particularly monophasic S. Typhimurium isolates. 
This corresponding resistance pattern (ASSuT) is that which is most commonly observed among the 
emerging monophasic S. Typhimurium definitive phage type 193 out of 120 strains (EFSA BIOHAZ Panel, 
2010b). In contrast, resistance to the clinically important antimicrobials, ciprofloxacin and cefotaxime, was 
relatively low among the isolates tested. However, levels of resistance to ciprofloxacin were generally higher 
in countries using ECOFFs or other sensitive breakpoints, as both CLSI and EUCAST clinical breakpoints for 
ciprofloxacin resistance are significantly higher than the ECOFF. Resistance to quinolones (ciprofloxacin and 
nalidixic acid) was also generally higher in S. Enteritidis isolates than in S. Typhimurium isolates of human 
origin.  
There was a rather poor correlation between ciprofloxacin and nalidixic acid resistance levels observed in 
human isolates in 2012. This could possibly be the result of the problem of detecting low-level ciprofloxacin 
resistance in Salmonella when using disc diffusion. In the ECDC external quality assurance scheme for 
Salmonella, it was also concluded that the use of different, sometimes non-standardised, interpretive criteria 
resulted in deviating results, rather than a lack of accuracy or performance in the laboratories (ECDC, 2012). 
In the EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and 
Campylobacter isolates, ECDC is therefore promoting the use of EUCAST methods and breakpoints in all 
laboratories submitting AST results to TESSy, and advise laboratories using disc diffusion for ciprofloxacin to 
also test for nalidixic acid (ECDC, 2014). 
About 30 % of human Salmonella spp. isolates from the 13 MSs which tested all antimicrobials in the test 
panel exhibited multi-drug resistance, meaning that they were clinically non-susceptible to at least three 
different antimicrobial classes. Two MSs recorded MDR levels above 50  %. However, about half of all 
isolates tested were susceptible to the complete range of antimicrobials reported for humans. Co-resistance 
to the critically important antimicrobials, ciprofloxacin and cefotaxime, was low and observed in a total of 
27 isolates (out of 13,496 isolates tested) reported by five of the 12 reporting MSs.  
The MDR levels observed in human isolates were sometimes higher than those observed in animals and 
meat. This can be explained by the fact that both clinically resistant and clinically intermediate results were 
combined to estimate MDR in human isolates and the clinical breakpoints for only 4 out of 10 antimicrobials 
(cefotaxime and ciprofloxacin regarding both CLSI and EUCAST, gentamicin and trimethoprim regarding 
only CLSI) had higher MIC values (i.e. being less sensitive) than the ECOFFs and for two antimicrobials 
(chloramphenicol and tetracyclines) the relationship was the reverse, i.e. the clinical breakpoint was more 
sensitive than the ECOFF. This resulted in a lower than expected difference in MDR estimates between 
human and animal/food isolates.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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A striking observation was that many human isolates were resistant to a large number of antimicrobials, 
some even to all 10. This could reflect the impact of use of antimicrobials in humans, in addition to that in 
food-producing animals, or exposure to sources of Salmonella  other than those associated with food-
producing animals. A proportion of the Salmonella infections occurring in humans in a given MS is likely to 
be associated with food-producing animals in that MS, while other infections will be associated with a variety 
of other sources, including imported foods and spices, foreign travel, other types of animals (such as pet 
reptiles) or the environment. Some human infections can also occur through spread between affected human 
patients. As mentioned above, travel-associated cases (where the information was provided) were excluded 
from the analysis in order to reduce this bias.  
In order to assess the importance of travel-associated infections, antimicrobial resistance was also 
analysed based on the most likely country of infection and aggregated by geographical region. Overall, 
human  Salmonella spp. isolates acquired within the EU/EEA countries exhibited greater resistance to 
ampicillin, streptomycin, sulfonamides and tetracyclines than isolates from any other region, while the 
highest levels of resistance to ciprofloxacin were observed in isolates acquired from Asia, Africa and 
European countries outside of the EU/EEA. 
In Salmonella isolates from animals and meat, information on antimicrobial resistance was reported by 
19  MSs and two non-MS in accordance with EFSA’s recommendations (EFSA, 2007) in 2012. The 
(quantitative) MIC results obtained using the methods recommended by EFSA provided the most 
harmonised and comparable set of data for reporting MSs, and these datasets have therefore been analysed 
in detail. For the second time, this EU Summary Report has examined the levels of resistance in isolates 
within different production types of animal species. Differences in animal husbandry and physiological 
differences between animals involved in different production types (e.g. fattening veal calves and dairy cattle) 
make evaluation of the antimicrobial resistance results at the animal species level difficult, where the 
production types of the species in question are not comparable. Sub-division of resistance data allows for 
more accurate analysis; however, this is possible only where sufficient information on production type has 
been submitted. In 2012, the large number of MSs providing data on isolates from Gallus gallus by 
production type allowed for more accurate analysis. However, more information is required at the production 
level for other animal species, particularly cattle, to improve these sections of the report in future years.  
As mentioned above, some antimicrobials such as ampicillin, sulfonamides and tetracyclines have been 
widely used for many years in veterinary medicine to treat bacterial diseases. The levels of resistance to 
these antimicrobials are generally moderate to high among isolates from food-producing animals and meat 
products thereof. For ampicillin, sulfonamides and tetracyclines, as well as chloramphenicol, resistance 
levels were highest in isolates from pigs, followed closely by isolates from turkeys and then cattle. Isolates 
from Gallus gallus displayed the least resistance to these antimicrobials within the reported data, but were 
still at moderate to high levels. Considering the production level data for Salmonella spp. and S. Enteritidis 
from Gallus gallus, higher levels of resistance were generally observed among isolates from broiler flocks 
than in isolates from laying hen flocks. This was particularly evident for tetracyclines and sulfonamides. This 
may reflect the relative infrequency with which laying hens are treated with antimicrobials compared with 
broilers, as well as the limited numbers of antimicrobial compounds which are authorised for the treatment of 
laying hens in many EU MSs. 
The highest occurrence of resistance to ciprofloxacin was noted in Salmonella from turkeys, fowl (Gallus 
gallus) and broiler meat. The ciprofloxacin resistance level for the Gallus gallus species can be further sub-
divided into production types and reveals a difference between Salmonella isolates from laying hens (19.4 % 
resistance) and broilers (46.3  % resistance). An equal number of MSs had significant increasing and 
decreasing national trends for ciprofloxacin and/or nalidixic acid resistance in Salmonella spp. isolates from 
Gallus gallus over the 2006 to 2012 period. These observations relating to Salmonella spp. may reflect the 
occurrence of S. Enteritidis phage type 1 in Gallus gallus within these MSs, since this phage type commonly 
displays resistance to nalidixic acid and ciprofloxacin. Similarly, in turkeys, the dissemination of certain 
serovars, such as S. Newport and S. Infantis, in some MSs, which, again, are commonly resistant to nalidixic 
acid and ciprofloxacin, may affect the overall levels of resistance among all Salmonella spp. In addition, the 
reporting of resistance results for an expanded number of individual serovars in this report enables some of 
the resistances which are associated with particular serovars to be clearly seen. 
Resistance to third-generation cephalosporins, such as cefotaxime, was detected in Salmonella isolates 
from turkeys, fowl (Gallus gallus), pigs, cattle and the meat derived from broilers and pigs, but at low or very 
low levels when all reporting MSs were considered. However, there was some variability in third-generation 
cephalosporin resistance observed between the different animal or meat origins in the reporting MSs. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Belgium, Poland and Portugal detected cefotaxime resistance in S. Enteritidis from Gallus gallus in 2012, 
whereas, in 2011, Austria and Hungary reported resistant isolates and, in 2010, cefotaxime resistance in 
S. Enteritidis from Gallus gallus was reported only by the Czech Republic. As S. Enteritidis is one of the main 
serovars affecting humans, the emergence of resistance to third-generation cephalosporins is extremely 
undesirable. 
Antimicrobial resistance in certain Salmonella serovars and phage types may be related not only to the 
selective pressure exerted by the use of antimicrobials, but also to the clonal diffusion of these Salmonella 
serovars and phage types, and may also be influenced by factors such as on-farm hygienic management 
and animal movements and trade. It was evident in both humans and animals that isolates of 
S. Typhimurium displayed higher levels of resistance than isolates of S. Enteritidis to ampicillin, 
chloramphenicol, streptomycin, sulfonamides and tetracyclines. This is usually observed among the data 
reported by MSs and is not surprising, since certain phage types of S. Typhimurium have an associated 
pattern of pentavalent resistance to these antimicrobials. The same pattern was observed in 2011, whereas 
in 2010 the majority of significant trends were increasing. Ultimately, it would be most useful to correlate 
trends and the occurrence of antimicrobial resistance with the usage of antimicrobial compounds in each 
animal production type that is monitored. 
The multi-drug resistance levels (proportions of isolates showing reduced susceptibility to more than three 
antimicrobial classes according to ECOFFs) in Salmonella spp. isolates were generally high in the animal 
populations investigated, with notable variations between reporting countries. A striking exception to this is 
the multi-resistance levels recorded in isolates from laying hens, which are generally low to moderate, in 
particular compared with those observed in isolates from broilers. Generally, the proportions of 
Salmonella  spp. isolates susceptible to all or resistant (or non-susceptible) to any one of up to nine 
antimicrobials differed substantially among the reporting countries, and the relative contribution of different 
serovars, which may exhibit particular MDR patterns, should be borne in mind when comparing the situation 
between the reporting countries. The occurrence of co-resistance to cefotaxime and ciprofloxacin 
(determined using ECOFFs) differed between MSs and was not detected in isolates from the majority of MSs 
reporting isolate-based data. In the MSs where it was detected, co-resistance to these antimicrobials in 
Salmonella  spp. occurred at very low to moderate levels in isolates from broiler meat, broilers, layers, 
turkeys, pigs and cattle. Applying clinical breakpoints, co-resistance to cefotaxime and ciprofloxacin was 
detected in Salmonella  isolates from meat from broilers and broilers. Co-resistance using ECOFFs was 
detected for a single Salmonella isolate from meat from pigs. 
An additional goal of the monitoring programme is to highlight strains of Salmonella which may be emerging 
in several MSs and which have particular patterns of resistance or show specific resistances of importance. 
Detailed analyses of multi-drug resistance patterns in Salmonella serovars, including analysis of high-
level resistance to ciprofloxacin and pentavalent resistance and investigation of co-resistance to both 
cefotaxime and ciprofloxacin, was possible for MSs reporting isolate-based data and is included for the first 
time in this report. This is particularly important for the antimicrobial ciprofloxacin, where isolates can develop 
increasing resistance in a step-wise and incremental manner. Pentavalent resistance (i.e. resistance to 
ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracyclines) is a characteristic shown by 
several serovars which have become highly prevalent over the last few decades. High-level ciprofloxacin 
resistance was observed in a limited number of S. Kentucky isolates from broilers, laying hens and turkeys, 
but not in isolates from pigs or cattle, although it was detected in isolates from pig meat. S. Infantis showing 
high-level ciprofloxacin resistance, together with resistance to a core antimicrobial pairing of sulfonamides 
and tetracyclines (but with other resistances which were not invariably present in all high-level ciprofloxacin 
Infantis isolates), was detected in meat from broilers, pig meat and broilers. The occurrence of S. Infantis 
with this resistance pattern in several MSs and in different types of animal or meat probably indicates that 
either a clone of S. Infantis showing such resistance has spread within Europe or several clones have gained 
such high-level ciprofloxacin resistance independently. In addition to showing high-level ciprofloxacin 
resistance, S. Infantis also featured as a serovar displaying ‘pentavalent’ resistance, that is resistance to 
ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracyclines. A small number of serovars 
displayed pentavalent resistance which is potentially significant because certain Salmonella serovars which 
have shown epidemic spread have shown such pentavalent resistance in the past. Therefore, describing 
those serovars which exhibit pentavalent resistance, their frequency of occurrence and whether they are 
distributed across one or several different types of animals or MSs is likely to provide useful information on 
new and emerging MDR serovars. 
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4. ANTIMICROBIAL RESISTANCE IN CAMPYLOBACTER 
4.1. Introduction 
 
Campylobacteriosis continues to be the most commonly reported zoonosis in humans in the EU. In 2012, the 
number of confirmed cases of Campylobacter reported in the EU however decreased by 4.3 % compared 
with 2011. The EU notification rate of confirmed cases of human campylobacteriosis shows a statistically 
significant increasing trend in the last five years, 2008 to 2012 (EFSA and ECDC, 2014). In 2012, about one 
quarter of the fresh broiler meat samples were reported positive, even though there were large differences 
between the MSs (EFSA and ECDC, 2014). In reporting countries, the prevalence of campylobacteriosis in 
broiler flocks remained mainly at levels similar to previous years (EFSA and ECDC, 2014). 
ZOONOTIC CAMPYLOBACTER 
The Campylobacter species most commonly associated with human infection are C. jejuni followed by 
C. coli and C. lari, but other species are also known to cause infections in humans. The infective dose of 
these bacteria is generally low. 
The incubation period in humans ranges from two to five days. Patients may experience mild to severe 
symptoms, commonly including watery, sometimes bloody, diarrhoea, abdominal pain, fever, headache 
and nausea. Infections are usually self-limiting and last only a few days; treatment with antimicrobials is 
therefore  usually  not  required.  Extra-intestinal  infections,  invasive  infections  or  post-infection 
complications such as reactive arthritis and neurological disorders can occur, but these are infrequent. 
C. jejuni is a recognised  antecedent cause of Guillain–Barré syndrome, a form of paralysis that can 
sometimes result in dysfunction of the respiratory and neurological systems and can even be fatal. 
Thermotolerant  Campylobacter  species  are  widespread  in  nature.  The  primary  reservoirs  are  the 
alimentary tract of birds and mammals including food-producing animals (poultry, cattle, pigs and sheep). 
Campylobacter species have been isolated from pet animals, including cats and dogs, from wild birds, 
from  water  and  from  various  environmental  samples.  Clinical  disease  resulting  from  infection  with 
thermotolerant Campylobacter species is rare in animals. 
Campylobacter can readily contaminate various food-stuffs including meat, particularly poultry meat, raw 
milk  and  dairy  products,  and  less  frequently  fish  and  fish  products,  mussels  and  fresh  vegetables. 
Considering sporadic human cases, consumption of poultry meat, drinking water from untreated water 
sources and contact with pets and other animals have been identified as significant and major sources of 
infection. Drinking water contaminated with Campylobacter has caused large outbreaks. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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4.2. Overview of reported data in humans, animals and food 
Fourteen MSs and Iceland provided data for 2012 on Campylobacter isolates from human cases. These 
countries reported qualitative data, i.e. interpreted antimicrobial susceptibility testing (AST) results for tested 
isolates (S, I or R), mainly derived from diffusion methods. 
In 2012, 15 MSs and 1 non-MS (Switzerland) reported quantitative dilution data on antimicrobial resistance 
in Campylobacter isolates from animals and food. AST was carried out only for C. jejuni and C. coli, all other 
Campylobacter  species  were  excluded  from  the  monitoring  programme  of  antimicrobial  resistance  in 
Campylobacter. Twelve MSs reported data where no method was specified.  
Table CA1 presents an overview of the countries reporting antimicrobial resistance data on Campylobacter 
spp. from humans and various animal and food categories in 2012. 
Table CA1.  Overview  of  countries  reporting  antimicrobial  resistance  data  using  MIC  and  disc 
diffusion zones on Campylobacter coli and Campylobacter jejuni from humans and various animal 
and food categories in 2012 
Bacterial 
species  Method  Origin  Total number of 
MSs reporting  Countries 
C. coli 
Diffusion  Human  8  MSs: EE, FR, IT, LT, LU, NL, RO, SI 
Dilution 
Human  9  MSs: AT, ES, HU, LU, MT, NL, SI, SK, UK 
Gallus gallus (fowl)  7 
MSs: AT, CZ, ES, FR, HU, NL, RO  
Non-MS: CH 
Turkeys  2  MSs: DE, NL 
Pigs  5 
MSs: DK,ES, FR, HU, NL 
Non-MS: CH 
Cattle (bovine animals)  3 
MSs: DE, ES, NL 
Non-MS: CH 
Meat from broilers 
(Gallus gallus)  7  MSs: AT, BE, CZ, EE, HU, NL, PL, RO 
Meat from turkeys  6  MSs: DE, EE, HU, NL, PL, RO 
Meat from pigs  2  MSs: BE, PL 
Meat from bovine 
animals  2  MSs: DE, PL 
C. jejuni 
Diffusion  Human  8 
MSs: EE, FR, IT, LT, LU, NL, RO, SI 
Non-MS: IS 
Dilution 
Human 
9  MSs: AT, ES, HU, LU, MT, NL, SI, SK, UK 
1  Non-MS: IS 
Gallus gallus (fowl)  11 
MSs: AT, CZ, DK, ES, FI, FR, HU, IT, NL, 
RO, SE 
Non-MS: CH 
Turkeys  2  MSs: DE, NL 
Pigs  1 
MS: HU 
Non-MS: CH 
Cattle (bovine animals)  5 
MSs: DE, DK ,ES, FI, NL 
Non-MS: CH 
Meat from broilers 
(Gallus gallus)  8  MSs: AT, BE, CZ, DK, EE, HU ,NL, PL, RO 
Meat from turkeys  6  MSs: DE, EE, HU, NL, PL, RO 
Meat from pigs  1  MS: PL 
Meat from bovine 
animals  1  MS: PL 
MIC:   minimum inhibitory concentration. 
Note:  For abbreviations of Member States (MS) and other reporting countries, see Appendix 7. 
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4.3. Antimicrobial resistance in Campylobacter isolates from humans 
METHODS AND INTERPRETIVE CRITERIA USED FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING 
OF CAMPYLOBACTER ISOLATES FROM HUMANS  
The method of testing for antimicrobial susceptibility varies between countries. Disc diffusion was the most 
common method in 2012, but often a combination of disc diffusion and dilution was used, depending on 
the  reason  for  the  testing.  In  several  countries,  the  reference  laboratories  type  only  a  fraction  of  the 
isolates. The remaining isolates  are typed by hospitals or local laboratories and the methods used by 
these  are  not  reported.  The  guidelines  used  for  the  methodology  and  interpretation  of  antimicrobial 
susceptibility testing for Campylobacter differed between countries and also within countries for different 
antimicrobials, but were more harmonised in 2012 than in 2011 (for detailed information, see Chapter 8 
Materials  and  methods,  Table  MM3).  The  guidelines  used  by  several  national  public  health  reference 
laboratories were from the French Society for Microbiology (CA-SFM), Clinical and Laboratory Standards 
Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST).  
Of  the  five  antimicrobials  tested  in  both  human  and  animal/food  isolates,  resistance  according  to  the 
EUCAST  clinical  breakpoints  and  ECOFFS  were  at  the  same  MIC  value  or  only  differing  by  one 
concentration step for ciprofloxacin, erythromycin and tetracycline, while no EUCAST clinical breakpoints 
were available for gentamicin and nalidixic acid. The CA-SFM breakpoints differed from the ECOFFS by 
two concentration steps for tetracycline, the combination of C. coli/erythromycin and the combination of 
C. jejuni/gentamicin. In all other cases the breakpoints for CA-SFM and the ECOFFs were at the same 
MIC  value  or  only  differing  by  one  concentration  step.  The  level  of  resistance  determined  by  CLSI 
breakpoints  and  ECOFFS  were  at  the  same  MIC  value  or  only  differing  by  one  concentration  step. 
Exceptions were for tetracycline and the combination of C. jejuni/erythromycin where there was a two-step 
difference.  CLSI  clinical  breakpoints  were  not  available  for  gentamicin  or  nalidixic  acid  (Figure 
CA1).Owing to the variety of breakpoints used under each set of guidelines, results should be interpreted 
with caution in the case of antimicrobials where there are major differences in the interpretive criteria.  
Figure CA1.  Comparison  of  clinical  breakpoints  and  epidemiological  cut-off  values  used  to 
interpret MIC data reported for Campylobacter spp. from humans, animals or food 
 
MIC:   minimum inhibitory concentration. 
Note:  CLSI (2010), EUCAST clinical breakpoints (2012), CA-SFM (2010), EUCAST ECOFFS (as of EFSA, 2007). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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4.3.1. Antimicrobial resistance in Campylobacter spp. in humans 
Fourteen MSs and Iceland submitted data for 2012 on antimicrobial susceptibility of Campylobacter spp. 
isolates  from  human  clinical  cases  to  ECDC.  This  accounted  for  38,835  Campylobacter  spp.  isolates, 
representing 17.9 % of the total number of confirmed cases of campylobacteriosis reported in the EU/EEA in 
2012 (N=217,261).Thirteen MSs and Iceland reported susceptibility results for more than 20 isolates, which 
was the limit set for presenting the level of resistance by country. Romania reported susceptibility results for 
fewer than 20 isolates and was included only in the analysis totals.  
In order to better assess the impact from food consumed within each reporting country on the antimicrobial 
resistance levels found in human  Campylobacter isolates, the analysis focused on domestically-acquired 
cases. Several countries however did not provide any information on travel (or non-travel) of their cases. 
Cases with unknown travel status were therefore also included in the analysis. A separate analysis was 
made on travel-associated cases by geographical regions. 
4.3.1.1. Resistance levels in Campylobacter spp. isolates from human cases 
A large variation was observed among the reporting countries with regard to the number of antimicrobials 
tested,  ranging  from  8  countries  testing  for  amoxicillin  to  all  15  countries  testing  for  ciprofloxacin  and 
erythromycin  (Table CA2).  This  most  likely  reflects  the  variation  in  the  clinical  importance  of  the 
antimicrobials. The highest average level of resistance in all Campylobacter spp. isolates from human cases 
was  observed  for  nalidixic  acid  (48.8 %;  N=21,491)  and  ciprofloxacin  (47.4 %;  N=36,172)  followed  by 
ampicillin (36.4 %; N=7,768) and tetracyclines (32.4 %; N=6,824) (Table CA2).  
The observed variability in resistance levels may reflect the differences in the Campylobacter population that 
people  are  exposed  to  in  different  countries.  Variability  may  also  arise  due  to  differences  in  testing  or 
sampling  methods  applied  by  individual  countries  as  well  as  the  use  of  different  interpretive  criteria. 
Sampling bias could also arise by only including isolates from hospitalised cases. This may explain some of 
the extreme observations.  
4.3.1.2. Comparison  of  resistance  levels  in  Campylobacter  spp.  isolates  acquired  within 
EU/EEA and in other geographical regions 
To compare resistance levels in isolates acquired across the world, isolates from travel-associated cases 
were classified into seven different geographical regions
15 EU/EEA, non-EU/EEA, Africa, Asia, North and 
Central America, South America and Oceania, based on the probable country of infection. Only a limited 
amount of isolates were tested and/or reported from travel-associated cases outside of Europe (Table CA3). 
Data on resistance to four antimicrobials (ciprofloxacin, erythromycin, nalidixic acid and tetracyclines) were 
reported for ≥10 isolates from infections acquired in three geographical regions (EU/EEA, Africa and Asia). 
The frequencies of resistance to  all four antimicrobials  were noticeably higher in  isolates  that  had  been 
acquired in Asia and Africa compared with those acquired within the EU/EEA, with about two-fold higher 
levels  of  ciprofloxacin  resistance  and  about  three-fold  higher  levels  of  resistance  to  erythromycin  (Table 
CA3).  
Since the resistance levels differ substantially between C. jejuni and C. coli, the two most commonly reported 
Campylobacter species, further results are presented separately for these two species. 
 
                                                 
15 Regional classification from the United Nations Statistical Division. Available online: 
http://unstats.un.org/unsd/methods/m49/m49regin.htm EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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Table CA2.  Antimicrobial resistance in Campylobacter spp. from humans per country in 2012, using clinical breakpoints
1 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  387  0.3  387  29.2  387  62.3  387  1.8  387  0.3  387  60.7  387  31.8 
Estonia  90  6.7  87  41.4  231  64.5  212  0.9  92  1.1  95  66.3  201  17.4 
France  4,727  0.2  4,728  31.3  4,643  52.9  4,727  3.7  4,727  0.2  4,728  54.8  –  – 
Hungary  –  –  –  –  71  77.5  71  1.4  –  –  –  –  –  – 
Italy  –  –  184  65.8  254  62.6  251  6.4  172  2.3  146  70.5  170  52.4 
Lithuania  –  –  –  –  195  85.1  227  0.4  –  –  –  –  –  – 
Luxembourg  561  0.2  561  47.2  561  62.0  561  2.7  561  0  561  62.6  561  47.2 
Malta  –  –  –  –  214  76.2  214  26.6  –  –  –  –  –  – 
Netherlands  –  –  –  –  3,483  58.5  2,976  2.6  –  –  –  –  1,519  32.8 
Romania  –  –  –  –  19  NA  19  NA  19  NA  19  NA  19  NA 
Slovakia  3  NA  125  28.0  1,109  31.8  1,302  1.5  27  11.1  –  –  1,235  11.4 
Slovenia  788  5.5  981  35.2  981  68.0  981  0.8  981  0.2  787  61.6  981  21.9 
Spain  228  1.8  228  49.1  228  83.8  228  7.9  228  3.1  228  96.1  228  72.8 
United Kingdom  214  14.5  487  66.1  23,796  42.6  23,868  3.0  1,048  0.4  14,540  44.2  1,523  43.8 
Total (14 MSs)  6,998  1.4  7,768  36.4  36,172  47.4  36,024  3.1  8,242  0.4  21,491  48.8  6,824  32.4 
Iceland  –  –  –  –  29  34.5  29  0  –  –  –  –  –  – 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM4.  
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Table CA3.  Antimicrobial resistance in Campylobacter spp. reported to be acquired within the EU and in other geographical regions in 2012, using 
clinical breakpoints 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Europe (EU/EEA countries)  7,000  1.4  7,848  36.8  36,386  40.5  36,080  3.1  8,256  0.4  21,543  48.9  6,847  32.4 
Europe (non-EU/EEA countries)  1  NA  3  NA  7  NA  7  NA  1  NA  4  NA  2  NA 
Africa  0  NA  6  NA  35  74.3  32  9.4  7  NA  23  78.3  7  NA 
Asia  4  NA  7  NA  63  81.0  62  8.1  9  NA  35  80.0  14  57.1 
Northern and Central America  No observations  No observations  8  NA  8  NA  1  NA  7  NA  2  NA 
South America  No observations  No observations  1  NA  1  NA  No observations  1  NA  No Observations 
Oceania  No observations  No observations  No observations  No observations  No observations  No observations  No Observations 
N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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4.3.2. Antimicrobial resistance in Campylobacter jejuni in humans 
As  in  previous  years,  C. jejuni  was  the  most  common  Campylobacter  species  identified  in  2012,  with 
81,621 cases  reported  in  the  EU/EEA.  In  2012,  13  MSs  and  Iceland  reported  data  on  antimicrobial 
resistance in C. jejuni for ≥20 isolates (ranging from 6 MSs for amoxicillin to all 14 countries for ciprofloxacin 
and erythromycin (Table CA4)).  
4.3.2.1. Resistance levels in Campylobacter jejuni isolates from human cases 
The  highest  frequencies  of  resistance  in  C. jejuni  isolates  were  observed  for  ciprofloxacin  (54.1 %; 
N=11,551) and nalidixic acid (53.3 %; N=6,765) (Table CA4).  
Macrolides, e.g. erythromycin, are the first choice drugs for the treatment of campylobacteriosis in humans 
(ECDC et al., 2009). The level of resistance for erythromycin reported in humans was low, on average 1.4 % 
(N=11,080). In the EU, the highest proportions of resistant isolates  were reported  by  Malta  with  10.9 % 
(N=138) and Italy with 5.4 % (N=202) (Table CA4). 
Ciprofloxacin is the second-choice drug for treatment of campylobacteriosis in humans (ECDC et al., 2009) 
although resistance evolves rapidly. Resistance to ciprofloxacin reported by the countries was very low to 
extremely high (0.3 % to 91.9 %). The highest levels of resistance, 91.9 % (N=99) and 84.1 % (N=182), were 
reported by Lithuania and Spain, respectively (Table CA4). Nalidixic acid is normally used as an indicator of 
ciprofloxacin resistance.  Resistance to nalidixic acid and ciprofloxacin was comparable and the levels of 
resistance to nalidixic acid ranged from 40.8 % to 96.2 % (Table CA4).  
4.3.2.2. Trends in resistance levels in Campylobacter jejuni isolates from human cases 
Country-specific trends in resistance to ciprofloxacin during the period 2008 to 2012 are presented in Figure 
CA2.  Only  countries  reporting  data  for  at  least  three  consecutive  years  and  10  isolates  per  year  were 
included. Trends of increasing resistance could be observed in most reporting countries over the period, with 
the exception of Italy and the United Kingdom. Increases were most noticeable in Estonia, Iceland, Lithuania 
(from 2009 and onwards) and Malta.  
Country-specific trends for erythromycin over the years 2008 to 2012 are presented in Figure CA3. There 
were  few  common  trends  between  countries  over  the  years.  The  exception  was  a  peak  in  resistance 
observed in 2010 in Iceland (3.1 %; N=32), Luxembourg (3.6 %; N=528) and Slovenia (2.4 %; N=911). In the 
years before and after 2010, resistance levels in all three countries were markedly lower. In some other 
countries, a peak was instead observed in 2011: Estonia (1.2 %; N=165), France (1.7 %; N=4,171), Italy 
(6.9 %; N=174), Lithuania (0.3 %, N=296) and the Netherlands (2.8 %, N=2,501). In the United Kingdom, a 
decreasing trend could be observed over the whole period.  
4.3.2.3. Multi-drug resistance among Campylobacter jejuni isolates from human cases 
Five MSs, Austria, Estonia, Luxembourg, Slovenia and Spain, tested at least 10 isolates for the full range of 
antimicrobials included in the human data collection for C. jejuni, and these isolates were included in the 
multi-drug resistance analysis. Overall, 18.0 % (N=1,799) of the human C. jejuni isolates were susceptible to 
all six antimicrobials, with particularly low levels of susceptibility reported from Spain (1.6 %; N=182) (Table 
CA5).  Multi-drug  resistance  was,  on  average,  high  in  the  five  MSs  (24.8 %;  N=1,799;  country  average 
24.8 %). There was large variation in the level of multi-resistance between countries ranging from 14.3 % 
(N=84) in Estonia to 42.3 % (N=182) in Spain (Table CA5). The proportions of C. jejuni isolates susceptible 
to all  or resistant (non-susceptible) to any  up to six  antimicrobials by MS  are  presented in Figure  CA4. 
Isolates resistant to up to five antimicrobials were reported from two MSs (Slovenia and Spain). No MS 
reported  any  isolates  resistant  to  all  six  antimicrobials.  Few  isolates  exhibited  co-resistance  to  both 
ciprofloxacin and erythromycin in the five MSs (1.4 %; N=1,799) (Table CA5).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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Table CA4.  Antimicrobial resistance in Campylobacter jejuni from humans per country in 2012, using clinical breakpoints
1  
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  345  0  345  28.4  345  61.2  345  1.4  345  0  345  59.4  345  31.3 
Estonia  89  5.6  86  40.7  219  63.9  200  0.5  91  1.1  93  66.7  189  16.4 
France  3,852  0  3,853  30.9  3,843  50.7  3,852  0.6  3,852  0  3,853  50.8  –  – 
Hungary  –  –  –  –  34  79.4  34  0  –  –  –  –  –  – 
Italy  –  –  139  68.3  201  64.7  202  5.4  141  2.8  125  70.4  142  54.2 
Lithuania  –  –  –  –  99  91.9  114  0.0  –  –  –  –  –  – 
Luxembourg  493  0  493  48.5  493  60.4  493  0.8  493  0.0  493  60.6  493  43.6 
Malta  –  –  –  –  138  71.7  138  10.9  –  –  –  –  –  – 
Netherlands  –  –  –  –  3,076  58.0  2,624  2.0  –  –  –  –  1,249  32.5 
Romania  –  –  –  –  3  NA  3  NA  3  NA  3  NA  3  NA 
Slovakia  3  NA  115  27.8  1,044  30.7  1,162  1.5  13  NA  -  -  1,151  11.6 
Slovenia  695  5.8  869  37.4  869  70.7  869  0.7  869  0.2  695  60.3  869  22.6 
Spain  182  0.5  182  52.2  182  84.1  182  3.3  182  0.5  182  96.2  182  72.0 
United Kingdom  10  NA  2  NA  1,005  43.1  862  1.5  7  NA  976  40.8  56  41.1 
Total (14 MSs)  5,669  0.8  6,084  34.7  11,551  54.1  11,080  1.4  5,996  0.2  6,765  53.3  4,679  28.3 
Iceland  –  –  –  –  27  33.3  27  0  –  –  –  –  –  – 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM4.  
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Figure CA2.  Resistance to ciprofloxacin in C. jejuni in humans in reporting MSs and one non-MS in 
the EU, 2008-2012, using clinical breakpoints
1 
Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
2 
%
 
r
e
s
i
s
t
a
n
t
 
i
s
o
l
a
t
e
s
 
     
     
     
   
 
  Year 
MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from the graphs. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see Table MM4.  
2.  Guidelines for clinical breakpoints: Austria (ECOFFs from EUCAST), Estonia (Clinical breakpoints (CBP) from CA-SFM), France 
(CBP from CA-SFM), Iceland (CBP from CLSI), Italy (CBP from CLSI), Lithuania (CBP from BSAC), Luxembourg (CBP from CA-
SFM), Malta (CBP from HPA/CLSI), the Netherlands (unspecified), Slovenia (CBP from CLSI for dilution, CBP from CA-SFM for 
disc diffusion), the United Kingdom (ECOFFs from EUCAST). See also Table MM2. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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Figure CA3.  Resistance to erythromycin in C. jejuni in humans in reporting MSs and one non-MS in 
the EU, 2008-2012, using clinical breakpoints
1 
Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
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MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from the graphs. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM4. 
2.  Guidelines for clinical breakpoints: Austria (ECOFFs from EUCAST), Estonia (CBP from CA-SFM), France (CBP from CA-SFM), 
Iceland (CBP from CLSI), Italy (CBP from CLSI), Lithuania (CBP from BSAC), Luxembourg (CBP from CA-SFM), the Netherlands 
(unspecified), Slovenia (CBP from CLSI for dilution, CBP from CA-SFM for disc diffusion), the United Kingdom (ECOFFs from 
EUCAST). See also Table MM3. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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Table CA5.  Complete  susceptibility,  multi-resistance  and  co-resistance  (non-susceptibility)  to 
ciprofloxacin and erythromycin, as determined by clinical breakpoints, in C. jejuni from humans by 
MS, 2012
1 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
Cip and Ery (%) 
Austria (N=345)  28.4  14.8  1.4 
Estonia (N=84)  8.3  14.3  0 
Luxembourg (N=493)  21.3  28.6  2.2 
Slovenia (N=695)  16.0  23.9  0.7 
Spain (N=182)  1.6  42.3  2.7 
Total (5 MSs) (N=1,799)  18.0  24.8  1.4 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; Cip: ciprofloxacin; 
Ery: erythromycin; MS: Member State. 
Susceptible to all: proportion of isolates susceptible to all antimicrobial substances of the ECDC common set for Campylobacter. 
Multi-resistant: proportion of isolates resistant to at least three different antimicrobial substances, belonging to any three antimicrobial 
families from the ECDC common antimicrobial set for Campylobacter. 
Co-resistant to Cip and Ery: proportion of isolates not susceptible to both Cip and Ery. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM4.  
Figure CA4.  Frequency distribution of completely susceptible isolates and resistant isolates to from 
one to six antimicrobials, as determined by clinical breakpoints, in C. jejuni from humans by MS, 
2012
1 
 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; MS: Member State. 
Susceptible: total number of isolates susceptible to all antimicrobial substances of the common set for C. jejuni. 
res1-res6: total number of isolates resistant to between one and six antimicrobial substances of the common set for C. jejuni. 
1.  Isolates from cases reported as related to travel outside the country were excluded from the graph. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM4.  
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4.3.3. Antimicrobial resistance in Campylobacter coli in humans 
C. coli was the second most common Campylobacter species identified in 2012, with 6,231 cases reported in 
the  EU/EEA.  In  2012,  nine  MSs  reported  data  on  antimicrobial  resistance  in  C. jejuni  for  ≥20  isolates 
(ranging from five MSs for amoxicillin to all nine countries for ciprofloxacin and erythromycin (Table CA6)). 
4.3.3.1. Resistance levels in Campylobacter coli isolates from human cases 
The  highest  percentage  of  resistance  among  C. coli  isolates  was  observed  for  nalidixic  acid  (69.9 %; 
N=1,002)  and  ciprofloxacin  (69.0 %;  N=1,322),  followed  by  tetracyclines  (49.7 %;  N=328)  and  ampicillin 
(36.0 %;  N=926)  (Table  CA6).  The  percentage  of  resistance  to  ciprofloxacin  was  highly  correlated  with 
resistance to nalidixic acid in four of the six countries which tested both antimicrobials and in two countries 
the percentage of resistance was higher to nalidixic acid than to ciprofloxacin. The percentage of human 
C. coli  isolates  resistant  to  erythromycin  was  15.1 %  (N=1,264),  which  was  considerably  higher  than  for 
C. jejuni (1.4 %). The highest levels of resistance to erythromycin were reported from Spain (27.3 %; N=44), 
but the number of isolates tested was low (Table CA6).  
4.3.3.2. Trends in resistance levels in Campylobacter coli isolates from human cases 
Country-specific trends in resistance to ciprofloxacin during the period 2008 to 2012 are presented in Figure 
CA5.  Only  countries  reporting  data  for  at  least  three  consecutive  years  and  10  isolates  per  year  were 
included. Increasing trends over the period were observed in Austria, Luxembourg, the Netherlands and 
Slovenia  (from  2009).  A  drop  in  resistance  was  observed  in  several  countries  in  2011:  France  (58.1 %, 
N=735), Italy (46.2 %; N=13), Lithuania (74.4 %; N=39), Malta (53.8 %; N=39), Slovenia (52.4 %, N=42) and 
Spain (78.4 %, N=51) (Figure CA5).  
There were few similarities in resistance trends for erythromycin between countries over the years 2008 to 
2012 (Figure CA6) except that a peak in resistance could be observed in several countries in 2011: Austria 
(8.3 %; N=36), Lithuania (2.2 %; N=45), Luxembourg (23.3 %; N=60), the Netherlands (15.5 %; N=110) and 
Slovenia (7.1 %; N=42). A trend of increasing resistance to erythromycin was observed in the Netherlands 
over the five-year period and a decreasing trend was observed in Italy, although in the case of Italy only a 
small number of isolates were tested (N=10-30). The peak in resistance observed in Spain in 2010 could be 
because only 10 isolates were tested that year. 
4.3.3.3. Multi-drug resistance among Campylobacter coli isolates from human cases 
Four  MSs,  Austria,  Luxembourg,  Slovenia  and  Spain,  tested  at  least  10  isolates  for  the  full  range  of 
antimicrobials included in the human data collection for C. coli and these isolates were included in the multi-
drug resistance analysis. Overall, only 6.4 % (N=188) of the human C. coli isolates were susceptible to all six 
antimicrobials, with particularly low levels of susceptibility reported in Slovenia (0 %; N=36) and Spain (0 %; 
N=44)  (Table  CA7).  On  average,  the  level  of  multi-drug  resistance  was  high  (35.1 %;  N=188;  country 
average  33.3 %)  (Table  CA7).  The  proportions  of  C. coli  isolates  susceptible  to  all  or  resistant  (non-
susceptible)  to  any  one  up  to  six  antimicrobials  by  MS  are  presented  in  Figure  CA7.  All  four  countries 
reported isolates resistant to up to four antimicrobials, three MSs reported isolates resistant to up to five 
antimicrobials  and  one  isolate  was  reported  from  one  MS  resistant  to  all  six.  The  overall  level  of  co-
resistance to both ciprofloxacin and erythromycin was moderate across these four countries (16.0 %; N=188) 
(Table CA7).  
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Table CA6.  Antimicrobial resistance in Campylobacter coli from humans per country in 2012, using clinical breakpoints
1  
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  42  2.4  42  35.7  42  71.4  42  4.8  42  2.4  42  71.4  42  35.7 
Estonia  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA  1  NA 
France  706  0  706  35.4  705  70.5  706  17.7  706  1.3  706  70.5  –  – 
Hungary  –  –  –  –  17  NA  17  NA  –  –  –  –  –  – 
Italy  –  –  11  NA  10  NA  11  NA  10  NA  8  NA  8  NA 
Lithuania  –  –  –  –  25  84.0  31  0  –  –  –  –  –  – 
Luxembourg  66  1.5  66  39.4  66  74.2  66  16.7  66  0  66  75.8  66  75.8 
Malta  –  –  –  –  37  73.0  37  13.5  –  –  –  –  –  – 
Netherlands  –  –  –  –  213  65.3  163  11.7  –  –  –  –  102  36.3 
Romania  –  –  –  –  2  NA  2  NA  2  NA  2  NA  2  NA 
Slovakia  –  –  –  –  5  NA  4  NA  –  –  –  –  5  NA 
Slovenia  36  8.3  55  34.5  55  74.5  55  1.8  55  0  36  86.1  55  30.9 
Spain  44  6.8  44  38.6  44  86.4  44  27.3  44  13.6  44  95.5  44  79.5 
United Kingdom  2  NA  1  NA  100  42.0  85  15.3  3  NA  97  42.3  3  NA 
Total (14 MSs)  897  1.0  926  36.0  1,322  69.0  1,264  15.1  929  1.8  1,002  69.9  328  49.7 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported; NA: not applicable - if fewer than 20 isolates were tested resistance was not calculated. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested isolates from travel-associated, domestic and unknown cases by country 
please see table MM4.  
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Figure CA5.  Resistance to ciprofloxacin in C. coli in humans in reporting MSs in the EU, 2008-2012, 
using clinical breakpoints
1 
Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
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MS: Member State. 
1.  Isolates from cases reported as related to travel outside the country were excluded from the graphs. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see Table MM4.  
2.   Guidelines for clinical breakpoints: Austria (ECOFFs from EUCAST), France (CBP from CA-SFM), Italy (CBP from CLSI), Lithuania 
(CBP from BSAC), Luxembourg (CCBP from A-SFM), Malta (CBP from HPA/CLSI), the Netherlands (unspecified), Slovenia (CBP 
from CLSI for dilution, CBP from CA-SFM for disc diffusion), Spain (CBP from CLSI). See also Table MM3. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
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Figure CA6.  Resistance to erythromycin in C. coli in humans in reporting MSs in the EU, 2008-2012, 
using clinical breakpoints
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Direct comparisons between countries should be avoided owing to the use of different interpretive criteria
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1.  Isolates from cases reported as related to travel outside the country were excluded from the graphs. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see Table MM4.  
2.  Guidelines for clinical breakpoints: Austria (ECOFFs from EUCAST), France (CBP from CA-SFM), Italy (CBP from CLSI), Lithuania 
(CBP from BSAC), Luxembourg (CBP from CA-SFM), the Netherlands (unspecified), Slovenia (CBP from CLSI for dilution, CBP 
from CA-SFM for disc diffusion), Spain (CBP from CLSI). See also Table MM3. 
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Table CA7.  Complete  susceptibility,  multi-resistance  and  co-resistance  (non-susceptibility)  to 
ciprofloxacin and erythromycin, as determined by clinical breakpoints, in C. coli from humans by MS, 
2012
1 
Country  Susceptible to all (%)  Multi-resistant (%)  Co-resistant to  
Cip and Ery (%) 
Austria (N=42)  9.5  16.7  2.4 
Luxembourg (N=66)  12.1  45.5  24.2 
Slovenia (N=36)  0  19.4  5.6 
Spain (N=44)  0  50.0  25.0 
Total (4 MSs) (N=188)  6.4  35.1  16.0 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; Cip: ciprofloxacin; 
Ery: erythromycin; MS: Member State. 
Susceptible to all: proportion of isolates susceptible to all antimicrobial substances of the ECDC common set for Campylobacter. 
Multi-resistant: proportion of isolates resistant to at least three different antimicrobial substances, belonging to any three antimicrobial 
families from the ECDC common antimicrobial set for Campylobacter. 
Co-resistant to Cip and Ery: proportion of isolates not susceptible to both Cip and Ery. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this table. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see table MM4.  
 
Figure CA7.  Frequency distribution of C. coli isolates completely susceptible or resistant to one to 
six antimicrobials, as determined by clinical breakpoints, from humans by MS, 2012
1 
 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances for C. coli; MS: Member 
States. 
Susceptible: total number of isolates susceptible to all antimicrobial substances of the common set for C. coli. 
res1–res6: total number of isolates resistant to between one and six antimicrobial substances of the common set for C. coli. 
1.  Isolates from cases reported as related to travel outside the country were excluded from this graph. For the proportion of tested 
isolates from travel-associated, domestic and unknown cases by country please see Table MM4.  
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4.4. Antimicrobial resistance in Campylobacter isolates from animals and food 
The countries reporting on Campylobacter resistance from various animal and food sampling origins, in 2012 
are presented in Table CA1. Antimicrobials selected by the different MSs, and non-MSs, for susceptibility 
testing of C. jejuni and C. coli, are shown in Chapter 8 Materials and methods, Table MM8. 
 
In this chapter, resistance to ciprofloxacin, erythromycin, gentamicin, nalidixic acid and tetracyclines is 
described in detail. The occurrence of resistance is tabulated, a portrait of temporal evolution and spatial 
distribution of resistance is drawn and the multi-resistance is analysed. These analyses were performed, and 
the corresponding results presented, depending on whether a minimum of four or more countries reported 
quantitative data for a given Campylobacter species and the origin of sample (animal population and food 
category), and whether data were related to at least 10 isolates per country, origin of sample and year. 
C. jejuni and C. coli are both addressed, as monitoring data on the prevalence of Campylobacter in broilers 
and broiler meat in some reporting countries can reveal that C. coli prevalence is either not negligible or 
even of the same magnitude as that of C. jejuni (EFSA and ECDC, 2014). 
•  Temporal trend graphs were generated, showing percentage resistance to different antimicrobials 
among  Campylobacter  isolates, per sample origin, over the period 2006 to 2012, by year of 
sampling. Temporal trend graphs were included only for countries which had reported on four or 
more years in the 2006 to 2012 period.  
•  The spatial distributions of ciprofloxacin and erythromycin resistance rates in C. jejuni  from 
Gallus gallus and C. coli from pigs are presented. For countries where resistance level figures for 
2012 were not available, 2011 figures were used instead. For cattle, the number of reporting 
countries was lower than in the case of the other animal species monitored and, therefore, no spatial 
distribution maps were generated. 
•  Multi-resistance was analysed in the isolate-based dataset of Campylobacter isolates tested for the 
full harmonised set of five antimicrobials (ciprofloxacin, erythromycin, gentamicin, streptomycin and 
tetracyclines) belonging to different classes. ‘Multi-resistance’ was defined as non-susceptibility to at 
least three different antimicrobial classes. The proportions of isolates susceptible to all and resistant 
(non-susceptible) to any one of up to five antimicrobials are presented. Co-resistance to ciprofloxacin 
and erythromycin was also estimated as these two antimicrobials are of particular interest in human 
medicine in the treatment of campylobacteriosis.  
Further information on reported MIC distributions and numbers of C. jejuni and C. coli isolates resistant to 
amoxicillin/clavulanic acid, ampicillin chloramphenicol, ciprofloxacin, clarithromycin, erythromycin, 
THE REVISION OF EUCAST ECOFFS FOR CAMPYLOBACTER 
There have been some recent minor revisions to the epidemiological cut-off value (ECOFF) provided by 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Thus, the EUCAST 
ciprofloxacin ECOFF for C. coli is currently susceptible (i.e. wild-type) ≤0.5 mg/L, a decline of one log 
value from the previous ECOFF value of resistant (i.e. non-wild-type) >1 mg/L described on the EUCAST 
website and recorded in Table MM11. Similarly, the ECOFF values for C. coli and erythromycin, C. coli 
and nalidixic acid and C. jejuni and both ciprofloxacin and tetracyclines have declined by one dilution 
step. Conversely, the ECOFF has increased by one log dilution for C. jejuni versus gentamicin and 
streptomycin. Although deviation from wild-type susceptibility is a fixed microbiological characteristic, as 
greater numbers of bacterial isolates are tested, the wild-type distribution may become better defined and 
minor changes in the ECOFF might therefore be expected. The breakpoints used in this report to 
discriminate between ‘microbiologically resistant’ and wild-type bacteria are identical to those used in 
previous reports for Campylobacter and so there should be no effect of methodological changes when 
comparisons are made between years. When EFSA’s recommendations are revised to include the latest 
EUCAST ECOFFs and new legislation (Decision 2013/652) incorporating those recommendations enters 
into force in 2014, then the historical data are likely to be re-interpreted, using the new EUCAST 
ECOFFs. Reference to the minimum inhibitory concentration distribution tables for C. coli and C. jejuni, 
which are published in the Level 3 tables, shows that the effect of these changes is in most cases likely to 
be small. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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gentamicin, imipenem, nalidixic acid, neomycin, streptomycin, sulfonamides, tetracyclines and tulathromycin 
can be found in the Level 3 tables published on the EFSA website. 
4.4.1. Antimicrobial resistance in Campylobacter isolates from food 
In 2012, more than four MSs provided quantitative antimicrobial resistance data for C. jejuni and/or C. coli 
isolates only from broiler meat, so the analysis of other food categories is not presented in this report. 
4.4.1.1. Meat from broilers and spent hens (Gallus gallus) 
Representative sampling and monitoring 
In the reporting MSs, data on antimicrobial resistance in Campylobacter isolates from meat from Gallus 
gallus derived from active monitoring programmes were based mainly on the random collection of broiler 
meat samples obtained either at the slaughterhouse, at the processing plant or at retail outlets. In Austria, 
Denmark, Estonia and Romania, representative random sampling of meat from broilers, whether neck skin, 
fresh meat, minced meat or meat preparation, was carried out entirely or primarily at wholesale or retail 
outlets. In Poland, sampling of broiler meat and broiler carcases was performed at retail outlets and at the 
slaughterhouse, respectively, while, in Hungary, meat samples were gathered at processing plants. In 
Belgium,  Campylobacter isolates were derived from carcase swabs of spent hens and chilled broiler 
carcases collected at the slaughterhouse.  
Resistance levels among C. jejuni and C. coli isolates from meat from broilers 
In 2012, eight and six MSs provided quantitative antimicrobial resistance data for C. jejuni  and C.  coli 
isolates, respectively, from broiler meat (Table CA8 and Table CA9). Although resistance is typically higher 
among  C. coli than C. jejuni, common features in the levels of resistance to ciprofloxacin, erythromycin, 
gentamicin, nalidixic acid and tetracyclines can be observed in the two Campylobacter species. For the 
commonly used antimicrobials, resistance to tetracyclines and nalidixic acid generally ranged from high to 
extremely high levels, whereas resistance to gentamicin varied less among reporting MSs and was either 
undetected or recorded at low levels. For clinically important antimicrobials, resistance to ciprofloxacin was 
high to extremely high in reporting MSs and closely paralleled the results obtained for nalidixic acid (as 
expected), whereas resistance to erythromycin was much lower considering all reporting MSs. However, the 
recorded levels of resistance to erythromycin were contrasting considering C. jejuni and C. coli, with higher 
levels generally observed in C. coli. In contrast to the other reporting MSs, Romania recorded a moderate 
resistance level to erythromycin in C. jejuni at 14.1  %. Belgium, the Netherlands and Romania reported 
moderate to high resistance to erythromycin in C. coli, whereas Austria, Hungary and Poland either did not 
detect resistance or reported low resistance. In Belgium, where resistance was monitored in a parallel 
fashion in carcases of spent hens and broilers, Campylobacter isolates from spent hens’ meat exhibited 
either similar or lower resistance levels to those observed in isolates from broiler meat. 
Table CA8.  Resistance (%)  to  ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter jejuni from meat from broilers in MSs reporting MIC data in 2012, 
using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  60  63.3  60  0  60  0  60  56.7  60  33.3 
Belgium
1  75  57.3  75  1.3  75  0  75  57.3  75  64.0 
Belgium
2  106  28.3  106  1.9  106  0  106  27.4  106  37.7 
Denmark  66  28.8  66  0  66  0  66  28.8  66  15.2 
Estonia  33  51.5  33  3.0  33  3.0  33  51.5  33  24.2 
Hungary  22  81.8  22  0  22  4.5  –  –  22  54.5 
Netherlands  241  55.6  241  0.8  241  0  241  55.6  241  50.6 
Poland  157  88.5  157  0  157  0  157  86.0  157  59.2 
Romania  64  81.3  64  14.1  64  6.3  64  82.8  64  59.4 
Total (8 MSs)  824  59.5  824  1.8  824  0.7  802  57.9  824  47.5 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no 
data reported. 
1.  Meat from broilers.  
2.  Meat from spent hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table CA9.  Resistance (%)  to  ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter coli from meat from broilers in MSs reporting MIC data in 2012, 
using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  30  73.3  30  0  30  0  30  73.3  30  33.3 
Belgium
1  30  80.0  30  26.7  30  0  30  70.0  30  86.7 
Belgium
2  43  65.1  43  16.3  43  4.7  43  65.1  43  62.8 
Hungary  47  87.2  47  2.1  47  0  –  –  47  34.0 
Netherlands  126  83.3  126  23.8  126  0.8  126  83.3  126  62.7 
Poland  116  89.7  116  5.2  116  0  116  89.7  116  64.7 
Romania  81  82.7  81  32.1  81  6.2  81  80.2  81  46.9 
Total (6 MSs)  473  82.7  473  16.5  473  1.7  426  81.0  473  57.3 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no 
data reported. 
1.  Meat from broilers.  
2.  Meat from spent hens. 
Multi-resistance among C. jejuni and C. coli isolates from meat from broilers and spent hens 
As only three MSs and one non-MS reported isolate-based resistance data on 10 or more isolates of 
C. jejuni  and C.  coli, respectively, from broiler meat, the corresponding multi-resistance analysis is not 
presented in this report. 
4.4.2. Antimicrobial resistance in Campylobacter isolates from animals 
4.4.2.1. Domestic fowl (Gallus gallus): broilers 
Representative sampling and monitoring 
In this section, data on antimicrobial resistance in Campylobacter isolates from fowl (Gallus gallus) are 
completely derived from broilers. The vast majority of samples was collected from healthy broilers at the 
slaughterhouse. Entire caeca or caecal content samples were collected in Austria, the Czech Republic, 
Spain and Sweden, cloacal swabs in Denmark and Switzerland, and faeces before slaughter in Finland. In 
contrast, in Romania, sampling of faeces was carried out on the farm in the framework of the national control 
programme for Salmonella. For the majority of the MSs specifying details of the sampling strategy, sampling 
was randomised throughout the year, with the exception of Finland, where sampling was more intense over 
the high-risk period of the summer months. In accordance with EFSA’s recommendations (EFSA, 2007), only 
one representative sample of caecal content per flock/batch, derived from either a unique carcase or a 
number of carcases, was gathered to account for clustering. Typically, given the relatively high prevalence of 
Campylobacter in broilers, representative subsets of C. jejuni and C. coli isolates recovered from caecal 
samples, each representing one flock, were randomly selected at the laboratory for susceptibility testing. No 
information on the sampling strategy was provided by two MSs (Hungary and the Netherlands). 
Resistance levels among C. jejuni and C. coli isolates from broilers 
For 2012, quantitative data on C. jejuni isolates from broilers were provided by 10 MSs and one non-MS 
(Table CA10), while quantitative data on C. coli isolates were submitted by six MSs and one non-MS (Table 
CA11). Generally, in both C. jejuni and C. coli, resistance to gentamicin and erythromycin was either 
undetected or recorded at low to moderate levels, while resistance to tetracyclines and quinolones 
(ciprofloxacin and nalidixic acid) was high to extremely high among reporting MSs. A striking exception to 
this was the low to moderate resistance in C. jejuni isolates reported by the Nordic countries (Denmark, 
Finland and Sweden); corresponding resistance data on C. coli were not detected by these MSs. Romania 
also reported low levels of resistance to quinolones in C. jejuni. Typically, resistance in C. coli was either 
similar or greater than that observed in C. jejuni in those MSs reporting results for both Campylobacter 
species. Considering C. jejuni and C. coli, levels of resistance to ciprofloxacin and nalidixic acid were rather EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  134
similar within each species as expected. Resistance to erythromycin and gentamicin in C. jejuni showed 
differences between reporting MSs, with either no resistance detected or resistance detected at low levels. 
Generally, resistance in C. coli and C. jejuni from broiler meat and broilers was reported at rather similar 
levels in the MSs reporting data on both animal and meat origins. An exception to this was resistance to 
quinolones (nalidixic acid and ciprofloxacin) in Romania where resistance levels in broilers (3.6 %) proved to 
be much lower than those recorded in isolates from broiler meat, which were approximately 80 %. 
Table CA10.  Resistance (%)  to  ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter jejuni from Gallus gallus (broilers) in countries reporting MIC 
data in 2012, using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  108  75.9  108  0  108  0  108  64.8  108  29.6 
Czech Republic  39  84.6  39  0  39  2.6  39  76.9  39  35.9 
Denmark  41  14.6  41  0  41  0  41  14.6  41  14.6 
Finland  83  2.4  83  0  83  0  83  2.4  83  2.4 
France  49  49.0  49  4.1  49  0  49  46.9  49  49.0 
Hungary  46  87.0  46  0  46  0  46  84.8  46  43.5 
Netherlands  102  61.8  102  0  102  0  102  61.8  102  59.8 
Romania  83  3.6  83  0  83  2.4  83  3.6  83  51.8 
Spain  32  96.9  32  3.1  32  6.3  32  93.8  32  90.6 
Sweden  100  17.0  100  0  100  0  100  17.0  100  2.0 
Total (10 MSs)  683  44.1  683  0.4  683  0.7  683  41.4  683  34.1 
Switzerland  171  33.3  171  0  171  0  171  33.3  171  22.2 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
Table CA11.  Resistance (%)  to  ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter coli from Gallus gallus (broilers) in countries reporting MIC data 
in 2012, using harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  33  66.7  33  0  33  0  33  66.7  33  45.5 
Czech Republic  17  94.1  17  0  17  5.9  17  76.5  17  41.2 
France  78  65.4  78  15.4  78  0  78  62.8  78  92.3 
Hungary  63  79.4  63  1.6  63  0  63  81.0  63  52.4 
Netherlands  23  82.6  23  21.7  23  4.3  23  82.6  23  69.6 
Spain  54  96.3  54  22.2  54  16.7  54  90.7  54  98.1 
Total (6 MSs)  268  78.4  268  11.2  268  4.1  268  75.7  268  73.1 
Switzerland  14  50.0  14  14.3  14  0  14  50.0  14  50.0 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 
Temporal trends in resistance among C. jejuni isolates from broilers 
Figures CA8 and CA9 present the observed temporal trends in antimicrobial resistance in C. jejuni isolates 
from  Gallus gallus over the period 2006 to 2012. As in previous years, resistance to ciprofloxacin and 
nalidixic acid varied greatly among reporting MSs in 2012. When considering resistance to both ciprofloxacin 
and nalidixic acid, statistically significant increasing trends were observed in Austria, Denmark, France, 
Spain and Switzerland for five or more years (Figure CA8). For erythromycin, levels of resistance remained 
absent or low over the period 2006 to 2012 and a statistically significant decreasing trend in erythromycin 
resistance was detected in the Czech Republic and Hungary over the reporting period (Figure CA9). With 
regards to gentamicin, resistance remained generally at levels lower than 10 % with slight fluctuations for all 
reporting countries over the period 2006 to 2012 (data not shown). For tetracyclines, important variations in EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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resistance levels were observed among reporting countries and statistically significant increasing trends 
were seen in the Czech Republic, Denmark, the Netherlands and Spain over the period 2006 to 2012 (data 
not shown). 
Figure CA8.  Trends  in  ciprofloxacin and nalidixic acid resistance in Campylobacter jejuni from 
Gallus gallus in reporting MSs and non-MSs, 2006–2012, quantitative data 
 
MS:   Member State. 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
for both ciprofloxacin and nalidixic acid in Austria (↑), Denmark (↑), France (↑), Spain (↑) and Switzerland (↑), for ciprofloxacin in the 
Czech Republic (↑) and for nalidixic acid in Hungary (↑).   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure CA9.  Trends  in  erythromycin resistance in Campylobacter jejuni  from  Gallus gallus  in 
reporting MSs and non-MSs, 2006–2012, quantitative data 
 
MS:  Member State. 
Note:  A statistically significant decreasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was 
observed in the Czech Republic (↓) and Hungary (↓).  
Temporal trends in resistance among C. coli isolates from broilers 
Figures CA10 and CA11 present observed trends in antimicrobial resistance in C. coli from Gallus gallus. In 
2012, as was the case in previous years, a high degree of variation was observed in levels of resistance to 
ciprofloxacin and nalidixic acid among reporting MSs. For ciprofloxacin and nalidixic acid, statistically 
significant increasing trends, for the last five or more years, were observed in Austria, France, Spain and 
Switzerland (Figure CA10). For erythromycin (Figure CA11), resistance was generally lower over the 
reporting period than for the other antimicrobials presented. A similar situation was observed for gentamicin 
over the period with resistance levels reported lower than 10 % with the exception of Spain (data not shown). 
Resistance to erythromycin and gentamicin increased significantly over the seven years presented in Spain. 
Over the same period, resistance levels to tetracyclines varied from 30 % to 100 % for most of the reporting 
countries. France, Spain and Switzerland also exhibited statistically increasing trends in resistance to 
tetracyclines (data not shown). 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  137
Figure CA10.  Trends  in  ciprofloxacin and nalidixic acid resistance in Campylobacter coli from 
Gallus gallus in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
MS:  Member State. 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
for both ciprofloxacin and nalidixic acid in Austria (↑), France (↑), Spain (↑) and Switzerland (↑) and for nalidixic acid in Hungary (↑). 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure CA11.  Trends  in  erythromycin resistance in Campylobacter  coli from Gallus gallus in 
reporting MSs and one non-MS, 2006–2012, quantitative data 
 
MS:   Member State.  
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Spain (↑).  
Spatial distribution of resistance among C. jejuni isolates from broilers 
Figures CA12 and CA13 show the spatial distribution of ciprofloxacin and erythromycin resistance in C. jejuni 
from  Gallus gallus. For both antimicrobials, overall resistance was lower among the reporting Nordic 
countries than in the rest of the European reporting countries. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure  CA12.    Spatial distribution of ciprofloxacin resistance among 
Campylobacter jejuni from broilers of Gallus gallus in countries reporting 
MIC data in 2012
1 
Figure  CA13.    Spatial distribution of erythromycin resistance among 
Campylobacter jejuni from broilers of Gallus gallus in countries reporting 
MIC data in 2012
1 
 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When quantitative 2012 data were not available, 2011 data have been used 
instead. MIC: minimum inhibitory concentration. 
1.  For Germany, Ireland and Norway, 2011 data were used. 
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Multi-resistance among C. jejuni and C. coli isolates from broilers 
In 2012, five MSs and one non-MS reported isolate-based data on resistance in C. jejuni isolates from 
broilers, while three MSs and one non-MS provided isolate-based data regarding resistance in C. coli 
isolates from broilers.  
Analysis of the multi-resistance showed that there was a large variation in the levels of complete 
susceptibility among the reporting countries. Complete susceptibility to the common set of antimicrobials for 
Campylobacter (five antimicrobials) was generally found in more than 20 % of the C. jejuni isolates tested in 
the reporting MSs, and reached up to 78.0 % in Denmark and 80.0 % in Sweden, while in Hungary and 
Spain the proportion of fully susceptible isolates was much lower. In C. coli isolates, complete susceptibility 
was generally either comparable or lower than that observed in C. jejuni.  
Multiple resistance (reduced susceptibility to three or more antimicrobial classes) was not recorded or was 
detected at levels lower than 5 % in C. jejuni isolates in most reporting countries, while in Spain 9.4 % of 
isolates exhibited multi-resistance (Table CA12). In C. coli the occurrence of multi-resistance was either 
comparable or greater than that reported in C. jejuni isolates (Table CA13). The frequency distributions 
(Figures CA14 and CA15) showed variation between different reporting countries. Most of the reporting 
countries detected resistance to a maximum of three antimicrobial classes in C. jejuni (Figure CA14), 
whereas multi-resistant C. coli isolates generally displayed reduced susceptibility to three to five different 
classes of antimicrobials (Figure CA15). 
The important co-resistance for public health, i.e. resistance to both ciprofloxacin and erythromycin, was 
generally undetected in C. jejuni isolates, while a number of C. coli isolates from Hungary, Spain and 
Switzerland exhibited such co-resistance. The term co-resistance has been defined as two or more 
resistance genes which are genetically linked, i.e. located adjacent or close to each other on a mobile 
genetic element (Chapman, 2003). For brevity, the term is used slightly more loosely in this report and 
indicates two or more phenotypic resistances to different classes of antimicrobials, exhibited by the same 
bacterial isolate. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table CA12.  Complete  susceptibility, multi-resistance and index of 
diversity in Campylobacter jejuni from broilers in MSs and non-MSs 
reporting isolate-based data, 2012 
Table CA13.  Complete  susceptibility, multi-resistance and index of 
diversity in Campylobacter coli from broilers in MSs and one non-MS 
reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant 
to  
Cip and Ery 
n  %  n  %  n  % 
Austria (N=108)  22  20.4  4  3.7  0.283  0  0 
Denmark (N=41)  32  78.0  0  0  0.202  0  0 
Hungary (N=46)  4  8.7  0  0  0.21  0  0 
Spain (N=32)  1  3.1  3  9.4  0.313  1  3.1 
Sweden (N=100)  80  80.0  0  0  0  0  0 
Switzerland (N=171) 98  57.3  1  0.6  0.23  0  0 
 
Country 
Susceptible to all Multi-resistant Index of 
diversity 
Co-resistant 
to 
Cip and Ery 
n  %  n  %  n  % 
Austria (N=33)  6  18.2  1  3.0  0.284  0  0 
Hungary (N=63)  9  14.3  3  4.8  0.307  1  1.6 
Spain (N=54)  1  1.9  30  55.6  0.793  12  22.2 
Switzerland (N=14) 4  28.6  3  21.4  0.549  2  14.3 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; n: number of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter.  
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the common antimicrobial set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to Cip and Ctx: the frequencies and percentages of isolates not susceptible to ciprofloxacin concentrations >1 mg/L and erythromycin concentrations >16 mg/L for C. coli and to ciprofloxacin 
concentrations >1 mg/L and erythromycin concentrations >16 mg/L for C. jejuni. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Figure CA14.  Frequency  distribution  of  Campylobacter jejuni isolates 
completely susceptible and resistant to one to five antimicrobials in 
broilers in MSs and non-MSs reporting isolate-based data, 2012 
Figure CA15.  Frequency  distribution  of  Campylobacter coli isolates 
completely susceptible and resistant to one to five antimicrobials, in 
broilers in MSs and one non-MS reporting isolate-based data, 2012 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; sus: susceptible to all antimicrobial substances of the EFSA 
common set for Campylobacter; res1–res5: resistance to one antimicrobial substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
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Multi-resistance patterns in C. jejuni and C. coli isolates from broilers 
Considering C. jejuni, isolate-based data were available from five contributing MSs which reported details of 
498 isolates. The isolates reported by Denmark (N=41), Hungary (N=46) and Sweden (N=100) are not 
addressed in this table as they were not multi-resistant. Analysis of the patterns of resistance to 
erythromycin, ciprofloxacin, tetracyclines, streptomycin and gentamicin was possible for 164 C. coli isolates 
from four contributing MSs which provided isolate-based data. Tables CA14 and CA15 summarise the 
different resistance patterns obtained and show the frequency with which these patterns were observed in 
each MS and for the MS group as a whole. Considering the isolates showing multi-resistance (i.e. resistance 
to any three or more antimicrobials of those listed above), the proportion of resistant isolates is expressed 
both as a proportion of the total multi-resistant isolates and as a proportion of the total number of C. jejuni 
isolates contributed by the reporting MS group. 
Among the 311 C. jejuni isolates from broilers from the reporting group of MSs submitting isolate-based data, 
2.6  % (n=8) exhibited multi-resistance (Table CA14). The commonest pattern of multi-resistance was 
resistance to ciprofloxacin, tetracyclines and streptomycin, occurring in six of eight resistant isolates reported 
by submitting MSs. A single isolate was reported which showed resistance to all of the antimicrobials in the 
multi-resistance panel, although this only accounted for 0.3 % of the total C. jejuni isolates for which isolate-
based data was available. The situation differed in C. coli where 2.4 % of the total number of C. coli isolates, 
for which isolate-based data was available, showed multi-resistance to all of the antimicrobials in the test 
panel. 
Table CA14.  Multi-resistance patterns of interest in Campylobacter jejuni from broilers in MSs one 
non-MS reporting isolate-based data, 2012 
Multi-resistance pattern 
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countries 
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  R  R  R    6 75.0  1.9  4  1  1 
  R  R    R  1 12.5  0.3  0  1  0 
R  R  R  R  R  1 12.5  0.3  0  1  0 
Total  8  100  2.6  4  3  1 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; 
Ery: erythromycin; Cip: ciprofloxacin; Tet: tetracyclines; Str: streptomycin; Gen: gentamicin; n: number of multi-resistant isolates; 
R:  minimum inhibitory concentration above the European Committee on Antimicrobial Susceptibility Testing epidemiological cut-off 
values. 
The proportion of isolates of C. jejuni from broilers showing multi-resistance, as well as the diversity of multi-
resistance within that multiple resistant population, was lower than that observed in C. coli from broilers. The 
proportion of the total number of C. coli isolates from broilers showing resistance to all antimicrobials in the 
panel (2.4 %) was identical to the figure found for pigs for C. coli isolates which showed an identical pattern 
of resistance (2.4 %). 
Among the 164 C. coli isolates from broilers tested in the reporting group of MSs submitting isolate-based 
data, 22.6 % (n=37) showed multi-resistance to three or more antimicrobials (Table CA15). The commonest 
resistance pattern detected was resistance to ciprofloxacin, tetracyclines and streptomycin occurring in 
10.4  % of the multi-resistant isolates. This pattern of resistance together with additional erythromycin 
resistance occurred in 3.7 % of isolates, while a further 2.4 % of isolates demonstrated additional resistance 
to gentamicin. These three resistance patterns accounted for more than 70 % of the multi-resistant isolates 
which were detected. Gentamicin resistance has a component of multiple drug resistance patterns and was 
only observed in Spain. This resistance was not detected in the other reporting MSs. Interestingly, Spain was 
the only MS providing isolate-based data to report gentamicin resistance in C. jejuni, although other MSs 
(the Czech Republic and Romania), which did not report isolate-based data, also detected gentamicin 
resistance in C. jejuni (Table CA10). The range of different resistance patterns observed was greater in EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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C. coli than for C. jejuni; Spain contributed isolates with a greater range of different resistance patterns than 
other MSs, although this may have merely reflected the small isolate sample size from other MSs. 
Table CA15.  Multi-resistance patterns of interest in Campylobacter coli from broilers in MSs and one 
non-MS reporting isolate-based data, 2012 
Multi-resistance pattern 
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countries 
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  R  R  R   17  46.0  10.4  1  2  13  1 
R  R  R  R   6  16.2  3.7  0  0  5  1 
R  R  R     4  10.8  2.4  0  1  3  0 
R  R  R  R  R  4 10.8  2.4  0  0  4  0 
  R  R  R  R  3 8.1  1.8  0  0  3  0 
  R  R    R  2 5.4  1.2  0  0  2  0 
R  R    R   1  2.7  0.6  0  0  0  1 
Total  37  100  22.6  1  3  30  3 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter and multi-resistant; 
Ery: erythromycin; Cip: ciprofloxacin; Tet: tetracyclines; Str: streptomycin; Gen: gentamicin; n:  number of multi-resistant isolates; 
R:  minimum inhibitory concentration above the European Committee on Antimicrobial Susceptibility Testing epidemiological cut-off 
values 
Comparison of resistance in broilers and meat from broilers 
Considering individual MSs, the levels of ciprofloxacin resistance were generally lower in C. coli and C. jejuni 
isolates from meat from broilers than in isolates from broilers. Generally, resistance levels to all 
antimicrobials were higher in C. coli than in C. jejuni for the same host species. Similarly, the levels of multi-
resistance (reduced susceptibility to at least three different antimicrobial classes) in C. coli isolates from 
broilers were much higher than those detected in C. jejuni isolates of the same origin. However, it should be 
borne in mind that, despite the high levels of resistance/multi-resistance observed, C. coli is much less 
prevalent in poultry than C. jejuni. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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4.4.2.2. Pigs 
Representative sampling and monitoring 
In the reporting MSs, antimicrobial resistance monitoring in Campylobacter isolates from pigs was based 
primarily on active monitoring plans involving random sampling of healthy pig carcases at the 
slaughterhouse. The sampling plan was typically stratified per slaughterhouse, by allocating the number of 
samples collected per slaughterhouse in proportion with the annual throughput of that slaughterhouse. An 
approximately equal distribution of the collected samples over the year enabled the different seasons to be 
covered. Only one representative faecal sample per epidemiological unit (batch/farm), either derived from a 
unique carcase or pooled from a number of carcases, was gathered to account for clustering, in accordance 
with EFSA’s recommendations (EFSA, 2007). In the reporting MSs, antimicrobial resistance monitoring in 
Campylobacter spp. in pigs focused on C. coli, as this is the more prevalent Campylobacter species in pigs. 
Because of the very low C. jejuni prevalence in pigs, the number of samples required to be collected to 
achieve a sufficient number of C. jejuni isolates would have been too large to be cost effective. In some 
reporting countries, representative subsets of C. coli isolates recovered from faecal samples were randomly 
selected at the laboratory for susceptibility testing, whereas, in others, all C. coli isolates were tested for 
susceptibility. 
Resistance levels among C. coli isolates from pigs 
In 2012, quantitative data were provided by five MSs and one non-MS (Switzerland) on C. coli isolates from 
pigs (Table CA16). C. coli isolates tested were mainly derived from fattening pigs (the production type was 
not specified for the Netherlands). As seen in 2011, the range of resistance to the antimicrobials studied 
varied greatly between the reporting countries in 2012. However, in general, the levels of resistance to 
tetracyclines observed were high to extremely high, while those to nalidixic acid, ciprofloxacin and 
erythromycin were moderate to high. Exceptions to this general pattern of resistance to these substances 
were observed for isolates from Denmark, which reported the lowest occurrence of resistance (at low to 
moderate levels), and Spain, which recorded the highest resistance, at levels classed as extremely high. 
Resistance to fluoroquinolones (ciprofloxacin) and quinolones (nalidixic acid) proved to be very similar in all 
reporting countries. In contrast, gentamicin resistance was either undetected or reported at low level. Only 
Spain recorded a moderate resistance to gentamicin.  
Table  CA16.    Resistance (%) to ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter coli from pigs
1 in countries reporting MIC data in 2012, using 
harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  103  11.7  103  6.8  103  0  103  11.7  103  14.6 
France  96  40.6  96  36.5  96  0  96  39.6  96  91.7 
Hungary  53  50.9  53  13.2  53  3.8  53  50.9  53  88.7 
Netherlands  232  12.5  232  11.2  232  0.4  232  12.5  232  88.4 
Spain  73  97.3  73  79.5  73  17.8  73  95.9  73  100 
Total (5 MSs)  557  32.0  557  23.9  557  2.9  557  31.6  557  76.8 
Switzerland  144  41.0  144  9.0  144  0.7  144  38.9  144  31.9 
MIC: minimum inhibitory concentration; MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates. 
1. The  C. coli isolates tested were derived from fattening pigs. For the Netherlands, the production level was not specified.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among C. coli isolates from pigs 
Figures CA16 and CA17 show the trends in antimicrobial resistance observed in C. coli from pigs over the 
period 2006–2012. For most of the antimicrobials considered, levels of resistance have remained relatively 
stable between 2006 and 2012. For ciprofloxacin and nalidixic acid, a statistically significant increasing trend 
was seen for Spain, while France and Switzerland reported significantly increasing levels of resistance to 
ciprofloxacin over the reporting period. Levels of erythromycin resistance increased significantly in France, 
the Netherlands and Spain and, for gentamicin, resistance increased significantly in Spain (data not shown). 
When considering tetracyclines (data not shown), marked differences in resistance were observed among 
reporting countries: Switzerland and Denmark reported resistance of around 30 % and 10 %, respectively, 
while France, Hungary, the Netherlands and Spain recorded levels greater than 80 %, over the 2006 to 2012 
period. Resistance to tetracyclines demonstrated a significantly increasing trend in Denmark during the 
period 2006 to 2012. 
Figure CA16.  Trends in ciprofloxacin and nalidixic acid resistance in Campylobacter coli from pigs 
in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in Spain (↑) for both ciprofloxacin and nalidixic acid and in France (↑) and Switzerland (↑) for ciprofloxacin; MS: Member State. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure CA17.  Trends in erythromycin resistance in Campylobacter coli from pigs in reporting MSs 
and one non-MS, 2006–2012, quantitative data 
 
MS:   Member State. 
Note: A statistically significant increasing trend over five or more years, as tested by a logistic regression model (p ≤0.05), was observed 
in France (↑), the Netherlands (↑) and Spain (↑);  
Spatial distribution of resistance among C. coli isolates from pigs 
Figures CA18 and CA19 show the spatial distributions of ciprofloxacin and erythromycin resistance in C. coli 
from pigs. For both erythromycin and ciprofloxacin, the highest levels of resistance were reported by 
Southern countries, while Northern countries reported lower levels. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure  CA18.    Spatial distribution of ciprofloxacin resistance among 
Campylobacter coli from pigs in countries reporting MIC data in 2012
1 
Figure  CA19.    Spatial distribution of erythromycin resistance among 
Campylobacter coli from pigs in countries reporting MIC data in 2012
1 
   
MIC: minimum inhibitory concentration; MS: Member State.  
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When quantitative 2012 data were not available, 2011 data have been used 
instead. 
1.  For Sweden, 2011 data were used. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Multi-resistance among C. coli isolates from pigs 
In 2012, three MSs and one non-MS reported isolate-based data on resistance in C. coli isolates from pigs. 
Analysis of the multi-resistance showed that there was a large variation in the levels of complete 
susceptibility and multi-resistance among the reporting countries. Isolates exhibiting complete susceptibility 
accounted for 33.0  % in Denmark and 14.6  % in Switzerland, while in Hungary and Spain none of the 
isolates tested were completely susceptible (Table CA17). Conversely, multi-resistance was low in Denmark 
(3.9 %), moderate in Switzerland (19.4 %), high in Hungary (49.1 %) and extremely high in Spain (97.3 %). 
The frequency distributions (Figure CA20) showed an important diversity between the reporting countries. 
Hungary, Spain and Switzerland reported isolates displaying reduced susceptibility to up to four or five 
different classes of antimicrobials. In addition, a high proportion of isolates showing co-resistance to 
ciprofloxacin and erythromycin was observed in isolates from Spain. 
Table CA17.  Complete susceptibility, multi-resistance and index of diversity in Campylobacter coli 
from fattening pigs in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ery 
n  %  n  %  n  % 
Denmark (N=103)  34  33.0  4  3.9  0.28  3  2.9 
Hungary (N=53)  0  0  26  49.1  0.662  5  9.4 
Spain (N=73)  0  0  71  97.3  0.74  56  76.7 
Switzerland (N=144)  21  14.6  28  19.4  0.471  6  4.2 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; 
n: number of isolates; Cip: ciprofloxacin; Ery: erythromycin. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to Cip and Ery: the frequencies and percentages of C. coli isolates not susceptible to ciprofloxacin concentrations >1 mg/L 
and erythromycin concentrations >16 mg/L. 
Figure CA20.  Frequency  distribution  of  Campylobacter coli isolates completely susceptible and 
resistant to one to five antimicrobials, in fattening pigs in MSs and one non-MS reporting isolate-
based data, 2012 
 
N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; MS: Member State; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Campylobacter; res1–res5: resistance to one antimicrobial 
substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
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Multi-resistance pattern in C. coli isolates from fattening pigs 
Isolate-based data was available for 373 C. coli isolates from fattening pigs, contributed by three reporting 
MSs and one non-MS, from which 34.6 % exhibited different patterns of multi-resistance (Table CA18). The 
commonest multi-resistance pattern observed in fattening pigs was resistance to ciprofloxacin, tetracyclines 
and streptomycin, occurring in 13.1  % of the total number of isolates for which isolate-based data was 
available. The next most common pattern of multi-resistance comprised resistance to the preceding 
antimicrobials, together with resistance to erythromycin. Taken together, these patterns of resistance 
accounted for more than 70 % of the total multiple drug resistance C. coli isolates from pigs. The range of 
multi-resistance patterns observed in C. coli from pigs was greater than that observed in broilers and unlike 
in broilers, gentamicin resistance, as part of the multi-resistance pattern, was observed in three of four 
reporting MSs. Although Denmark contributed a large number of isolates (N=103), the diversity of resistance 
patterns observed in Denmark, and the numbers of multi-resistant isolates as a proportion of the total 
isolates reported, was lower than for the remaining three MSs which reported data. Most (greater than 85 %) 
multiply resistant C. coli isolates from pigs were resistant to tetracyclines and streptomycin as a component 
of the multi-resistance pattern. Most isolates which were resistant to gentamicin were also resistant to 
streptomycin. Resistance to ciprofloxacin and tetracyclines was observed in more than 90  % of multi-
resistance C. coli isolates from pigs. 
Table CA18.  Multi-resistance patterns of interest in Campylobacter coli from fattening pigs in MSs 
and one non-MS reporting isolate-based data, 2012 
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  R  R  R    49 38.0  13.1  2 18  11  18 
R  R  R  R    43 33.3  11.5  0  3  39  1 
R  R  R     10  7.8 2.7 1  1  7  1 
R  R  R  R  R  9  7.0 2.4 0  1  8  0 
R    R  R    7  5.4 1.9 0  2  1  4 
  R  R  R  R  4 3.1  1.1  0 1  2 1 
R  R    R    4  3.1 1.1 1  0  0  3 
R  R  R    R  2  1.6 0.5 0  0  2  0 
R    R  R  R  1  0.8 0.3 0  0  1  0 
Total  129  100  34.6  4  26  71  28 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter 
and multi-resistant; Ery: erythromycin; Cip: ciprofloxacin; Tet: tetracyclines; Str: streptomycin; Gen: gentamicin; n: number of multi-
resistant isolates; R: minimum inhibitory concentration above the European Committee on Antimicrobial Susceptibility Testing 
epidemiological cut-off values. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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4.4.2.3. Cattle (bovine animals) 
Representative sampling and monitoring 
In 2012, data on antimicrobial resistance among C. jejuni isolates from cattle include samples collected both 
at the slaughterhouse (Denmark, Finland, Germany, Spain and Switzerland) and at the farm level (the 
Netherlands). These countries tested different production types and ages of cattle, including veal calves, 
young meat production animals, adult cattle and dairy cows; Denmark and Finland did not specify the type of 
cattle which were tested. Slaughterhouse sampling programmes were randomised over the year and 
stratified by the number of slaughtered animals by abattoirs across the MSs. The sampling was evenly 
distributed throughout the year or a significant part of the year to account for a possible seasonal effect. Only 
one caecal or faecal sample per bovine animal carcase was collected. In the reporting MSs, antimicrobial 
resistance monitoring in Campylobacter spp. in cattle focused on C. jejuni, as this is the more prevalent 
Campylobacter species in cattle. In some reporting countries, representative subsets of Campylobacter 
isolates recovered from animal samples were randomly selected at the laboratory for susceptibility testing, 
while, in some others, all isolates were tested for susceptibility. 
Resistance levels among C. jejuni isolates from cattle 
For 2012, five MSs and one non-MS provided quantitative data on C. jejuni  isolates from cattle (Table 
CA19). C. jejuni isolates tested were derived from veal calves (Germany, the Netherlands), young cattle 
(Spain, Switzerland), dairy cows (the Netherlands) and production type unspecified (Denmark and Finland). 
As seen in 2011, the range of resistance to the antimicrobials studied varied greatly between the reporting 
countries in 2012. The levels of resistance to ciprofloxacin, nalidixic acid and tetracyclines were generally 
high, while resistance to erythromycin and gentamicin was either not detected or recorded at low to very low 
levels.  
Table CA19.  Resistance (%)  to  ciprofloxacin, erythromycin, gentamicin, nalidixic acid and 
tetracyclines among Campylobacter jejuni from cattle
1 in countries reporting MIC data in 2012, using 
harmonised epidemiological cut-off values 
Country 
Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All cattle 
Denmark  89  14.6  89  1.1  89  0  89  15.7  89  0 
Finland  72  13.9  72  0  72  0  72  13.9  72  2.8 
Germany  73  49.3  73  2.7  73  0  73  43.8  73  76.7 
Netherlands  178  31.5  178  0  178  0.6  178  31.5  178  61.8 
Spain  68  63.2  68  0  68  0  68  64.7  68  60.3 
Total (5 MSs)  480  32.9  480  0.6  480  0.2  480  32.5  480  43.5 
Switzerland  38  36.8  38  2.6  38  0  38  39.5  38  44.7 
Veal calves 
Germany  73  49.3  73  2.7  73  0  73  43.8  73  76.7 
Netherlands  137  38.7  137  0  137  0.7  137  38.7  137  78.1 
Total (2 MSs)  210  42.4  210  1.0  210  0.5  210  40.5  210  77.6 
Young cattle (1–2 years) 
Spain  68  63.2  68  0  68  0  68  64.7  68  60.3 
Switzerland  38  36.8  38  2.6  38  0  38  39.5  38  44.7 
Dairy cows 
Netherlands  41  7.3  41  0  41  0  41  7.3  41  7.3 
Unspecified type of cattle 
Denmark  89  14.6  89  1.1  89  0  89  15.7  89  0 
Finland  72  13.9  72  0  72  0  72  13.9  72  2.8 
Total (2 MSs)  161  14.3  161  0.6  161  0  161  14.9  161  1.2 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
1.  Data presented in this table were derived from a variety of production types. These include veal calves (Germany, the 
Netherlands), young cattle (Spain, Switzerland), dairy cows (the Netherlands) and production type unspecified (Denmark and 
Finland).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among C. jejuni isolates from cattle 
Figures CA21 and CA22 show the temporal trends in resistance for C. jejuni from cattle. As seen in C. coli in 
pigs, levels of resistance for C. jejuni in cattle have remained relatively stable over the 2006–2012 reporting 
period for individual MSs. In general, resistance to ciprofloxacin, nalidixic acid and tetracyclines was 
relatively higher than levels of resistance to erythromycin and gentamicin for the reporting MSs. When 
considering trends in ciprofloxacin, nalidixic acid (Figure CA21) and gentamicin resistance, no significant 
changes were observed over the reporting period. For erythromycin, a significantly decreasing trend was 
observed in the Netherlands when tested by a logistic regression model (Figure CA22), and for tetracyclines 
a significantly decreasing trend was observed in Austria and a significantly increasing trend was observed in 
the Netherlands (data not shown). 
Figure CA21.  Trends  in  ciprofloxacin and nalidixic acid resistance in Campylobacter jejuni from 
cattle in reporting MSs, 2006–2012, quantitative data 
 
MS:   Member State.  
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤ 0.05), were observed in any 
of the reporting countries;  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure CA22.  Trends  in  erythromycin resistance in Campylobacter jejuni from cattle in reporting 
MSs, 2006–2012, quantitative data 
 
MS:   Member State. 
Note: A statistically significant decreasing trend over five or more years, as tested by a logistic regression model (p ≤ 0.05),  was 
observed in the Netherlands (↓);  
Multi-resistance among C. jejuni isolates from cattle 
In 2012, three MSs and one non-MS reported isolate-based data on resistance in C. jejuni isolates from 
differing cattle populations (Table CA20). Difference in the cattle populations monitored may most likely 
partly explain the variability observed in summary indicators of multi-resistance among reporting countries. 
Germany, which monitored veal calves specifically, reported the highest level of multi-resistance (12.3 %) 
and the lowest level of complete susceptibility (16.4  %) among the reported data, while Spain and 
Switzerland, which monitored young cattle (1–2 years), recorded high levels of complete susceptibility and 
similar low levels of multi-resistance at around 5 %. Conversely, Denmark, which reported resistance data on 
an unspecified cattle population, recorded an extremely high level of complete susceptibility and did not 
detect any multi-resistant C. jejuni isolates. While the resistant isolates monitored were only resistant to one 
substance in Denmark, other reporting countries (Germany, Spain and Switzerland) detected isolates 
displaying reduced susceptibility to up to three or four different classes of antimicrobials (Figure CA23). In 
addition, only a few isolates exhibited co-resistance to both ciprofloxacin and erythromycin. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table CA20.  Complete susceptibility, multi-resistance and index of diversity in Campylobacter jejuni 
from cattle in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to
Cip and Ery 
n  %  n  %  n  % 
Denmark (N=89)  75  84.3  0  0  0  0  0 
Germany (N=73)  12  16.4  9  12.3  0.434  2  2.7 
Spain (N=68)  17  25.0  4  5.9  0.323  0  0 
Switzerland (N=38)  18  47.4  2  5.3  0.428  1  2.6 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; 
n: number of isolates; Cip: ciprofloxacin; Ery: erythromycin. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for Campylobacter. 
Multi-resistant: resistant to at least three different antimicrobial substances, belonging to any three antimicrobial families from the 
common antimicrobial set. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to Cip and Ery: the frequencies and percentages of C. jejuni  isolates not susceptible to ciprofloxacin concentrations 
>1 mg/L and erythromycin concentrations >4 mg/L. 
Figure CA23.  Frequency  distribution  of  Campylobacter jejuni isolates completely susceptible and 
resistant to one to five antimicrobials, in cattle in MSs and one non-MS reporting isolate-based data, 
2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter; 
sus: susceptible to all antimicrobial substances of the EFSA common set for Campylobacter; res1–res5: resistance to one antimicrobial 
substance/resistance to five antimicrobial substances of the common set for Campylobacter. 
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Multi-resistance pattern in C. jejuni isolates from cattle 
Isolate-based data were available for 268 C. jejuni isolates submitted by four reporting countries. Denmark 
did not detect multi-resistance in C. jejuni from cattle. In the remaining reporting countries the most common 
pattern of multi-resistance was resistance to ciprofloxacin, tetracyclines and streptomycin, occurring in 80 % 
of multi-resistance isolates (Table CA21). Gentamicin resistance was not detected in multi-resistance 
isolates of C. jejuni from cattle. 
Table CA21.  Multi-resistance patterns of interest in Campylobacter jejuni from cattle in MSs and one 
non-MSs reporting isolate-based data, 2012 
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  R  R  R   12  80.0  6.7  7  4  1 
R  R  R  R   2  13.3  1.1  1  0  1 
R  R  R     1  6.7  0.6  1  0  0 
Total  15  100  8.4  9  4  2 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for Campylobacter 
and multi-resistant; Ery: erythromycin; Cip: ciprofloxacin; Tet: tetracyclines; Str: streptomycin; Gen: gentamicin; n: number of multi-
resistant isolates; R: minimum inhibitory concentration above the European Committee on Antimicrobial Susceptibility Testing 
epidemiological cut-off values. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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4.5.  Overview of the findings on antimicrobial resistance in Campylobacter at reporting 
Member State group level, 2012 
Figure CA24 shows the resistance levels in the reporting MS group based on the quantitative data submitted 
in 2012 for the various animal species and meat derived from those animal species. These data may derive 
from different MS groups, which should be considered when interpreting the figure. As was the case in 
previous years, C. coli isolates tended to be more resistant than C. jejuni isolates. Direct comparisons of the 
levels of resistance in Campylobacter from Gallus gallus and in broiler meat may not be entirely appropriate 
because different MSs have reported different proportions of isolates tested from meat and live fowl. The 
levels of resistance sometimes differ between different MSs and the relative contribution of individual MSs 
can affect the summary group level figures. 
Figure CA24.  Resistance to ciprofloxacin, erythromycin, gentamicin, nalidixic acid and tetracyclines 
in Campylobacter jejuni and Campylobacter coli from fowl, pigs and cattle at reporting MS group 
level in 2012 
 
MS: Member State. 
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4.6. Discussion 
Campylobacter causes a large number of human cases of gastro-enteritis and has been the most frequently 
reported cause of human food-borne zoonoses in the EU since 2004 (EFSA and ECDC, 2014). The majority 
of campylobacteriosis cases are self-limiting, however chronic symptoms (Guillain–Barré syndrome, acute 
transverse myelitis, myocarditis, and reactive arthritis) may also develop as a result of intestinal infection. 
Bacteraemia is very rare, except for infections with C. fetus. Resistance to antimicrobials in Campylobacter is 
of concern because of the large number of cases of human infection and the fact that some cases require 
treatment. Treatment of enteric infections in humans may involve administration of fluoroquinolones, such as 
ciprofloxacin, or macrolides, such as erythromycin (ECDC et al., 2009). The rapid increase in resistance in 
C. jejuni to fluoroquinolones concurrent with discoveries of associations between postinfectious irritable 
bowel syndrome and a longer duration of untreated Campylobacter infection (Kirkpatrick and Tribble, 2011) 
is therefore worrying. 
In 2012, information on antimicrobial resistance in Campylobacter isolates from human cases of 
campylobacteriosis was collated from 14 MSs and one non-MS (Iceland). The data submitted by these 
countries represented isolates from 18  % of the human campylobacteriosis cases reported within the 
EU/EEA in 2012. A novelty in this year’s report was that isolates from cases notified as having been acquired 
during travelling outside of the reporting country, were excluded from all analysis except the analysis on 
resistance in difference geographical regions. This was done to better assess the impact on Campylobacter 
isolates from food consumed within each reporting country on the antimicrobial resistance levels found in 
human isolates in that country. Please note however that imported food, which can constitute a large 
proportion of the food available in some countries, is not covered by this report. 
There was a large variation in the guidelines used for interpreting the susceptibility tests for human 
Campylobacter isolates among countries. In two MSs, two different guidelines were also applied in order to 
cover all antimicrobials under monitoring. Although the clinical breakpoints used for the dilution test for 
Campylobacter  were less variable than those for Salmonella, the breakpoints for disc diffusion differed 
significantly depending on the guidelines used, particularly for ciprofloxacin. Disc diffusion was still the most 
common method of testing for antimicrobial susceptibility in human isolates, sometimes in combination with 
gradient strip. Only four countries used micro-broth dilution. The disc diffusion method and clinical 
breakpoints established by EUCAST in 2012 are therefore much welcomed and is recommended by the 
ECDC in the EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and 
Campylobacter isolates (ECDC, 2014).  
There was also a large variation with regard to the number of antimicrobials tested among the reporting 
countries, which reflects the clinical importance of the antimicrobials. Erythromycin and ciprofloxacin were 
the antimicrobials for which the greatest numbers of human Campylobacter spp. isolates were tested. The 
levels of resistance in human C. jejuni  isolates to erythromycin was overall low, but moderately high in 
C. coli, although the number of tested isolates for this bacterial species was small. Very high resistance 
levels to ciprofloxacin were reported in human Campylobacter isolates, with increasing trends observed in 
several MSs.  
In order to assess the importance of travel-associated infections, antimicrobial resistance was also 
analysed based on the most likely country of infection reported. Human isolates acquired in Asia and Africa 
had the highest frequency of resistance to the antimicrobials tested, with two and three times higher 
resistance levels to ciprofloxacin and erythromycin than in isolates acquired within the EU/EEA. This could 
affect which antimicrobials could be applied for successful treatment of severe travel-associated cases.  
Human antimicrobial susceptibility data were available for the full range of antimicrobials from five MSs for 
C. jejuni and from four MSs for C. coli. Overall, only one in six (18.0 %) human C. jejuni isolates and one in 
twenty (6.4 %) human C. coli isolates were fully susceptible to all antimicrobials. On average, one quarter of 
C. jejuni (24.8 %) and one third of C. coli (35.1 %) isolates exhibited multi-drug resistance, meaning that 
they were clinically non-susceptible to at least three different antimicrobial groups. The clinical breakpoints 
used to interpret the human data were, in some cases, more sensitive than the ECOFFs when intermediate 
and resistant results were combined. The human data also covered two penicillins which were not included 
in the animal/food testing. All these factors could explain the generally higher proportion of multi-resistance 
observed in humans compared with animals, particularly for C. jejuni, which was the most common species 
in humans. Co-resistance to the critically important antimicrobials ciprofloxacin and erythromycin was, on EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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average, low for C. jejuni (1.4 %) but detected in one out of six (16.0 %) C. coli isolates, although in the case 
of C. coli fewer isolates were tested. 
The data relating to the susceptibility of Campylobacter of food and animal origin reported by MSs were, 
in general well harmonised with almost all MSs adopting the EFSA guidelines and recommendations. 
Overall, levels of antimicrobial resistance in Campylobacter isolates from animals and food were similar to 
those in 2011. Considering all reporting MSs, ciprofloxacin resistance in C. jejuni from Gallus gallus and 
cattle was 44.1 % and 32.9 % respectively, while in C. coli from Gallus gallus and pigs it was 78.4 % and 
32.0 %.  
Among Campylobacter isolates from Gallus gallus and broiler meat, very high to extremely high levels of 
resistance, to one or more antimicrobials, were reported by a number of MSs, with the exception of some 
Nordic countries, as well as Central and Eastern European countries, particularly when using ECOFFs as 
interpretive criteria of reduced susceptibility or ‘microbiological resistance’. For example, extremely high 
resistance rates to ciprofloxacin were notably detected. Over the period 2009–2011, the highest levels of 
resistance to quinolones and fluoroquinolones were in general detected in Campylobacter  isolates from 
Gallus gallus. In 2012, however, the highest levels of resistance to these antimicrobials were detected in 
Campylobacter isolates from broiler meat. In those MSs which reported resistance in Campylobacter isolates 
from both broiler meat and broilers, levels of resistance were generally similar, although C. coli isolates from 
broiler meat tended to exhibit slightly higher resistance compared with C. coli isolates from broilers. 
Interestingly, C. jejuni and C. coli isolates from meat from spent hens tested in Belgium presented lower 
levels of ciprofloxacin resistance than those observed in isolates from meat from broilers. 
This high level of ciprofloxacin resistance in Campylobacter from broiler meat is of particular concern, since 
the EFSA Panel on Biological Hazards (BIOHAZ), in its recent scientific opinion on the quantification of the 
risk of campylobacteriosis posed to humans by broiler meat, estimated that the handling, preparation and 
consumption of broiler meat may account for 20 % to 30 % of human campylobacteriosis cases, while 50 % 
to 80 % of cases may be attributed to the chicken (broiler) reservoir as a whole (EFSA BIOHAZ Panel, 
2010a). In 2012, ciprofloxacin resistance in C. coli isolates from humans was 69.0 % for all contributing MSs 
(range: 42.0–86.4 %) and 32.0 % in pigs (range: 11.7–97.3 %). However, the picture is clearly complex in 
relation to the sources of human infections because these may be related to consumption of pig or poultry 
meat (as well as other sources). International trade also means that consumers may be exposed to meat 
produced in a number of different countries. Similar considerations apply when comparing resistance levels 
in humans and animals for other resistances. However, resistance to gentamicin, in C. coli from humans, 
meat from broilers, broilers and pigs does show similarities at the MS level. While gentamicin resistance was 
reported in C. coli from Gallus gallus (16.7 %) and pigs (17.8 %) from Spain but was not reported in broilers 
(Austria, France), meat from broilers (Austria) or pigs (France), C. coli  from human infections showed 
13.6  %, 2.4  % and 1.3  % gentamicin resistance in Spain, Austria and France, respectively. However, 
Campylobacter strains from the broiler reservoir may also reach humans via routes other than food (e.g. the 
environment or by direct contact). 
In 2012, ciprofloxacin resistance in C. jejuni  isolates from humans was 54.1  % for all contributing MSs 
(range: 30.7  %–91.9  %) and 44.1  % in broilers (range: 2.4  %–96.9  %). These figures and the possible 
reasons why the levels of resistance in humans and animals may or may not show correlations have been 
discussed in detail in previous reports in a dedicated farm to fork chapter which has not been included in the 
analysis for 2012. However, similar factors will apply to the 2012 data and readers are referred to earlier EU 
Summary Reports for detailed discussion of the ciprofloxacin and erythromycin results in campylobacter 
isolates from man and animals. 
Over the period 2006 to 2012, statistically significant increasing trends in ciprofloxacin and nalidixic acid 
resistance in C. jejuni from broilers were observed over five or more years in five reporting countries; this 
was also observed in C. coli from broilers in three MSs. Considering C. coli from pigs a statistically significant 
increasing trend for ciprofloxacin/nalidixic acid resistance, was observed for three reporting countries. 
Comparison of these results and trends with the relevant antimicrobial usage figures might reveal interesting 
insights into the development of resistance. 
Regarding resistance to erythromycin, a representative of the macrolides (commonly used in the treatment 
of human campylobacteriosis) in all reporting MSs, erythromycin resistance in C. jejuni from Gallus gallus 
and cattle was 0.4  % and 0.6  %, respectively, while, in C. coli  from  Gallus gallus and pigs, resistance 
equalled 11.2 % and 23.9 %, respectively. This situation in which low to moderately high levels of resistance 
were registered is similar to that observed over the 2009 to 2011 period. In countries which reported results EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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for C. coli from both pigs and Gallus gallus and C. jejuni from Gallus gallus, resistance to erythromycin has 
usually been highest in C. coli isolates from pigs and lower in the isolates from the other sources, for each 
country, over the period 2009 to 2011. Similar results have also been observed in other studies in which 
macrolide-resistant isolates of C. coli from food animals have mainly been of porcine origin (Gibreel and 
Taylor, 2006).  
Levels of erythromycin resistance increased in C. coli from broilers in some reporting countries between 
2011 and 2012. Several MSs, are implementing policies to reduce the amount of antimicrobials used in 
livestock production and it is important to gauge the effect this may have on the occurrence of resistance.  
Two MSs provided data on multiple drug resistance for C. coli  and  C. jejuni  from both humans and 
animals. Although some lack of harmonisation
16 may preclude detailed direct comparison of the multi-
resistance figures in isolates from animals and humans, some trends are evident. The MS with the higher 
proportion of multi-resistance in broilers (in both Campylobacter spp.) also reported a high proportion of 
multi-resistance in isolates from humans. Considering these two MSs, parallel trends are also evident for 
certain other resistance characteristics (for example gentamicin and erythromycin resistance, co-resistance 
to ciprofloxacin and erythromycin). In the MS that provided the most comprehensive data among the 
reporting MSs, it is interesting that the figures for co-resistance to erythromycin and ciprofloxacin for C. coli 
isolates from humans are intermediate between those for broilers and pigs. The breakpoints used to define 
resistance in C. coli, from humans and animals, for ciprofloxacin and erythromycin are, however, slightly 
different (Figure CA1) and although this is a small difference of one dilution, ideally the criteria in this type of 
analysis should be fully harmonised. 
Campylobacter generally develops resistance to the different antimicrobials in the common test panel by 
different mechanisms. Resistance to ciprofloxacin and erythromycin in Campylobacter is usually the result of 
mutation with or without the additional action of efflux pumps (Piddock et al., 2003; Ge et al., 2005; 
Luangtongkum et al., 2009). Additionally, the efflux pump CmeABC has been shown to confer a degree of 
resistance to erythromycin, ciprofloxacin and tetracyclines (Ge et al., 2005). Some isolates of both C. coli 
and C. jejuni, from animals and humans, showed resistance to erythromycin, ciprofloxacin and tetracyclines, 
raising the possibility that CmeABC may have been responsible, or contributed to the observed pattern of 
resistance. In multiple resistant isolates of C. coli and C. jejuni which were gentamicin resistant, streptomycin 
resistance was also observed, occurring for example, in seven of nine gentamicin resistant and multiply 
resistant C. coli isolates and in one of the two C. jejuni  isolates from broilers which showed gentamicin 
resistance. Recently a cluster of aminoglycoside modifying enzymes has been reported in C. coli from broiler 
chickens in China (Qin et al., 2012). A novel genomic island carrying multiple aminoglycoside resistance 
genes on the C. coli chromosome was identified by the researchers who showed that the genomic island can 
be transferred experimentally to C. jejuni and was associated with particular clones of C. jejuni in broilers in 
China where it was first detected. The aminoglycoside modifying enzymes found to be present on this 
genomic island, include those conferring resistance to gentamicin and streptomycin, as well as to certain 
other aminoglycosides (neomycin, kanamycin and tobramycin). The occurrence of isolates of C. coli and 
C. jejuni, resistant to both gentamicin and streptomycin, suggests that resistance genes to each of these 
aminoglycosides have been acquired by these multiple resistant isolates. The genomic island described by 
Qin et al. (2012) contained a truncated tetracycline resistance gene, illustrating the potential of this set of 
aminoglycoside resistance genes to capture other resistance genes. Streptomycin and tetracycline 
resistance were commonly associated with each other in multiple drug-resistant strains of both C. coli and 
C. jejuni. Conjugative plasmids have been described in C. jejuni, which can carry clusters of aminoglycoside 
resistance genes (Nirdnoy et al., 2005); however, it appears that both streptomycin and gentamicin 
resistance can occur independently of each other in at least some C. coli and C. jejuni isolates. 
                                                 
16 The antimicrobial substances included in the analysis of multiple drug resistance in isolates from humans and animals and the 
interpretive thresholds of resistance, either clinical breakpoints or ECOFFs, have not yet been harmonised between both sectors. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  160
5. ANTIMICROBIAL RESISTANCE IN INDICATOR ESCHERICHIA COLI 
5.1. Introduction 
Commensal  E. coli  is commonly chosen as an indicator of antimicrobial resistance in Gram-negative 
bacterium, as it is commonly present in animal faeces, is relevant to human medicine and can often acquire 
conjugative plasmids, which are resistance determinants transferred between enteric bacteria. Commensal 
E. coli, present in the intestine of farm animals, have a reservoir of resistance genes that can spread 
horizontally to zoonotic and other bacteria present in the food chain. Commensal indicator organisms, rather 
than pathogenic types of E. coli, such as enterotoxigenic E. coli (ETEC) or verotoxigenic E. coli (VTEC), are 
the target of the monitoring of indicator E. coli. The monitoring of antimicrobial resistance in indicator E. coli, 
isolated from either randomly selected healthy animals or derived carcases and meat thereof, and chosen to 
be representative of the general population, provides valuable data on the resistance occurring in that 
population. 
Determining the occurrence of resistance to antimicrobials in indicator E. coli provides data useful for 
investigating the relationship with the selective pressure exerted by the use of antimicrobials on the intestinal 
population of bacteria in food-producing animals. Indicator E. coli are also useful as representatives of the 
Enterobacteriaceae to monitor the emergence and changes in the proportion of bacteria possessing ESBLs. 
The EFSA monitoring guidelines (EFSA, 2008) recommend that monitoring may be carried out at the farm or 
slaughterhouse levels and that at least 90 % of the animal population in a MS should be included in the 
sampling frame. Samples should be collected randomly from selected holdings or flocks, or randomly 
selected within the slaughterhouse. Samples collected (and subsequently tested) in accordance with the 
EFSA recommendations should therefore be comparable between MSs. 
5.2. Antimicrobial resistance in indicator Escherichia coli isolates from animals and food 
In total, 11 MSs and 2 non-MSs (Norway and Switzerland) reported quantitative MIC data on antimicrobial 
resistance in commensal (indicator) E. coli isolates from animals in 2012. In addition, five of these countries 
provided MIC data on isolates collected from food. Table EC1 shows the countries that reported data 
concerning indicator E. coli  in 2012. Antimicrobials selected by the different MSs and non-MSs for MIC 
susceptibility testing of indicator E. coli are shown in Chapter 8 Materials and methods, Table MM9. 
Antimicrobial susceptibility data were interpreted using ECOFFs to determine organisms exhibiting reduced 
susceptibility, i.e. showing ‘microbiological resistance’ (as opposed to ‘clinical resistance’). For reasons of 
continuity and because other amendments have also been made to the ECOFFs for some other 
antimicrobial - organism combinations by EUCAST, the ECOFFs used in this report have been those 
adopted in EFSA’s 2008 recommendations (EFSA, 2008). Of particular note is that ‘microbiological 
resistance’ to ciprofloxacin was addressed using ECOFF Cip  >0.03 mg/L in this report (see Section 5.5 
Discussion, for further details). 
The proportions of resistant isolates to the antimicrobial agents ampicillin, cefotaxime, chloramphenicol, 
ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides and tetracyclines are described in detail 
later in this chapter. The tables of occurrence of resistance were generated, and multi-drug resistance 
analysis was performed if more than four countries reported quantitative data per sampling origin. In addition, 
only data where 10 or more isolates were available per country, per sampling origin, per year, are included in 
the report. In the graphs illustrating trends in the evolution of antimicrobial resistance over time, results for 
MIC data interpreted using ECOFFs are shown. Only a few MSs have reported data for the seven 
consecutive years from 2006 to 2012, as the monitoring of resistance in indicator E. coli is performed on a 
voluntary basis. 
Where the minimum criteria for detailed analysis were met, multi-resistance was analysed in the isolate-
based dataset on the indicator E. coli isolates tested for the full harmonised set of nine antimicrobials 
belonging to different classes. Multi-resistance is defined as non-susceptibility to at least three different 
antimicrobial classes. The proportions of isolates susceptible to all antimicrobial substances tested and 
resistant (non-susceptible) to any one up to nine substances are presented. Co-resistance to cefotaxime and 
ciprofloxacin was estimated as these two antimicrobials are of particular interest in human medicine. Co-
resistance was addressed using both ECOFFs (Ctx >0.25 mg/L and Cip >0.03 mg/L) and clinical breakpoints 
(Ctx >2 mg/L and Cip >1 mg/L). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  161
Table  EC1.    Overview of countries reporting MIC and disc inhibition zones on indicator 
Escherichia coli from animals and food in 2012 
Method  Origin  Total number of 
MSs reporting  Countries 
Diffusion 
Cattle (bovine animals)  1  MS: PT 
Meat from broilers (Gallus gallus)  1  MS: SI 
Meat from pigs  1  MS: SI 
Meat from bovine animals  1  MS: SI 
Dilution 
Gallus gallus (fowl)  8 
MSs: AT, BE, DK, FR, HU, NL, PL, SE 
Non-MSs: CH, NO 
Turkeys  3  MSs: DE, NL, PL 
Pigs  7 
MSs: AT, BE, DK, FR, HU, NL, PL 
Non-MS: CH 
Cattle (bovine animals)  7 
MSs: AT, BE, DE, DK, FI, NL, PL 
Non-MS: CH 
Meat from broilers (Gallus gallus)  5 
MSs: DK, ES, HU, NL, SE 
Non-MS: NO 
Meat from turkeys  3  MSs: DE, HU, NL 
Meat from pigs  4  MSs: DK, ES, HU, NL 
Meat from bovine animals  5  MSs: DE, DK, ES, HU, NL 
MIC: minimum inhibitory concentration. 
Note: For abbreviations of Member States (MS) and other reporting countries see Appendix 7.  
For further information on reported MIC distributions and numbers of resistant isolates for ampicillin, 
apramycin,  cefazolin, cefepime, cefotaxime, cefoxitin, cefpodoxime, ceftazidime, ceftiofur, ceftriaxone, 
cephalothin, chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, imipenem, kanamycin, 
meropenem, nalidixic acid, neomycin,  spectinomycin, streptomycin, sulfonamides, trimethoprim and 
tetracyclines for E. coli in 2012, please refer to the Level 3 Tables published on the EFSA website. 
5.2.1. Antimicrobial resistance in indicator Escherichia coli isolates from food 
In 2012, six MSs and one non-MS (Norway) reported quantitative MIC data for E. coli isolates from meat 
from bovine animals, broilers (Gallus gallus) and pigs. 
5.2.1.1. Representative sampling and monitoring 
The antimicrobial resistance data in indicator E. coli isolates from the three kinds of meat reported by 
Denmark,  Germany, the Netherlands, Spain, Sweden and Norway mostly derived from active and 
representative monitoring programmes. Only one MS did not report details on either the sampling stages or 
on the sampling design of meat samples. In Denmark, E. coli  isolates  originated from meat sampled at 
wholesale and retail outlets, collected randomly in all regions of the country and spread evenly throughout 
the year, in the framework of three centrally coordinated sampling plans corresponding to each kind of meat. 
In Sweden, E. coli isolates originated from broiler meat collected randomly in all regions of the country and 
sampled between 23 October 2012 and 24 January 2013.  
5.2.1.2. Meat from broilers (Gallus gallus) 
The occurrence of resistance to selected antimicrobials in indicator E. coli isolates from broiler meat, in four 
reporting MSs and one non-MS, in 2012, is presented in Table EC2.  
Considering data from the four reporting MSs, resistance levels to ampicillin, sulfonamides and tetracyclines 
were high at 33.7 %, 28.6 % and 22.2 %, respectively. The resistance to these antimicrobials was highly 
variable across the reporting MSs, ranging from 18.5 % to 57.7 % for ampicillin, from 16.3 % to 45.7 % for 
sulfonamides and from 11.7 % to 34.3 % for tetracyclines. Conversely, resistance to chloramphenicol and 
gentamicin at the reporting MS group level was low at 4.0  % and 3.2  %, respectively; resistance levels EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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ranged from 0  % to 12.5  % for chloramphenicol and from 0  % to 6.9  % for gentamicin. Resistance to 
ciprofloxacin and nalidixic acid, among reporting MSs, was 29.1 % and 24.1 %, respectively. The overall 
level of resistance to cefotaxime across the reporting MSs was low in 2012, at 3.0 %.  
5.2.1.3. Meat from pigs 
Among the four reporting MSs, E. coli isolated from pig meat displayed high levels of resistance to ampicillin 
sulfonamides and tetracyclines (20.4 %, 23.2 % and 23.5 %, respectively). Chloramphenicol resistance was 
low at 2.6 %. Overall, gentamicin resistance was 1.5 % in the reporting group of MSs; it was not detected in 
two MSs. The proportion of E. coli isolates resistant to ciprofloxacin and nalidixic acid among the reporting 
MSs was low at 5.6 % and 5.1 %. The occurrence of resistance to cefotaxime among all reporting MSs was 
low at 1.1 %.  
5.2.1.4. Meat from bovine animals 
Among the four reporting MSs, E. coli isolated from meat bovine animals displayed moderate levels of 
resistance to ampicillin and sulfonamides (18.7 % for both antimicrobials) and high level of resistance to 
tetracyclines (20.8  %). Chloramphenicol resistance was low, at 6.6  %, for the reporting group of MSs. 
Overall, gentamicin resistance was 2.1 % in the reporting group of MSs; it was not detected in Denmark and 
Hungary. The proportion of E. coli isolates resistant to ciprofloxacin and nalidixic acid among the reporting 
MSs were 6.9 % and 5.9 %, respectively. The occurrence of resistance to cefotaxime among all reporting 
MSs was low at 1.7 % with one MS reporting no resistance. 
5.2.1.5. Multi-resistance among Escherichia coli isolates from meat 
As too few MSs reported multi-resistance isolate-based data on more than 10 isolates of indicator E. coli in 
food, tables and graphs on multi-resistance are not presented in this report. 
5.2.1.6. Comparison of resistance among Escherichia coli isolates from meat and animals 
Four MSs reported on antimicrobial resistance in meat, but those which did generally reported comparable 
resistance levels in meat as in the corresponding source animal species. Indeed, Denmark reported 
resistance in isolates from broiler meat broadly comparable to that recorded in isolates from broilers. 
Resistance recorded by Denmark in isolates from pig meat is roughly similar to that reported from pigs. 
Similarly, in cattle, resistance in isolates from meat from cattle recorded in Denmark and Germany was 
roughly comparable to that reported for bovine animals in the same MSs (Tables EC4 and EC15), for which 
Germany reported on isolates from young meat production animals and Denmark reported on isolates from 
unspecified cattle type. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table  EC2.    Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides and 
tetracyclines among indicator Escherichia coli from meat from broilers ( Gallus gallus) in countries reporting MIC data in 2012, using harmonised 
epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res N  % Res  N  % Res N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  197  21.8  197  1.0  197  0.5  197  3.6  197  0  197  3.6  197  8.1  197  16.8  197  11.7 
Hungary  64  26.6  64  0  64  12.5  64  75.0  64  3.1  64  75.0  64  14.1  64  35.9  64  32.8 
Netherlands  175  57.7  175  8.0  175  6.9  175  41.1  175  6.9  175  38.9  175  41.1  175  45.7  175  34.3 
Sweden  92  18.5  92  0  92  0  –  –  92  3.3  92  4.3  92  6.5  92  16.3  92  14.1 
Total (4 MSs)  528  33.7  528  3.0  528  4.0  436  29.1  528  3.2  528  24.1  528  19.5  528  28.6  528  22.2 
Norway  197  6.1  197  0.5  197  0  –  –  197  0  197  2.0  197  3.0  197  8.1  –  – 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 
Table  EC3.    Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides and 
tetracyclines among indicator Escherichia coli from meat from pigs in MSs reporting MIC data in 2012, using harmonised epidemiological cut-off values 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 
   
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res N  % Res  N  % Res N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  73  32.9  73  1.4  73  1.4  73  1.4  73  0  73  0  73  35.6  73  30.1  73  27.4 
Hungary  14  28.6  14  0  14  7.1  14  28.6  14  0  14  28.6  14  21.4  14  35.7  14  35.7 
Netherlands  98  8.2  98  1.0  98  2.0  98  3.1  98  2.0  98  3.1  98  15.3  98  16.3  98  18.4 
Spain  11  36.4  –  –  11  9.1  11  27.3  11  9.1  11  27.3  11  45.5  –  –  11  27.3 
Total (4 MSs)  196  20.4  185  1.1  196  2.6  196  5.6  196  1.5  196  5.1  196  25.0  185  23.2  196  23.5 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table  EC4.    Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides and 
tetracyclines among indicator Escherichia coli from meat from bovine animals in MSs reporting MIC data in 2012, using harmonised epidemiological cut-
off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Denmark  46  4.3  46  0  46  0  46  2.2  46  0  46  2.2  46  4.3  46  4.3  46  6.5 
Germany  71  39.4  71  4.2  71  16.9  71  14.1  71  4.2  71  12.7  71  35.2  71  38.0  71  43.7 
Hungary  31  9.7  31  3.2  31  0  31  3.2  31  0  31  3.2  31  6.5  31  6.5  31  12.9 
Netherlands  141  14.9  141  0.7  141  5.0  141  5.7  141  2.1  141  4.3  141  16.3  141  16.3  141  15.6 
Total (4 MSs)  289  18.7  289  1.7  289  6.6  289  6.9  289  2.1  289  5.9  289  18.0  289  18.7  289  20.8 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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5.2.2. Antimicrobial resistance in indicator Escherichia coli isolates from animals 
5.2.2.1. Domestic fowl (Gallus gallus) 
Representative sampling and monitoring 
In this section, data on antimicrobial resistance in indicator E. coli isolates from fowl (Gallus gallus) are 
presented separately for broilers and laying hens. The majority of MSs collected isolates as part of their 
national monitoring programmes of antimicrobial resistance. In all reporting countries except Norway, 
monitoring programmes were based on random sampling of healthy broilers at the slaughterhouse. Indicator 
E. coli isolates were isolated from caecal contents in Austria and France, from intestinal content in Sweden 
and from cloacal swabs in Denmark and Switzerland, by sampling healthy broilers at slaughter. In Norway, 
indicator E. coli were isolated from faeces sampled from Gallus gallus on the farm. Hungary and Poland did 
not report information on the sample type, sampling context and sampling stage.  
Resistance levels among Escherichia coli isolates from Gallus gallus 
In 2012, seven MSs and one non-MS provided quantitative data concerning antimicrobial resistance in E. coli 
from broilers, among which two MSs (Poland and Sweden) also provided comparable data concerning E. coli 
from laying hens (Table EC5). In addition, Norway reported E. coli resistance data in parent breeders for 
broiler production, while Belgium reported data at Gallus gallus species level without distinguishing between 
animal populations of origin.  
Generally, the occurrence of resistance in E. coli isolates from broilers varied markedly between reporting 
countries. Resistance to ampicillin, streptomycin, sulfonamides and tetracyclines was generally high to very 
or extremely high in most reporting countries, with the exceptions of Sweden, reporting low to moderate 
resistance to these substances, and Denmark, recording low to moderate resistance to streptomycin and 
tetracyclines. Resistance to chloramphenicol was generally low to moderate with only Poland reporting high 
resistance and Denmark and Sweden no or very low resistance. In all reporting countries, gentamicin 
resistance was reported at very low to low levels.  
Resistance to ciprofloxacin and nalidixic acid was generally high to very or extremely high among the 
reporting countries, with the exception of Denmark recording low resistance to these substances. A side-by-
side comparison of resistance to ciprofloxacin and nalidixic acid in each reporting country shows that similar 
levels of resistance to both antimicrobials were typically recorded. Resistance to cefotaxime was generally 
low in most reporting countries, although two MSs reported moderate levels of resistance.  
Resistance features in E. coli isolates from laying hens, tested in Poland and Sweden, were similar to those 
observed in isolates from broilers in the same MSs, although resistance levels in laying hens were  in some 
cases less than half those reported in broilers. However, in Sweden, where resistance is typically low, 
resistance levels to cefotaxime, chloramphenicol, gentamicin, sulfonamides and tetracyclines were similar in 
broilers and laying hens. Although lower levels of resistance were typically reported in Sweden compared 
with Poland, Poland recorded high resistance to ciprofloxacin in laying hens.  
In addition, Norway reported resistance data on E. coli isolates from parent breeders for broiler production at 
low to moderate levels. 
Belgium was the only MS to report resistance data at the species level of Gallus gallus, potentially including 
a mixture of data on broilers and laying hens: high to extremely high resistance levels to all the antimicrobials 
tested except to gentamicin were recorded. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table  EC5.    Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among indicator Escherichia coli from 
Gallus gallus in countries reporting MIC data in 2012, using harmonised epidemiological cut-off 
values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus                             
Austria  130  26.9  130  3.1  130  8.5  130  65.4  130  0.8 
Belgium  325  79.7  325  28.0  325  44.6  325  79.7  325  5.8 
Denmark  115  20.0  115  1.7  115  0  115  7.8  115  0 
France  201  58.2  201  10.4  201  6.5  201  35.8  201  1.5 
Hungary  105  52.4  105  7.6  104  9.6  104  74.0  104  1.9 
Netherlands  292  69.9  292  5.8  292  16.4  292  51.4  292  8.6 
Poland  328  61.0  328  10.7  328  12.5  328  63.7  328  5.5 
Sweden  255  11.8  255  0.4  255  0.4  –  –  255  0.8 
Total (8 MSs)  1,751  52.7  1,751  10.2  1,750  15.4  1,495  57.6  1,750  4.0 
Norway  113  15.0  113  0.9  113  0  –  –  113  0 
Switzerland  185  32.4  185  2.2  185  1.1  185  46.5  185  0.5 
Broilers                               
Austria  130  26.9  130  3.1  130  8.5  130  65.4  130  0.8 
Denmark  115  20.0  115  1.7  115  0  115  7.8  115  0 
France  201  58.2  201  10.4  201  6.5  201  35.8  201  1.5 
Hungary  105  52.4  105  7.6  104  9.6  104  74.0  104  1.9 
Netherlands  292  69.9  292  5.8  292  16.4  292  51.4  292  8.6 
Poland  171  86.0  171  13.5  171  21.1  171  82.5  171  8.2 
Sweden  194  14.4  194  0  194  0.5  –  –  194  0.5 
Total (7 MSs)  1,208  50.4  1,208  6.2  1,207  9.9  1,013  52.7  1,207  3.8 
Switzerland  185  32.4  185  2.2  185  1.1  185  46.5  185  0.5 
Laying hens                               
Poland  157  33.8  157  7.6  157  3.2  157  43.3  157  2.5 
Sweden  61  3.3  61  1.6  61  0  –  –  61  1.6 
Total (2 MSs)  218  25.2  218  6.0  218  2.3  157  43.3  218  2.3 
Parent breeders for broiler production                      
Norway  113  15.0  113  0.9  113  0  –  –  113  0 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table EC5 (continued).  Resistance (%)  to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, 
gentamicin, nalidixic acid, streptomycin, sulfonamides and tetracyclines among indicator 
Escherichia coli from Gallus gallus in countries reporting MIC data in 2012, using harmonised 
epidemiological cut-off values 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
All Gallus gallus                         
Austria  130  65.4  130  42.3  130  44.6  130  30.8 
Belgium  325  77.8  325  81.5  325  80.0  325  68.3 
Denmark  115  7.8  115  11.3  115  20.9  115  7.8 
France  201  29.4  201  40.3  201  57.7  201  76.1 
Hungary  104  71.2  104  26.0  104  32.7  104  36.5 
Netherlands  292  50.0  292  58.2  292  62.7  292  50.7 
Poland  328  54.0  328  36.3  328  46.0  328  44.5 
Sweden  255  10.6  255  7.8  255  9.4  255  11.4 
Total (8 MSs)  1,750  47.4  1,750  42.9  1,750  48.6  1,750  44.9 
Norway  113  0.9  113  1.8  113  8.8  113  5.3 
Switzerland  185  45.9  185  14.6  185  24.9  185  33.5 
Broilers                         
Austria  130  65.4  130  42.3  130  44.6  130  30.8 
Denmark  115  7.8  115  11.3  115  20.9  115  7.8 
France  201  29.4  201  40.3  201  57.7  201  76.1 
Hungary  104  71.2  104  26.0  104  32.7  104  36.5 
Netherlands  292  50.0  292  58.2  292  62.7  292  50.7 
Poland  171  73.1  171  58.5  171  66.7  171  66.7 
Sweden  194  12.4  194  8.8  194  9.8  194  10.8 
Total (7 MSs)  1,207  43.2  1,207  38.4  1,207  45.4  1,207  43.3 
Switzerland  185  45.9  185  14.6  185  24.9  185  33.5 
Laying hens                         
Poland  157  33.1  157  12.1  157  23.6  157  20.4 
Sweden  61  4.9  61  4.9  61  8.2  61  13.1 
Total (2 MSs)  218  25.2  218  10.1  218  19.3  218  18.3 
Parent breeders for broiler production 
Norway  113  0.9  113  1.8  113  8.8  113  5.3 
MS: Member State; MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among indicator Escherichia coli isolates from broilers of 
Gallus gallus 
Figures EC1 to EC5 display temporal trends in resistance to selected antimicrobials in indicator E. coli from 
broilers of Gallus gallus over the seven-year study period of 2006 to 2012. It is of note that the 2010 and 
2011 resistance levels in Germany presented in these figures combine data on broilers and laying hens, 
while in the other reporting countries resistance data derive from broilers only. 
The figures illustrate the wide variation in resistance between MSs for many of the antimicrobials. Spain and 
the Netherlands tended to report the highest levels of resistance to most antimicrobials over the period, 
although Austria, Spain and the Netherlands reported the highest resistance to quinolones between 2010 
and 2012 and France, Spain and the Netherlands reported the highest resistance to tetracyclines from 2007 
to 2012. Conversely, Denmark often recorded the lowest resistance levels reported. 
The resistance to ciprofloxacin reported over the study period was high to very high for all reporting 
countries, with the exception of Denmark for the whole period, of Germany for the years 2010 and 2011 
(combine broiler and laying hen data), and of Norway for the period 2011 to 2012, which in all three cases 
was below 20 %. Figure EC3 clearly demonstrates the close similarity in resistance levels to ciprofloxacin 
and nalidixic acid in most MSs. There was less variation between countries in the resistance to cefotaxime 
and chloramphenicol, which, in most countries, was at a moderate or low level. However, although 
resistance levels in 2012 tended to be generally similar to those observed in 2011, there were a few 
exceptions; for example, in Poland (data not shown) and Switzerland, resistance to ampicillin and cefotaxime 
in broiler flocks increased from 2011 to 2012. Such inter-annual evolutions need to be confirmed by longer 
term trends. 
Resistance levels for many of the antimicrobials were broadly stable or had shown only gradual increases or 
decreases. Nevertheless, there was evidence of statistically significant trends in the occurrence of resistance 
to some of the antimicrobials over five or more years. Austria reported significant increases in resistance to 
ciprofloxacin, nalidixic acid and streptomycin. France reported significant increases in resistance to 
ampicillin, cefotaxime, ciprofloxacin and streptomycin. Denmark also reported statistically significant 
increasing trends in resistance to ampicillin and cefotaxime, although resistance levels are lower than those 
recorded in France. Switzerland also reported an increase in resistance to ampicillin, ciprofloxacin and 
nalidixic acid. Contrastingly, the Netherlands reported significant declines in resistance to cefotaxime and 
ciprofloxacin, in particular over the last three years. There were no significant trends in resistance to 
tetracyclines in any of the reporting countries.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure  EC1.    Trends in ampicillin resistance in indicator Escherichia coli from broilers of Gallus 
gallus
1 in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
Note: Statistically significant increasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed 
in Denmark (↑), France (↑) and Switzerland (↑). MS: Member State. 
1. The data from Germany in 2010 and 2011 originated from broilers and laying hens. 
Figure  EC2.    Trends in cefotaxime resistance in indicator Escherichia coli from broilers of Gallus 
gallus in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Denmark (↑), France (↑) and the Netherlands (↓). MS: Member State. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC3.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
broilers of Gallus gallus
1 in reporting MSs and two non-MSs, 2006–2012, quantitative data 
 
MS: Member State. 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Austria (↑) and Switzerland (↑) for both ciprofloxacin and nalidixic acid and in France (↑) and the Netherlands (↓) 
for ciprofloxacin.  
1. The data from Germany in 2010 and 2011 originated from broilers and laying hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC4.  Trends in streptomycin resistance in indicator Escherichia coli from broilers of Gallus 
gallus
1 in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
Note: A statistically significant increasing trend over six years, as tested by a logistic regression model (p ≤0.05), was observed in 
Austria (↑) and France (↑). MS: Member State. 
1. The data from Germany in 2010 and 2011 originated from broilers and laying hens. 
Figure EC5.  Trends in tetracyclines resistance in indicator Escherichia coli from broilers of Gallus 
gallus
1 in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p  ≤0.05), were observed in any 
of the reporting countries. MS: Member State. 
1. The data from Germany in 2010 and 2011 originated from broilers and laying hens. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among indicator Escherichia coli from broilers of Gallus gallus 
The spatial distributions of nalidixic acid and tetracycline resistance in E. coli from Gallus gallus are shown in 
Figures EC6 and EC7. The Nordic countries reported the lowest levels of resistance to both antimicrobials. 
The highest resistance to tetracyclines tended to be reported by the most western countries, while the spatial 
pattern for nalidixic acid was less clear. 
Figure EC6.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
broilers
1 of Gallus gallus in countries reporting MIC data in 2012
2 
 
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead.  
1.  The data from Norway originated from parent breeders for broiler production and data from Belgium originated from unspecified 
production type. 
2.  For Finland, Germany, Ireland and Spain, 2011 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure  EC7.    Spatial distribution of tetracycline resistance among indicator Escherichia coli from 
broilers
1 of Gallus gallus in countries reporting MIC data in 2012
2 
 
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead.  
1.  The data from Norway originated from parent breeders for broiler production and data from Belgium originated from unspecified 
production type. 
2.  For Finland, Germany, Ireland and Spain 2011 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Multi-resistance among indicator Escherichia coli isolates from broilers 
In 2012, three MSs and one non-MS provided isolate-based data regarding resistance in indicator E. coli in 
broilers. Among the reporting countries, variations were observed in the percentages of completely 
susceptible isolates, which varied from 13.5 % in Hungary to 56.5 % in Denmark. Although all reporting 
countries recorded multi-resistant isolates, their proportions differed substantially between them, reaching up 
to 47.1 % in Hungary (Table EC6). The frequency distributions (Figure EC8) showed that isolates resistant to 
as many as five antimicrobials were reported from all reporting countries, and three MSs reported a few 
isolates resistant to seven substances. Co-resistance to cefotaxime and ciprofloxacin was undetected in the 
Nordic MS or detected at only low or very low levels in central European MSs (Table EC6). 
Table EC6.  Complete susceptibility, multi-resistance and index of diversity in Escherichia coli from 
broilers in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to 
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=130)  22  16.9  56  43.1  0.493  1(0)  0.8(0) 
Denmark (N=115)  65  56.5  15  13.0  0.250  0(0)  0(0) 
Hungary (N=104)  14  13.5  49  47.1  0.537  7(1)  6.7(1.0) 
Switzerland (N=185)  49  26.5  46  24.9  0.383  4(0)  2.2(0) 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli; n: number 
of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for E. coli. 
Multi-resistant: resistant to at least 3 different antimicrobial substances, belonging to any three antimicrobial families from the common 
antimicrobial set for E. coli. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to cefotaxime (Ctx) and ciprofloxacin (Cip): the effectives and percentages of E. coli isolates non-susceptible to 
concentrations greater than epidemiological cut-off values (Ctx >0.25 mg/L and Cip >0.03 mg/L). Figures in parentheses indicate the 
occurrence of co-resistance to Cip and Ctx determined using clinical breakpoints (Ctx >2 mg/L and Cip >1 mg/L). 
Figure EC8.  Frequency distribution of Escherichia coli isolates completely susceptible and resistant 
to one to nine antimicrobials in broilers in MSs and non-MSs reporting isolate-based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli; sus: 
susceptible to all antimicrobial substances of the EFSA common set for E. coli; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for E. coli. 
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Multi-/co-resistance patterns among indicator Escherichia coli isolates from broilers 
As expected, most isolates resistant to ciprofloxacin were also resistant to nalidixic acid when using ECOFFs 
as thresholds. Several E. coli isolates from Hungary were resistant to cefotaxime but not to ceftazidime, 
hence they appear in Table EC6 but not in Table EC7. Considering resistance patterns in isolates co-
resistant to ciprofloxacin and cefotaxime (Table EC8), a number of isolates were also resistant to 
sulfonamides, streptomycin and tetracyclines. Trimethoprim resistance was also observed, while resistance 
to nalidixic acid and ampicillin was expected in isolates co-resistant to cefotaxime and ciprofloxacin. 
Analysing occurrence of higher levels of resistance to ciprofloxacin in E. coli reveals marked differences 
between MSs (Table EC9). 
Table EC7.  Multi-/co-resistance patterns of interest in Escherichia coli from broilers in MSs and one 
non-MS reporting isolate-based data, 2012 
Multi-/co-resistance pattern  Group of reporting 
countries (N=534) 
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        R    R          253 98.1  47.4  85  9  74  85 
  R  R    R              5 1.9  0.9  1  0  0  4 
Total  258  100  48.3  86  9  74  89 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli and multi-
resistant; Amp: ampicillin; Caz: ceftazidime; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Nal: nalidixic 
acid; Str: streptomycin; Su: sulfonamides; Tet: tetracyclines; Tmp: trimethroprim; n: number of multi-/co-resistant isolates; R: minimum 
inhibitory concentration above the European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values 
(ECOFFs). 
Table EC8.  Co-resistance to cefotaxime and ciprofloxacin in Escherichia coli from broilers in MSs 
and one non-MS reporting isolate-based data, 2012 
Country 
Resistance to both 
Cip and Ctx, 
applying ECOFFs
1 
Resistance to both 
Cip and Ctx, applying 
clinical breakpoints
1 
Multi-resistance patterns of 
isolates resistant to both 
Cip and Ctx, applying ECOFFs
1 
(number of isolates)  n (%)  n (%) 
Austria (N=130)  1 (0.8 %)  0 (0 %)  AmpCtxChlCipNalSuTet (1) 
Denmark (N=115)  0 (0 %)  0 (0 %)  NA 
Hungary (N=104)  7 (6.7 %)  1 (1.0 %) 
AmpCtxCipNal (3) 
AmpCtxCipNalSuTetTmp (1) 
AmpCtxCipNalStrSuTmp (1) 
AmpCtxCipNalStrSuTetTmp (1) 
AmpCtxChlCipNalSuTmp (1) 
Total (3 MSs) (N=349)  8 (2.3 %)  1 (0.3 %)   
Switzerland (N=185)  4 (2.2 %)  0 (0 %) 
AmpCtxCipNalSuTet (2) 
AmpCtxCipNal (1) 
AmpCtxCipNalSuTetTmp (1) 
MS: Member State; N: total number isolates for which relevant data are available; n: number of co-resistant isolates; Cip: ciprofloxacin; 
Ctx: cefotaxime.  
1.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs) and clinical 
breakpoints were applied. 
.   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table EC9.  Ciprofloxacin resistance assessed at differing thresholds in indicator Escherichia coli 
from broilers in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Isolates 
resistant 
at 
>0.03mg/L
1 
Cip 
Isolates 
resistant 
at 
>1mg/L
2 
Cip 
Isolates 
resistant 
at 
>2mg/L
3 
Cip 
Isolates 
resistant 
at 
>4mg/L
4 
Cip 
Resistance patterns of isolates 
resistant at >4mg/L Cip 
(number of isolates) 
n (%)  n (%)  n (%)  n (%) 
Austria (N=130)  85 (65.4 %)  8 (6.2 %)  4 (3.1 %)  4 (3.1 %) 
ChlCipNalStrSuTet (1) 
AmpCipNalStrSuTet (1) 
AmpCipNalStrSuTetTmp (1) 
AmpChlCipGenNalSuTmp (1) 
Denmark (N=115)  9 (7.8 %)  1 (0.9 %)  1 (0.9 %)  0 (0 %)  NA 
Hungary (N=104)  77 (74 %)  35 (33.7 %)  28 (26.9 %)  24 (23.1 %)
CipNal (4) 
AmpCipNal (3) 
AmpCipNalTet (2) 
AmpCipNalStrSuTetTmp (2) 
CipNalTet (1) 
CipNalSuTet (1) 
CipNalSuTetTmp (1) 
AmpCipNalTmp (1) 
AmpCipNalTetTmp (1) 
AmpCipNalSuTmp (1) 
AmpCipNalSuTet (1) 
AmpChlCipNalSuTmp (1) 
AmpChlCipNalSuTetTmp (1) 
AmpChlCipNalStrSuTet (1) 
AmpChlCipNalStrSuTetTmp (1) 
AmpChlCipGenNalStrSuTetTmp (1) 
AmpCtxChlCipNalSuTmp (1) 
Total (3 MSs)(N=349)  171 (49.0 %)  44 (12.6 %)  33 (9.5 %)  28 (8.0 %)   
Switzerland (N=185)  86 (46.5 %)  11 (5.9 %)  10 (5.4 %)  9 (4.9 %) 
AmpCipNalTet (5) 
CipNal (1) 
CipNalSuTetTmp (1) 
AmpCipNalSuTetTmp (1) 
AmpCipGenNalStrSuTmp (1) 
MS: Member State; N: total number isolates for which relevant data are available; n: number of resistant isolates; Cip: ciprofloxacin. 
1.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2. EUCAST  clinical  breakpoint. 
3. High  breakpoint. 
4.  Very high breakpoint. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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5.2.2.2. Pigs 
Representative sampling and monitoring 
In 2012, seven MSs and one non-MS (Switzerland) provided quantitative antimicrobial resistance data on 
indicator E. coli in pigs which were included in the following analysis (Table EC10). These data were not split 
by production type, as isolates originated from either fattening pigs or breeding animals (Belgium) or the 
production type was not specified. The majority of MSs collected isolates as part of their national monitoring 
programme of antimicrobial resistance, mostly based on random sampling of healthy slaughter pig carcases 
at the slaughterhouse. A two-stage stratified sampling design, with slaughterhouses as primary sampling 
units and carcases as secondary units, with proportional allocation of the number of samples to the annual 
throughput of the slaughterhouse, was typically applied in the reporting countries. The sample collection was 
approximately evenly distributed over the year. Only one representative faecal sample per epidemiological 
unit (batch), either derived from a unique carcase or pooled from a number of carcases, was gathered to 
account for clustering. Hungary did not report detailed information on sample type and sampling context. 
Resistance levels among Escherichia coli isolates from pigs 
In 2012, resistance to ampicillin in E. coli isolates from pigs was generally high among reporting MSs, 
ranging from 22.0 % to 48.5 % - except in Austria which recorded a 12.9 % resistance, while resistance to 
streptomycin, sulfonamides and tetracyclines was high to very high in all reporting countries, ranging from 
36.8  % to 59.9  %, 22.9  % to 60.0  % and 29.2  % to 69.1  %, respectively. Conversely, resistance to 
chloramphenicol was low to moderate in most reporting countries, with the notable exception of Belgium 
reporting, as in 2011, a high resistance of 30.2 %, while gentamicin resistance was generally recorded at low 
to very low levels. Resistance to ciprofloxacin and nalidixic acid was low to moderate among all reporting 
countries, ranging between 0.7  % and 16.6  %, and resistance to cefotaxime was either not detected or 
reported at low levels in all reporting countries.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table EC10.  Resistance  (%)  to  ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among isolates of indicator Escherichia 
coli from pigs in countries reporting MIC data in 2012, using harmonised epidemiological cut-off 
values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria
1  140  12.9  140  0  140  2.1  140  5.0  140  0 
Belgium
2  205  48.3  205  2.9  205  30.2  205  16.6  205  1.0 
Denmark
1  152  28.9  152  0.7  152  3.3  152  0.7  152  0.7 
France
1  200  22.0  200  2.0  200  9.5  200  8.5  200  3.0 
Hungary
1  68  48.5  68  1.5  68  14.7  68  13.2  68  2.9 
Netherlands
1  284  25.0  284  0  284  11.6  284  1.1  284  2.1 
Poland
3  190  29.5  190  2.6  190  8.9  190  11.6  190  2.6 
Total (7 MSs)  1,239  29.5  1,239  1.4  1,239  12.0  1,239  7.5  1,239  1.8 
Switzerland
1  185  20.0  185  1.1  185  4.9  185  3.2  185  1.1 
 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
Austria
1  140  5.0  140  52.1  140  22.9  140  50.7 
Belgium
2  205  12.2  205  53.7  205  60.0  205  61.5 
Denmark
1  152  0.7  152  42.1  152  34.9  152  35.5 
France
1  200  3.0  200  46.0  200  44.0  200  63.5 
Hungary
1  68  10.3  68  36.8  68  35.3  68  69.1 
Netherlands
1  284  1.1  284  59.9  284  45.4  284  56.3 
Poland
3  190  6.3  190  46.8  190  35.8  190  48.9 
Total (7 MSs)  1,239  4.9  1,239  50.3  1,239  41.7  1,239  54.7 
Switzerland
1  185  3.2  185  46.5  185  38.9  185  29.2 
MIC: minimum inhibitory concentration; N: number of isolates tested; % Res: percentage of resistant isolates; MS: Member State. 
1. Fattening  pigs.   
2. Breeding  animals. 
3.  Unspecified production type. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Temporal trends in resistance among indicator Escherichia coli isolates from pigs 
Figures EC9 to EC13 display the trends in resistance to selected antimicrobials in indicator E. coli from pigs 
over the period 2006 to 2012. There was variation in the resistance levels in different MSs, particularly for 
tetracyclines (Figure EC13). However, the differences between MSs were often not as marked as was 
observed for isolates from Gallus gallus. In some cases, this was because the resistance levels tended to be 
lower than those observed in Gallus gallus (e.g. ampicillin; Figure EC9), whereas, for others, it was due to 
the resistance levels all being higher than those recorded in Gallus gallus (e.g. streptomycin; Figure EC12). 
Cefotaxime resistance has been below 5 % in all countries since 2005, and at a lower level than in Gallus 
gallus (Figure EC10). Resistance to both ciprofloxacin and nalidixic acid has also generally been at a low 
level since 2005 (Figure EC11). 
For many of the antimicrobials, the resistance levels were relatively stable with only minor fluctuations or 
gradual changes. There were fewer statistically significant trends than observed among isolates from Gallus 
gallus. Denmark reported significant increases in resistance to ampicillin, Switzerland reported significant 
increases in resistance to ciprofloxacin and nalidixic acid. In contrast, the Netherlands reported significant 
declines in resistance to ampicillin, ciprofloxacin and tetracyclines, and France reported significant declines 
in resistance to streptomycin and tetracyclines. No statistically significant trends were observed in resistance 
to cefotaxime. 
Figure EC9.  Trends in ampicillin resistance in indicator Escherichia coli from pigs in reporting MSs 
and one non-MS, 2006–2012, quantitative data 
 
MS: Member State. 
Note: Statistically significant increasing and decreasing trends over seven years, as tested by a logistic regression model (p ≤0.05), 
were observed in Denmark (↑) and the Netherlands (↓).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC10.  Trends in cefotaxime resistance in indicator Escherichia coli from pigs in reporting 
MSs and non-MS, 2006–2012, quantitative data 
 
MS: Member State. 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries.  
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC11.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
pigs in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
MS: Member State. 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Switzerland (↑) for both ciprofloxacin and nalidixic acid, in France (↑) and the Netherlands (↓) for ciprofloxacin.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC12.  Trends in streptomycin resistance in indicator Escherichia coli from pigs in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
Note: A statistically significant decreasing trend over seven years, as tested by a logistic regression model (p ≤0.05), was observed in 
France (↓). MS: Member State. 
Figure EC13.  Trends in tetracycline resistance in indicator Escherichia coli from pigs in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
Note: Statistically significant decreasing trend over seven years, as tested by a logistic regression model (p ≤0.05), were observed in 
France (↓) and the Netherlands (↓). MS: Member State. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among indicator Escherichia coli isolates from pigs 
The spatial distribution of nalidixic acid and tetracycline resistance in indicator E. coli from pigs is shown in 
Figures EC14 and EC15, respectively. For nalidixic acid, most countries reported low levels of resistance so 
the spatial pattern was less clear. Figure EC15 illustrates the variability in levels of tetracyclines resistance in 
E. coli across the EU and the absence of a clear spatial distribution.  
Figure EC14.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
pigs in countries reporting MIC data in 2012
1 
 
MS: Member State; MIC: minimum inhibitory concentration. 
Note:  Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead.  
1. For Estonia, Germany, Spain and Sweden, 2011 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC15.  Spatial distribution of tetracycline resistance among indicator Escherichia coli from 
pigs in countries reporting MIC data in 2012
1 
 
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead.  
1. For Estonia, Germany, Spain and Sweden, 2011 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Multi-resistance among indicator Escherichia coli isolates from fattening pigs 
Three MSs and one non-MS tested the complete harmonised set of antimicrobials for E. coli and reported 
isolate-based data. Around 40 % of the isolates tested were susceptible to the nine antimicrobials of the set 
in three reporting countries, while the proportion was lower than 25 % in Hungary. Multi-resistance levels (i.e. 
reduced susceptibility to three or more antimicrobial classes) were high in all reporting countries (Table 
EC11), ranging between about one-quarter and half of the indicator E. coli isolates from pigs. The frequency 
distributions (Figure EC16) showed that all reporting countries detected multi-resistance to as many as six or 
seven antimicrobial classes. Very few isolates exhibited co-resistance to cefotaxime and ciprofloxacin using 
either ECOFFs or clinical breakpoints as interpretive criteria (Table EC11). 
Table EC11.  Complete susceptibility, multi-resistance and index of diversity in Escherichia coli from 
fattening pigs in MSs and one non-MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Multi-resistant  Index of 
diversity 
Co-resistant to 
Cip and Ctx 
n  %  n  %  n  % 
Austria (N=140)  53  37.9  34  24.3  0.379  0(0)  0(0) 
Denmark (N=152)  63  41.5  49  32.2  0.428  0(0)  0(0) 
Hungary (N=68)  16  23.5  34  50.0  0.516  0(0)  0(0) 
Switzerland (N=185)  80  43.2  64  34.6  0.420  1(0)  0.5(0) 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli; n: number 
of isolates. 
Susceptible to all: isolate susceptible to all antimicrobial substances of the EFSA common set for E. coli. 
Multi-resistant: resistant to at least 3 different antimicrobial substances, belonging to any three antimicrobial families from the common 
antimicrobial set for E. coli. 
Index of diversity: see definition in Section 8.4.2.1 of Chapter 8 Materials and methods. 
Co-resistant to cefotaxime (Ctx) and ciprofloxacin (Cip): the effectives and percentages of E. coli isolates non-susceptible to 
concentrations greater than epidemiological cut-off values (Ctx >0.25 mg/L and Cip >0.03 mg/L). Figures in parentheses indicate the 
occurrence of co-resistance to Cip and Ctx determined using clinical breakpoints (Ctx >2 mg/L and Cip >1 mg/L). 
Figure EC16.  Frequency  distribution  of  Escherichia coli isolates completely susceptible and 
resistant to one to nine antimicrobials in fattening pigs in MSs and one non-MS reporting isolate-
based data, 2012 
 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli; sus: 
susceptible to all antimicrobial substances of the EFSA common set for E. coli; res1–res9: resistance to one antimicrobial 
substance/resistance to nine antimicrobial substances of the common set for E. coli.  
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Multi-/co-resistance patterns among indicator Escherichia coli isolates from fattening pigs 
Indicator E. coli isolates resistant to cefotaxime and ciprofloxacin were only observed in Switzerland among 
reporting countries and streptomycin, sulphonamide and tetracycline resistance was also often present in the 
isolates tested (Table EC13). These additional resistances (together with trimethoprim resistance in some 
cases) were also noted in E. coli isolates showing high-level ciprofloxacin resistance (Table EC14). 
Table EC12.  Multi-/co-resistance patterns of interest in Escherichia coli from fattening pigs in MSs 
and one non-MS reporting isolate-based data, 2012 
Multi-/co-resistance pattern  Group of reporting 
countries (N=545) 
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n %  group  %  n  n  n  n 
        R    R          20 95.2  3.7  7  1  7  5 
  R  R    R              1 4.8  0.2 0 0 0 1 
Total  21  100  3.9  7  1  7  6 
MS: Member State; N: total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli and multi-
resistant; Amp: ampicillin; Caz: ceftazidime; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Nal: nalidixic 
acid; Str: streptomycin; Su: sulfonamides; Tet: tetracyclines; Tmp: trimethroprim; n: number of multi-/co-resistant isolates; R: minimum 
inhibitory concentration above European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values 
(ECOFFs). 
Table EC13.  Co-resistance to cefotaxime and ciprofloxacin in Escherichia coli from fattening pigs in 
MSs and one non-MS reporting isolate-based data, 2012 
Country 
Resistance to both
Cip and Ctx, 
applying ECOFFs
1 
Resistance to both 
Cip and Ctx, applying 
clinical breakpoints
1 
Multi-resistance patterns of 
isolates resistant to both 
Cip and Ctx, applying ECOFFs
1 
(number of isolates)  n (%)  n (%) 
Austria (N=140)  0 (0 %)  0 (0 %)  NA 
Denmark (N=152)  0 (0 %)  0 (0 %)  NA 
Hungary (N=68)  0 (0 %)  0 (0 %)  NA 
Total (3 MSs) (N=360)  0 (0 %)  0 (0 %)   
Switzerland (N=185)  1 (0.5 %)  0 (0 %)  AmpCtxCip (1) 
MS: Member State; N: total number isolates for which relevant data are available; n: number of co-resistant isolates; Cip: ciprofloxacin; 
Ctx: cefotaxime; NA: not applicable. 
1.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs) and clinical 
breakpoints were applied. 
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Table EC14.  Ciprofloxacin resistance assessed at differing thresholds in indicator Escherichia coli 
from fattening pigs in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Isolates 
resistant 
at 
>0.03 
mg/L
1 
Cip 
Isolates 
resistant 
at 
>1 mg/L
2 
Cip 
Isolates 
resistant 
at 
>2 mg/L
3 
Cip 
Isolates 
resistant 
at 
>4 mg/L
4 
Cip 
Resistance patterns of isolates 
resistant at >4 mg/L Cip 
(number of isolates) 
n (%)  n (%)  n (%)  n (%) 
Austria (N=140)  7 (5.0 %)  4 (2.9 %)  4 (2.9 %)  4 (2.9 %) 
AmpCipNalStrSuTetTmp (2) 
CipNalStrTetTmp (1) 
AmpCipNalTet (1) 
Denmark (N=152)  1 (0.7 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA 
Hungary (N=68)  9 (13.2 %)  2 (2.9 %)  2 (2.9 %)  2 (2.9 %) 
AmpCipNalTet (1) 
AmpCipNalStrSuTetTmp (1) 
Total (3 MSs) (N=360)  17 (4.7 %)  6 (1.7 %)  6 (1.7 %)  6 (1.7 %)   
Switzerland (N=185)  6 (3.2 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA 
MS: Member State; N: total number isolates for which relevant data are available; n: number of resistant isolates; Cip: ciprofloxacin; NA: 
not applicable. 
1.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2. EUCAST  clinical  breakpoint. 
3. High  breakpoint. 
4.  Very high breakpoint. 
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5.2.2.3. Cattle (bovine animals) 
Representative sampling and monitoring 
In 2012, quantitative data for E. coli in cattle were provided by seven MSs and one non-MS (Switzerland) 
(Table EC15). These countries tested different production types and ages of cattle, including calves, young 
cattle, meat production animals, adult cattle and dairy cows; Denmark and Poland did not specify the type of 
cattle that were tested. 
Among the reporting MSs, antimicrobial resistance monitoring in indicator E. coli isolates from cattle was 
chiefly based on monitoring plans of healthy bovine animals randomly selected within the slaughterhouses 
(Austria, Denmark, Finland and Switzerland). Indicator E. coli isolates were isolated from caecal contents in 
Austria, from recto-anal swabs in Switzerland and from faeces in Denmark and Finland by sampling healthy 
cattle at slaughter. Belgium and Poland did not report information on the sample type, sampling context and 
sampling stage. 
The overall results for cattle presented in Table EC15 include all isolates of E. coli that were collected from 
this animal species by MSs which tested more than 10 isolates from cattle in total.  Results are also 
presented for the specific production levels of cattle from which these E. coli isolates originated. Some MSs 
tested fewer than 10 isolates from individual production types. In such cases, the data for these production 
types are included in the overall results for cattle but are not presented in the production level-specific 
sections of this table. 
Resistance levels among Escherichia coli isolates from cattle 
The occurrence of resistance to gentamicin and nalidixic acid was less common, with an overall level at the 
reporting MS group of 3.1 %, and 8.6 %, respectively. Two countries reported no resistance to cefotaxime, 
with the highest resistance levels being 8.8 % and 2.6 %, recorded by Belgium and Poland among mixed 
herds and unspecified production type, respectively.  
In indicator E. coli isolates from calves of less than one year of age, tested in Austria, Germany and the 
Netherlands, resistance to ampicillin, streptomycin, sulfonamides and tetracyclines was generally moderate 
to high, while resistance to chloramphenicol and gentamicin was recorded at low to moderate and low levels, 
respectively. The occurrence of resistance to (fluoro)quinolones and third-generation cephalosporins was 
less common, as ciprofloxacin and nalidixic acid resistance was reported at low to moderate levels, while 
resistance to cefotaxime was low to very low. Switzerland, which monitored indicator E. coli resistance in 
bovine animals for meat production, recorded similar features of resistance to the same panel of substances, 
although at a slightly lower level.  
Austria which also submitted data concerning young cattle (aged one to two years) and adult cattle (over two 
years) reported lower resistance levels in these age groups than in calves of less than one year; only 
resistance to streptomycin, sulfonamides and tetracyclines was detected at around 5 %, while no resistance 
was recorded to the other substances of the common panel. The Netherlands reported much lower 
resistance, at around 1 % levels, among dairy cows than among veal calves. 
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Table EC15.  Resistance  (%)  to  ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines among isolates of Escherichia coli from 
cattle in countries reporting MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
All cattle                               
Austria  273  5.9  273  0.7  273  2.2  273  2.2  273  0.7 
Belgium  364  56.0  364  8.8  364  31.0  364  33.8  364  6.0 
Denmark  98  5.1  98  0  98  2.0  98  0  98  0 
Finland  295  1.7  295  0  295  0  –  –  295  0.3 
Germany  515  46.8  515  2.5  515  17.5  515  16.5  515  6.4 
Netherlands  559  13.6  559  0.5  559  7.7  559  3.4  559  1.4 
Poland  190  7.9  190  2.6  190  2.6  190  5.3  190  2.6 
Total (7 MSs)  2,294  24.5  2,294  2.4  2,294  11.3  1,999  12.2  2,294  3.1 
Switzerland  187  14.4  187  0.5  187  3.7  187  3.2  187  5.9 
Calves (under 1 year)                            
Austria  151  10.6  151  1.3  151  3.3  151  4.0  151  1.3 
Germany  515  46.8  515  2.5  515  17.5  515  16.5  515  6.4 
Netherlands  285  25.6  285  0.7  285  14.4  285  6.0  285  2.5 
Total (3 MSs)  951  34.7  951  1.8  951  14.3  951  11.4  951  4.4 
Young cattle (1–2 years)                            
Austria  73  0  73  0  73  0  73  0  73  0 
Meat production animals                            
Switzerland  187  14.4  187  0.5  187  3.7  187  3.2  187  5.9 
Adult over 2 years                             
Austria  49  0  49  0  49  2.0  49  0  49  0 
Dairy cows                               
Netherlands  274  1.1  274  0.4  274  0.7  274  0.7  274  0.4 
Mixed herds                               
Belgium  364  56.0  364  8.8  364  31.0  364  33.8  364  6.0 
Finland  295  1.7  295  0  295  0  –  –  295  0.3 
Total (2 MSs)  659  31.7  659  4.9  659  17.1  364  33.8  659  3.5 
MIC: minimum inhibitory concentration; MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates. 
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Table EC15 (continued).  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, 
gentamicin, nalidixic acid, streptomycin, sulfonamides and tetracyclines among isolates of 
Escherichia coli from cattle in countries reporting MIC data in 2012, using harmonised 
epidemiological cut-off values 
Country 
Nalidixic acid  Streptomycin  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res 
All cattle                         
Austria  273  1.8  273  12.5  273  11.4  273  14.7 
Belgium  364  28.6  364  51.6  364  59.3  364  58.2 
Denmark  98  0  98  6.1  98  6.1  98  7.1 
Finland  295  0  295  5.4  295  3.4  295  2.4 
Germany  515  12.0  515  43.3  515  50.1  515  53.0 
Netherlands  559  2.9  559  16.3  559  17.0  559  25.2 
Poland  190  5.3  190  8.9  190  17.4  190  11.6 
Total (7 MSs)  2,294  8.6  2,294  25.1  2,294  28.3  2,294  30.6 
Switzerland  187  3.2  187  24.6  187  26.2  187  24.6 
Calves (under 1 year) 
Austria  151  3.3  151  18.5  151  17.2  151  22.5 
Germany  515  12.0  515  43.3  515  50.1  515  53.0 
Netherlands  285  5.3  285  30.9  285  32.6  285  48.1 
Total (3 MSs)  951  8.6  951  35.6  951  39.6  951  46.7 
Young cattle (1–2 years) 
Austria  73  0  73  5.5  73  4.1  73  5.5 
Meat production animals 
Switzerland  187  3.2  187  24.6  187  26.2  187  24.6 
Adult over 2 years                       
Austria  49  0  49  4.1  49  4.1  49  4.1 
Dairy cows                         
Netherlands  274  0.4  274  1.1  274  0.7  274  1.5 
Mixed herds                         
Belgium  364  28.6  364  51.6  364  59.3  364  58.2 
Finland  295  0  295  5.4  295  3.4  295  2.4 
Total (2 MSs)  659  15.8  659  31.0  659  34.3  659  33.2 
MIC: minimum inhibitory concentration; MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates. 
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Temporal trends in resistance among indicator Escherichia coli isolates from cattle 
Figures EC17 to EC21 display the trends in resistance to selected antimicrobials in E. coli from cattle. It 
should be noted that the figures presented for each country combine the results for all cattle production types 
and/or ages submitted each year. As in the other livestock species, the resistance levels varied substantially 
between MSs for several of the antimicrobials, including ampicillin, streptomycin and tetracyclines. Austria 
and Denmark reported the lowest levels of resistance for many of the antimicrobials. As in pigs, cefotaxime 
resistance has been below 5 % in all countries since 2005 (Figure EC18). 
Considering the previous years of reporting, the resistance levels reported by Denmark in 2011 and 2012 
were broadly comparable. In Austria, the studied population changed in 2012 with calves being over-
represented compared with the other age of groups in the years before 2012; therefore, statistical trends 
were not calculated. Switzerland reported decreases in resistance to most antimicrobials between 2010 and 
2012, which is most probably because the study population in 2010 was veal calves less than six months old 
whereas in 2011 older cattle (>12 months) were sampled. In Germany, resistance rates were much lower in 
2011 than in 2010 and in 2012. However, in 2010 and 2012 veal calves were tested while in 2011 young 
beef animals were tested which usually differ in management and antimicrobial exposure. 
Some countries, such as Denmark and the Netherlands, have shown relatively stable resistance levels or 
only minor fluctuations or trends since 2006 whereas other countries, such as Germany and Switzerland, 
have shown more substantial fluctuations in resistance levels that are, at least partially, due to the sampling 
of different cattle production types in different years. There have been numerous statistically significant 
trends in resistance levels since 2006; for example, Germany and the Netherlands showed significant 
declines in resistance to five of the antimicrobials. Significant decreasing trends were also observed in 
Denmark and Switzerland.  
Figure EC17.  Trends in ampicillin resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
M: Member State. 
Note: Statistically significant increasing or decreasing trends over five or more years, as tested by a logistic regression model (p ≤0.05), 
were observed in Germany (↓), the Netherlands (↓) and Switzerland (↓).  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC18.  Trends in cefotaxime resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
M: Member State. 
Note: No statistically significant trends over five or more years, as tested by a logistic regression model (p ≤0.05), were observed in any 
of the reporting countries.  
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Figure EC19.  Trends in ciprofloxacin and nalidixic acid resistance in indicator Escherichia coli from 
cattle in reporting MSs and one non-MS, 2006–2012, quantitative data 
 
M: Member State. 
Note: Statistically significant decreasing trends over five or more years, as tested by a logistic regression model (p  ≤0.05), were 
observed in Germany (↓) and the Netherlands (↓) for both ciprofloxacin and nalidixic acid, in Denmark (↓) and Estonia (↓) for 
ciprofloxacin.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC20.  Trends in streptomycin resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
Note: Statistically significant increasing and decreasing trends over five or more years, as tested by a logistic regression model 
(p ≤0.05), were observed in Estonia (↓), Germany (↓), the Netherlands (↓) and Switzerland (↓). MS: Member State. 
Figure EC21.  Trends in tetracycline resistance in indicator Escherichia coli from cattle in reporting 
MSs and one non-MS, 2006–2012, quantitative data 
 
Note: Statistically significant increasing and decreasing trends over five or more years, as tested by a logistic regression model 
(p ≤0.05), were observed in Germany (↓), the Netherlands (↓) and Switzerland (↓). MS: Member State. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Spatial distribution of resistance among indicator Escherichia coli isolates from cattle 
The spatial distributions of nalidixic acid and tetracycline resistance among E. coli from cattle are shown in 
Figures EC22 and EC23. Nevertheless, there was still some evidence that the lowest resistance to 
tetracyclines occurred in the northern countries and the highest occurred in the southern and western 
countries. With respect to nalidixic acid, the majority of countries reported low levels of resistance and no 
spatial pattern was evident. 
Figure EC22.  Spatial distribution of nalidixic acid resistance among indicator Escherichia coli from 
cattle in countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting MIC data for fewer than 10 isolates or purely qualitative data (as proportion of resistant isolates).  
1.  For Spain, 2011 data were used.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Figure EC23.  Spatial distribution of tetracycline resistance among indicator Escherichia coli from 
cattle in countries reporting MIC data in 2012
1 
 
MIC: minimum inhibitory concentration; MS: Member State. 
Note: Percentages shown in this map refer to countries that reported quantitative MIC data for more than 10 isolates in 2012. When 
quantitative 2012 data were not available, 2011 data were used instead. The countries labelled as ‘qualitative data’ therefore 
include those reporting MIC data for fewer than 10 isolates or purely qualitative data (as proportion of resistant isolates).  
1.  For Spain, 2011 data were used.  
Multi-resistance among indicator Escherichia coli isolates from cattle 
No tables and graphs on multi-resistance are presented in this report for E. coli in cattle because too few 
MSs reported multi-resistance isolate-based data on more than 10 isolates for the different production types 
of cattle. 
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5.3. Multi-drug resistance patterns in indicator E. coli in 2012 
The MDR patterns in indicator E. coli from broilers and fattening pigs, in MSs reporting isolate-based data, 
are shown in Appendix 4, Table MDRP37, and Appendix 4, Table MDRP38, respectively. 
5.3.1. Multi-drug resistance in E. coli isolates from broilers 
A large number of different resistance patterns in indicator E. coli isolates from broilers were evident (57 
different patterns displayed by 534 isolates), reflecting the diverse nature of the E. coli strains which have 
been tested. Although no single pattern occurred at a frequency of greater than 3 % amongst the MDR 
patterns obtained from broilers, a common core of resistance to ampicillin, sulfonamides and tetracyclines, 
generally with resistance to ciprofloxacin and frequently with resistance to streptomycin and trimethoprim, 
was discernible. Several resistance patterns which occurred at a higher frequency included resistance to 
cefotaxime; however, cefotaxime resistance also occurred as a component of infrequent resistance patterns. 
Ciprofloxacin resistance frequently occurred as a component of MDR in E. coli  from broilers and was 
observed in 72.3 % of MDR isolates (120 out of 166). 
5.3.2. Multi-drug resistance in E. coli isolates from fattening pigs 
The overall range of different patterns observed in indicator E. coli  isolates from pigs in MSs reporting 
isolate-based data was similar to that seen in broilers, with a large number of different resistance patterns 
evident (54 different patterns displayed by 565 isolates), again reflecting the diverse nature of the E. coli 
strains which have been tested. Particular MDR patterns were predominant in fattening pigs, with two 
patterns occurring at a frequency of greater than 14 % amongst the MDR patterns obtained, and each of 
these patterns comprising more than 5 % of the E. coli isolates for which isolate-based data was available. In 
pigs, E. coli with either of two MDR patterns (pattern one: streptomycin, sulfonamides and tetracyclines, and 
pattern two: streptomycin, sulfonamides, tetracyclines, ampicillin and trimethoprim), therefore, accounted for 
approximately 10  % of the total number of E. coli  isolates for which isolate-based data were available. 
Resistance to streptomycin, sulfonamides and tetracyclines formed a common core in both of these MDR 
patterns and also occurred as a recurring core pattern in isolates showing additional resistances. 
Considering those resistance patterns occurring at a higher frequency in pigs, these did not generally include 
resistance to cefotaxime; however, cefotaxime resistance did occur as a component of infrequent resistance 
patterns. Ciprofloxacin resistance occurred infrequently as a component of MDR in pigs and was present in 
16 % of porcine MDR E. coli isolates (32 out of 200). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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5.4. Overview of findings on indicator E. coli resistance at reporting MS group level, 2012 
Figures EC24 and EC25 display the resistance levels among E. coli isolates in the reporting MS group, 
based on quantitative data submitted in 2012. These data were not all derived from the same group of MSs, 
which needs to be considered when interpreting these figures.  
The levels of resistance were broadly similar for meat from broilers, pigs and bovine animals for all reporting 
MSs for these antimicrobials (Figure EC24). The situation was different for ciprofloxacin and nalidixic acid, 
where resistance was high in meat from broilers considering all reporting MSs at 29.1  % and 24.1  % 
respectively, but low in meat from pigs and meat from bovine animals at less than 7 %. 
The resistance levels observed in E. coli isolates from cattle were lower than in E. coli isolates from either 
Gallus gallus or pigs, most notably for ampicillin, streptomycin, sulfonamides and tetracyclines (Figure 
EC25). The variations at the reporting MS group level between years could be attributable to different MSs 
contributing data and different production types of livestock being sampled. The MSs that provided data for 
all three livestock species in both 2011 and 2012 usually reported the lowest resistance levels among cattle. 
As in previous years, isolates from pigs had the highest levels of resistance to streptomycin and 
tetracyclines, while isolates from Gallus gallus had the highest resistance to ampicillin, ciprofloxacin, nalidixic 
acid and sulfonamides. Resistance to chloramphenicol and gentamicin was relatively low in all types of 
livestock, with the highest resistance level occurring in Gallus gallus. This differs from the situation in 2010, 
when the highest resistance levels for these two antimicrobials were observed in cattle. Chloramphenicol has 
not been used for food production animals in the EU for several years; thus, the resistance observed must 
either indicate persistence of resistance genes or co-selection resulting from use of related compounds (such 
as florfenicol). The lowest levels of resistance were usually observed to cefotaxime; the highest level of 
resistance to this antimicrobial occurred in isolates from Gallus gallus, which was also the case in previous 
years. 
Figure EC24.  Resistance in indicator Escherichia coli from meat from broilers, meat from pigs and 
meat from bovine animals to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, 
nalidixic acid, streptomycin, sulfonamides and tetracyclines at reporting MS group level, in 2012 
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Figure EC25.  Resistance  in  indicator  Escherichia coli from fowl, pigs and cattle to ampicillin, 
cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides 
and tetracyclines at reporting MS group level, in 2012 
 
MS: Member State. 
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5.5. Discussion 
Antimicrobial resistance in indicator commensal E. coli from animals and food can be used to examine the 
reservoir of resistance genes occurring in those bacteria that could be transferred to bacteria that are 
pathogenic for humans and/or animals. The major factor influencing the occurrence of resistance to 
antimicrobials in indicator E. coli is likely to be the selective pressures exerted by use of antimicrobials in the 
different food animal populations; variations in usage between animal species may also contribute to the 
observed differences in resistance levels between the animal species. Indicator E. coli are thus also of 
interest when investigating possible associations between the usage of antimicrobials in a given country and 
the occurrence of resistance in an animal species, because of their ubiquity in food-producing animals. Multi-
resistance data, available for the first time in 2012, indicates that the co-resistance phenomenon should be 
considered when analysing the relationship between antimicrobial use and resistance in animals.  
A total of 11 MSs and 2 non-MSs provided quantitative MIC data, in 2012, on at least one of the livestock 
species. Reported antimicrobial resistance data in E. coli isolates from food-producing animals and food, 
derived mainly from active and representative monitoring programmes, were chiefly based on randomised 
sampling performed at the slaughterhouse. At the reporting MS group level, a high level of resistance was 
observed to several antimicrobials among food-producing animals, with some countries reporting a very or 
extremely high occurrence of resistance. As resistance levels tend to vary substantially between countries, 
the variation in resistance in Gallus gallus, pigs and cattle observed between the years 2009 and 2012, at 
the overall MS group level, may partly result from different MSs contributing to data as well as different 
production types of livestock being sampled. 
In 2012, four MSs reported on antimicrobial resistance in each category of meat, but those which did 
generally reported comparable resistance levels in meat as in the corresponding source animal species. 
Resistance levels were generally higher among E. coli isolates from Gallus gallus and pigs than isolates from 
cattle. This was the second year that resistance data were reported separately for different production types 
of Gallus gallus and cattle. However, only two countries provided data on laying hens, and both of these MSs 
also provided data on broilers. Although there is limited information available for 2011 and 2012 on which to 
draw firm conclusions, resistance levels were generally higher among broilers than in laying hens. Similarly, 
in 2012, only two MSs reported on more than one production type or age group of cattle. The Netherlands 
reported much higher resistance levels among younger animals and a similar trend to higher resistance in 
young animals was also observed in Austria. Regional differences in the occurrence of resistance were 
evident for some antimicrobials for indicator E. coli from broilers and pigs. This may reflect differences in the 
structure of the respective livestock sectors, with pyramidal production systems more common in pigs and 
broilers. 
Generally, the highest resistance levels were identified for ampicillin, sulfonamides and tetracyclines, 
which are commonly used therapeutically in animals. Moreover, some countries have shown statistically 
significant increasing or decreasing trends in resistance to these antimicrobials over five or more years since 
2006. At the MS group level, resistance to gentamicin was highest in Gallus gallus (4.0 %) and lowest in pigs 
(1.8 %). Gentamicin is an interesting antimicrobial because there are differences in the degree of usage in 
different MSs of this and other antimicrobials to which cross-resistance may occur (for example apramycin).  
Resistance was also identified to fluoroquinolones (ciprofloxacin), a class of antimicrobials recognised to be 
critically important in human medicine. Although resistance was generally similar in E. coli from meat from 
broilers, pigs and cattle, for all of the antimicrobials tested for the group of reporting MSs, resistance to 
nalidixic acid and ciprofloxacin was a notable exception, as much higher levels of resistance were recorded 
in E. coli isolates from meat from broilers than from meat from the other species. Similarly, the occurrence of 
resistance to nalidixic acid and ciprofloxacin was higher in E. coli from broilers than in isolates from pigs and 
cattle. As resistance to fluoroquinolones commonly includes a mutational component, this suggests that 
either E. coli from broilers are exposed to greater selective pressure from the overall use of fluoroquinolones, 
or the use of fluoroquinolones at a particular part of the production pyramid (which selects for mutational 
resistance there) engenders resistance which is subsequently disseminated to flocks lower in the pyramid by 
the spread and transfer of resistant bacterial clones. Although the occurrence of high-level fluoroquinolone 
resistance is likely to be influenced by the degree of fluoroquinolone usage, it is also likely to be influenced 
by the degree to which terminal hygiene and disinfection procedures allow strains, which have developed 
some resistance, to persist and colonise the subsequent group of animals. The occurrence of resistance to 
nalidixic acid was often similar then that for ciprofloxacin, suggesting that mutation in the topoisomerase 
enzymes (gyrA or parC) may, in those cases, have been responsible for resistance. However, in some MSs, 
the occurrence of resistance to ciprofloxacin was slightly higher than that obtained for nalidixic acid. In these EU summary report on antimicrobial resistance in zoonotic and indicator bacteria 
from humans, animals and food 2012 
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cases, mechanisms such as transferable fluoroquinolone resistance conferred by qnr genes may have been 
responsible for resistance; as such plasmid-mediated mechanisms can result in that phenotypic pattern of 
resistance. One country has shown statistically significant decreasing trends in resistance to ciprofloxacin in 
all species over five or more years since 2006. 
 
Resistance to third-generation cephalosporins (cefotaxime), another class categorised as critically important 
in human medicine, was infrequently detected in 2012. There were few countries which reported significant 
increasing or decreasing trends in resistance to cefotaxime over five or more years since 2006. EFSA has 
published recommendations for surveillance of indicator E. coli resistant to cefotaxime, which would extend 
the scope of the current monitoring by including selective culture for such organisms (EFSA, 2012b). Current 
procedures rely on random selection of indicator E. coli isolates from primary culture plates; selective culture 
could additionally be used to detect the presence or absence of isolates resistant to cefotaxime in a sample 
(within the detection limit of the chosen method). Monitoring using selective media for cefotaxime resistance 
would thus detect cefotaxime-resistant E. coli present as a minor component of the total bacterial flora in the 
test sample and which might only occasionally be detected by random sampling from non-selective culture 
plates.  The  occurrence  of  third-generation  cephalosporin  resistance  was  still  generally  low,  although  a 
number of reporting MSs recorded high to moderate levels in E. coli from Gallus gallus, and resistance was 
typically higher in isolates from Gallus gallus than in pigs or cattle. The findings in relation to third-generation 
cephalosporin resistance are discussed further in Chapter 7. 
Although the levels of multi-resistance
17 were relatively high in indicator E. coli isolates from both broilers and 
pigs in most reporting countries, co-resistance to cefotaxime and ciprofloxacin was detected at very low or 
low levels in broilers, but not in pigs, in the reporting MSs in 2012. This year, for the first time in this report, 
the multi-drug resistance patterns shown by indicator E. coli from broilers and pigs from MSs reporting 
isolate-based  data  have  been  included.  A  common  core  of  resistance  to  ampicillin,  sulfonamides  and 
tetracyclines, generally with resistance to ciprofloxacin and frequently with resistance to streptomycin and 
trimethoprim, was discernible in broilers where no single pattern or patterns of resistance occurred at a high 
frequency. In fattening pigs, two MDR patterns were predominant (pattern one: streptomycin, sulfonamides, 
tetracyclines and streptomycin, and pattern two: sulfonamides, tetracyclines, ampicillin and trimethoprim) and 
each accounted for more than 5 % of the total number of E. coli isolates from fattening pigs for which isolate-
based data were available. The occurrence of these particular patterns might reflect spread of particular 
clones  of  bacteria  which  exhibit  that  pattern  of  resistance  or  dissemination  of  plasmids  carrying  those 
resistances  and  possibly  being  transmitted  between  different  strains  of  E. coli.  In  broilers,  ciprofloxacin 
resistance was particularly noted in MDR patterns and resistance to this compound can be mediated through 
chromosomal  mutations  or  through  transferable  mechanisms  of  resistance.  Ciprofloxacin  resistance 
frequently occurred as a component of MDR in E. coli from broilers and was observed in 72.3 % of MDR 
                                                 
17 Proportions of isolates showing reduced susceptibility to at least three antimicrobial classes according to  epidemiological cut-off 
values. 
REVISION OF EPIDEMIOLOGICAL CUT-OFF VALUES FOR CIPROFLOXACIN FOR E. COLI 
The epidemiological cut-off value (ECOFF) for E. coli versus ciprofloxacin has been recently revised by 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Wild-type isolates are now 
considered  to  have  a  ciprofloxacin  minimum  inhibitory  concentration  (MIC)  lower  than  or  equal  to 
0.06 mg/L,  an  increase  from  the  previous  ECOFF  of  0.03  mg/L.  The  proportion  of  isolates  showing 
microbiological resistance according to this breakpoint will alter when the new breakpoint is adopted and 
in  fact  will  be  reduced.  For  reasons  of  continuity  and  to  comply  with  the  current  legislation  where 
applicable,  the  ECOFFs  used  in  this  report  have  been  those  adopted  in  EFSA’s  recommendations 
(EFSA, 2007, 2008). For these reasons, the most recent revisions by EUCAST have not been included in 
this report. The report for 2013 will incorporate all of these changes in a comprehensive revision, which 
will also re-evaluate the historical data using the revised ECOFFs, as well as taking into account revised 
EU legislation in this area, which will include revised ECOFFs. 
The reported MIC distributions for E. coli versus ciprofloxacin are available on the EFSA website in ‘Level 
3 Tables’. From these it can be seen that the total number of  E. coli reported was 8,580. Of these, 
32.7 % were resistant considering the ECOFF of >0.03 mg/L whereas 25.6 % were resistant considering 
the ECOFF of >0.06 mg/L. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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isolates (120 out of 166), whereas ciprofloxacin resistance occurred infrequently as a component of MDR in 
pigs and was present in 16.0 % (32 out of 200) of porcine MDR E. coli isolates. 
Several resistance patterns, which occurred at a higher frequency in E. coli from broilers, included resistance 
to cefotaxime; however, cefotaxime resistance also occurred as a component of infrequent resistance 
patterns in this species. Considering the resistance patterns occurring at a higher frequency in pigs, these 
did not generally include resistance to cefotaxime; however, cefotaxime resistance did occur as a component 
of infrequent resistance patterns. Resistance to cefotaxime may be conferred by ESBL or AmpC beta-
lactamase enzymes; in E. coli the former are generally carried on plasmids, whereas AmpC resistance may 
be carried on plasmids or relate to mutations of the promoter region of the endogenous beta-lactamase 
carried by E. coli. Further characterisation of cefotaxime resistance shown by these isolates, which has been 
recommended by EFSA (EFSA, 2012b) in particular phenotypic and genetic characterisation of the 
resistance, would allow particular resistance patterns to be identified which are associated with the carriage 
of ESBL or AmpC enzymes. This has potential implications for control through the identification of 
antimicrobials which might encourage the spread of cefotaxime resistance through co-selection. 
A recent study in Spain examined the integrons carried by E. coli isolates recovered from healthy broilers 
and pigs (Marchant et al., 2013). Integrons can be associated with particular antimicrobial resistance genes 
and in the Spanish study both class 1 and class 2 integrons were detected in pigs and chickens. 
Class  1  integrons classically carry the resistance gene sul1; additionally, both types of integrons in the 
Spanish study often carried genes associated with streptomycin and trimethoprim resistance, while 
resistance genes conferring chloramphenicol and gentamicin resistance were detected in the variable region 
of class 1 integrons only. The widespread occurrence of integrons and their associated antimicrobial 
resistance genes in animal E. coli is likely to account for some of the resistance patterns (or associations 
between resistances) which are evident in the MDR tables and probably explains why sulfonamide, 
streptomycin and trimethoprim resistance are common components of MDR patterns. The Spanish study 
also reported that the presence of integrons was associated with resistance to amoxicillin (equivalent to 
ampicillin for resistance purposes) and tetracyclines. The common core patterns of resistance to ampicillin, 
streptomycin, sulfonamides, tetracyclines and trimethoprim (and combinations thereof) frequently observed 
in the monitoring of E. coli isolates are probably therefore related to the presence of integrons. 
There may be numerous permutations in the ways in which resistance genes may be arranged or 
accumulated by E. coli, and attempting to relate the resistance phenotype to the likely underlying 
mechanisms of resistance is therefore difficult. Full resistance to all of the antimicrobials in the test panel was 
noted only for a single E. coli isolate from pigs and there might be numerous ways in which such resistance 
might develop. It is interesting, however, that such resistance has been described before in E. coli isolates 
from animals and has been reported, for example, in E. coli recovered from cattle in France (Meunier et al., 
2010). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS  
6.1. Introduction 
 
The EFSA’s assessment of the public health significance of MRSA in animals and food (EFSA, 2009c) and 
the Joint Scientific Report of ECDC, EFSA and EMEA on MRSA in livestock, companion animals and food 
(EFSA, 2009a) provide more background information and recommendations on MRSA. A principal 
recommendation is that monitoring of food-producing animals, in particular intensively reared animals, is 
carried out periodically in conjunction with a systematic surveillance of MRSA in humans so that trends in the 
diffusion and evolution of zoonotically-acquired MRSA in humans can be identified. In particular, isolate 
samples, representative of various animal and food origins, should be analysed for lineage determination, 
antimicrobial susceptibility and virulence-associated traits. These issues were reviewed in the recent EFSA 
Scientific Report proposing technical specifications to improve the harmonisation of the monitoring and 
reporting of the prevalence, genetic diversity and multi-resistance profile of MRSA in food-producing animals 
and food thereof (EFSA, 2012c) (see Section 6.3 Discussion below for further information). 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 
MRSA has been recognised as an important cause of healthcare-associated infections in humans for 
decades. Strains of MRSA have also emerged which are particularly associated with community-
associated infections in humans. Moreover, in recent years, MRSA has also been detected in several 
animal species, notably including pigs and companion animals as well as some other farm animal 
species. Hospital-associated MRSA and community-associated MRSA are those strains predominantly 
affecting humans, while they generally do not involve food-producing animals; however, livestock-
associated MRSA may also be harboured by humans, especially where there is occupational contact with 
affected livestock. Livestock-associated MRSA may cause illness in humans, although transmissibility 
between humans has been shown to be very limited, even in healthcare facilities. 
Antimicrobial susceptibility in European invasive Staphylococcus aureus isolates is reported by the 
Member States (MSs) to the European Antimicrobial Resistance Surveillance Network (EARS-Net) 
(ECDC, 2013). Molecular typing data are not reported and, thus, where there may be possible links to the 
animal reservoir, these cannot be detected easily with current monitoring procedures, at least at the 
European level. Recent EARS-Net data showed decreasing or stabilising percentages of MRSA in 
reported invasive S. aureus  isolates (both healthcare and community associated) in most European 
countries, which might reflect the beneficial impact of improved infection control routines implemented in 
several countries. However, MRSA remains a human public health priority, as the percentage of MRSA 
remains above 25 % in 7 out of 30 countries, mainly in Eastern and Southern Europe (ECDC, 2013).  
Molecular typing techniques, such as spa-typing and multi-locus sequence typing (MLST), are commonly 
used in S. aureus to sub-type strains and determine lineages. In spa-typing, different genetic types or 
strains of MRSA are designated by a number with the prefix t, while in MLST, strains are designated by a 
sequence type (ST) number. Using such typing results, often in conjunction with certain other virulence 
and antimicrobial resistance characteristics, it is possible to sub-divide strains of MRSA into groups 
characterised by differing epidemiology. These techniques are of particular relevance, for instance, in the 
investigation of outbreaks, such as in the clinical case of hospital-associated MRSA, in transmission 
events, for example of livestock-associated MRSA, and in the detection of emerging strains showing new 
and/or multiple resistance patterns. 
Pigs are acknowledged as an important source of colonisation of a particular strain of MRSA (designated 
ST398-multi-locus sequence type 398) for pig farmers and veterinarians, and their families, through direct 
or indirect contact with pigs. In some countries, other livestock (for example poultry and veal calves) have 
also become colonised. This recently recognised strain, MRSA ST398, which appears to be primarily 
acquired by occupational exposure to colonised pigs (or other colonised farmed livestock), can, on 
occasion, cause infections in humans and can be introduced into healthcare settings. In order to increase 
awareness and to assess the occurrence of MRSA in pig primary production across the EU, the 
occurrence and diversity of MRSA and MRSA ST398 in pig holdings in MSs were assessed through an 
EU-wide baseline survey (EFSA, 2009b, 2010a). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6.2. Methicillin-resistant Staphylococcus aureus - reports from individual MSs 
Livestock-associated MRSA isolates are the principal focus of this chapter, which summarises the 
prevalence of MRSA results in various food-producing animal species and food reported by MSs to EFSA in 
2012. The chapter also includes prevalence data on companion animals reported by an increasing number 
of MSs compared with 2011. Ten MSs - Belgium (cattle), Finland (pigs), Germany (cattle, turkeys and food), 
Hungary (cattle, Gallus gallus, geese, goats, pigs, sheep and turkeys), Ireland (dogs), the Netherlands (birds, 
cats, cattle, dogs, goats, pigs, sheep and solipeds), Poland (food), Slovakia (cats, cattle, chinchillas, dogs, 
Gallus gallus, goats, pigs and sheep), Slovenia (food) and Spain (food) - and one non-MS, Switzerland 
(pigs), submitted data on MRSA prevalence in animals and food in their national zoonoses reports for 2012 
(Table MRSA1). The methods for the isolation of MRSA from animals and food to date have not been 
harmonised at the EU level and, therefore, the methods used by individual reporting MSs may differ in 
sensitivity. 
In addition, data on antimicrobial resistance of MRSA isolates and Staphylococcus aureus from food-
producing animals were reported by only two countries in 2012. 
Table MRSA1.  Overview of countries reporting data on MRSA in animals and food in 2012 
Data  Origin  Total number of 
MSs reporting  Countries 
Animals 
Companion animals: cats and dogs  3  MSs: IE, NL, SK 
Cattle (bovine animals)  5  MSs: BE, DE, HU, NL, SK 
Sheep and goats  3  MSs: HU, NL, SK 
Pigs  4 
MSs: FI, HU, NL, SK 
Non-MS: CH 
Poultry: Gallus gallus (fowl), geese and turkeys  3  MSs: DE, HU, SK 
Solipeds, domestic  1  MS: NL 
Other animals: birds and chinchillas  2  MSs: NL, SK 
Food 
Cheeses, dairy products and milk  3  MSs: DE, ES, PL 
Fish, fishery products and crustaceans   1  MS: PL 
Fruits  1  MS: ES 
Meat  3  MSs: DE, ES, SI 
Other food  1  MS: DE 
Note: For abbreviations of Member States (MS) and other reporting countries see Appendix 7. MRSA: Methicillin-resistant 
Staphylococcus aureus. 
6.2.1. Methicillin-resistant Staphylococcus aureus in food 
In 2012, four MSs - Germany, Poland, Slovenia and Spain - reported information on the occurrence of MRSA 
in various categories of food, as summarised in Table MRSA2. Germany investigated a wide range of meat 
from turkeys and bovine animals for MRSA. Poland examined samples of raw fish and raw cows’ milk for the 
presence of MRSA. Slovenia investigated 74 samples of meat from pigs, among which 14 samples tested 
positive for MRSA. Spain examined a range of food products for MRSA and the positive isolates were 
obtained from fruits (two isolates: 1.8 %), meat from broilers (25 isolates: 12.4 %) and meat from pigs (one 
isolate: 0.8 %). The corresponding spa-typing data were not available from those reporting MSs, positive 
isolates being reported of unspecified spa-type. 
Generally, meat from several different sources proved positive for MRSA, including meat from poultry, pigs 
and cattle. Certain types of poultry meat tested positive for MRSA most frequently, reaching a prevalence 
greater than 60 % in turkey meat, exceeding that observed in the other kinds of meat tested (beef and pork). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MRSA2.  MRSA in food, 2012 
Food species/ 
country  Description  Sample  
unit 
Number 
of units 
tested 
Number (%) 
positive for 
MRSA 
Meat from broilers (Gallus gallus) 
Spain  Meat preparation  Single  201  25 (12.4) 
Meat from turkeys 
Germany 
Carcase, at slaughterhouse
1, monitoring  Slaughter 
Batch  353  242 (68.6) 
Fresh, at retail, monitoring  Single   749  282 (37.7) 
Spain  Minced meat/meat products/meat preparation
2   Single   11  0 
Meat from pigs             
Slovenia  Fresh, at cutting plant, monitoring  Single   74  14 (18.9) 
Spain  Fresh/minced meat/meat products
3  Single  122  1 (0.8) 
Meat from bovine animals 
Germany 
Carcase, at slaughterhouse, monitoring   Single   312  96 (30.8) 
At retail, monitoring   Single   421  44 (10.5) 
Milk, cows' 
Poland  Raw milk for manufacture-intended for manufacture of 
Raw or low heat-treated products, monitoring  Single  12  1 (8.3) 
Milk, goats' 
Spain  Raw milk for manufacture, at processing plant, 
Monitoring  Single  5  0 
Fish  
Poland  Raw, at processing plant  Single  100  4 (4.0) 
Fruits 
Spain  Pre-cut and ready-to-eat, at retail, monitoring  Single  109  2 (1.8) 
MRSA: Methicillin-resistant Staphylococcus aureus. 
1.  Sample type: neck skin. 
2.  Meat preparation (N=6, n=0); minced meat (N=1, n=0); meat products (N=4, n=0). 
3.  Fresh (N=60, n=1); minced meat (N=3, n=0); meat products (N=59, n=0). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6.2.2. Methicillin-resistant Staphylococcus aureus in animals 
6.2.2.1. Monitoring MRSA in food-producing animals 
Belgium, Germany, Finland, the Netherlands and Switzerland reported information on the prevalence of 
MRSA in food-producing animals and/or their immediate environment within a monitoring, surveillance or 
unspecified sampling context. The results are summarised in Table MRSA3. 
Regarding the monitoring approaches, in Finland, a national prevalence survey was performed in the 68 pig 
breeding holdings with a specific pathogen-free status through nasal swabbing of 60 randomly selected 
animals, per holding, and boot swabbing of every unit of the holding between October 2011 and March 2013. 
In Switzerland, the monitoring of MRSA in pigs was based on random sampling of 397 healthy slaughter pig 
carcases in the slaughter plants accounting for 85 % of the total pig production in the country. The sampling 
plan was stratified proportionally to the annual production of the slaughterhouse and evenly distributed over 
the year to address any seasonal effect.  
MRSA prevalence in fattening pigs in Switzerland was comparatively moderate at 18.1 % (72 isolates from 
397 samples tested), while in Finland MRSA was not detected in either boot swabs or nasal swabs collected 
at farms in national monitoring. Of particular note was the extremely high MRSA prevalence recorded in the 
Netherlands in slaughter pigs (99.0 %) and cattle (79.0 %), both sampled at the slaughterhouse by nasal 
swabbing in 2012. Germany reported a high prevalence (45.0 %) in calves under one year of age sampled at 
slaughter, while, considering the same animal population sampled on the farm by means of environmental 
dust sampling, the prevalence of positive herds was 19.2 %. A flock prevalence of 12.8 % was also recorded 
in fattening flocks of turkeys in Germany. Belgium also reported a high prevalence (47.1 %) in calves under 
one year of age sampled at the slaughterhouse, while the prevalences in herds of calves under one year 
sampled on the farm and in dairy cows were of the same magnitude (10.2 % and 9.9 %, respectively). 
A number of different spa-types were reported (Table MRSA3, shown as footnotes). The majority of isolates 
from pigs in Switzerland were spa-type t034, with lower numbers of t011; both of these spa-types are 
associated with MRSA CC398 and accounted for 97 % (70 out of 72) of the MRSA isolates from fattening 
pigs in Switzerland, with the remaining MRSA isolates belonging to spa-type t208, which is associated with 
ST49. Belgium provided spa-type data for MRSA isolates from calves less than one year old on the farm and 
at the slaughterhouse, as well as from adult dairy cattle on farms. Spa-type t011 was predominant in 
samples from calves as well as in adult dairy cows and is associated with ST398. The other spa-types 
reported from Belgian cattle were present in much lower numbers and of these, t1456 and t1451 were both 
detected in the baseline survey of breeding pigs (EFSA, 2009b) and are associated with CC398 and related 
to t011. Spa-types t1985, t3423 and t6228 are also all associated with CC398 but were not detected in the 
baseline survey of breeding pigs. Spa-type t121 is associated with MLST ST8, while t037 and t388 are 
associated with ST239 and both of these MRSA sequence types (ST8 and ST239) are considered to be 
hospital-associated strains of MRSA. t037 ST239 was also recovered from Belgian poultry in 2011 (Butaye 
and Nemeghaire, 2012). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MRSA3.  MRSA in food-producing animals (excluding clinical investigations), 2012 
Animal 
species/ 
country 
Production type/description   Sample  
unit 
Number 
of units 
tested 
Number (%) 
positive for 
 MRSA 
Turkeys 
Germany 
Breeding flocks, unspecified, at farm, dust, 
monitoring  Flock  16  0
Meat production flocks, at farm, dust, monitoring  Flock  235  30 (12.8)
Pigs 
Finland 
Breeding animals, at farm, boot swabs, survey - 
national survey  Holding  68  0
Breeding animals, at farm, nasal swabs, survey - 
national survey  Holding  68  0
Netherlands  At slaughterhouse, nasal swabs, monitoring  Herd
1  104  103 (99.0)
Switzerland
2  Fattening pigs, at slaughterhouse, nasal swabs, 
monitoring  Animal  397  72 (18.1)
Cattle (bovine animals) 
Belgium 
Calves (under 1 year), at farm, nasal swabs
3  Herd  187  19 (10.2)
Calves (under 1 year), at slaughterhouse, nasal 
swabs
4 
Slaughter  
batch  104  49 (47.1)
Dairy cows, at farm, nasal swabs, monitoring
5  Animal  141  14 (9.9)
Germany 
Calves (under 1 year), at farm, dust, monitoring  Herd  240  46 (19.2)
Calves (under 1 year), at slaughterhouse, nasal 
swabs, monitoring  Animal  320  144 (45.0)
Netherlands  At slaughterhouse, nasal swabs, monitoring  Herd
1  100  79 (79.0)
Goats 
Netherlands  At farm, monitoring  Animal  221  0
Sheep 
Netherlands  At farm, monitoring  Animal  467  0
MRSA: Methicillin-resistant Staphylococcus aureus. 
1.  10 animals per herd. 
2.  61 and 9 isolates were of the spa-types t034 and t011, respectively, which belonged to CC398 and 2 of the spa-type t208 (ST49). 
3.  Isolates belonged to the spa-types t011 (16), t1456 (1), t121 (1) and t1985 (1). 
4.  Isolates belonged to the spa-types t011 (40), t1456 (1), t1451 (3), t1985 (3), t3423 (1) and one was not typed. 
5.  Isolates belonged to the spa-types t011 (8), t1456 (1), t6228 (2), t037 (1), t388 (1) and one was not typed. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6.2.2.2. Clinical investigations for MRSA in food-producing animals 
Clinical investigations often differ from monitoring data in food-producing animals or meat in that selective 
culture methods may not be used, the number of units tested may be low and the sample may involve a 
biased sample population. These data are not prevalence data and cannot be extrapolated at the 
population/group level. However, the results were nevertheless presented in this report, because it is 
considered important to report the range of animals/animal populations which can be affected. 
In 2012, three MSs (Hungary, the Netherlands and Slovakia) reported information on results of clinical 
investigations for MRSA in different kinds of food-producing animals, which tested, most frequently, negative 
(Table MRSA4). Only the Netherlands reported six positive for MRSA (out of 11 samples tested) in a clinical 
investigation context in pigs.  
Table MRSA4.  MRSA in food-producing animals, clinical investigations, 2012 
Animal 
species/ 
country 
Production type/description   Sample  
unit 
Number of 
units 
tested 
Number (%) 
positive for 
MRSA 
Gallus gallus (fowl) 
Hungary  At farm  Flock  24  0 
Slovakia  Broilers day-old chicks, at farm, organ/tissue  animal  3  0 
Turkeys 
Hungary  At farm  Flock  7  0 
Geese 
Hungary  At farm  Flock  13  0 
Pigs 
Hungary  At farm  Holding  11  0 
Netherlands  –  Animal  11  6 (54.5) 
Slovakia  Fattening pigs, at farm  Animal  7  0 
Cattle (bovine animals) 
Hungary  At farm  Herd  39  0 
Netherlands  –  Animal  11  0 
Slovakia 
Calves (under 1 year), at farm  Animal  3  0 
Dairy cows, at farm, milk  Animal  130  0 
Goats 
Hungary  At farm  Herd  2  0 
Netherlands  –  Animal  14  0 
Slovakia  Animals over 1 year, at farm, milk  Animal  6  0 
Sheep 
Hungary  At farm  Herd  2  0 
Netherlands  –  Animal  1  0 
Slovakia  Milk ewes, at farm, milk  Animal  2  0 
MRSA: Methicillin-resistant Staphylococcus aureus. 
6.2.2.3. Clinical investigations for MRSA in companion animals 
Three MSs reported data on MRSA in companion animals compared with one in 2011 (Table  MRSA5). 
Ireland, the Netherlands and Slovakia reported MRSA data from samples taken from pets and horses. In all 
of these cases, the bacteria were isolated from clinical specimens sent for routine bacteriology. MRSA was 
confirmed in 14 horses, 10 dogs and 3 cats in the Netherlands and in 1 dog in Ireland, in 2012. The 
corresponding spa-typing data were not available.  
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MRSA5.  MRSA in companion animals, clinical investigations, 2012 
Animal 
species/ 
country 
Production type/description  Sample  
unit 
Number of 
units tested 
Number (%)
 positive for 
MRSA 
Cats 
Netherlands  Pet animals  Animal  32  3 (9.4) 
Slovakia  Pet animals  Animal  8  0 
Dogs 
Ireland  At farm  Animal  92  1 (1.1) 
Netherlands  Pet animals  Animal  63  10 (15.9) 
Slovakia 
Pet animals, faeces  Animal  5  0 
Pet animals, organ/tissue  Animal  2  0 
Pet animals  Animal  133  0 
Solipeds, domestic 
Netherlands  Horses  Animal  48  14 (29.2) 
MRSA: Methicillin-resistant Staphylococcus aureus. 
6.2.2.4. Temporal trends in the occurrence of MRSA  
Although methodological differences may occur between reporting countries, where repeat studies were 
performed in countries the same methods were usually employed. This was, for example, the case in 
Switzerland where a pre-enrichment in Mueller-Hinton broth, supplemented with 6.5  % salt, followed by 
culture through selective broth, containing cefoxitin and aztreonam, and final plating onto an MRSA-selective 
agar, were typically performed. 
Germany reported annual results on the occurrence of MRSA in calves, at the herd/farm level, in 2010 and 
2012 and, in both years, similar moderate levels of prevalence were registered at 19.6 % (of 296 samples 
tested) and 19.2 % (of 240 samples tested), respectively (Table MRSA6). Germany also reported results on 
the occurrence of MRSA in fattening turkeys for meat production, at the flock level, in 2010 and 2012, and 
the prevalence reported was moderate in both years (19.6 % in 2010 and 12.8 % in 2012). No data on the 
genotypes of the strains of MRSA isolated were reported to EFSA. 
The Netherlands also monitored, consistently, the prevalence of MRSA in goats and sheep over the period 
2011 to 2012. Interestingly, out of around 200 samples tested in goats and the 450 samples tested in sheep 
in 2012, none of them tested positive. 
Switzerland reported results on the yearly prevalence of MRSA in fattening pigs over the period 2009 to 
2012. Prevalence had significantly increased in 2012 compared with the previous years, when it was low: 
from 2.2 % in 2009, the prevalence increased threefold in 2010 and 2011 (5.9 % and 5.6 %, respectively) 
and reached 18.1 % in 2012. The marked increase is primarily the result of the diffusion of clones of spa-
types t034 and t011, both belonging to the clonal complex CC398, within the Swiss population of fattening 
pigs. Switzerland also noted the continuing presence of ST49 t208 at a much lower frequency in pigs in 
2012. Switzerland was the first country to describe the presence of this previously undescribed clonal lineage 
of MRSA in pigs (Overesch et al., 2011), suggesting that selection may have occurred within the Swiss pig 
population. Evidence to support the fact that MRSA ST49 t208 may have emerged in pigs in Switzerland 
includes the observation that methicillin-susceptible S. aureus (MSSA), belonging to spa-type t208, had 
previously been described in Switzerland in pigs. However, occurrence data for the years 2011 and 2012 
suggest that ST49 strains did not show a spread, similar to CC398 strains, in the sampled population over 
the same period. This spa-type is otherwise rarely recorded in Europe, having been described in only one 
human infection in the United Kingdom and in three cases of skin infection and laryngeal ulceration in wild 
squirrels (Overesch et al., 2011). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MRSA6.  Temporal occurrence of MRSA in animals 
Country  Year  Production type/description   Sample unit 
Number 
of units 
tested 
Number (%) 
positive for 
MRSA 
Germany 
2010  Cattle (bovine animals), calves (under  
1 year), at farm, monitoring  Herd  296  58 (19.6) 
2012  Cattle (bovine animals), calves (under  
1 year), at farm, monitoring  Herd  240  46 (19.2) 
Germany 
2010  Turkeys, meat production flocks, at 
farm, dust, monitoring  Flock  112  22 (19.6) 
2012  Turkeys, meat production flocks, at 
farm, dust, monitoring  Flock  235  30 (12.8) 
Netherlands 
2011  Goats, at farm, monitoring  Animal  214  0 
2012  Goats, at farm, monitoring  Animal  221  0 
Netherlands 
2011  Sheep, at farm, monitoring  Animal  564  0 
2012  Sheep, at farm, monitoring  Animal  467  0 
Switzerland 
2009  Fattening pigs, at slaughter, nasal 
swabs  Animal  405  8 (2.2)
1 
2010  Fattening pigs, at slaughter, nasal 
swabs  Animal  392  23 (5.9)
2 
2011  Fattening pigs, at slaughterhouse, 
nasal swabs, monitoring  Animal  392  22 (5.6)
3 
2012  Fattening pigs, at slaughterhouse, 
nasal swabs, monitoring  Animal  397  72 (18.1)
4 
MRSA: Methicillin-resistant Staphylococcus aureus. 
1.  In 2009, isolates were reported as unspecified genotypes. 
2.  In 2010, 17 isolates were of genotype ST398-t034-V, one was of genotype ST398-t011-V and five were of genotype ST49-t208-V. 
3.  In 2011, 19 isolates were of genotype ST398-t034-V, one was of genotype ST398-t011-V, one was of genotype ST49-t208-V and 
one was of genotype ST1-t2279-IVc. 
4.  In 2012, 61 isolates belonged to genotype CC398-t034, nine belonged to genotype CC398-t011 and two belonged to genotype 
ST49-t208. 
6.2.3. Susceptibility testing of methicillin-resistant Staphylococcus aureus isolates 
In 2012, data on the susceptibility of MRSA and S. aureus isolates were reported only by Belgium and 
Switzerland. Both countries used a broth dilution method and EUCAST ECOFFs to determine the 
susceptibility of isolates to cefotoxin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusidic acid, 
gentamicin, kanamycin, linezolid, mupirocin, quinupristin/dalfopristin, sulfamethoxazole, tetracyclines, 
tiamulin and vancomycin. All of the 78 MRSA strains isolated from cattle in Belgium and the 72 MRSA 
isolates from pigs in Switzerland were resistant to cefoxitin, as expected (data not shown). 
6.2.3.1. MRSA isolates from cattle 
Considering the susceptibility of MRSA isolates from cattle reported by Belgium, 3 isolates belonged to spa-
type t1456 (CC398), 3 isolates belonged to spa-type t1451 (CC398) and 64 isolates belonged to spa-type 
t011 (CC398). For the remaining eight isolates tested in 2012, no spa-typing data were available. 
Among MRSA isolates (N=78) from different types of cattle (dairy cows, meat production animals, young 
cattle (one to two years)) in Belgium tested in 2012, with the exception of resistance to vancomycin, 
resistance was detected for all antimicrobials tested (Table MRSA7). Resistance was reported at extremely 
high levels for tetracycline (96.2 % resistant), clindamycin and erythromycin (88.5 % resistant), kanamycin 
(82.1 % resistant), gentamicin (78.2 % resistant); at high levels for ciprofloxacin (42.3 % resistant), fusidic 
acid (28.2 % resistant), quinupristin/dalfopristin and sulfamethoxazole (24.4 % resistant); at moderate levels 
for tiamulin (17.9 % resistant), chloramphenicol (12.8 % resistant) and mupirocin (11.5 % resistant); and at 
low levels for linezolid (1.3 % resistant). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6.2.3.2. MRSA isolates from fattening pigs 
Considering the susceptibility of MRSA isolates from fattening pigs reported by Switzerland, 2 isolates 
belonged to the genotype spa-type t208 (ST49), 9 isolates belonged to spa-type t011 (CC398) and 
61  isolates belonged to spa-type t034 (CC398). Thirty-four isolates belonging to the most commonly 
detected genotype CC 398-t034 shared an identical resistance profile. These showed resistance to beta-
lactams, tetracyclines, macrolides, lincosamides, trimethoprim, pleuromutilins, streptomycin and 
quinupristin/dalfopristin. Twenty-one additional isolates were resistant to all these antimicrobials except for 
streptomycin, whereas two isolates had additional resistance to all tested aminoglycosides. 
Among MRSA isolates (N=72) from pigs in Switzerland, no resistance was detected to chloramphenicol, 
fusidic acid, linezolid and vancomycin (Table MRSA7). Resistance was reported at extremely high levels to 
tetracycline (100 % resistant), clindamycin and erythromycin (90.3 % resistant), tiamulin (86.1 % resistant) 
and quinupristin/dalfopristin (84.7  % resistant), and at low levels for gentamicin and kanamycin (6.9  % 
resistant), ciprofloxacin (4.2 % resistant), sulfamethoxazole (2.8 % resistant) and mupirocin (1.4 % resistant). 
Thirty-four isolates, belonging to the most commonly detected genotype CC 398-t034, in fattening pigs in 
Switzerland shared an identical resistance profile exhibiting resistance to beta-lactams, tetracyclines, 
macrolides, lincosamides, trimethoprim, pleuromutilins, streptomycin and quinupristin/dalfopristin. Genes 
conferring multiple antibiotic resistance have been detected in MRSA ST398 isolates, such as vga genes 
conferring resistance to pleuromutilins, streptogramin A and lincosamides (Hauschild et al., 2012) and the cfr 
gene providing resistance to pleuromutilins, streptogramin A, lincosamides, phenicols and oxazolidinones 
(Kehrenberg et al., 2009). Only a single MRSA isolate from Belgian cattle was resistant to linezolid, 
suggesting that cfr genes, if present, were rare in this population. The genes vga(A) and vga(C) confer 
resistance to the lincosamide clindamycin but not to the macrolide erythromycin (Kadlec et al., 2010); 
however, resistance to the lincosamide clindamycin and the macrolide erythromycin occurred at the same 
level in both Swiss pigs and Belgian cattle, perhaps suggesting that erm genes may be responsible and that 
they are constitutively expressed. Indeed, erm  genes were frequently detected in bovine MRSA CC398 
isolates in a recent Belgian study (Vandendriessche et al., 2013). Tetracycline resistance is common in 
MRSA CC398 (De Neeling et al., 2007). Considering the aminoglycosides gentamicin and kanamycin, there 
are differences in the occurrence of resistance in Swiss pigs and Belgian cattle, which may reflect the 
exposure of these different animal species to antimicrobials. Resistance to ciprofloxacin and fusidic acid can 
arise by mutation and again differences in the occurrence of resistance are evident in cattle and pigs in the 
different countries. Studies in Belgium have also detected differences in the occurrence of resistance in 
MRSA isolates from veal calves and pigs, with the levels of resistance proving higher in veal calves 
(Vandendriessche et al., 2013). Vancomycin is one of the antimicrobials of last resort for treating S. aureus 
infections in humans and resistance to this antimicrobial is currently infrequent. None of the isolates from 
cattle and pigs, tested for susceptibility, was resistant to vancomycin.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MRSA7.  Resistance (%) to chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusidic 
acid, gentamicin, kanamycin, linezolid, mupirocin, quinupristin/dalfopristin, sulfamethoxazole, 
tetracyclines, tiamulin and vancomycin among MRSA from food and animals in countries reporting 
MIC data in 2012, using harmonised epidemiological cut-off values 
Country 
Chloramphenicol  Ciprofloxacin  Clindamycin  Erythromycin  Fusidic acid 
N  %  Res N %  Res N %  Res N %  Res N %  Res 
Cattle (bovine animals)                         
Belgium  78 12.8  78 42.3  78  88.5 78  88.5 78  28.2 
Pigs                               
Switzerland  72  0 72  4.2 72  90.3 72  90.3 72  0 
 
Country 
Gentamicin  Kanamycin  Linezolid  Mupirocin  Quinupristin/
Dalfopristin 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Cattle (bovine animals)                         
Belgium  78  78.2 78  82.1 78  1.3 78  11.5 78  24.4 
Pigs                               
Switzerland  72  6.9 72  6.9 72  0 72  1.4 72  84.7 
 
Country 
Sulfamethoxazole  Tetracyclines  Tiamulin  Vancomycin 
N  % Res  N  % Res  N  % Res  N  % Res 
Cattle (bovine animals)                       
Belgium 78  24.4  78  96.2  78  17.9  78  0 
Pigs                         
Switzerland 72  2.8  72  100  72  86.1  72  0 
MRSA: Methicillin-resistant Staphylococcus aureus; MIC: minimum inhibitory concentration; N: number of isolates tested; %  Res: 
percentage of resistant isolates. 
Note: All MRSA isolates tested were also resistant to cefoxitin, as expected. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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6.3. Discussion 
Although food is not currently considered to be a relevant source of MRSA infection or colonisation of 
humans (EFSA, 2009c), the monitoring of MRSA in various food products performed in several MSs 
consistently indicates that MRSA can be detected, quite frequently, in different types of food. In situations 
where livestock are colonised by MRSA, meat or raw milk produced from these animals may also on 
occasion be contaminated with MRSA, as generally shown by the monitoring results. The detection of MRSA 
in low numbers of samples of raw fish (Poland) and fruit (Spain) may also possibly indicate contamination 
from colonised workers preparing such food. Nevertheless, it is of note that the laboratory techniques used to 
detect MRSA employ selective bacterial culture and, therefore, low levels of contamination can be detected. 
In each case, molecular typing would be very useful in investigating the strains of MRSA involved, which 
might assist in interpreting the findings and unravelling the epidemiology. 
Where data are available in classes of animals tested both on the farm and at slaughter, comparison of the 
proportion of MRSA-positive animals generally reveals a higher prevalence when animals are tested at 
slaughter compared with animals tested on farms. This may reflect either cross-colonisation of animals 
during transport to abattoirs (or while in temporary lairage pens at the slaughterhouse) or acquisition of the 
organism from various sources encountered during transport and lairage (pens, human contact, vehicles and 
so forth). It is therefore of note that the high prevalence of MRSA in pigs (99.0 %) and in cattle (79.0 %) in 
the Netherlands was assessed at slaughter. 
Livestock-associated (LA)-MRSA is considered a poor coloniser of humans and occurs uncommonly in 
persons without contact with livestock (Graveland et al., 2010). However, considering those people who do 
have contact with livestock, recent research has shown that livestock veterinarians can carry MRSA CC398 
for prolonged periods (Verkade et al., 2013), while studies of pig farmers and their household members 
(Garcia-Graells et al., 2013) showed that the risk of acquisition of MRSA by household members was 
strongly dependent on their exposure to pigs on the farm. Similar findings have been reported in relation to 
fattening turkeys and persons living on fattening turkey farms in Germany, where people with frequent 
access to the turkey accommodation were found to be more likely to carry MRSA (Richter et al., 2012). An 
increased risk of MRSA carriage has also been reported in personnel working at broiler slaughterhouses, 
especially where personnel have direct contact with live birds (Mulders et al., 2010). The technique of whole-
genome mapping has recently been used in the Netherlands to show that veterinarians can carry and 
transmit different LA-MRSA strains at the same time (Bosch et al., 2013). LA-MRSA is not generally 
considered to spread via food and the selective techniques used for isolation mean that low levels of 
contamination can be identified. The public health risk posed by LA-MRSA has been assessed to be of minor 
importance as long as the occurrence of strains with acquired toxin genes remains very uncommon 
(Vandendriessche et al., 2013). 
Two MSs reported spa-type data for MRSA isolates from food-producing animals and the results from 
Belgium for cattle were interesting in that spa-types t121 (associated with MLST ST8) and t037 and t388 
(associated with ST239) are considered to be hospital-associated strains of MRSA. t037 ST239 was also 
recovered from Belgian poultry in 2011 (Butaye and Nemeghaire, 2012). The occurrence of ST239 in 
different food-producing animals in different years indicates that this is a further strain of MRSA able to 
colonise different animal species and reinforces the value of such ongoing surveillance. 
 
EFSA TEHNICAL SPECIFICATION ON HARMONISED MONITORING OF MRSA 
In 2012, EFSA published a Scientific Report describing technical specifications for the harmonised 
monitoring and reporting of antimicrobial resistance in methicillin-susceptible  Staphylococcus aureus 
(MRSA) in food-producing animals and food (EFSA, 2012c). The technical specifications should enable 
collection of harmonised data from Member States on both the degree on which food-producing animals 
(and food produced from them) are colonised with MRSA, and the strains of MRSA involved. A new 
definition of MRSA includes those strains harbouring the mecC gene and the laboratory methods adapted 
accordingly, so that those strains can be also targeted by the harmonised routine monitoring. The 
situation with regard to MRSA and some food-producing animal species has changed substantially over 
the last decade; therefore, the proposed monitoring aims to provide a means to detect, without undue 
delay, further developments which may occur, in particular regarding the possible emergence of MRSA 
strains displaying particular virulence or resistance patterns and/or their potential transfer and diffusion 
between human and animal populations. Ongoing evolution and development of the situation relating to 
MRSA in food-producing animals may be exemplified by the recent description of MRSA ST49 in pigs in 
Switzerland (Overesch et al., 2011). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.  THIRD-GENERATION CEPHALOSPORIN RESISTANCE IN ESCHERICHIA COLI AND 
SALMONELLA 
7.1. Introduction 
 
RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS: THE IMPORTANCE OF ESBLS AND AMPC 
ENZYMES 
Extended-spectrum beta-lactamases (ESBLs) are considered to be an important emerging issue in 
Gram-negative bacteria of public health significance. Bacteria which possess ESBL resistance are 
usually resistant to third-generation cephalosporins, which are critically important antibiotic drugs for the 
treatment of systemic or invasive Gram-negative bacterial infections in humans. These drugs play a 
critical role in the treatment of certain invasive Salmonella infections, particularly in children, in whom the 
use of fluoroquinolones may not be favoured because of certain potential adverse effects. A low level of 
resistance in Salmonella may therefore still constitute an important finding. Commensal bacteria, such as 
indicator  Escherichia coli, may contribute to the dissemination of ESBL resistance because such 
resistance is usually transferable.  
Salmonella and E. coli may become resistant to third-generation cephalosporins by several different 
mechanisms. Among these different mechanisms, the most common is the acquisition of beta-lactamase 
enzymes on plasmids (small covalently closed circles of DNA which can be transferred between bacteria 
during bacterial conjugation). There are several different types of beta-lactamase which can confer 
resistance to third-generation cephalosporins. These are conveniently sub-divided into four classes, 
designated A to D: ESBL enzymes of the TEM, SHV and CTX-M families belong to class A, while class C 
includes the AmpC beta-lactamases. 
Wild-type  Salmonella isolates never possess a beta-lactamase of any class. For beta-lactamases to 
occur in Salmonella, acquisition must generally have occurred by conjugation, usually with other 
Enterobacteriaceae through transfer of plasmids. Although all four different types of beta-lactamase 
classes have been described in Salmonella globally, within the EU, the most important types of beta-
lactamase resistance acquired by Salmonella are primarily ESBL resistance and, secondly, AmpC 
resistance. E. coli can acquire beta-lactamases from other bacteria in a similar fashion to Salmonella but, 
since it also possesses an endogenous AmpC beta-lactamase, in some circumstances this can be 
activated, conferring resistance to third-generation cephalosporins. 
The position has been further complicated in recent years by the emergence of resistance to 
carbapenems in human medicine. Carbapenems are used for the treatment of highly resistant infections 
in humans, including, for example, the treatment of infections with Gram-negative bacteria which 
possess ESBL enzymes. These compounds are not used in food-producing animals anywhere within the 
EU. Resistance to carbapenems in Gram-negative bacteria is usually related to the acquisition of 
carbapenemase enzymes and a number of different types are recognised. Although carbapenem 
antimicrobials are not used in food-producing animals in the EU, resistance has occasionally been 
detected in bacteria carried by animals (Woodford et al., 2013) and dissemination from humans to 
animals directly or through environmental routes is suspected. In view of the great importance of the 
carbapenem compounds, they have been added to the panels of antimicrobials recommended for testing 
by Member States to improve surveillance for resistance (EFSA, 2012b). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  215
The EFSA guidelines for monitoring resistance in indicator E. coli (EFSA, 2008) state that cefotaxime is a 
good substrate for what are currently the most common and important ESBLs in humans in Europe, the 
CTX-M enzymes, which can therefore be used as an indicator for ESBL resistance. ECOFFs for Salmonella 
and E. coli for the antimicrobial cefotaxime facilitate detection of CTX-M ESBLs, but resistance to cefotaxime 
may, of course, be conferred by mechanisms of resistance other than ESBLs, such as certain other types of 
beta-lactamases, including AmpC beta-lactamases. In this chapter, the occurrence of resistance is given, 
where available, for both cefotaxime and ceftazidime. As very few MSs reported data on resistance to 
ceftiofur, and because this compound is not considered optimal for the detection of ESBL enzymes, results 
for ceftiofur are not included in this chapter. Furthermore, because this report covers only phenotypic 
monitoring, it is not possible to determine the class or exact type of beta-lactamase enzyme which is 
responsible for conferring the resistance detected to third-generation cephalosporins. 
The monitoring reported here and performed in accordance with EFSA’s guidelines (EFSA, 2008), does not 
utilise selective primary isolation media containing cephalosporins so the results generally relate to 
organisms chosen effectively at random from primary culture media. In certain types of monitoring, selective 
media containing cephalosporins may be used to investigate the presence or absence of cephalosporin-
resistant organisms in a particular sample (within the limit of detection) and, in that case, a different type of 
result would be obtained from such monitoring, which has a greater sensitivity. Ideally, the establishment of 
optimum phenotypic testing systems for sensitive, specific and rapid detection of ESBLs would be a very 
important component of antimicrobial resistance monitoring programmes. Recommendations for such 
monitoring recently developed by EFSA (EFSA, 2012b) notably put forward further testing of isolates which 
are resistant to third-generation cephalosporins, including testing to establish whether isolates have an 
ESBL- or AmpC-producing phenotype. 
7.2.  Third-generation cephalosporin resistance in Salmonella isolates from animals and 
food  
7.2.1. Third-generation cephalosporin resistance in Salmonella isolates from food 
In 2012, the results of testing for resistance to third-generation cephalosporins in Salmonella spp. isolates 
recovered from meat from broilers, meat from pigs and meat from bovine animals were reported by 11, 12 
and 4 MSs, respectively (Table ESBL1). In most reporting MSs, resistance was either not detected or 
reported at low levels in the three kinds of meat. Resistance to cefotaxime was typically equal or similar to 
that observed to ceftazidime at the MS level. Considering all MSs, the apparent difference in resistance to 
each compound in meat from broilers largely reflects differences in the number of sensitive isolates 
contributing to the denominator. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table ESBL1.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from meat 
from broilers, pigs and bovine animals tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Meat from broilers             
Belgium  109  0  109  0 
Czech Republic  47  0  47  0 
Germany  94  12.8  94  11.7 
Hungary  168  0.6  –  – 
Ireland  70  2.9  70  2.9 
Latvia  32  0  –  – 
Netherlands  74  31.1  74  29.7 
Poland  93  0  93  0 
Portugal  37  0  –  – 
Romania  189  1.1  –  – 
Slovakia  14  0  14  0 
Total (11 and 7 MSs)  927  4.3  501  7.0 
Meat from pigs             
Belgium  262  1.5  262  1.5 
Czech Republic  33  3.0  33  3.0 
Denmark  41  0  –  – 
Estonia  22  0  22  0 
Germany  163  0.6  163  0.6 
Hungary  16  0  –  – 
Ireland  69  0  69  0 
Italy  85  0  85  0 
Latvia  13  0  –  – 
Netherlands  52  0  52  0 
Poland  22  0  20  0 
Romania  125  1.6  –  – 
Total (12 and 8 MSs)  903  0.9  706  0.8 
Meat from bovine animals             
Germany  16  0  16  0 
Ireland  24  0  24  0 
Italy  13  0  13  0 
Netherlands  18  5.6  18  5.6 
Total (4 MSs)  71  1.4  71  1.4 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Similar observations of resistance to cefotaxime or ceftazidime generally not detected or reported at low 
levels may be made in S. Enteritidis from meat from broilers (Table ESBL2) and in S. Typhimurium isolates 
and monophasic S. Typhimurium isolates from meat from pigs (Tables ESBL3 and ESBL4). Exceptions to 
this are resistance to cefotaxime and ceftazidime in Salmonella spp. isolates from broiler meat recorded at 
levels greater than 10 % in Germany and around 30 % in the Netherlands (Table ESBL1). 
Table ESBL2.  Resistance (%) to cefotaxime and ceftazidime in S. Enteritidis isolates from meat from 
broilers tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Belgium  31  0  31  0 
Latvia  23  0  –  – 
Poland  26  0  26  0 
Total (3 and 2 MSs)  80  0  57  0 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Table ESBL3.  Resistance (%) to cefotaxime and ceftazidime in S. Typhimurium isolates from meat 
from pigs tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Belgium  105  1.0  105  1.0 
Denmark  18  0  –  – 
Germany  58  0  58  0 
Hungary  10  0  –  – 
Ireland  22  0  22  0 
Italy  18  0  18  0 
Latvia  13  0  –  – 
Netherlands  16  0  16  0 
Poland  11  0  –  – 
Romania  43  2.3  –  – 
Total (10 and 5 MSs)  314  0.6  219  0.5 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Table ESBL4.  Resistance (%) to cefotaxime and ceftazidime in monophasic S. Typhimurium isolates 
from meat from pigs tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Denmark  22  0  –  – 
Germany  37  0  37  0 
Ireland  23  0  23  0 
Total (3 and 2 MSs)  82  0  60  0 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.2.2. Third-generation cephalosporin resistance in Salmonella isolates from animals 
7.2.2.1. Resistance levels in Gallus gallus (fowl) 
Resistance to third-generation cephalosporins in Salmonella  spp. from Gallus gallus  is shown in Table 
ESBL5. A low level of resistance to cefotaxime of 4.5  %, and to ceftazidime of 4.8  %, was reported in 
Salmonella spp. isolates from all reporting MSs, reflecting either no or very low to low resistance recorded in 
nearly all reporting countries. Only Belgium recorded much higher levels of resistance at 18.1  % to 
cefotaxime and 17.3 % to ceftazidime. 
Table  ESBL5.    Resistance (%) to cefotaxime and ceftazidime in Salmonella  spp. isolates from 
Gallus gallus tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Austria  176  0.6  176  0.6 
Belgium  664  18.1  664  17.3 
Czech Republic  386  0.3  386  0.3 
Denmark  28  0  –  – 
Germany  238  0.8  238  0.8 
Hungary  261  0.4  –  – 
Ireland  38  0  38  0 
Italy  328  5.2  328  3.4 
Latvia  14  0  –  – 
Netherlands  192  4.2  192  4.2 
Poland  739  0.7  739  0.8 
Portugal  174  2.3  –  – 
Romania  964  5.3  964  5.7 
Slovakia  85  0  85  0 
Spain  179  0.6  179  0.6 
United Kingdom  236  0  216  0 
Total (16 and 12 MSs)  4,702  4.5  4,205  4.8 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Considering differing populations of Gallus gallus separately, levels of resistance to third-generation 
cephalosporins in Salmonella ssp. isolates from broiler, laying hen and breeding flocks were reported by 13, 
12 and 4 MSs, respectively, in 2012 (Table ESBL6) and were generally either not detected or recorded at 
low levels. The levels of resistance in broilers were generally slightly higher than those reported when all 
Gallus gallus were considered, as most reporting MSs detected resistance, while, in laying hen and breeding 
flocks, resistance was generally not recorded. In Salmonella spp. from laying hen and breeding flocks, only 
three (Austria, Italy and Romania) and two MSs (Italy and Romania) detected low level resistance to third-
generation cephalosporins out of the 12 and 4 reporting MSs, respectively. In broilers, three MSs reported 
levels of resistance to third-generation cephalosporins greater than 5 %. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table  ESBL6.    Resistance (%) to cefotaxime and ceftazidime in Salmonella  spp. isolates from 
broilers, laying hens and breeding hens of Gallus gallus tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Broilers             
Austria  113  0  113  0 
Czech Republic  351  0.3  351  0.3 
Denmark  24  0  –  – 
Hungary  175  0.6  –  – 
Ireland  38  0  38  0 
Italy  105  13.3  105  7.6 
Netherlands  130  6.2  130  6.2 
Poland  189  0.5  189  0.5 
Portugal  122  3.3  –  – 
Romania  784  6.4  784  6.3 
Slovakia  55  0  55  0 
Spain  29  3.4  29  3.4 
United Kingdom  170  0  153  0 
Total (13 and 10 MSs)  2,285  3.5  1,947  3.5 
Laying hens             
Austria  63  1.6  63  1.6 
Germany  51  0  51  0 
Hungary  86  0  –  – 
Italy  161  1.2  161  1.2 
Latvia  14  0  –  – 
Netherlands  54  0  54  0 
Poland  132  0  132  0 
Portugal  32  0  –  – 
Romania  145  0  145  2.8 
Slovakia  29  0  29  0 
Spain  150  0  150  0 
United Kingdom  66  0  63  0 
Total (12 and 9 MSs)  983  0.3  848  0.8 
Breeding flocks             
Czech Republic  27  0  27  0 
Italy  36  2.8  36  2.8 
Poland  15  0  15  0 
Romania  32  3.1  32  6.3 
Total (4 MSs)  110  1.8  110  2.7 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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The resistance to cefotaxime and ceftazidime in S. Enteritidis isolates from Gallus gallus, broilers and laying 
hens, reported, respectively, by 13, 6 and 10 MSs (Table ESBL7), was most generally not detected in 
reporting MSs. In contrast, resistance to both cefotaxime and ceftazidime was reported at moderate levels 
(14.8 %) in Belgium. Among the reporting MSs on broilers, Portugal observed resistance to cefotaxime, at 
the low level of 5.3 %. Considering isolates from laying hens, Romania was the only MS to report resistance 
to ceftazidime at a level of 6.1 %, while resistance to cefotaxime was not detected in this country.  
Table  ESBL7.    Resistance (%) to cefotaxime and ceftazidime in S.  Enteritidis isolates from 
Gallus gallus tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
All Gallus gallus             
Austria  36  0  36  0 
Belgium  81  14.8  81  14.8 
Czech Republic  251  0  251  0 
Germany  80  0  80  0 
Hungary  26  0  –  – 
Italy  31  0  31  0 
Latvia  11  0  –  – 
Netherlands  38  0  38  0 
Poland  496  0.6  496  0.8 
Portugal  27  3.7  –  – 
Romania  76  0  76  5.3 
Slovakia  47  0  47  0 
Spain  45  0  45  0 
Total (13 and 10 MSs)  1,245  1.3  1,181  1.7 
Broilers             
Austria  21  0  21  0 
Czech Republic  236  0  236  0 
Poland  131  0  131  0 
Portugal  19  5.3  –  – 
Romania  10  0  10  0 
Slovakia  21  0  21  0 
Total (6 and 5 MSs)  438  0.2  419  0 
Laying hens             
Austria  15  0  15  0 
Germany  21  0  21  0 
Hungary  25  0  –  – 
Italy  28  0  28  0 
Latvia  11  0  –  – 
Netherlands  38  0  38  0 
Poland  91  0  91  0 
Romania  66  0  66  6.1 
Slovakia  25  0  25  0 
Spain  43  0  43  0 
Total (10 and 8 MSs)  363  0  327  1.2 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 
Resistance to third-generation cephalosporins in S. Typhimurium isolates from Gallus gallus (Table ESBL8) 
was reported by five MSs. Belgium was the only MS to detect resistance at levels of 10.6 % to cefotaxime 
and 14.9 % to ceftazidime. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Table  ESBL8.    Resistance (%) to cefotaxime and ceftazidime in S. Typhimurium isolates from 
Gallus gallus tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Austria  10  0  10  0 
Belgium  47  10.6  47  14.9 
Germany  42  0  42  0 
Hungary  10  0  –  – 
Poland  15  0  15  0 
Total (5 and 4 MSs)  124  4.0  114  6.1 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
7.2.2.2. Resistance levels in turkeys 
Resistance to cefotaxime and ceftazidime in Salmonella spp. isolates from turkeys, mainly fattening turkeys, 
is shown in Table ESBL9. Nine MSs reported results for cefotaxime and eight MSs reported results for 
ceftazidime. Resistance to both cefotaxime and ceftazidime was reported by Italy and Poland at low 
proportions, whereas Spain reported 1.2 % resistance to cefotaxime only.  
Table ESBL9.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from turkeys 
tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Turkeys             
Austria  38  0  38  0 
Czech Republic  27  0  27  0 
Germany  87  0  87  0 
Hungary  174  0  –  – 
Ireland  14  0  14  0 
Italy  48  4.2  48  4.2 
Poland  55  3.6  55  3.6 
Spain  169  1.2  169  0 
United Kingdom  142  0  141  0 
Total (9 and 8 MSs)  754  0.8  579  0.7 
Fattening turkeys             
Austria  38  0  38  0 
Czech Republic  20  0  20  0 
Germany  12  0  12  0 
Hungary  174  0  –  – 
Spain  169  1.2  169  0 
Total (5 and 4 MSs)  413  0.5  239  0 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
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7.2.2.3. Resistance levels in pigs 
Resistance to cefotaxime and ceftazidime in Salmonella spp. isolates from pigs is shown in Table ESBL10. 
Ten MSs reported results for cefotaxime and eight MSs reported results for ceftazidime; however, most of 
them did not detect any resistance making the overall level of resistance at the MS group level in pigs low at 
2.3  % for cefotaxime and 2.6  % for ceftazidime. Three MSs detected both cefotaxime and ceftazidime 
resistance in Salmonella spp. isolates from pigs. In fattening pigs, cefotaxime and ceftazidime resistance 
was observed only by Spain (6.3  % and 2.1  %, respectively) while, in breeding pigs, Belgium recorded 
cefotaxime and ceftazidime resistance at similar levels of 11.2 % and 9.6 %, respectively. Germany reported 
low levels of resistance to both cefotaxime and ceftazidime in pigs of unspecified production type. 
Table ESBL10.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from pigs 
tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
All pigs             
Belgium  187  11.2  187  9.6 
Denmark  374  0  –  – 
Estonia  32  0  32  0 
Germany  627  2.1  627  2.1 
Hungary  38  0  –  – 
Ireland  24  0  24  0 
Italy  25  0  25  0 
Netherlands  263  0  263  0 
Poland  10  0  10  0 
Spain  48  6.3  48  2.1 
Total (10 and 8 MSs)  1,628  2.3  1,216  2.6 
Fattening pigs             
Denmark  374  0  –  – 
Estonia  14  0  14  0 
Hungary  38  0  –  – 
Netherlands  17  0  17  0 
Spain  48  6.3  48  2.1 
Total (5 and 3 MSs)  491  0.6  79  1.3 
Breeding pigs             
Belgium  187  11.2  187  9.6 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Results relating to resistance to third-generation cephalosporins in S. Typhimurium from pigs, were reported 
by five and four MSs for cefotaxime and ceftazidime, respectively, and are shown in Table ESBL11. Among 
reporting MSs, Belgium and Germany were the only countries to report cefotaxime and ceftazidime 
resistance in S. Typhimurium, at the same levels, for both substances, of 10.7 % and 1.1 %, respectively. 
The overall levels of resistance for all reporting MSs were, therefore, at low levels of 2.3 % for cefotaxime 
and 2.6 % for ceftazidime. 
Table ESBL11.  Resistance (%) to cefotaxime and ceftazidime in S. Typhimurium isolates from pigs 
tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
All pigs             
Belgium  75  10.7  75  10.7 
Denmark  63  0  –  – 
Germany  273  1.1  273  1.1 
Ireland  15  0  15  0 
Netherlands  55  0  55  0 
Total (5 and 4 MSs)  481  2.3  418  2.6 
Fattening pigs             
Denmark  63  0  –  – 
Breeding pigs             
Belgium  75  10.7  75  10.7 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 
The occurrence of resistance to cefotaxime and ceftazidime in monophasic S. Typhimurium isolates from 
pigs is shown in Table ESBL12. Six MSs reported results for cefotaxime and five MSs reported results for 
ceftazidime. Resistance to third-generation cephalosporins was detected by Belgium at moderate levels for 
both antimicrobials (19.5 % for cefotaxime and 14.6 % for ceftazidime) and by Germany at a very low level 
(0.9 % for both antimicrobials), while Spain recorded resistance only to cefotaxime at 7.1 %. 
Table ESBL12.  Resistance  (%)  to  cefotaxime and ceftazidime in monophasic S. Typhimurium 
isolates from pigs tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Belgium  41  19.5  41  14.6 
Denmark  81  0  –  – 
Germany  228  0.9  228  0.9 
Netherlands  39  0  39  0 
Poland  10  0  10  0 
Spain  14  7.1  14  0 
Total (6 and 5 MSs)  413  2.7  332  2.4 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
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7.2.2.4. Resistance levels in cattle 
Among the seven MSs reporting data on resistance to cefotaxime and five for ceftazidime in Salmonella spp. 
from cattle (Table ESBL13), only Belgium reported resistance of 2.4 % to both antimicrobials in 2012. None 
of the S. Typhimurium isolates tested exhibited any resistance to these compounds amongst the six and 
four, respectively, reporting MSs (Table ESBL14). 
Table ESBL13.  Resistance (%) to cefotaxime and ceftazidime in Salmonella spp. isolates from cattle 
tested by MSs and non-MS in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Belgium  42  2.4  42  2.4 
Finland  19  0  –  – 
Germany  68  0  68  0 
Ireland  36  0  36  0 
Italy  14  0  14  0 
Netherlands  68  0  68  0 
Sweden  17  0  –  – 
Total (7 and 5 MSs)  264  0.4  228  0.4 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Table ESBL14.  Resistance (%) to cefotaxime and ceftazidime in S. Typhimurium isolates from cattle 
tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
Belgium  25  0  25  0 
Finland  16  0  –  – 
Germany  35  0  35  0 
Ireland  24  0  24  0 
Netherlands  24  0  24  0 
Sweden  12  0  –  – 
Total (6 and 4 MSs)  136  0  108  0 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.2.3. Salmonella serovars from animals demonstrating resistance to third-generation 
cephalosporins 
Third-generation cephalosporin resistance was identified in a range of Salmonella  serovars in 2012. 
Reporting MSs do not necessarily list all of the Salmonella serovars identified, and so the list of affected 
serovars is likely to be incomplete. In 2010, 2011 and 2012, the following third-generation cephalosporin-
resistant serovars were identified from one or more sources (pigs, Gallus gallus and/or cattle) and from one 
or more MSs: S. Derby,  S. Enteritidis,  S. Infantis,  S. Kentucky,  S. Livingstone,  S. London,  S. Java  and 
S.  Typhimurium. In addition to these serovars, S. 1,9,12:l,v:-,  S. Choleraesuis,  S. Lamberhurst, 
S. Montevideo  and  S.  Ordonez with third-generation cephalosporin resistance were identified in 2011. 
Isolates from turkeys (S. Bovismorbificans from France, S. Bredeney from Hungary and S. Muenchen from 
Spain) and domestic solipeds (S. Typhimurium DT104 from Ireland) were also found to express resistance to 
third-generation cephalosporins in 2011. Among the serovars identified as resistant to third-generation 
cephalosporins, monophasic S. Typhimurium was identified in pigs from Belgium, Germany and Spain in 
2012 (Table ESBL 12).  
7.2.4. Reporting of specific data on ESBL in Salmonella 
In 2012, EFSA published a report (EFSA, 2012b) providing detailed recommendations and discussions 
relating to how future surveillance for third-generation cephalosporin, ESBL, AmpC and carbapenem 
resistance monitoring could be enhanced. Using for the first time the new functionalities of the EFSA Data 
Collection Framework recently introduced, one MS (Spain) reported data on the identity of the ESBL and 
other enzymes detected in Salmonella isolates from fattening pigs. Two isolates (of serovars S. Derby and 
monophasic S. Typhimurium) were reported producing CTX-M-1 and CTX-M-14, respectively. CTX-M-1 is an 
ESBL enzyme which has been previously recognised in pigs in several MSs. One S. Typhimurium isolate 
produced the enzyme OXA-1, which confers resistance to the action of clavulanic acid, a beta-lactamase 
enzyme inhibitor, by breaking down the clavulanate compound. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.3. Third-generation cephalosporin resistance in indicator E. coli from food and animals 
7.3.1. Third-generation cephalosporin resistance in indicator E. coli isolates from food 
Three MSs (Denmark, Hungary and the Netherlands) reported results for resistance to cefotaxime in E. coli 
isolates from meat from broilers, meat from pigs and meat from bovine animals in 2012, and Sweden and 
Germany also reported data from meat from broilers and meat from bovine animals, respectively. Germany 
and the Netherlands tested ceftazidime and recorded similar resistance levels to those obtained for 
cefotaxime. Overall, resistance to third-generation cephalosporins was either not detected or reported at low 
levels ranging between 0.5 % and 8.0 %. Interestingly, the 2012 results for broiler meat from the Netherlands 
(8.0 % for cefotaxime and 6.3 % for ceftazidime) represent a decrease in the figures obtained for 2011, when 
31.9 % of isolates were resistant to both antimicrobials. 
Table ESBL15.  Resistance  (%)  to  cefotaxime and ceftazidime in E. coli isolates from meat from 
broilers, meat from pigs and meat from bovine animals tested by MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Meat from broilers             
Denmark  197  1.0  –  – 
Hungary  64  0  –  – 
Netherlands  175  8.0  175  6.3 
Sweden  92  0  –  – 
Total (4 and 1 MSs)  528  3.0  175  6.3 
Norway  197  0.5  –  – 
Meat from pigs             
Denmark  73  1.4  –  – 
Hungary  14  0  –  – 
Netherlands  98  1.0  98  1.0 
Total (3 and 1 MSs)  185  1.1  98  1.0 
Meat from bovine animals             
Denmark  46  0  –  – 
Germany  71  4.2  71  4.2 
Hungary  31  3.2  –  – 
Netherlands  141  0.7  141  0.7 
Total (4 and 2 MSs)  289  1.7  212  1.9 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.3.2. Third-generation cephalosporin resistance in indicator E. coli isolates from animals 
7.3.2.1. Resistance levels in Gallus gallus (fowl) 
Table ESBL16 summarises data on resistance in indicator E. coli isolates from Gallus gallus tested by eight 
reporting MSs, as well as Norway and Switzerland, distinguishing, where possible, between broilers and 
laying hens. All reporting countries tested resistance to cefotaxime and five reporting MSs also tested 
isolates for ceftazidime resistance. The levels of resistance reported were generally low, although Belgium 
reported 28 % resistance in Gallus gallus. The level of cefotaxime resistance (5.8 %) in E. coli from broilers 
reported by the Netherlands in 2012 represents a decline compared with 2011 and 2010, when 8.1 % and 
18  % resistance, respectively, was reported. In the case of Poland where resistance to cefotaxime and 
ceftazidime was reported in isolates from both broilers and laying hens, the levels of resistance, when 
considering isolates from broiler flocks, were approximately twice that reported from laying hens.  
Table ESBL16.  Resistance  (%)  to  cefotaxime and ceftazidime in indicator E. coli isolates from 
Gallus gallus tested by MSs and non-MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N %  Res N %  Res 
All Gallus gallus             
Austria  130  3.1  130  3.1 
Belgium  325  28.0  325  24.9 
Denmark  115  1.7  –  – 
France  201  10.4  201  9.5 
Hungary  105  7.6  –  – 
Netherlands  292  5.8  292  6.2 
Poland  328  10.7  328  6.1 
Sweden  255  0.4  –  – 
Total (8 and 5 MSs)  1,751  10.2  1,276  11.1 
Norway  113  0.9  –  – 
Switzerland  185  2.2  185  2.2 
Broilers             
Austria  130  3.1  130  3.1 
Denmark  115  1.7  –  – 
France  201  10.4  201  9.5 
Hungary  105  7.6  –  – 
Netherlands  292  5.8  292  6.2 
Poland  171  13.5  171  8.2 
Sweden  194  0  –  – 
Total (7 and 4 MSs)  1,208  6.2  794  6.9 
Switzerland  185  2.2  185  2.2 
Laying hens             
Poland  157  7.6  157  3.8 
Sweden  61  1.6  –  – 
Total (2 and 1 MSs)  218  6.0  157  3.8 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.3.2.2. Resistance levels in pigs 
Table ESBL17 shows resistance to cefotaxime and ceftazidime in indicator E. coli from pigs. Overall, the 
levels of resistance in reporting countries were low generally. Austria and the Netherlands detected no 
resistance in indicator E. coli from pigs. 
Table ESBL17.  Resistance (%) to cefotaxime and ceftazidime in indicator E. coli isolates from pigs 
tested by MSs and non-MSs in 2012 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
Austria  140  0  140  0 
Belgium  205  2.9  205  3.4 
Denmark  152  0.7  –  – 
France  200  2.0  200  2.0 
Hungary  68  1.5  –  – 
Netherlands  284  0  284  0 
Poland  190  2.6  190  2.6 
Total (7 and 5 MSs)  1,239  1.4  1,019  1.6 
Switzerland  185  1.1  185  1.1 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.3.2.3. Resistance levels in cattle 
The results of examinations for third-generation cephalosporin resistance in indicator E. coli from cattle are 
shown in Table ESBL18. Seven MSs and Switzerland tested indicator E. coli  isolates from cattle for 
cefotaxime and five MSs and Switzerland tested these isolates for ceftazidime resistance. The overall 
occurrence of resistance to cefotaxime was 2.4 % and to ceftazidime was 2.6 % in all reporting MSs and this 
represents an increase on the figures of 0.9 % and 0.6 %, respectively, reported in 2011. Denmark and 
Finland did not detect cefotaxime resistance in indicator E. coli from cattle in 2012, and in the remaining MSs 
a low or very low level (0.4-9.9 %) of resistance to both antimicrobials was detected. 
Table ESBL18.  Resistance (%) to cefotaxime and ceftazidime in indicator E. coli isolates tested from 
cattle by MSs and non-MS in 2012 
Country 
Cefotaxime  Ceftazidime 
N  % Res  N  % Res 
All cattle             
Austria  273  0.7  273  0.4 
Belgium  364  8.8  364  9.9 
Denmark  98  0  –  – 
Finland  295  0  –  – 
Germany  515  2.5  515  1.7 
Netherlands  559  0.5  559  0 
Poland  190  2.6  190  2.1 
Total (7 and 5 MSs)  2,294  2.4  1,901  2.6 
Switzerland  187  0.5  187  0 
Calves (under 1 year)             
Austria  151  1.3  151  0.7 
Germany  515  2.5  515  1.7 
Netherlands  285  0.7  285  0 
Total (3 MSs)  951  1.8  951  1.1 
Young cattle (1–2 years)             
Austria  73  0  73  0 
Meat production animals             
Switzerland  187  0.5  187  0 
Adult over 2 years             
Austria  49  0  49  0 
Dairy cows             
Netherlands  274  0.4  274  0 
Mixed herds             
Belgium  364  8.8  364  9.9 
Finland  295  0  –  – 
Total (2 and 1 MSs)  659  4.9  364  9.9 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
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7.4. Comparison of cefotaxime resistance in Salmonella spp. and indicator E. coli isolates 
from animals 
Indicator commensal E. coli in healthy animals may constitute a reservoir of resistance genes which can be 
transferred to zoonotic organisms, such as Salmonella, and this process may be particularly enhanced in 
some circumstances, for example under selection pressure resulting from antimicrobial usage. Once 
Salmonella  isolates have acquired plasmids carrying genes conferring resistance to third-generation 
cephalosporins (either ESBL or AmpC resistance genes), the dissemination of such resistant Salmonella 
clones will also play a major part in influencing the occurrence of third-generation cephalosporin resistance.  
Considering the prevalence of resistance to cefotaxime and resistance in MSs to Salmonella spp. and E. coli 
in all species for which relevant data are available, then in all reporting MSs where resistance was detected 
in 2012, the prevalence of resistance is higher in E. coli than it is in Salmonella spp. with the sole exception 
of Belgium and isolates from pigs. Table ESBL19 summarises the data and illustrates some interesting 
observations relating to the occurrence of cefotaxime resistance in Salmonella spp. and E. coli in MSs. 
Where resistance is detected in Salmonella  spp. in a MS, it is also invariably present in E. coli  in that 
reporting MS and usually occurs at a higher level (with only one exception). Some MSs do not report 
cefotaxime resistance in Salmonella  spp. or in E. coli  for some food-producing animals. The degree of 
resistance observed in Salmonella spp. and E. coli may be correlated, in those MSs, which have a high level 
of resistance in Salmonella spp. and have a high level of resistance in E. coli. However, the correlation does 
not always hold true and would not be expected to hold where clonal dissemination of particular strains of 
Salmonella were responsible for the observed prevalence of resistance in Salmonella spp. It tends to appear 
that, in most MSs, commensal E. coli is the primary reservoir of beta-lactamase resistance, which is less 
frequently observed in Salmonella spp. 
The data reported by the Netherlands are interesting because occurrence of resistance is assessed on a 
large number of samples tested. Resistance in E. coli isolates was detected at low levels in meat from pigs 
(1.0 %) and bovine animals (0.7 %), but at higher levels in meat from broilers (8.0 %). The figure for broilers 
represents a considerable decline from the figure reported in 2011 (31.9  %). It is desirable that these 
resistance figures are as low as possible. In the last years, a number of initiatives have occurred in the 
Netherlands, including changes to relevant antimicrobial authorisations and strenuous efforts to reduce 
antimicrobial consumption in livestock, which may have influenced the observed resistance levels. The 
decline in cefotaxime resistance observed in broilers in the Netherlands (18 %, 8.1 % and 5.8 % in 2010, 
2011 and 2012, respectively) parallels the decline observed in broiler meat. In other MSs, a low occurrence 
of resistance to cefotaxime was generally recorded, since many countries tested a rather small sample size 
or reported only single-resistant isolates. As a result, minor fluctuations in the observed percentage of 
resistance are probably to be expected.  
All MSs detected resistance to cefotaxime in broilers except Sweden; the prevalence ranged from 1.7 % to 
13.5 %. Where MSs reported data for both pigs and broilers, the levels observed in pigs were consistently 
lower. In cattle, some MSs reported that cefotaxime resistance in cattle was intermediate, lying between that 
observed in pigs and broilers (Austria, Belgium and the Netherlands), while Poland found that levels in pigs 
and cattle were very similar and Switzerland observed that cefotaxime resistance in pigs exceeded that 
observed in cattle. However, it is of note that differences in the types of cattle sampled may make direct 
comparisons between MSs inappropriate. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table ESBL19.  Resistance (%)to cefotaxime in Salmonella spp. and indicator E. coli isolates in MSs in 2012 testing both bacterial species in either 
Gallus gallus, pigs or cattle 
Country 
Gallus gallus  Pigs  Cattle 
Salmonella spp.  E. coli  Salmonella spp.  E. coli  Salmonella spp.  E. coli 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Austria  176  0.6  130  3.1 – – –  –  – –  –  – 
Belgium  664 18.1  325 28.0  187  11.2 205  2.9  42  2.4  364  8.8 
Denmark  28  0  115 1.7  374  0  152 0.7  –  –  –  – 
Finland  – – – –  –  –  – –  19  0  295 0 
Germany  – – – –  –  –  – –  68  0  515  2.5 
Hungary  261 0.4  105 7.6  38  0  68 1.5  –  –  –  – 
Netherlands  192 4.2  292 5.8  263  0  284  0  68  0  559 0.5 
Poland  739 0.7  328  10.7  10  0  190 2.6  –  –  –  – 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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7.5. Discussion 
In 2012, as in 2011, resistance to third-generation cephalosporins was generally detected at low levels in 
Salmonella and indicator E. coli isolates recovered from major food-producing animals and meat thereof. In 
most MSs, the prevalence of resistance to cefotaxime in both Salmonella spp. and E. coli was equal to that 
observed for ceftazidime. Although resistance assessed using ECOFFs tends to usually detect resistance to 
both compounds, this is not always the case and differences in resistance to each compound may be 
observed, reflecting whether the ESBL enzyme conferring resistance is primarily a cefotaximase or a 
ceftazidimase. ESBLs belonging to the CTX-M family (primarily, though not entirely, cefotaximases) are 
currently the most important types of ESBL in both animals and humans in the majority of MSs. However, 
EFSA has recommended that both cefotaxime and ceftazidime are included in future harmonised mandatory 
monitoring to ensure optimal detection of all ESBLs (EFSA, 2012b) (see box below), as surveillance 
procedures should anticipate possible changes in the status of different ESBL enzymes. 
While resistance to cefotaxime in Salmonella spp. isolates recovered from meat from broilers was reported at 
low or moderate levels in most reporting MSs, one MS recorded around 30 % resistance to both cefotaxime 
and ceftazidime in 2012 and 2011. In most MSs, the observed levels of resistance in meat from broilers and 
Gallus gallus (or broilers) showed many similarities; however, in a number of MSs, differences in the levels of 
cefotaxime resistance in meat and the species from which the meat was produced were observed. For 
example, in Belgium, resistance to cefotaxime or ceftazidime was not detected in Salmonella spp. from meat 
from broilers, while resistance to the same compounds was reported at moderate levels in Gallus gallus. 
Conversely, in Germany and the Netherlands, the cefotaxime resistance was recorded at a lower level in 
Salmonella spp. isolates from Gallus gallus than in isolates from poultry meat. The reasons underlying the 
absence of a clear correlation between the prevalence of resistance observed in livestock and then in meat 
derived from those animals within a MS may be related to the lack of direct comparability between the target 
populations used for the monitoring in retail meat and in broilers. The retail meat monitored may notably 
include not only domestic poultry meat, but also imported meat from other countries.  
Considering all MSs, resistance to cefotaxime in Salmonella spp. recovered from meat from pigs and cattle 
was 0.9 % and 1.4 % respectively, which are both lower than the figure of 4.3 % reported for meat from 
broilers. Two factors contribute to this observed difference: (1) the proportion of reporting MSs which did not 
report resistance to cefotaxime in meat from pigs and cattle was higher than that for meat from broilers, and 
(2) in MSs which did report resistance, the levels of resistance reported for Salmonella spp. from meat 
broilers were higher than for meat from pigs and cattle. 
The results have been presented by animal production type (where available and relevant) and this is the 
second year in which animal production type has been included in this way. Differences in the occurrence of 
resistance may be related to husbandry methods, age or stage of production, the degree of antimicrobial 
usage or the influence the structure of the particular livestock industry may have on clonal spread of resistant 
organisms. The prevalence of resistance to cefotaxime in Salmonella spp. was higher in broilers than in 
laying hens (when resistance was detected) for all MSs (except Austria). Laying hens tend to be infrequently 
treated with antimicrobials, especially once in lay. S. Enteritidis from broilers and layers were susceptible to 
cefotaxime from most MSs, although Belgium reported moderate cefotaxime resistance in S. Enteritidis from 
Gallus gallus and was the only MS to report moderate resistance in S. Typhimurium from Gallus gallus. 
Romania reported isolates resistant to ceftazidime, but susceptible to cefotaxime in laying hens, suggesting 
that a ceftazidimase enzyme may have been present. Salmonella spp. resistant to cefotaxime was most 
frequently observed in broilers and the proportion of MSs observing any degree of resistance was higher 
than that for other animal species (turkeys, pigs and cattle). 
Breeding animals may play a role in the clonal dissemination of resistance in particular serovars of 
Salmonella when animals colonised at breeding units are moved to fattening farms. A proportion of the 
reporting MSs observed cefotaxime resistance in Salmonella spp. isolates from breeding flocks of Gallus 
gallus and from breeding pigs. Belgium, Germany and Spain all reported cefotaxime resistance in 
S. Typhimurium or monophasic S. Typhimurium from pigs, and both of these serovars are significant causes 
of human salmonellosis. In cattle, the level of resistance for Salmonella spp. from cattle was very low and the 
S. Typhimurium isolates tested were all susceptible to cefotaxime. Only one MS (Belgium) reported third-
generation cephalosporin resistance in Salmonella spp. isolates from cattle. 
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Some  Salmonella  serovars have particular public health significance because they either are common 
causes of human salmonellosis or have acquired resistance to a large number of different antimicrobial 
compounds (or even exhibit both of these traits). Resistance to third-generation cephalosporins was detected 
in a number of serovars of particular public health importance, including S. Typhimurium,  S. Enteritidis, 
S. Infantis, S. Kentucky, S. Java and monophasic S. Typhimurium. Among those serovars showing multiple 
antimicrobial resistance, S. Kentucky and S. Java are particularly important because they also often show 
other resistances, including resistance to fluoroquinolones (the other main antimicrobial used in the first-line 
treatment of human salmonellosis). Previous outbreaks of ESBL-producing salmonellae affecting poultry and 
humans have occurred, for example involving S. Virchow (Weill et al., 2004; Bertrand et al., 2006), and it is 
important that the monitoring performed can identify such serovars. It may be assumed that, even though the 
monitoring has not been designed to detect outbreaks, it should hopefully reflect indirectly serovars involved 
in a large outbreak(s). Considering these Salmonella serovars of particular public health importance, no 
resistance to cefotaxime was detected in S. Typhimurium in meat from pigs in the period 2010 to 2011, while 
two MSs (Belgium and Romania) detected cefotaxime resistance in the same serovar of the same origin in 
2012. Belgium, Poland and Portugal detected cefotaxime resistance in S. Enteritidis from Gallus gallus in 
2012, as Austria and Hungary did in 2011; however, no cefotaxime resistance was detected in S. Enteritidis 
in meat from broilers in 2012. 
Although thorough cooking and appropriate food hygiene procedures kills any bacteria present on food and 
prevents cross-contamination of foods with resistant or susceptible bacteria, it is highly desirable that the 
level of resistance in zoonotic organisms is very low or zero, especially in relation to important antimicrobials 
for human treatment. Among the strains of E. coli occurring in animals, some may be able to cause infections 
in humans (many will be largely harmless animal commensals) and some, although they are primarily 
commensals of animals, may be able to transiently or permanently colonise the human intestine. During 
transient colonisation or passage through the human intestine, E. coli  may be able to exchange their 
resistance plasmids with the commensal E. coli  flora of humans. Therefore, it is also desirable that 
resistance to important antimicrobials for human treatment is also very low or zero in animal strains of E. coli, 
which might otherwise form a reservoir of resistance genes. 
 
FUTURE HARMONISED MONITORING OF ESBLS AND AMPC ENZYMES 
EFSA’s Scientific Report on the harmonised monitoring and reporting of antimicrobial resistance in 
Salmonella,  Campylobacter and indicator E. coli and Enterococcus spp. bacteria transmitted through 
food (EFSA, 2012b) has discussed further enhancement of surveillance in this area. In particular, 
detailed recommendations have been made for the isolation and identification of extended-spectrum 
beta-lactamases (ESBL) and AmpC E. coli and methods have been described which would promote a 
harmonised and, therefore, comparable approach to monitoring across the EU. Further characterisation 
of isolates in this way will allow possible links between animals and humans to be investigated and 
provide a better indication of the overall significance of any resistance to third-generation cephalosporins 
which is detected. Based on the proposals of EFSA, the European Commission has put forward and 
discussed with the Member States a new piece of legislation on the harmonised monitoring of 
antimicrobial resistance in food-producing animals and food, including details provisions on the 
monitoring of ESBL- and AmpC-producing Salmonella  and indicator commensal E. coli. The new 
legislation (Decision 2013/652) will enter into force in 2014. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8. MATERIALS AND METHODS 
8.1. Antimicrobial susceptibility data from humans available in 2012 
MSs report results from AST to ECDC through TESSy. The data used in this report were submitted in 
connection to the annual data collection for the European Union Summary Report of Trends and Sources of 
Zoonoses and Zoonotic Agents end of May 2013. 
8.1.1. Salmonella data of human origin  
Nineteen MSs, as well as Iceland and Norway, provided data for 2012. The antimicrobials reported on for 
Salmonella are ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfonamides, tetracyclines and trimethoprim. Some countries reported on all of these and 
others on only a few. Countries reported qualitative data, i.e. interpreted AST results for tested isolates 
(susceptible (S), intermediate (I) or resistant (R)), with the exception of Norway which used the isolate-based 
reporting under piloting at ECDC to report measured IZDs. The Norwegian data were then interpreted by 
ECDC, using the most recent clinical breakpoints from EUCAST where applicable and otherwise breakpoints 
from CLSI (Table MM1). 
The public health reference laboratories were asked via e-mail to provide an update about which methods 
and which guidelines were being used for testing and interpretation. It should be noted that the public health 
reference laboratories in several countries type only a fraction of the isolates. The remaining isolates are 
then typed by hospitals or local laboratories, and the methods used by these are often unknown. Eight MSs 
plus Iceland and Norway used only disc diffusion methods, six other MSs used only dilution methods and 
another four MSs used a combination of the two depending on the situation and the antimicrobial (Table 
MM1 (continued)). The method used in one MS was unknown. 
The guidelines used for the interpretation differed between countries (Table MM1). Nine countries used 
guidelines from CLSI, two used guidelines from EUCAST, five used a combination of the two and another 
five countries used another guideline (often national). Compared with 2011, two MSs and Iceland had 
changed to EUCAST from CLSI (and more followed in 2013). Clinical breakpoints were applied in all 
countries but two, which used EUCAST ECOFFs. For 4 of the 11 antimicrobials addressed, the MIC value for 
the CLSI breakpoints and the EUCAST ECOFFs are equivalent: chloramphenicol, nalidixic acid, 
sulfonamides and tetracyclines. Please note that CLSI define clinical resistance breakpoints as ‘more than or 
equal to’ a certain MIC value, while EUCAST use ‘more than’ a certain value. This means that a CLSI 
breakpoint of ≥32 mg/L is the same as a EUCAST breakpoint of >16 mg/L.; see Table MM1 and Figure SA1. 
For three antimicrobials (cefotaxime, ciprofloxacin and gentamicin), the MIC values or zone diameters differ 
markedly between the clinical breakpoints and the ECOFFs. This is particularly the case for ciprofloxacin, for 
which the ECOFF is three times more sensitive than the EUCAST clinical breakpoint and five times more 
sensitive than the CLSI clinical breakpoint (Figure SA1). Results for these three antimicrobials must therefore 
be interpreted with caution, and no direct comparison between countries should be made.  
Results are presented for countries reporting data for more than 20 isolates for the antimicrobial in question. 
Trend lines within the period 2008 to 2012 are shown for those countries reporting data for at least three 
consecutive years and 10 isolates per year. Countries which did not detect any resistant isolates during the 
period are mentioned but not shown in the graphs. Results are presented separately for the top three most 
important serovars: S. Enteritidis, S. Typhimurium and monophasic S. Typhimurium. 
In order to better assess the impact from food consumed within each reporting country on the antimicrobial 
resistance levels found in human Salmonella isolates, the analysis focused on domestically acquired cases. 
However, since several countries had not provided any information on travel (or non-travel) of their cases, 
cases with unknown travel status were included in the analysis. The proportion of travel-associated, 
domestic and unknown cases among the tested Salmonella isolates is presented in Table MM2. An analysis 
was also made on the most likely country of infection of each disease case to compare resistance levels in 
human Salmonella infections acquired within the EU/EEA with those acquired when travelling in regions 
outside the EU/EEA.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM1.  Breakpoints used by MSs for the interpretation of 2012 susceptibility data on Salmonella of human origin 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Kanamycin 
Guidelines 
MIC mm MIC mm MIC  mm  MIC mm  MIC mm  MIC mm 
Austria –  ≤13 –  ≤16 –  ≤16 –  ≤18 –  ≤13 –  ≤13  EUCAST 2012 for Amp, Ctx, Chl, Cip, Gen. 
CLSI 2012 for Kan 
Denmark  >8 –  >0.5 –  >16  –  >0.06 –  >2  –  >4 –  EUCAST ECOFFS. Neomycin is reported 
under kanamycim 
Estonia  ≥32  ≤13  ≥1  ≤27  ≥32  ≤12  ≥0.125 <30 ≥16  ≤12 –  ≤13  WHO Collaborating Centre 2010, DTU Food 
(breakpoints based on CLSI) 
France  – <16  – <23  –  <23  >1 <22  –  <16  – <15  CA-SFM  2011 
Germany  >8 –  >8 –  NA  NA  >2 –  >4  –  >16 –  German  DIN  standard   
Greece
1  –  ≤13 –  ≤22 –  ≤12 –  ≤15 –  ≤12 –  ≤13 CLSI  2011 
Hungary  >8  <14 >2  <17 >8  <17  >0.064  – >4  <14  –  <14  EUCAST 2012 except for Kan where CLSI 
2012 was applied 
Ireland  >8 –  >2 –  >8  –  >1 –  >4  –  ≥64 –  EUCAST 2012 except for Kan where CLSI 
2012 was applied 
Italy  ≥32  ≤13  ≥64  ≤14  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13 CLSI  M100-S17-S19 
Latvia
1  ≥32  ≤13 NA NA NA  NA  ≥4  ≤15  NA NA NA  NA  CLSI 
Lithuania
1  ≥32  ≤13  ≥64  ≤14  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13 CLSI  M100-S17-S19 
Luxembourg –  ≤13 –  ≤22 –  ≤12 –  ≤15 –  ≤12 –  ≤13 CLSI  2012 
Malta  ≥16 –  ≥4 NA  ≥16 NA  ≥2 –  ≥8 –  NA  NA  Biomerieux Vitek II system; follows EUCAST 
2010 
Netherlands
1  >4 –  >0.5 –  >16  –  >0.06 –  >2  – NA  NA  EUCAST ECOFFS from 2007. For Str EFSA 
and Su CLSI 
Romania
1  ≥32  ≤13  ≥4  ≤22  ≥32  ≤12  ≥4  ≤15  ≥16  ≤12  ≥64  ≤13 CLSI  2012 
Slovakia  >8 <14  >2 <17  >8  <17  >2 <19  >4  <14  NA  NA  EUCAST 
Slovenia –  ≤13 –  ≤22 –  ≤12 –  ≤15 –  ≤12 –  ≤13  CLSI M100-S22, 2012 
Spain –  ≤13 –  ≤22 –  ≤12 –  ≤15 –  ≤12 –  ≤13  CLSI-2010 M100-S-20 Vol.30 
United Kingdom ≥8 –  ≥1 –  ≥8 –  ≥0.125 –  ≥4 –  ≥16  –  HPA methodology based on Frost (1994) 
Iceland  – <14  NA  NA  –  <17  – <19  NA  NA  NA  NA  EUCAST  2012 
Norway  – <14  NA  NA  –  <17  – <19  NA  NA  NA  NA  EUCAST  2012 
MS: Member State; MIC, minimum inhibitory concentration; –: this method is not used for the antimicrobial in question; NA: not applicable since this antimicrobial is not reported to The European 
Surveillance System or fewer than 20 isolates tested; EUCAST: European Committee on Antimicrobial Susceptibility Testing; ECOFF: epidemiological cut-off value; WHO: World Health Organization; DTU: 
Technical University of Denmark; CA-SFM: French Society for Microbiology; DIN: Deutsches Institut für Normung; CLSI: Clinical and Laboratory Standards Institute; HPA: Health Protection Agency.  
1. Interpretive criteria and comments shown are from the 2010 or 2011 report as clinical breakpoints for 2012 were not reported. 
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Table MM1 (continued). Breakpoints used by MSs for the interpretation of 2012 susceptibility data on Salmonella of human origin 
Country 
Nalidixic acid  Streptomycin Sulfonamides Tetracyclines Trimethoprim
Guidelines  Method 
MIC mm MIC mm  MIC mm  MIC mm MIC mm 
Austria –  ≤13 –  ≤11 –  ≤12 –  ≤11 –  ≤14  EUCAST 2012 for Tmp. CLSI 2012 for Nal, Str, Su, Tet  Disc diffusion 
Denmark  >16 –  >16 –  >256  –  >8 –  >2 –  EUCAST ECOFFS. EFSA ECOFF for sulfonamides  Dilution 
Estonia  ≥32  ≤13  ≥32  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  WHO Collaborating Centre 2010, DTU Food (breakpoints 
based on CLSI)  Disc diffusion 
France  >16 <15  – <15  –  <12  – <17  – <13 CA-SFM 2011. Combination trimethoprim/sulfamethoxazole 
tested 
Disc diffusion and 
dilution (gradient 
strip) 
Germany  >16 –  >16 –  NA NA NA  NA  >  16 –  German DIN standard. Combination 
trimethoprim/sulfamethoxazole tested  Dilution 
Greece
1  –  ≤13 –  ≤11 NA  NA  –  ≤11 –  ≤10  CLSI 2011  Disc diffusion 
Hungary  – <14  – <12  –  <13  – <12  >4 <11 CLSI 2012 except for Stx EUCAST 2012. Combination 
trimethoprim/sulfamethoxazole tested 
Disc diffusion and 
dilution (gradient 
strip) 
Ireland >16  –  >32  –  ≥512 –  ≥16 –  >4 –  EUCAST 2012 except for Su and Tet CLSI 2012 and Str 
EFSA 2007  Dilution 
Italy  ≥32  ≤13 –  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI M100 S17 S19  Disc diffusion 
Latvia
1  NA NA  NA NA NA  NA  NA NA  ≥16  ≤10 CLSI  Not  reported 
Lithuania
1  ≥32  ≤13 –  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10  CLSI M100-S17-S19  Disc diffusion 
Luxembourg –  ≤13 –  ≤11 –  ≤12 –  ≤11 –  ≤10  CLSI 2012. Combination trimethoprim/sulfamethoxazole 
tested  Disc diffusion 
Malta  NA NA  NA NA NA  NA  NA NA ≥160 –  Biomerieux Vitek II system; follows EUCAST 2010 except for 
Stx. Combination trimethoprim/sulfamethoxazole tested  Dilution 
Netherlands  >16  –  >32  –  –  –  >8  –  NA  NA  EUCAST ECOFFS. For Str EFSA and Su CLSI  Dilution 
Romania
1  ≥32  ≤13  ≥32  ≤11  ≥512  ≤12  ≥16  ≤11  ≥16  ≤10 CLSI  2012 
Disc diffusion and 
dilution (gradient 
strip) 
Slovakia  >16 <12  NA  NA  >256  <13  >8 <12  >4 <13 CLSI except for Stx EUCAST. Combination 
trimethoprim/sulfamethoxazole tested 
Disc diffusion and 
dilution 
Slovenia –  ≤13 –  ≤11 –  ≤12 –  ≤11 –  ≤10  CLSI M100-S22, 2012  Disc diffusion 
Spain –  ≤13 –  ≤11 –  –  –  ≤11 –  ≤10  CLSI-2010 M100-S-20 Vol.30. Combination 
trimethoprim/sulfamethoxazole tested  Disc diffusion 
United Kingdom ≥16 –  ≥16 –  ≥64 –  ≥8 –  ≥2  –  HPA methodology based on Frost (1994)  Dilution (in agar 
breakpoint) 
Iceland  –  NA  NA  NA  NA  NA  NA  NA  –  < 13  EUCAST 2012  Disc diffusion 
Norway –  ≤13 –  ≤11 –  ≤12 –  ≤11  –  <13  CLSI 2012 except for Stx EUCAST 2012  Disc diffusion 
MS: Member State; MIC: minimum inhibitory concentration; –: this method is not used for the antimicrobial in question; NA: not applicable since this antimicrobial is not reported to The European 
Surveillance System or fewer than 20 isolates tested; EUCAST: European Committee on Antimicrobial Susceptibility Testing; ECOFF: epidemiological cut-off value; WHO: World Health Organization; DTU: 
Technical University of Denmark; CA-SFM: French Society for Microbiology; DIN: Deutsches Institut für Normung; CLSI: Clinical and Laboratory Standards Institute; HPA: Health Protection Agency. 
1. Interpretive criteria and comments shown are from the 2010 or 2011 report as clinical breakpoints for 2012 were not reported.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM2.  Proportion of tested Salmonella spp. isolates from human cases associated with travel, 
domestic cases and cases with unknown travel information by country in 2012 
Country 
Tested isolates  Travel-associated  Domestic  Unknown 
N % %  % 
Austria 1,888  4  96  0 
Denmark 609  36  64  0 
Estonia 238  8  92  0 
France 1,278  0  0  100 
Germany 2,039  2  98  0 
Greece 112  5  88  7 
Hungary 588  0  100  0 
Ireland 306  29  12  59 
Italy 134  1  13  86 
Latvia 60  2  98  0 
Lithuania 1,744  0  0  100 
Luxembourg 135  0  0  100 
Malta 88  0  100  0 
Netherlands 1,160  11  89  0 
Romania 137  0  0  100 
Slovakia 1,010  1  99  0 
Slovenia 392  0  0  100 
Spain 1,880  0  76  23 
United Kingdom  8,644  28  21  51 
Total (19 MSs)  22,442  13  47  39 
Iceland 33  33  45  21 
Norway 1,322    73  17  10 
MS: Member State; N: number of the tested isolates. 
Multi-drug resistance of human Salmonella  spp.  to 10 antimicrobials were also analysed. The 
10  antimicrobials included were ampicillin, cefotaxime, chloramphenicol, ciprofloxacin/nalidixic acid, 
gentamicin, kanamycin, streptomycin, sulfonamides, tetracyclines and trimethoprim. Of these, only 
kanamycin is not on the list of antimicrobials tested for in food and animal isolates. Resistance to nalidixic 
acid and ciprofloxacin was addressed together: in the event that an isolate was resistant or exhibited 
intermediate resistance to either of these antimicrobials, the isolate was classified as non-susceptible to the 
combined antimicrobial ciprofloxacin/nalidixic acid, as the two substances belong to the same antimicrobial 
family.  
Multi-drug resistance of an isolate was defined as non-susceptibility to at least three different antimicrobial 
classes (Magiorakos et al., 2012). Co-resistance to ciprofloxacin and cefotaxime was also estimated as 
these two antimicrobials are considered the most important for treatment of severe salmonellosis (ECDC et 
al., 2009). Only countries which reported the results of tests on the full range of antimicrobials were included 
in the analysis.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.1.2. Campylobacter data of human origin 
Fourteen MSs and Iceland provided data for 2012. The antimicrobials reported on for Campylobacter were 
amoxicillin, ampicillin, ciprofloxacin, erythromycin, gentamicin, nalidixic acid and tetracyclines. Some 
countries reported on all of these and others on only a few (Table MM3). Countries reported qualitative data, 
i.e. interpreted AST results for tested isolates (S, I or R). 
National public health reference laboratories were asked to provide the methods and guidelines used for 
testing and interpretation. AST for Campylobacter seems to be performed in local or regional laboratories to 
a higher extent than for Salmonella and the methods and guidelines used outside of the national public 
health laboratories may therefore not be known. Five countries used disc diffusion for their routine testing, 
while six countries used dilution or gradient strip (Table MM3). Four countries used both disc diffusion and 
dilution, depending on the circumstances and the antimicrobial.  
The guidelines used for the interpretation at the national level differed between countries (Table MM3). Four 
countries used guidelines from the French Society for Microbiology (CA-SFM), three used guidelines from 
CLSI (M45-A), two used guidelines from EUCAST, two used a combination of CA-SFM and CLSI and four 
used other guidelines. Of the five antimicrobials reported on from both human and animal/food isolates, the 
EUCAST clinical breakpoints and ECOFFS were at the same MIC values except for ciprofloxacin and the 
combination C. coli/erythromycin, where the ECOFF was one dilution higher than the clinical breakpoint. No 
clinical breakpoints were available for gentamicin and nalidixic acid. The CA-SFM breakpoints were generally 
also in the same range or one dilution higher or lower than the ECOFF except for the combination 
C. coli/erythromycin, and tetracycline, where it was two dilution steps higher than the ECOFFs. The CLSI 
breakpoints were often set at up to two dilutions higher than the ECOFF (Figure CA1). Results for the 
antimicrobials for which there are major differences in the interpretive criteria should be interpreted with 
caution, and direct comparisons between countries should be avoided. 
Results are presented for countries reporting data for more than 20 isolates for the antimicrobial in question. 
Trend lines within the period 2008 to 2012 are shown for those countries reporting data for at least three 
consecutive years and 10 isolates per year. Countries which did not detect any resistant isolates during the 
period are mentioned but not shown in the graphs. Results are presented separately for the two most 
important Campylobacter species: C. jejuni and C. coli.  
In order to better assess the impact from food consumed within each reporting country on the antimicrobial 
resistance levels found in human Campylobacter isolates, the analysis focused on domestically acquired 
cases. However, since several countries had not provided any information on travel (or non-travel) of their 
cases, cases with unknown travel status were included in the analysis. The proportion of travel-associated, 
domestic and unknown cases among the tested Campylobacter isolates is presented in Table MM4. An 
analysis was also made on the most likely country of infection of each disease case to compare resistance 
levels in human Campylobacter infections acquired within the EU/EEA with those acquired when travelling in 
regions outside the EU/EEA.  
Multi-drug resistance of human C. jejuni and C. coli to six antimicrobials was also analysed. The six 
antimicrobials were amoxicillin, ampicillin, ciprofloxacin/nalidixic acid, erythromycin, gentamicin and 
tetracyclines. Of these, amoxicillin and ampicillin are not on the list of antimicrobials tested for in food and 
animal isolates. Resistance was addressed to both nalidixic acid and ciprofloxacin together: in the event that 
an isolate was resistant or exhibited intermediate resistance to either of these antimicrobials, the isolate was 
classified as non-susceptible to the combined antimicrobial ciprofloxacin/nalidixic acid, as the two 
substances belong to the same antimicrobial family.  
Multi-drug resistance of an isolate was defined as non-susceptibility to at least three different antimicrobial 
classes (Magiorakos et al., 2012). Co-resistance to ciprofloxacin and erythromycin was also estimated as 
these two antimicrobials are considered the most important for treatment of severe salmonellosis (ECDC et 
al., 2009). Only countries which reported the results of tests on the full range of antimicrobials were included 
in the analysis.  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM3.  Breakpoints used by MSs for the interpretation of 2012 susceptibility data on Campylobacter of human origin 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid Tetracyclines 
Guidelines  Method 
MIC mm MIC mm  MIC  mm  MIC  mm  MIC mm  MIC  mm MIC  mm 
Austria >8  –  >8  –  >0.5  –  >4
1 >8
2 –  >2  –  >16  –  >2  – 
EUCAST 2012 Combination 
amoxicillin/clavulanate 
tested 
Dilution 
Estonia  >16/2  <  14  >16  <14 >1  <22 >4  <17  >4  <16  >16  <15  >8  <17 
CA-SFM 2010 Combination 
amoxicillin/clavulanate 
tested 
Disc diffusion 
France  –  <  14  –  <14 –  <22 –  <17  –  <16  –  <15  NA  NA 
CA-SFM. Combination 
amoxicillin/clavulanate 
tested 
Disc diffusion 
Italy NA  NA  –  ≤6 –  ≤6 –  ≤6 –  ≤6 –  ≤6 –  ≤6 
CLSI M45-A Vol.26 no 19 
for Cip and Ery. Same 
criteria applied for remaining 
antimicrobials 
Disc diffusion 
Hungary  NA NA NA NA  >4  –  >4
1 >16
2  NA  NA  NA NA NA  NA  NA  Unspecified  reference  Dilution 
(gradient strip) 
Lithuania
3  NA NA NA NA  –  ≤17 –  ≤19  NA  NA  NA  NA  NA  NA  BSAC for disc diffusion  Disc diffusion 
Luxembourg  –  < 14  –  < 14  >1  –  >4  –  –  <16  –  <15  NA  <17  CA-SFM 2012  
Disc diffusion 
and dilution 
(gradient strip) 
Malta  NA NA NA NA  ≥1 –  ≥4  –  NA  NA NA NA  NA  NA  Personal communication 
from HPA in 2004 
Dilution 
(gradient strip) 
Netherlands
3 NA NA NA NA  ≥1.0–1.5  ≤ 19–20  ≥1.5–2.0 <13–≤23  NA  NA NA NA ≥2–8  ≤17–28  Survey in 12 clinical labs in 
the Netherlands in 2009 
Disc diffusion 
and dilution 
Romania
3  NA NA NA NA  NA  NA  NA  NA NA  NA NA NA  NA  NA 
CA-SFM 2010 Combination 
amoxicillin/clavulanate 
tested 
Disc diffusion 
MS: Member State; MIC: minimum inhibitory concentration; –: this method is not used for the antimicrobial in question; NA: not applicable since this antimicrobial is not reported to The European 
Surveillance System or fewer than 20 isolates tested; EUCAST: European Committee on Antimicrobial Susceptibility Testing; CA-SFM: French Society for Microbiology; CLSI: Clinical and Laboratory 
Standards Institute; BSAC: British Society for Antimicrobial Chemotherapy; HPA: Health Protection Agency. 
1. 
 Breakpoint used for C. jejuni. 
2.  Breakpoint used for C. coli. 
3.  Interpretive criteria and comments shown are from the 2010 or 2011 report; clinical breakpoints for 2012 were not reported. 
 
Table continued overleaf. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM3 (continued). Breakpoints used by MSs for the interpretation of 2012 susceptibility data on Campylobacter of human origin 
Country 
Amoxicillin  Ampicillin  Ciprofloxacin  Erythromycin  Gentamicin  Nalidixic acid  Tetracyclines 
Guidelines  Method 
MIC mm MIC mm MIC mm MIC mm MIC mm MIC mm MIC mm 
Slovakia
3  NA NA NA NA  ≥4 –  ≥32  – NA NA NA NA  ≥16 –  CLSI  Dilution 
Slovenia –  <  14  –  <14  ≥4 <22 ≥32 <17  – <16  – <15  – <17 
CA-SFM 2010 for disc 
diffusion and CLSI M45-A 
for Cip and Ery gradient 
strip. Combination 
amoxicillin/clavulanate 
tested 
Disc 
diffusion and 
dilution 
(gradient 
strip) 
Spain >16/2  –  NA  NA  ≥4 –  ≥32 –  >4 –  >16 –  ≥16 – 
CA-SFM 2010 for Amx, 
Gen, Nal. CLSI-2010 
M45AE for Cip, Ery, Tet 
Combination 
amoxicillin/clavulanate 
tested 
Dilution 
(gradient 
strip) 
United 
Kingdom
3  – –  >16 –  >1 –  >4 –  >1 –  >16 –  >2 –  EUCAST 
Dilution 
(microbroth 
and gradient 
strip) 
Iceland  NA NA NA NA  ≥4  ≤6  ≥32  ≤6 NA NA NA NA NA NA  CLSI  M45A2  2010 
Disc 
diffusion and 
dilution 
(gradient 
strip) 
MS: Member State; MIC: minimum inhibitory concentration; NA: not applicable since this antimicrobial is not reported to The European Surveillance System or fewer than 20 isolates tested; –: this method is 
not used for the antimicrobial in question; CA-SFM: French Society for Microbiology; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing. 
1. Breakpoint used for C. jejuni. 
2. Breakpoint used for C. coli. 
3. Interpretive criteria and comments shown are from the 2010 or 2011 report; clinical breakpoints for 2012 were not reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM4.  Proportion of tested Campylobacter spp. isolates from human cases associated with 
travel, domestic cases and cases with unknown travel information by country in 2012 
Country 
Tested isolates  Travel-associated  Domestic  Unknown 
N %  %  % 
Austria 387  0  0  100 
Estonia 246  6  94  0 
France 4,728  0  0  100 
Hungary 71  0  100  0 
Italy 319  9  24  67 
Lithuania 228  0  72  27 
Luxembourg 561  0  0  100 
Malta 214  0  100  0 
Netherlands 3,708  6  94  0 
Romania 19  0  0  100 
Slovakia 1,371  1  99  0 
Slovenia 982  0  2  98 
Spain 228  0  75  25 
United Kingdom  25,715  1  11  89 
Total (14 MSs)  38,777  1  22  77 
Iceland 58  50  34  16 
MS: Member State; N: number of the tested isolates. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.2. Antimicrobial susceptibility data from animals and food available in 2012 
8.2.1. Data reported under Directive 2003/99/EC in 2012 
MSs generated data on antimicrobial susceptibility through the testing of zoonotic and indicator bacteria 
isolated from various animal species/production types and food categories, sampled through a number of 
different national schemes. Isolates may have been collected by different monitoring approaches, either by 
active monitoring of animals and foods or, in some cases, by passive monitoring based on diagnostic 
submission of samples from clinical cases of disease in animals, or from foods sampled as part of 
investigatory work. In the case of passive monitoring, the isolates tested often constituted a sub-sample of 
the total isolates available at the National Reference Laboratory (NRL). Clinical investigation data were not 
accounted for in this report. 
Dilution and disc diffusion testing methods were used by reporting MSs for susceptibility testing, and both 
quantitative and qualitative data were reported at the EU level.  
‘Quantitative data’ derived from dilution methods consisted of the number of isolates having a specific MIC 
value (measured in mg/L) relative to the total number of isolates tested, for each antimicrobial agent and 
in each specific food/animal category. 
‘Quantitative data’ derived from diffusion methods comprised the number of isolates having a specific IZD 
(measured in mm) relative to the total number of isolates tested, for each antimicrobial agent and in 
each food/animal category.  
‘Qualitative data’ consisted of the number of isolates out of the total number of isolates that were resistant to 
each antimicrobial agent in each food/animal category; qualitative data can be generated either from 
MIC determination or from disc diffusion testing. 
For the year 2012, 26 MSs and 3 non-MSs reported data on antimicrobial resistance in tested Salmonella 
and Campylobacter, commensal E. coli or MRSA isolates from food-producing animals and/or food. Data on 
antimicrobial resistance in tested Salmonella and Campylobacter have been reported on a mandatory basis 
under Directive 2003/99/EC and data on antimicrobial resistance in tested commensal E. coli and 
commensal enterococci or MRSA isolates have been reported by the MSs on a voluntary basis. An overview 
of the MSs and non-MSs reporting antimicrobial resistance data (which were included in this report) in 2012 
is shown in Table MM5. 
Table MM5.  MSs reporting data in 2012 from animals and food and description of data included in 
the report  
Bacteria 
Number of MSs and non-MSs 
reporting quantitative or 
qualitative data 
Number of the tested included in the report 
MIC dilution  Diffusion 
Salmonella  24 MSs+3 non-MSs  73,840  3,821 
Campylobacter  15 MSs+1 non-MS  18,191  – 
Indicator Escherichia coli  13 MSs+2 non-MSs  63,298  – 
MRSA
1  1 MS+1 non-MS  2,100  – 
MS: Member State; MIC: minimum inhibitory concentration; MRSA: methicillin-resistant Staphylococcus aureus. 
1. In 2012, 10 MSs and one non-MS reported data on the occurrence of MRSA. 
For the purpose of this report, only quantitative dilution and quantitative disc diffusion data have been 
considered. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  243
8.2.1.1. Resistance data in Salmonella and Campylobacter from animals and food 
Quantitative (MIC) results on antimicrobial resistance in Salmonella isolates from animals and food were 
reported by 20 MSs and 2 non-MSs (Norway and Switzerland) in 2012. The information collected by these 
countries was in accordance with EFSA’s recommendations (EFSA, 2007); these data are described in 
Chapter 3. The countries reported results for only low numbers of isolates (fewer than 10) have been 
excluded from the analysis. 
In 2012, 15 MSs and 1 non-MS (Switzerland) reported data on antimicrobial resistance in Campylobacter. All 
Campylobacter results were reported as MIC values in accordance with EFSA’s recommendations (EFSA, 
2007). These data are described in Chapter 4. 
8.2.1.2. Resistance data in indicator bacteria 
For indicator (commensal) E. coli, a total of 11 MSs and 2 non-MSs (Norway and Switzerland) reported 
quantitative dilution (MIC) results from animals or meat derived from those animals; these data are described 
in Chapter 5. Some countries reported results for only low numbers of isolates (fewer than 10); these data 
have been excluded from the analysis. Slovenia and Portugal reported quantitative results for indicator 
E. coli isolates tested according to CLSI recommendations and using the CLSI disc diffusion method. 
8.2.1.3. Resistance data to third-generation cephalosporins 
In relation to third-generation cephalosporin resistance in indicator E. coli and Salmonella  spp., EFSA’s 
recommendations suggest the use of cefotaxime alone to detect important types of resistance (EFSA, 2007). 
Most MSs reported results for cefotaxime; some also reported results for ceftazidime; these data are 
described in Chapter 7. Cefotaxime is likely to detect the presence of most cefotaximases (CTX-M 
enzymes), which appear to be currently the most prevalent type of ESBL enzymes in bacteria isolated from 
food-producing animals in the EU. The use of cefotaxime will also detect the presence of AmpC enzymes in 
Salmonella or E. coli. Some ESBLs are ceftazidimases rather than cefotaximases (particularly enzymes in 
the TEM and SHV families of ESBLs). Although testing both cefotaxime and ceftazidime is therefore optimal 
for the detection of all ESBLs and AmpC enzymes, EFSA’s guidelines have recommended testing 
cefotaxime to detect all CTX-M enzymes mainly for reasons of affordability. 
8.2.1.4. Data on methicillin-resistant Staphylococcus aureus (MRSA) 
Data relating to MRSA prevalence were reported by 10 MSs and one non-MS (Switzerland). Among these, 
Switzerland reported data on resistance in MRSA isolates from pigs and Belgium in MRSA isolates from 
cattle. The methods for collecting and testing samples for MRSA are not harmonised between MSs and as a 
result MSs may use differing procedures. Owing to the variety of methods employed by MSs, these are 
explained in detail within Chapter 6 to enable readers to better follow the procedures carried out by individual 
countries. 
There is an important difference between the methods used to isolate Salmonella,  Campylobacter  and 
indicator E. coli and that used to isolate MRSA. For the former group of organisms, there is no selective 
medium used to isolate from primary samples organisms possessing a particular resistance, whereas, for 
MRSA, antimicrobials are used to selectively isolate only those Staphylococcus aureus isolates which are 
resistant to methicillin. Some MSs may have sampled particular production types of animals (for example 
laying hens in Gallus gallus or veal calves in cattle), and this introduces another source of possible variation 
which may account for observed differences between MSs. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.3. Antimicrobials used for susceptibility testing in animals and food 
The antimicrobials incorporated in this summary analysis were selected based on their relative public health 
importance and as representatives of different antimicrobial classes, taking into account EFSA’s reports and 
recommendations on the harmonised monitoring and reporting of antimicrobial susceptibility data (EFSA 
2007, 2008). 
8.3.1. Antimicrobials for susceptibility testing of Salmonella 
In 2012, both dilution and disc diffusion methods were used to test the susceptibility of Salmonella isolates 
from animals and food by MSs. Tables MM6 and MM7 show the antimicrobials selected by the different 
countries for susceptibility testing. Quantitative dilution results allowed MIC distributions to be reported for 
Salmonella  for the following antimicrobials: ampicillin, apramycin, cefotaxime, ceftazidime, ceftiofur, 
chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, kanamycin, nalidixic acid, neomycin, 
spectinomycin, streptomycin, sulfonamides, trimethoprim and tetracyclines. For further information on 
reported MIC distributions and the number of resistant isolates, refer to the Level 3 tables published on the 
EFSA website. 
Data on Salmonella which were reported as disc diffusion data are presented in Appendix 2. Although results 
may not be directly comparable between MSs, it is anticipated that in most cases procedures will not have 
changed markedly over time within a country, and therefore comparisons of the proportion of resistant 
isolates over time in that country may be possible. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Table MM6.  Antimicrobials  selected for susceptibility testing of Salmonella isolates from animals 
and food by MSs and non-MSs reporting quantitative data as MIC distributions, in 2012 
Country 
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Austria  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Belgium  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Czech Republic  ●    ●  ●    ●  ●      ●    ●      ●  ●  ●  ● 
Denmark  ●  ●  ●    ●  ●  ●  ●  ●  ●    ●  ●  ●  ●  ●  ●  ● 
Estonia  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Finland  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Germany  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Hungary  ●    ●      ●  ●      ●    ●      ●  ●  ●  ● 
Ireland  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Italy  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Latvia  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Netherlands  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Norway  ●    ●      ●        ●    ●      ●  ●  ●  ● 
Poland  ●    ●  ●    ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Portugal  ●    ●      ●  ●      ●    ●      ●  ●  ●  ● 
Romania  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Slovakia  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Spain  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
Sweden  ●    ●      ●  ●    ●  ●  ●  ●      ●  ●  ●  ● 
Switzerland  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●      ●  ●  ●  ● 
United Kingdom  ●    ●  ●    ●  ●      ●    ●      ●  ●  ●  ● 
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Sulfonamides may include a variety of substances. 
Table MM7.  Antimicrobials  selected for susceptibility testing of Salmonella isolates from animals 
and food by MSs reporting quantitative data as disc inhibition zones, in 2012 
Country 
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Greece    ●    ●  ●  ●    ●        ●    ●  ●  ●    ● 
Spain  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ●  ● 
MS: Member State. 
Note: Sulfonamides may include a variety of substances. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.3.2. Antimicrobials for susceptibility testing of Campylobacter 
In 2012, all quantitative Campylobacter data were reported as MIC values, generated by dilution methods. 
Table MM8 shows the antimicrobials selected by the different countries for susceptibility testing of 
Campylobacter isolates. In this report, antimicrobial resistance was reported separately for C. jejuni  and 
C. coli. 
MIC distributions were analysed for the following antimicrobials: ciprofloxacin, chloramphenicol, 
erythromycin, gentamicin, nalidixic acid, streptomycin and tetracyclines. These antimicrobials were selected 
based on public health relevance and as representatives of different classes of antimicrobials. For further 
information on reported MIC distributions and the number of resistant isolates, refer to the Level 3 tables 
published on the EFSA website. 
Table MM8.  Antimicrobials  selected for susceptibility testing of Campylobacter isolates from 
animals and food by MSs and non-MSs reporting quantitative data as MIC distributions, in 2012 
Country 
A
m
o
x
i
c
i
l
l
i
n
 
A
m
p
i
c
i
l
l
i
n
 
C
h
l
o
r
a
m
p
h
e
n
i
c
o
l
 
C
i
p
r
o
f
l
o
x
a
c
i
n
 
C
l
a
r
i
t
h
r
o
m
y
c
i
n
 
E
r
y
t
h
r
o
m
y
c
i
n
 
G
e
n
t
a
m
i
c
i
n
 
I
m
i
p
e
n
e
m
 
N
a
l
i
d
i
x
i
c
 
a
c
i
d
 
N
e
o
m
y
c
i
n
 
S
t
r
e
p
t
o
m
y
c
i
n
 
S
u
l
f
o
n
a
m
i
d
e
s
 
T
e
t
r
a
c
y
c
l
i
n
e
s
 
T
u
l
a
t
h
r
o
m
y
c
i
n
 
Austria  ●  ●  ●  ●     ●  ●  ●  ●  ●  ●    ●    
Belgium        ●  ●     ●  ●     ●     ●    ●    
Czech Republic           ●     ●  ●     ●     ●    ●    
Denmark        ●  ●     ●  ●     ●     ●    ●    
Estonia           ●     ●  ●     ●     ●    ●    
Finland           ●     ●  ●     ●     ●    ●    
France           ●     ●  ●     ●     ●    ●    
Germany        ●  ●     ●  ●     ●     ●    ●    
Hungary        ●  ●     ●  ●     ●     ●    ●    
Italy        ●  ●     ●  ●     ●     ●    ●    
Netherlands     ●  ●  ●  ●  ●  ●     ●  ●  ●  ●  ●  ● 
Poland           ●     ●  ●     ●     ●    ●    
Romania        ●  ●     ●  ●     ●     ●    ●    
Spain     ●  ●  ●     ●  ●     ●     ●    ●    
Sweden           ●     ●  ●     ●     ●    ●    
Switzerland        ●  ●     ●  ●     ●     ●    ●    
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Sulfonamides may include a variety of substances. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.3.3. Antimicrobials for susceptibility testing of Escherichia coli 
In 2012, both dilution and disc diffusion methods were used to test the susceptibility of E. coli isolates from 
animals and food. Tables MM9 and MM10 show the antimicrobials selected by the different countries for 
susceptibility testing. In this report, susceptibility data from food and animal isolates are presented.  
MIC distributions were analysed for the following antimicrobials: ampicillin, apramycin,  cefotaxime, 
ceftazidime, ceftiofur, chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, kanamycin, 
meropenem, nalidixic acid, neomycin,  spectinomycin, streptomycin, sulfonamides, trimethoprim and 
tetracyclines. These antimicrobials were selected based on their public health relevance and as 
representatives of different antimicrobial classes. For further information on reported MIC distributions and 
the number of resistant isolates, refer to the Level 3 tables published on the EFSA website. 
Table MM9.  Antimicrobials  selected for susceptibility testing of Escherichia coli isolates from 
animals and food by MSs and non-MSs reporting quantitative data as MIC distributions, in 2012 
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Austria  ●    ●  ●    ●  ●     ●    ●  ●     ●  ●  ●  ● 
Belgium  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●     ●  ●  ●  ● 
Denmark  ●  ●  ●    ●  ●  ●  ●  ●  ●     ●  ●  ●  ●  ●  ●  ● 
Finland  ●    ●      ●  ●  ●  ●  ●  ●  ●     ●  ●  ●  ● 
France  ●    ●  ●    ●  ●    ●  ●     ●     ●  ●  ●  ● 
Germany  ●    ●  ●    ●  ●    ●  ●  ●  ●     ●  ●  ●  ● 
Hungary  ●    ●      ●  ●     ●     ●     ●  ●  ●  ● 
Netherlands  ●    ●  ●    ●  ●  ●  ●  ●  ●  ●     ●  ●  ●  ● 
Norway  ●    ●      ●       ●     ●      ●  ●  ●  ● 
Poland  ●    ●  ●    ●  ●    ●  ●  ●  ●     ●  ●  ●  ● 
Spain  ●    ●      ●  ●    ●  ●  ●  ●     ●  ●  ●  ● 
Sweden  ●    ●      ●  ●  ●  ●  ●  ●  ●     ●  ●  ●  ● 
Switzerland  ●    ●  ●    ●  ●  ●  ●  ●  ●    ●     ●  ●  ●  ● 
MS: Member State; MIC: minimum inhibitory concentration. 
Note: Sulfonamides may include a variety of substances. 
Table MM10.  Antimicrobials  selected  for  susceptibility testing of Escherichia coli isolates from 
animals and food by one MS reporting quantitative data as disc inhibition zones, in 2012 
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Portugal  ●  ●  ●  ● ●  ●  ●   ● ● ● ● ●   ● ●   ● ●   ●  ●  ●   ● ● ●
Slovenia   ●   ●    ●  ● ●    ● ●   ● ●   ● ●     ●  ● ● ●  
MS: Member State. 
Note: Sulfonamides may include a variety of substances. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.3.4. Antimicrobials for susceptibility testing of MRSA 
In 2012, Belgium reported data on susceptibility testing of MRSA isolates from cattle and Switzerland 
reported data from pigs. Details of the antimicrobials selected by Belgium and Switzerland are provided in 
Chapter 6. For further information on reported MIC distributions and the number of resistant isolates, refer to 
the Level 3 tables published on the EFSA website. 
8.4. Data description and analysis 
8.4.1. Description and analysis of antimicrobial resistance data 
Methods to interpret, describe, and analyse antimicrobial resistance data were presented in detail in the 
2004 to 2007 Community Summary Report on Antimicrobial Resistance (EFSA, 2010b). 
Overview tables of the resistance data reported 
Quantitative MIC data, generated by dilution methods recommended by EFSA, have been reported and 
analysed together; quantitative IZD data, which constitute a relatively small fraction of the total data, have not 
been included in the analysis of quantitative data and have been described separately in Appendix 2. The 
IZD data reported by MSs under Directive 2003/99/EC for the years 2004 to 2007 were interpreted as 
described in previous EU Summary Reports. Some MSs reported antimicrobial resistance data as both 
quantitative and qualitative data; in that case, only the quantitative data have been included. Data generated 
from the antimicrobial susceptibility testing and reported as quantitative/qualitative by MSs have been 
described in the overview tables of individual chapters. 
MIC distributions, ECOFFs and the occurrence of resistance 
For each combination of microorganism, antimicrobial and food or animal category tested, MIC distributions 
have been presented as frequency tables, giving the number of isolates tested having a given MIC at each 
test dilution (mg/L) of the antimicrobial. MIC distributions are available as Level 3 tables on the EFSA 
website. 
Quantitative MIC data for Salmonella  were, wherever possible, interpreted using ECOFFs as listed in 
Decision 2007/407/EC (corresponding to those published by EUCAST at the time of publication of the 
Decision) and presented in Table MM11. Subsequent amendments by EUCAST to the ECOFFs have not yet 
been incorporated; this will be achieved by issue of a revised Decision. An isolate was defined as 
‘microbiologically resistant’ (i.e. displaying a decreased susceptibility) to a selected antimicrobial when its 
MIC value was above the ECOFF. A more sensitive MIC breakpoint or ECOFF (i.e. a lower MIC breakpoint 
or ECOFF) might be expected to result in more isolates being defined as clinically or microbiologically 
resistant, respectively; the number of isolates affected in that way will of course depend on the distribution of 
MIC results. 
 
REVISION OF ECOFFS 
The epidemiological cut-off value (ECOFF) for E. coli versus ciprofloxacin has been recently revised by 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Wild-type isolates are now 
considered to have a ciprofloxacin minimum inhibitory concentration greater than 0.06 mg/L, an increase 
from the previous ECOFF of greater than 0.03 mg/L. The proportion of isolates showing microbiological 
resistance according to this breakpoint will alter when the new breakpoint is adopted and in fact will be 
reduced. For reasons of continuity and to comply with the current legislation where applicable, the 
ECOFFs used in this report have been those adopted in EFSA’s recommendations (EFSA 2007, 2008) 
and quoted in Commission Decision 2007/407/EC. For these reasons, the most recent revisions by 
EUCAST have not been included in this report. The report for 2013, will incorporate all of these changes 
in a comprehensive revision, which will also re-evaluate the historical data using the revised ECOFFs, as 
well as taking into account revised EU legislation in this area, which will include the revised ECOFFs. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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The occurrence of resistance to a number of antimicrobials was determined (giving the percentage of 
isolates ‘microbiologically resistant’ out of those tested) for Salmonella, Campylobacter, indicator E. coli and 
enterococcal isolates from Gallus gallus, turkeys, pigs and cattle, and meat from Gallus gallus, pigs and 
cattle and are presented and analysed in tables on the occurrence of resistance in this report. These are the 
animal and food categories most frequently reported on by most MSs. Additionally, for the first time, data 
have been presented at the production-type level where possible. Data are included only if quantitative MIC 
data are provided by more than four MSs or disc diffusion data are provided by more than two MSs for the 
bacterium–animal/food category combination. An exception to this rule has nevertheless been made in the 
chapters on Salmonella serovars of public health importance (see below) and on MRSA. Data reported from 
fewer than 10 tested isolates per combination and per MS are not included. Data are reported in separate 
chapters dedicated to each microorganism and in Appendix 1 for Salmonella data obtained from disc 
diffusion. In addition, the occurrence of resistance (i.e. resistance levels) in reporting MS groups was 
calculated as totals (the total number of resistant isolates out of the total number of tested isolates across 
reporting MSs), and not the weighted means. 
Resistance in Salmonella serovars of public health importance 
In this report, antimicrobial resistance in tested Salmonella isolates were aggregated to give a value for 
Salmonella spp. for each country and food/animal category. In addition, whenever sufficient data were 
transmitted by MSs for a particular food/animal category, the most prevalent Salmonella  serovars, 
S. Enteritidis and S. Typhimurium, were also reported separately for that food/animal category. Additional 
tables have been included in this year’s report to describe the occurrence of antimicrobial resistance among 
Salmonella serovars of public health importance. In order to present a complete overview of the animal 
populations and food categories in which specific Salmonella serovars of public health importance have 
been recovered, data derived from fewer than four reporting countries have been included. 
Data description 
Throughout the report, the following definitions apply: 
Level or occurrence of antimicrobial resistance means the percentage of resistant isolates as a 
proportion of the isolates tested of that microorganism. 
MS reporting group means the MSs that provided data and were included in the relevant table of 
antimicrobial resistance for that bacterium–food or animal category–antimicrobial combination. 
Terms used to describe the antimicrobial resistance levels are: 
rare:  .........................   <0.1 % 
very low: ..................   0.1 % to 1 % 
low:   .........................   >1 % to 10 % 
moderate: ................   >10 % to 20 % 
high: ........................   >20 % to 50 % 
very high:  .................   >50 % to 70 % 
extremely high:  ........   >70 % 
These terms are applied to all antimicrobials. However, the significance of a given level of resistance will 
depend on the particular antimicrobial and its importance in human and veterinary medicine. 
Temporal trends in resistance 
Where the minimum criteria were met for the inclusion of data in this report (i.e. more than 10 isolates tested 
by a MS and more than four MSs reporting results for that antimicrobial, microorganism, food or animal 
category), then temporal trend graphs were generated showing the resistance to different antimicrobials over 
the 2006 to 2012 period, by plotting the level of resistance for each year of sampling. Only countries which 
had reported for four or more years in the 2006 to 2012 period were included. 
In order to assess the statistical significance of temporal trends, the proportions of resistance were modelled 
against time in a logistic regression. Results were provided only where there were five years or more of 
available data to use in the model, and where the likelihood ratio test suggested that the model was 
meaningful. This analysis was carried out in SAS9.2 using the PROC LOGISTIC function for each country EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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where temporal trend data were presented in the report. The PROC LOGISTIC function uses a logit 
transform to model proportion of prevalence against year, and provides estimates for both intercepts and 
slope. Models resulting in a p-value of <0.05 were considered to be significant. 
For ciprofloxacin and nalidixic acid, resistance trends over time were visually explored for Salmonella, 
Campylobacter and indicator E. coli by trellis graphs, using the lattice package in the R software 
(http://www.r-project.org). Graphs were created for those countries for which resistance data were available 
for four or more years, for at least one of the two antimicrobials. MS-specific resistance levels trend graphs 
use a unique scale and countries are shown in alphabetical order.  
Spatial analysis of resistance through maps 
MS-specific antimicrobial resistance levels for selected bacterium/food or animal category combinations were 
plotted in maps for 2012, using ArcGIS 9.3. In the maps, resistance levels are presented with colours 
reflecting the continuous scale of resistance to the antimicrobial of interest among reporting MSs; thus, there 
might be some apparent discrepancies between the colours and resistance levels between maps. 
Percentages shown in this map refer to countries that reported quantitative MIC data for more than 
10 isolates in 2012. When quantitative 2012 data were not available, the 2011 level of resistance was used 
instead and referred by a footnote to the map. The countries labelled as ‘qualitative data’ therefore include 
those reporting IZD data, MIC data for fewer than 10 isolates or purely qualitative data (as proportion of 
resistant isolates). 
Table MM11.  Epidemiological cut-off values used to interpret MIC distributions (mg/L) for bacteria 
from animals and food – the given values define the microbiologically resistant isolates 
Antimicrobial agent 
Salmonella  Escherichia coli  Campylobacter 
jejuni 
Campylobacter 
coli 
mg/L mg/L mg/L mg/L 
Ampicillin  >4   >8       
Apramycin  >16  >16       
Avilamycin             
Cefotaxime  >0.5  >0.25       
Ceftazidime  >2  >0.5       
Ceftiofur  >2  >1       
Chloramphenicol  >16  >16  >16  >16 
Ciprofloxacin  >0.06  >0.03  >1  >1 
Erythromycin        >4  >16 
Florfenicol  >16  >16       
Gentamicin  >2  >2  >1  >2 
Linezolid             
Nalidixic acid  >16  >16  >16  >32 
Neomycin  >4  >8       
Spectinomycin     >64       
Streptomycin  >32  >16  >2  >4 
Sulfonamides  >256
1  >64       
Quinupristin/dalfopristin             
Tetracyclines  >8  >8  >2  >2 
Trimethoprim  >2  >2       
Vancomycin             
MIC: minimum inhibitory concentration. 
1.   Cut-off values were not defined by the European Committee on Antimicrobial Susceptibility Testing; instead cut-off values defined 
by the European Union Reference Laboratory on antimicrobial resistance (Technical University of Denmark) were used. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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8.4.2. Analysis of multi-resistance and co-resistance data 
As a consequence of the availability of antimicrobial resistance data at an isolate-based level in an important 
number of MSs, the analysis of multi-resistance and co-resistance data becomes a feasible and important 
exercise in the light of the public health relevance of the emergence of multi-resistant bacteria. As a matter of 
fact, the analysis and reporting on multi-resistance in the 2012 EU Summary Report on antimicrobial 
resistance was previously recommended and endorsed by the Task Force on Zoonoses Data Collection at 
its meeting on antimicrobial resistance in April 2013.  
The intention is to focus mainly on multi-/co-resistance patterns involving critically important antimicrobials 
according to the bacterial species, such as cephalosporins, fluoroquinolones and macrolides, and to 
summarise important information in the EU Summary Report. The occurrence of the isolates of a 
serotype/resistance pattern of interest is studied at the MS level and at the reporting MS group/EU level, as 
the overall picture for all MSs might show a more definite pattern of emergence and spread. In addition, the 
analysis of data may reveal the existence of new or emerging patterns of multi-resistance, particularly in 
Salmonella serotypes. 
8.4.2.1. Analysis of multi-resistance patterns 
Definitions 
For the purpose of this analysis, a multi-resistant isolate is one defined as resistant to at least three different 
antimicrobial substances, belonging to any three antimicrobial families listed in the harmonised set of 
antimicrobials included in the EFSA recommendations (EFSA, 2007, 2008). Table MM12 lists those 
recommended antimicrobials.  
Resistance to nalidixic acid and ciprofloxacin is addressed together: an isolate that is resistant to either of the 
two will be termed resistant to the combined antimicrobial ciprofloxacin/nalidixic acid, as the two substances 
belong to the same antimicrobial family.  
By contrast, a fully susceptible isolate is one defined as non-resistant to all of the antimicrobial substances 
included in the set of substances recommended for Salmonella, Campylobacter and indicator E. coli. 
The term co-resistance has been defined as two or more resistance genes which are genetically linked, i.e. 
located adjacent or close to each other on a mobile genetic element (Chapman, 2003). For brevity, the term 
is used slightly more loosely in this report and indicates two or more phenotypic resistances to different 
classes of antimicrobials, exhibited by the same bacterial isolate. 
Table MM12.  Harmonised set of antimicrobials listed in the EFSA recommendations 
Zoonotic bacteria  Indicator bacteria 
Salmonella  Campylobacter coli/C. jejuni  Escherichia coli 
Ampicillin (Amp)  Ciprofloxacin (Cip)  Ampicillin (Amp) 
Cefotaxime (Ctx)  Erythromycin (Ery)  Cefotaxime (Ctx) 
Chloramphenicol (Chl)  Gentamicin (Gen)   Chloramphenicol (Chl) 
Ciprofloxacin (Cip)  Streptomycin (Str)  Ciprofloxacin (Cip) 
Gentamicin (Gen)  Tetracycline (Tet)  Gentamicin (Gen) 
Nalidixic acid (Nal)     Nalidixic acid (Nal) 
Streptomycin (Str)    Streptomycin  (Str) 
Sulfonamides (Su)     Sulfonamides (Su) 
Tetracycline (Tet)     Tetracycline (Tet) 
Trimethoprim (Tmp)     Trimethoprim (Tmp) 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Data analysis 
The frequency and percentage of isolates that are considered susceptible/resistant to all of the antimicrobials 
tested were determined for Salmonella  (Salmonella spp., S. Enteritidis,  S. Typhimurium and  monophasic 
S. Typhimurium),  Campylobacter  species and indicator E. coli  for each country and each animal 
population/food category. Isolates for which no susceptibility data were provided for some of the antimicrobial 
substances were disregarded. Data analysis was presented for a particular country only when the number of 
tested isolates was at least 10, except for monophasic Salmonella Typhimurium. 
Summary indicators of multi-resistance 
To illustrate the relative proportions of multi-resistant isolates and the diversity of the resistance to multiple 
antimicrobials, graphical illustration was chosen. The percentages of isolates susceptible and resistant to 
one, two, three, etc., antimicrobials are shown using a composite bar graph displaying stacked bars, but only 
for certain combinations of bacterium–animal population or food category–MS of particular interest.  
The objective is first to give an overview of the situation on multi-resistance through summary indicators: 
-  the proportion of fully susceptible isolates; 
-  the proportion of multi-resistant isolates; 
-  an index/indices of diversity, such as the entropy measure
18, summarising the distributions of isolate 
frequencies and, thus, the diversity among the different categories of multi-resistance (resistance to 
one, two, three, etc., antimicrobials).  
The ‘summary indicators’ of multi-resistance can be calculated and reported yearly and, therefore, used to 
follow evolution of the multi-resistance situation across animal populations/food categories and MSs over 
time.  
Diversity of multi-resistance 
Resistance can be limited to resistance to only one or two antimicrobial substances, or resistance can be 
equally spread out from resistance from the lower to the higher number of antimicrobial substances. In other 
words, the frequencies across the categories resistant to one, two, three substances, and so on, can follow 
different types of distributions: skewed to the right with higher frequencies for the lower numbers resistant; 
highly peaked or fully spread out; or even, at least in theory, with higher frequencies for the larger numbers 
resistant. The entropy measure quantifies the degree of diversity of resistance. The standardised 
unweighted entropy takes values between 0 and 1. It takes the value 0 if all resistance is of one single type 
(e.g. resistance to exactly two antimicrobial substances) and takes the maximal value 1 if resistance to any 
number of antimicrobial substances is occurring equally often. The unweighted version does not take any 
order into account. Therefore, particular frequencies at the lower numbers resistant lead to the same entropy 
value when having these particular frequencies at the higher number resistant. The weighted entropy takes 
higher values if resistance appears to higher numbers of antimicrobial substances. 
8.4.2.2. Analysis of co-resistance 
The co-resistance patterns of interest 
Co-resistance to cefotaxime and ciprofloxacin was estimated in Salmonella and E. coli isolates, as these two 
antimicrobials are of particular interest in human medicine. Co-resistance was addressed using both 
ECOFFs and clinical breakpoints in isolates of these bacteria. In C. jejuni and C. coli isolates, co-resistance 
to ciprofloxacin and erythromycin was estimated as these two antimicrobials are of particular interest in 
human medicine in the treatment of severe campylobacteriosis. The interpretive ECOFFs used to address 
co-resistance to ciprofloxacin and erythromycin were, for C. jejuni, Cip>1  mg/L and Ery>4  mg/L and, for 
C. coli, Cip>1  mg/L and Ery>16  mg/L. These values may be considered as very similar to clinical 
breakpoints. 
                                                 
18 Weighted or unweighted entropy measures may be considered. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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APPENDIX 1.  Frequency distributions of salmonella serovars in animals and food in 2012 
antimicrobial resistance data 
Appendix Table SER1.  Frequency  distribution  of  Salmonella serovars in meat from broilers 
(Gallus gallus), in 2012 
Serovars  Countries and total number of MSs reporting 
Meat from broilers 
(Gallus gallus) 
N %  f 
S. Infantis  8 MSs: CZ, EE, DE, HU, IT, PL, RO, SK  339  45.81 
S. Enteritidis  7 MSs: BE, CZ, DE, LV, NL, PL, SK  99  13.38 
S. Kentucky  3 MSs: HU, IE, RO  67  9.05 
S. Paratyphi B  2 MSs: BE, NL  39  5.27 
S. Java  1 MS: DE  31  4.19 
S. Indiana  2 MSs: CZ, PL  23  3.11 
S. Newport  2 MSs: CZ, PL  19  2.57 
S. Heidelberg  1 MS: NL  15  2.03 
S. Virchow  1 MS: RO  13  1.76 
S. Colindale  1 MS: RO  12  1.62 
S. Agona  2 MSs: CZ, SK  11  1.49 
S. Typhimurium  3 MSs: IE, IT, LV  11  1.49 
S. Hadar  2 MSs: IT, RO  9  1.22 
S. Bredeney  1 MS: RO  7  0.95 
S. Ohio  1 MS: CZ  6  0.81 
S. Ruzizi  1 MS: RO  6  0.81 
S. Rissen  1 MS: RO  5  0.68 
S. 6,7:-:1,5  1 MS: CZ  4  0.54 
S. Djugu  1 MS: RO  4  0.54 
S. Grampian  1 MS: RO  4  0.54 
S. Brandenburg  1 MS: RO  3  0.41 
S. Montevideo  1 MS: CZ  3  0.41 
S. Derby  2 MSs: CZ, DE  2  0.27 
S. Gloucester  1 MS: RO  1  0.14 
S. Isangi  1 MS: EE  1  0.14 
S. Kottbus  1 MS: CZ  1  0.14 
S. Livingstone  1 MS: RO  1  0.14 
S. Mbandaka  1 MS: IT  1  0.14 
S. Minnesota  1 MS: LV  1  0.14 
S. Thompson  1 MS: IT  1  0.14 
S. enterica subsp. enterica  1 MS: DE  1  0.14 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590    259
Appendix Table SER2.  Frequency distribution of Salmonella serovars in meat from pigs, in 2012 
Serovars  Countries and total number of MSs reporting 
Meat from pigs 
N %  f 
S. Typhimurium  12 MSs: BE, CZ, DK, EE, DE, HU, IE, IT, LV, NL, PL, RO  322  47.08 
S. Derby  8 MSs: CZ, EE, DE, HU, IE, IT, NL, RO  109  15.94 
S. Typhimurium, monophasic  8 MSs: CZ, DK, DE, HU, IE, IT, NL, SK  108  15.79 
S. Infantis  6 MSs: CZ, EE, DE, IE, IT, RO  27  3.95 
S. Bredeney  2 MSs: IT, RO  16  2.34 
S. Rissen  2 MSs: IT, RO  15  2.19 
S. enterica subsp. enterica  4 MSs: CZ ,EE, DE, IT  15  2.19 
S. Ruzizi  1 MS: RO  11  1.61 
S. Brandenburg  2 MSs: IT, NL  8  1.17 
S. Gloucester  1 MS: RO  6  0.88 
S. Kortrijk  1 MS: RO  5  0.73 
S. Agona  1 MS: EE  4  0.58 
S. Virchow  1 MS: RO  4  0.58 
S. Choleraesuis  2 MSs: CZ, IT  3  0.44 
S. Livingstone  3 MSs: EE, IT, RO  3  0.44 
S. Panama  1 MS: IT  3  0.44 
S. Bovismorbificans  1 MS: RO  2  0.29 
S. Colindale  1 MS: RO  2  0.29 
S. Enteritidis  2 MSs: CZ, RO  2  0.29 
S. Give  1 MS: IT  2  0.29 
S. Kapemba  1 MS: IT  2  0.29 
S. Thompson  1 MS: IT  2  0.29 
S. enterica subsp. salamae  1 MS: IT  2  0.29 
S. Bareilly  1 MS: EE  1  0.15 
S. Bsilla  1 MS: RO  1  0.15 
S. Dublin  1 MS: IE  1  0.15 
S. Kottbus  1 MS: IT  1  0.15 
S. London  1 MS: IT  1  0.15 
S. Manhattan  1 MS: IT  1  0.15 
S. Minnesota  1 MS: EE  1  0.15 
S. Montevideo  1 MS: RO  1  0.15 
S. Muenchen  1 MS: IT  1  0.15 
S. Muenster  1 MS: IT  1  0.15 
S. enterica subsp. diarizonae  1 MS: IT  1  0.15 
N: number of isolates tested; % f: percentage frequency of isolates tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER3.  Frequency distribution of Salmonella serovars in meat from bovine animals, 
in 2012 
Serovars  Countries and total number of MSs reporting 
Meat from bovine 
animals 
N %  f 
S. Typhimurium  7 MSs: CZ, EE, FI, DE, IE, IT, NL  24  39.34 
S. Derby  3 MSs: CZ, IE, IT  10  16.39 
S. Typhimurium, monophasic  3 MSs: DE, IE, NL  7  11.48 
S. Dublin  1 MS: IE  5  8.20 
S. enterica subsp. enterica  2 MSs: CZ, DE  3  4.92 
S. Infantis  2 MSs: HU, IE  2  3.28 
S. Rissen  1 MS: IT  2  3.28 
S. 9,12:lv:-  1 MS: CZ  1  1.64 
S. Hadar  1 MS: IT  1  1.64 
S. Kentucky  1 MS: IE  1  1.64 
S. London  1 MS: CZ  1  1.64 
S. Montevideo  1 MS: CZ  1  1.64 
S. Muenster  1 MS: IT  1  1.64 
S. Newport  1 MS: IE  1  1.64 
S. Saintpaul  1 MS: IE  1  1.64 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER4.  Frequency distribution of Salmonella serovars in Gallus gallus (fowl), in 2012 
Serovars  Countries and total number of MSs reporting 
Gallus gallus 
(fowl) 
N %  f 
S. Enteritidis  15 MSs: AT, BE, CZ, DK, DE, HU, IT, LV, NL, PL, PT, 
RO, SK, ES, UK  1,253  28.96 
S. Infantis  14 MSs: AT, BE, CZ, DK, DE, HU, IT, LV, PL, RO, SK, 
ES, SE, UK  781  18.05 
S. Mbandaka  9 MSs: AT, BE, CZ, HU, IT, PL, RO, ES, UK  237  5.48 
S. Tennessee  5 MSs: AT, BE, CZ, HU, RO  203  4.69 
S. Kentucky  8 MSs: BE, CZ, DK, HU, IE, IT, RO, ES  168  3.88 
S. Paratyphi B  2 MSs: BE, NL  166  3.84 
S. Typhimurium  12 MSs: AT, BE, DK, FI, DE, HU, IT, PL, RO, ES, SE, UK  161  3.72 
S. Senftenberg  7 MSs: AT, BE, HU, IT, RO, ES, UK  156  3.61 
S. Minnesota  1 MS: BE  126  2.91 
S. Livingstone  8 MSs: AT, BE, HU, IT, RO, ES, SE, UK  117  2.70 
S. Agona  7 MSs: AT, BE, HU, IT, RO, ES, UK  95  2.20 
S. Montevideo  9 MSs: AT, BE, CZ, DK, HU, IT, RO, ES, UK  84  1.94 
S. Liverpool  1 MS: RO  70  1.62 
S. Thompson  6 MSs: AT, BE, HU, IT, RO, ES  48  1.11 
S. Hadar  5 MSs: AT, BE, IT, RO, ES  42  0.97 
S. Typhimurium, monophasic  9 MSs: AT, BE, DK, DE, IT, NL, PT, ES, UK  40  0.92 
S. enterica subsp. enterica  3 MSs: CZ, DE, IT  39  0.90 
S. Rissen  5 MSs: BE, IT, RO, ES, UK  37  0.86 
S. Ohio  4 MSs: AT, CZ, ES, UK  33  0.76 
S. Corvallis  3 MSs: IT, RO, ES  32  0.74 
S. Kottbus  5 MSs: AT, BE, CZ, HU, IT  32  0.74 
S. Kedougou  2 MSs: IT, UK  28  0.65 
S. Derby  4 MSs: CZ, DK, IT, RO  21  0.49 
S. Indiana  4 MSs: CZ, HU, PL, UK  19  0.44 
S. Taksony  1 MS: RO  17  0.39 
S. 6,7:-:1,5  2 MSs: CZ, ES  16  0.37 
S. Virchow  5 MSs: BE, DE, IT, PT, ES  14  0.32 
S. Bredeney  5 MSs: BE, HU, IT, RO, ES  13  0.30 
S. Bovismorbificans  3 MSs: AT, DK, HU  12  0.28 
S. Braenderup  4 MSs: AT, BE, CZ, ES  12  0.28 
S. Muenchen  2 MSs: IT, ES  11  0.25 
S. Newport  7 MSs: BE, CZ, HU, IT, RO, ES, UK  11  0.25 
S. Anatum  4 MSs: BE, IT, ES, UK  10  0.23 
S. Give  4 MSs: AT, BE, IT, UK  10  0.23 
S. Uganda  1 MS: RO  10  0.23 
S. Cerro  4 MSs: BE, HU, IT, ES  9  0.21 
S. Havana  4 MSs: BE, IT, ES, UK  9  0.21 
S. Lille  1 MS: CZ  9  0.21 
S. 6,7:z29  1 MS: BE  8  0.18 
S. Blockley  2 MSs: IT, RO  8  0.18 
S. Java  2 MSs: DE, UK  8  0.18 
S. Lexington  2 MSs: BE, IT  7  0.16 
S. Amsterdam  2 MSs: BE, RO  6  0.14 
S. Coeln  2 MSs: AT, IT  6  0.14 
S. Gallinarum biovar Pullorum  2 MSs: IT, RO  6  0.14 
S. Albany  1 MS: RO  5  0.12 
S. Dabou  1 MS: ES  5  0.12 
S. Dublin  3 MSs: AT, BE, UK  5  0.12 
S. Glostrup  1 MS: RO  5  0.12 
S. Isangi  1 MS: IT  5  0.12 
Table continued overleaf. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER4 (continued). Frequency distribution of Salmonella serovars in Gallus gallus 
(fowl), in 2012 
Serovars  Countries and total number of MSs reporting 
Gallus gallus 
(fowl) 
N %  f 
S. London  3 MSs: AT, IT, ES  5  0.12 
S. Saintpaul  4 MSs: AT, BE, HU, IT  5  0.12 
S. Stanley  2 MSs: CZ, HU  5  0.12 
S. 6,7:-:-  2 MSs: BE, UK  4  0.09 
S. Abony  1 MS: HU  4  0.09 
S. Bareilly  1 MS: DK  4  0.09 
S. Haifa  1 MS: IT  4  0.09 
S. 3,19:-:-  1 MS: BE  3  0.07 
S. 9:-:-  1 MS: BE  3  0.07 
S. Cubana  2 MSs: RO, ES  3  0.07 
S. Goverdhan  1 MS: DK  3  0.07 
S. Hessarek  1 MS: BE  3  0.07 
S. Idikan  1 MS: BE  3  0.07 
S. Orion  1 MS: UK  3  0.07 
S. Worthington  2 MSs: AT, BE  3  0.07 
S. 4:i:-  1 MS: BE  2  0.05 
S. Altona  1 MS: ES  2  0.05 
S. Brandenburg  2 MSs: BE, ES  2  0.05 
S. Gallinarum biovar Gallinarum  1 MS: RO  2  0.05 
S. Goldcoast  2 MSs: ES, UK  2  0.05 
S. Llandoff  2 MSs: AT, BE  2  0.05 
S. Oranienburg  1 MS: AT  2  0.05 
S. Ouakam  1 MS: BE  2  0.05 
S. Szentes  1 MS: CZ  2  0.05 
S. Veneziana  1 MS: IT  2  0.05 
S. 1,3,19:-:-  1 MS: ES  1  0.02 
S. 13,23:i:-  1 MS: BE  1  0.02 
S. 4,12:-:-  1 MS: BE  1  0.02 
S. 4,12:-:1,2  1 MS: SK  1  0.02 
S. 4,12:d:-  1 MS: BE  1  0.02 
S. 6,7:d:-  1 MS: BE  1  0.02 
S. 6,7:z10:-  1 MS: UK  1  0.02 
S. 6,8:z10:-  1 MS: BE  1  0.02 
S. Agama  1 MS: UK  1  0.02 
S. Chester  1 MS: RO  1  0.02 
S. Djugu  1 MS: BE  1  0.02 
S. Durham  1 MS: UK  1  0.02 
S. Gallinarum  1 MS: AT  1  0.02 
S. Heidelberg  1 MS: IT  1  0.02 
S. Jerusalem  1 MS: BE  1  0.02 
S. Manhattan  1 MS: IT  1  0.02 
S. Meleagridis  1 MS: UK  1  0.02 
S. Mikawasima  1 MS: ES  1  0.02 
S. Muenster  1 MS: IT  1  0.02 
S. Orion var. 15  1 MS: UK  1  0.02 
S. Sandiego  1 MS: BE  1  0.02 
S. Schwarzengrund  1 MS: UK  1  0.02 
S. Soerenga  1 MS: ES  1  0.02 
S. Toulon  1 MS: IT  1  0.02 
S. Weltevreden  1 MS: IT  1  0.02 
S. Yoruba  1 MS: BE  1  0.02 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER5.  Frequency distribution of Salmonella serovars in turkeys, in 2012 
Serovars  Countries and total number of MSs reporting 
Turkeys 
N %  f 
S. Derby  5 MSs: CZ, IE, IT, ES, UK  172  25.15 
S. Stanley  3 MSs: AT, CZ, HU  78  11.40 
S. Kentucky  5 MSs: CZ, HU, PL, SK, ES  59  8.63 
S. Saintpaul  6 MSs: AT, CZ, DE, HU, IT, PL  51  7.46 
S. Newport  5 MSs: CZ, HU, IT, SK, UK  47  6.87 
S. Typhimurium, monophasic  4 MSs: DE, IT, ES, UK  28  4.09 
S. Infantis  3 MSs: AT, DE, HU  27  3.95 
S. Bredeney  2 MSs: HU, IT  25  3.65 
S. Kedougou  1 MS: UK  25  3.65 
S. Hadar  3 MSs: DE, IT, ES  23  3.36 
S. Kottbus  4 MSs: CZ, HU, IT, UK  20  2.92 
S. Indiana  2 MSs: ES, UK  17  2.49 
S. London  1 MS: ES  17  2.49 
S. Typhimurium  7 MSs: AT, BE, FI, DE, IT, ES, UK  17  2.49 
S. Blockley  1 MS: IT  11  1.61 
S. Mbandaka  1 MS: UK  10  1.46 
S. Bovismorbificans  3 MSs: AT, HU, UK  8  1.17 
S. Enteritidis  5 MSs: AT, CZ, DE, HU, SK  8  1.17 
S. Agona  4 MSs: AT, HU, ES, UK  7  1.02 
S. Senftenberg  3 MSs: HU, ES, UK  5  0.73 
S. Schwarzengrund  1 MS: IT  4  0.58 
S. Orion var. 15  1 MS: UK  3  0.44 
S. 6,7:z10:-  1 MS: UK  2  0.29 
S. Bardo  1 MS: UK  2  0.29 
S. Haifa  1 MS: IT  2  0.29 
S. Montevideo  2 MSs: AT, ES  2  0.29 
S. enterica subsp. enterica  2 MSs: DE, IT  2  0.29 
S. 3,15:-:-  1 MS: UK  1  0.15 
S. 4,12:-:-  1 MS: BE  1  0.15 
S. 4,12:b:-  1 MS: ES  1  0.15 
S. Agama  1 MS: UK  1  0.15 
S. Anatum  1 MS: IT  1  0.15 
S. Dabou  1 MS: ES  1  0.15 
S. Dembe  1 MS: ES  1  0.15 
S. Java  1 MS: DE  1  0.15 
S. Ohio  1 MS: UK  1  0.15 
S. Tennessee  1 MS: HU  1  0.15 
S. Wisbech  1 MS: ES  1  0.15 
S. Worthington  1 MS: AT  1  0.15 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER6.  Frequency distribution of Salmonella serovars in pigs, in 2012 
Serovars  Countries and total number of MSs reporting 
Pigs 
N %  f 
S. Typhimurium  11 MS: BE, DK, EE, FI, DE, HU, IE, LV, NL, ES, SE  515  35.49 
S. Typhimurium, monophasic  8 MSs: BE, DK, DE, IE, IT, NL, PL, ES  421  29.01 
S. Derby  8 MSs: BE, DK, EE, DE, HU, IT, NL, ES  280  19.30 
S. Infantis  5 MSs: BE, DK, EE, DE, HU  45  3.10 
S. Livingstone  3 MSs: BE, DK, IT  22  1.52 
S. Agona  2 MSs: BE, EE  21  1.45 
S. Rissen  3 MSs: BE, IT, ES  19  1.31 
S. enterica subsp. enterica  3 MSs: EE, DE, IT  13  0.90 
S. group O:4  1 MS: HU  12  0.83 
S. Choleraesuis  2 MSs: EE, IT  11  0.76 
S. London  3 MSs: DK, IT, ES  11  0.76 
S. Enteritidis  5 MSs: BE, DK, EE, DE, HU  10  0.69 
S. Mbandaka  2 MSs: BE, DK  10  0.69 
S. 4:i:-  1 MS: BE  8  0.55 
S. Worthington  1 MS: EE  6  0.41 
S. Anatum  1 MS: BE  5  0.34 
S. Bovismorbificans  1 MS: HU  3  0.21 
S. Brandenburg  2 MSs: BE, DK  3  0.21 
S. Bredeney  2 MSs: HU, ES  3  0.21 
S. Senftenberg  2 MSs: BE, IT  3  0.21 
S. Give  2 MSs: BE, DK  2  0.14 
S. Kapemba  1 MS: ES  2  0.14 
S. Kentucky  2 MSs: IE, ES  2  0.14 
S. Lexington  1 MS: EE  2  0.14 
S. Montevideo  1 MS: EE  2  0.14 
S. Paratyphi B  1 MS: BE  2  0.14 
S. 4,12:-:1,2  1 MS: DK  1  0.07 
S. 4,5,12:-:1,2  1 MS: DK  1  0.07 
S. 4,5:b  1 MS: ES  1  0.07 
S. 6,7:-:l,w  1 MS: DK  1  0.07 
S. Abony  1 MS: IT  1  0.07 
S. Brikama  1 MS: ES  1  0.07 
S. Coeln  1 MS: IT  1  0.07 
S. Gloucester  1 MS: BE  1  0.07 
S. Goldcoast  1 MS: DK  1  0.07 
S. Heidelberg  1 MS: DK  1  0.07 
S. Jerusalem  1 MS: BE  1  0.07 
S. Kedougou  1 MS: IT  1  0.07 
S. Minnesota  1 MS: BE  1  0.07 
S. Muenchen  1 MS: DK  1  0.07 
S. Panama  1 MS: IT  1  0.07 
S. Rideau  1 MS: BE  1  0.07 
S. Stanley  1 MS: DK  1  0.07 
S. enterica subsp. salamae  1 MS: IT  1  0.07 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table SER7.  Frequency distribution of Salmonella serovars in bovine animals, in 2012 
Serovars  Countries and total number  
of MSs reporting 
Cattle (bovine 
animals) 
N %  f 
S. Typhimurium  9 MSs: BE, EE, FI, DE, IE, IT, NL, ES, SE  166  55.33 
S. Dublin  7 MSs: BE, EE, DE, IE, LV, NL, SE  66  22.00 
S. Typhimurium, monophasic  5 MSs: DE, IE, IT, NL, ES  29  9.67 
S. Enteritidis  2 MSs: BE, EE  8  2.67 
S. Montevideo  2 MSs: BE, ES  5  1.67 
S. Java  1 MS: DE  4  1.33 
S. Rissen  1 MS: ES  3  1.00 
S. enterica subsp. enterica  2 MSs: EE, IT  3  1.00 
S. 9:-:-  1 MS: BE  2  0.67 
S. Chester  1 MS: EE  2  0.67 
S. Derby  1 MS: ES  2  0.67 
S. Livingstone  1 MS: BE  2  0.67 
S. London  1 MS: IT  2  0.67 
S. Agona  1 MS: SE  1  0.33 
S. Duesseldorf  1 MS: SE  1  0.33 
S. Hadar  1 MS: DE  1  0.33 
S. Lille  1 MS: ES  1  0.33 
S. Muenchen  1 MS: IT  1  0.33 
S. enterica subsp. diarizonae  1 MS: SE  1  0.33 
MS: Member State; N: number of isolates tested; % f: percentage frequency of isolates tested. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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APPENDIX 2.  Antimicrobial resistance in Salmonella - qualitative data 
2.1. Introduction 
In 2012, two MSs, Greece and Spain, reported on antimicrobial resistance in Salmonella from animals 
(Greece: Gallus gallus) and food (Greece, meat from broilers and meat from pig, and Spain, egg products) as 
quantitative disc diffusion data, which have been analysed as qualitative data and presented in this chapter. 
In food, both countries reported less than 10 isolates. These disc diffusion data have been analysed using 
the breakpoints for resistance specified by the reporting MS and in accordance with the method used 
(Appendix Tables QSA1–QSA3). 
In the case of data reported exclusively as qualitative data, when information on the thresholds used to 
interpret the resistance was also available, it has been possible to pool the data submitted by MSs and 
present them in this section. It should, however, be noted that countries may not have used the same 
threshold values or qualitative methods and so direct comparisons between the proportions of resistant 
isolates in MSs reporting only qualitative data should be interpreted with caution. For this reason, tables do 
not show the summary figure for the reporting MS group and the spatial distributions of the levels of 
resistance for Salmonella based on qualitative data are not shown here; this is in accordance with previous 
reports. Furthermore, for those countries that reported quantitative data on antimicrobial resistance as 
presented in Chapter 3, corresponding qualitative data have been excluded from the overview tables and 
analyses presented in this chapter.  
Resistance to the following antimicrobial agents are described in detail below: ampicillin, chloramphenicol, 
ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and tetracyclines. 
Appendix Table QSA1.  Overview of MSs reporting qualitative data on Salmonella spp. from animals 
and food in 2012 
Origin 
Qualitative data 
Total number of
MSs reporting  Countries 
Gallus gallus (fowl)  3 
MSs: CY, LU, SI 
Non-MS: IS 
Turkeys  3  MSs: CY, IE, SI 
Pigs  3 
MSs: AT, IE, LV 
Non-MS: IS 
Cattle (bovine animals)  3  MSs: AT, IE, LU 
Meat from broilers (Gallus 
gallus)  5 
MSs: AT, ES, LT, LU, SI 
Non-MS: IS 
Meat from other poultry 
species  5  MSs: AT, ES, LT, PL, SI  
Meat from pigs  4 
MSs: AT, ES, LT, LU 
Non-MS: IS 
Meat from bovine animals  3  MSs: AT, LU, ES 
Meat, mixed meat  2  MSs: ES, SI 
Fishery products  1  MS: ES 
Foodstuffs (unspecified)  1  MS: PT 
Note: For abbreviations of Member States (MS) and other reporting countries, see Appendix 7. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table QSA2.  Overview of MSs reporting qualitative data on Salmonella Typhimurium from 
animals and food in 2012 
Origin 
Qualitative data 
Total number of
MSs reporting  Countries 
Gallus gallus (fowl)  1  MS: CY 
Pigs  2  MSs: AT, IE 
Cattle (bovine animals)  3  MSs: AT, IE, LU 
Meat from pigs  1  MS: AT 
Meat, mixed meat  1  MS: SI 
Foodstuffs (unspecified)  1  MS: PT 
Note: For abbreviations of Member States (MS) and other reporting countries, see Appendix 7. 
Appendix  Table  QSA3.    Overview of MSs reporting qualitative data on Salmonella Enteritidis from 
animals and food in 2012 
Origin 
Qualitative data 
Total number of 
MSs reporting  Countries 
Gallus gallus (fowl)  3  MSs: CY, LU, SI 
Meat from broilers (Gallus gallus)  3  MSs: AT, LT, LU 
Meat from other poultry species  2  MSs: AT, LT 
Meat, mixed meat  1  MS: SI 
All foodstuffs  1  MS: PT 
Note: For abbreviations of Member States (MS) and other reporting countries, see Appendix 7. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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2.2. Antimicrobial resistance in Salmonella isolates from food (qualitative data) 
Meat from broilers (Gallus gallus), meat from pigs, meat from bovine animals 
Resistance levels among Salmonella spp. isolates 
Austria, Slovenia and Spain reported qualitative data on resistance among Salmonella spp. from meat from 
broilers in 2012. Austria and Spain, and the Netherlands and Spain, reported qualitative data on resistance 
among Salmonella spp. from meat from pigs and from meat from bovine animals, respectively. The results 
are presented in the table Appendix Tables QSA4. 
2.3. Antimicrobial resistance in Salmonella isolates from animals (qualitative data) 
2.3.1. Fowl  (Gallus gallus) 
2.3.1.1. Resistance levels among Salmonella 
Four MSs and one non-MS reported qualitative data for isolates of Salmonella from Gallus gallus. The 
results are presented in the table Appendix Tables QSA5. 
2.3.2. Pigs 
Resistance levels among Salmonella 
Austria and Iceland were the only countries to report qualitative data for isolates of Salmonella spp. from 
pigs. The results are presented in the table Appendix Tables QSA6. 
2.3.3.  Cattle (bovine animals) 
Resistance levels among Salmonella 
Austria was the only MS reported qualitative data for isolates of Salmonella spp. from cattle in 2012.The 
results are presented in the table Appendix Tables QSA6. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table QSA4.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and 
tetracyclines among Salmonella spp. isolates from meat from broilers, from pigs and from bovine animals in MSs reporting qualitative data in 2012 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Meat from broilers 
Austria  61  1.6  61  0  61  3.3  61  1.6  61  0  61  73.8  61  67.2  61  68.9 
Slovenia  15  6.7  –  –  15  0  15  100  15  0  15  100  15  100  15  100 
Spain  40  10.0  –  –  22  0  40  2.5  40  2.5  40  17.5  –  –  22  18.2 
Meat from pigs 
Austria  19  57.9  19  0  19  15.8  19  0  19  0  19  10.5  19  57.9  19  68.4 
Spain  67  43.3  18  5.6  51  25.5  50  0  67  0  67  10.4  37  70.3  51  86.3 
Meat from bovine animals 
Netherlands  18  33.3  18  5.6  18  0  18  11.1  18  0  18  11.1  18  61.1  18  44.4 
Spain  44  11.4  29  0  40  2.5  43  0  44  2.3  44  13.6  34  5.9  39  5.1 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
Appendix Table QSA5.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and 
tetracyclines among Salmonella spp. isolates from Gallus gallus in MSs reporting qualitative data in 2012 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Cyprus  27  37.0  –  –  27  3.7  27  40.7  27  29.6  27  37.0  27  33.3  27  40.7 
Greece  72  0  72  0  72  0  72  0  71  0  72  13.9  72  100  72  8.3 
Luxembourg  15  0  –  –  13  0  15  13.3  15  0  13  0  15  0  15  0 
Slovenia  63  12.7  –  –  63  1.6  63  77.8  63  0  63  77.8  63  77.8  63  77.8 
Iceland  10  0  –  –  10  0  10  0  –  –  –  –  10  0  –  – 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table QSA6.  Resistance (%) to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, sulfonamides and 
tetracyclines among Salmonella spp. isolates from pigs and cattle in countries reporting qualitative data in 2012 
Country 
Ampicillin  Cefotaxime  Chloramphenicol  Ciprofloxacin  Gentamicin  Nalidixic acid  Sulfonamides  Tetracyclines 
N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res  N  % Res 
Pigs 
Austria  40  12.5  40  0  40  0  40  0  40  0  40  2.5  40  20.0  40  22.5 
Iceland  11  45.5  –  –  11  0  11  0  –  –  –  –  –  –  –  – 
Cattle 
Austria  38  0  38  0  38  0  38  0  38  5.3  38  0  38  0  38  0 
MS: Member State; N: number of isolates tested; % Res: percentage of resistant isolates; –: no data reported. 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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2.4. Discussion 
Very few countries reported qualitative data for Salmonella in 2012. Furthermore, it is difficult to compare 
accurately the data collected using disc diffusion techniques with those deriving from dilution methods and 
collected quantitatively as MIC data. Therefore, as in previous years, a detailed analysis and interpretation of 
the results has not been undertaken. 
Greece used CLSI disc diffusion methods to test the Salmonella isolates recovered from Gallus gallus, and 
interpreted the results using CLSI breakpoints. The results will not be directly comparable to the results 
obtained by MSs performing broth microdilution MIC determinations and applying EUCAST ECOFFs to 
interpret those results and have therefore been presented separately. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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APPENDIX 3.  Frequency distribution of complete susceptibility and multiple resistance 
Appendix Table MDR1.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from meat from broilers (Gallus gallus) in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Czech Republic (N=47)  30  63.8 1  2.1 0 0 9  19.2 6  12.8 
Germany (N=94)  23 24.5  7  7.5  3  3.2  22 23.4  13 13.8 
Ireland (N=70)  51  72.9 3  4.3 0 0 8  11.4 1  1.4 
Romania (N=188)  13 6.9  4 2.1  8 4.3  45  23.9  53  28.2 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Czech Republic (N=47)  1  2.1 0 0 0 0 0 0 0 0 
Germany (N=94)  9  9.6  15  16.0 1  1.1 1  1.1 0 0 
Ireland (N=70)  6  8.6 1  1.4 0 0 0 0 0 0 
Romania (N=188)  42  22.3  19  10.1 3  1.6 0 0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table MDR2.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from meat from pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Czech Republic (N=33)  12  36.4 2  6.1 5  15.2 2  6.1 6  18.2 
Denmark (N=41)  12  29.3  3  7.3 2  4.9 9  22.0  14  34.2 
Estonia  (N=22)  19  86.4 0 0 0 0 2  9.1 1  4.6 
Germany (N=163)  62  38.0  15 9.2  7 4.3  9 5.5  44  27.0 
Ireland (N=69)  15  21.7 6  8.7 7  10.1 5  7.3  21  30.4 
Italy (N=85)  32 37.6  9 10.6  1  1.2  9 10.6  21 24.7 
Romania (N=125)  30 24.0  24 19.2  1  0.8  33 26.4  18 14.4 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Czech Republic (N=33)  5  15.2 1  3.0 0 0 0 0 0 0 
Denmark (N=41)  0 0 1  2.4 0 0 0 0 0 0 
Estonia (N=22)  0 0 0 0 0 0 0 0 0 0 
Germany (N=163)  17  10.4 9  5.5 0 0 0 0 0 0 
Ireland (N=69)  6  8.7 7  10.1 2  2.9 0 0 0 0 
Italy (N=85)  7  8.2 5  5.9 1  1.2 0 0 0 0 
Romania (N=125)  14  11.2 5  4.0 0 0 0 0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table MDR3.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from broilers in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Austria (N=113)  82  72.6 7  6.2 1  0.9  16  14.2 7  6.2 
Czech Republic (N=351)  271  77.2 11  3.1  2  0.6 35  10.0 24  6.8 
Denmark (N=24)  17  70.8 0 0 0 0 0 0 7  29.2 
Hungary (N=175)  13  7.4 19  10.9 15  8.6 90  51.4 35  20.0 
Ireland (N=38)  31  81.6 3  7.9 1  2.6 1  2.6 2  5.3 
Italy (N=105)  55  52.4  2 1.9  5 4.8  10 9.5  11  10.5 
Romania (N=781)  135 17.3  99 12.8  76  9.7 117  15.0 137  17.5 
Spain (N=29)  6  20.7  11  37.9 2  6.9 1  3.5 4  13.8 
United Kingdom (N=17)  5  29.4 4  23.5 6  35.3 2  11.8 0 0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=113)  0 0 0 0 0 0 0 0 0 0 
Czech Republic (N=351)  4  1.1 4  1.1 0 0 0 0 0 0 
Denmark (N=24)  0 0 0 0 0 0 0 0 0 0 
Hungary (N=175)  3  1.7 0 0 0 0 0 0 0 0 
Ireland (N=38)  0 0 0 0 0 0 0 0 0 0 
Italy (N=105)  5  4.8  13  12.4 2  1.9 2  1.9 0 0 
Romania (N=781)  100  12.8  79  10.1  26 3.3  7 0.9  8 1.0 
Spain (N=29)  4  13.8 1  3.5 0 0 0 0 0 0 
United Kingdom (N=17)  0 0 0 0 0 0 0 0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR4.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from laying hens in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Austria (N=63)  47  74.6 6  9.5 1  1.6 3  4.8 4  6.4 
Germany (N=51)  44  86.3 2  3.9 4  7.8 0 0 0 0 
Hungary (N=86)  59  68.6 7  8.1 4  4.7  11  12.8 1  1.2 
Italy (N=161)  111  68.9  24  14.9  3 1.9  10 6.2  8 5.0 
Romania (N=145)  72  49.7 14  9.7  4  2.8 16  11.0 25  17.2 
Spain (N=150)  119  79.3  21  14.0 2  1.3 1  0.7 2  1.3 
United Kingdom (N=11)  10  90.9 0 0 0 0 1  9.1 0 0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=63)  2  3.2 0 0 0 0 0 0 0 0 
Germany (N=51)  0 0 1  2.0 0 0 0 0 0 0 
Hungary (N=86)  1  1.2 3  3.5 0 0 0 0 0 0 
Italy (N=161)  2  1.2 3  1.9 0 0 0 0 0 0 
Romania (N=145)  10  6.9 4  2.8 0 0 0 0 0 0 
Spain (N=150)  4  2.7 0 0 0 0 1  0.7 0 0 
United Kingdom (N=11)  0 0 0 0 0 0 0 0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR5.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella Enteritidis from broilers in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB   Resistant to 2 AMB   Resistant to 3 AMB  Resistant to 4 AMB 
n  % n % n % n % n % 
Austria (N=21)  20  95.2 1  4.8 0 0 0 0 0 0 
Czech Republic (N=236)  231  97.9 4  1.7 1  0.4 0 0 0 0 
Romania (N=10)  4  40.0 0 0 1  10.0 4  40.0 0 0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB   Resistant to 8 AMB   Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=21)  0 0 0 0 0 0 0 0 0 0 
Czech Republic (N=236)  0 0 0 0 0 0 0 0 0 0 
Romania (N=10)  0 0 0 0 0 0 1  10.0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR6.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella Enteritidis from laying hens in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB   Resistant to 2 AMB   Resistant to 3 AMB  Resistant to 4 AMB 
n  % n % n % n % n % 
Austria (N=15)  15  100 0 0 0 0 0 0 0 0 
Germany (N=21)  21  100 0 0 0 0 0 0 0 0 
Hungary (N=25)  23  92.0 1 4 1  4.0 0 0 0 0 
Italy (N=28)  22  78.6 6  21.4 0 0 0 0 0 0 
Romania (N=66)  49  74.2 5  7.6 1  1.5 5  7.6 5  7.6 
Spain (N=43)  32  74.4 9  20.9 1  2.3 0 0 0 0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB   Resistant to 8 AMB   Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=15)  0 0 0 0 0 0 0 0 0 0 
Germany (N=21)  0 0 0 0 0 0 0 0 0 0 
Hungary (N=25)  0 0 0 0 0 0 0 0 0 0 
Italy (N=28)  0 0 0 0 0 0 0 0 0 0 
Romania (N=66)  1  1.5 0 0 0 0 0 0 0 0 
Spain (N=43)  1  2.3 0 0 0 0 0 0 0 0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR7.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from turkeys in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n %  n % n % 
Austria (N=38)  7 18.4 21 55.3  0  0  1 2.6  1  2.6 
Czech Republic (N=27)  2 7.4  10  37.0 4  14.8  2  7.4 1 3.7 
Germany (N=87)  20 23.0 10 11.5  6  6.9  5 5.8 31 35.6 
Hungary (N=174)  11 6.3  53  30.5  14 8.1 52  29.9 6 3.5 
Ireland (N=14)  12  85.7 0  0 0  0  2  14.3 0  0 
Italy (N=48)  0  0 4 8.3 5  10.4  6  12.5  19  39.6 
Spain (N=169)  3 1.8 2 1.2 3 1.8  5  3.0  23  13.6 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n  % n % n  % 
Austria (N=38)  8  21.1  0  0  0 0  0 0  0  0 
Czech Republic (N=27)  2  7.4  6  22.2  0 0  0 0  0  0 
Germany (N=87)  15  17.2  0  0  0 0  0 0  0  0 
Hungary (N=174)  17  9.8  21  12.1  0 0  0 0  0  0 
Ireland (N=14)  0 0  0  0 0  0  0  0  0  0 
Italy (N=48)  9  18.8  2  4.2  0  0 3 6.3 0 0 
Spain (N=169)  42  24.9  76  45.0 14 8.3 0  0 1  0.6 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR8.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from fattening pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Denmark (N=374)  179 47.9 53 14.2 15  4.0 31  8.3 74 19.8 
Estonia (N=14)  9  64.3 0  0 0  0 4  28.6 1 7.1 
Germany (N=627)  89 14.2 28  4.5 28  4.5 24  3.8  220 35.1 
Hungary (N=38)  9 23.7  1  2.6  1  2.6 11 29.0 11 29.0 
Ireland (N=24)  2 8.3 6  25.0 1 4.2 3  12.5 4  16.7 
Italy (N=25)  10  40.0 2 8.0 1 4.0 4  16.0 4  16.0 
Spain (N=48)  3 6.2  13  27.1 4 8.3 1 2.1  11  22.9 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Denmark (N=374)  18 4.8 4 1.1 0  0 0  0 0  0 
Estonia (N=14)  0  0 0  0 0  0 0  0 0  0 
Germany (N=627)  162  25.8  52 8.3  23 3.7 0  0 1 0.2 
Hungary (N=38)  4  10.5 1 2.6 0  0 0  0 0  0 
Ireland (N=24)  3  12.5 1 4.2 4  16.7 0  0 0  0 
Italy (N=25)  1 4.0 2 8.0 0  0 1 4.0 0  0 
Spain (N=48)  9  18.8 5  10.4 1 2.1 1 2.1 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR9.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella Typhimurium from fattening pigs in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Denmark (N=63)  31  49.2 1 1.6 4 6.4 9  14.3 8  12.7 
Germany (N=273)  24 8.8 9 3.3  19 7.0 6 2.2  47  17.2 
Ireland (N=15)  0  0 4  26.7 1 6.7 1 6.7 1 6.7 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Denmark (N=63)  9  14.3 1 1.6 0  0 0  0 0  0 
Germany (N=273)  126 46.2 32 11.7 10  3.7  0  0  0  0 
Ireland (N=15)  3  20.0 1 6.7 4  26.7 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR10.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella spp. from cattle in MSs and non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Belgium (N=42)  8  19.0 4 9.5 9  21.4 7  16.7 5  11.9 
Finland (N=19)  15  78.9 0  0 2  10.5 0  0 1 5.3 
Germany (N=68)  45  66.2 8  11.8 1 1.5 3 4.4 8  11.8 
Ireland (N=36)  12  33.3 2 5.6 1 2.8 0  0 5  13.9 
Italy (N=14)  8  57.1 0  0 0  0 0  0 2  14.3 
Sweden (N=17)  14  82.4 0  0 0  0 1 5.9 0  0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Belgium (N=42)  5  11.9 2 4.8 2 4.8 0  0 0  0 
Finland (N=19)  1 5.3 0  0 0  0 0  0 0  0 
Germany (N=68)  2 2.9 0  0 1 1.5 0  0 0  0 
Ireland (N=36)  15  41.7 1 2.8 0  0 0  0 0  0 
Italy (N=14)  3  21.4 1 7.1 0  0 0  0 0  0 
Sweden (N=17)  2  11.8 0  0 0  0 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR11.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to nine antimicrobials, in 
Salmonella Typhimurium from cattle in MSs reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n % n % n % n % n % 
Belgium (N=25)  1 4.0 4  16.0 8  32.0 4  16.0 2 8.0 
Finland (N=16)  12  75.0 0  0 2  12.5 0  0 1 6.3 
Germany (N=35)  24  68.6 7  20.0 1 2.9 0  0 0  0 
Ireland (N=24)  7  29.2 0  0 1 4.2 0  0 0  0 
Sweden (N=12)  9  75.0 0  0 0  0 1 8.3 0  0 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Belgium (N=25)  4  16.0 1 4.0 1 4.0 0  0 0  0 
Finland (N=16)  1 6.3 0  0 0  0 0  0 0  0 
Germany (N=35)  2 5.7 0  0 1 2.9 0  0 0  0 
Ireland (N=24)  15  62.5 1 4.2 0  0 0  0 0  0 
Sweden (N=12)  2  16.7 0  0 0  0 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR13.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to five antimicrobials, in 
Campylobacter jejuni from broilers in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  % n % n % n % n % n % 
Austria (N=108)  22  20.4  58 53.7  24 22.2 4  3.7 0  0 0  0 
Denmark (N=41)  32  78.0 6 14.6 3  7.3 0  0 0  0 0  0 
Hungary (N=46)  4  8.7  24 52.2  18 39.1 0  0 0  0 0  0 
Spain (N=32)  1  3.1 2  6.3  26 81.3 2  6.3 0  0 1  3.1 
Sweden (N=100)  80  80.0  20 20.0 0  0 0  0 0  0 0  0 
Switzerland (N=171)  98  57.3  51 29.8  21 12.3 1  0.6 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
Appendix Table MDR14.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to five antimicrobials, in 
Campylobacter coli from broilers in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  % n % n % n % n % n % 
Austria (N=33)  6  18.2  16 48.5  10 30.3 1  3.0 0  0 0  0 
Hungary (N=63)  9  14.3  23 36.5  28 44.4 3  4.8 0  0 0  0 
Spain (N=54)  1  1.9 0  0  23 42.6  18 33.3 8 14.8 4  7.4 
Switzerland (N=14)  4  28.6 1  7.1 6 42.9 2 14.3 1  7.1 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR15.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to five antimicrobials, in 
Campylobacter coli from fattening pigs in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  % n % n % n % n % n % 
Denmark (N=103)  34  33.0  50 48.5  15 14.6 4  3.9 0  0 0  0 
Hungary (N=53)  0  0 9 17.0  18 34.0  21 39.6 4  7.6 1  1.9 
Spain (N=73)  0  0 0  0 2  2.7  19 26.0  44 60.3 8 11.0 
Switzerland (N=144)  21  14.6  55 38.2  40 27.8  26 18.1 2  1.4 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
Appendix Table MDR16.  Frequency  distribution  of  completely  susceptible isolates and resistant isolates to from one to five antimicrobials, in 
Campylobacter jejuni from cattle in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB  Resistant to 5 AMB 
n  % n % n % n % n % n % 
Denmark (N=89)  75  84.3  14 15.7 0  0 0  0 0  0 0  0 
Germany (N=73)  12  16.4  29 39.7  23 31.5 8 11.0 1  1.4 0  0 
Spain (N=68)  17  25.0  18 26.5  29 42.7 4  5.9 0  0 0  0 
Switzerland (N=38)  18  47.4 9 23.7 9 23.7 1  2.6 1  2.6 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR17.  Frequency distribution of completely susceptible isolates and resistant isolates to from one to nine antimicrobials, in E. coli 
from broilers in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  % n % n % n % n % 
Austria (N=130)  22  16.9 30 23.1 22 16.9 13 10.0 22 16.9 
Denmark (N=115)  65  56.5  30  26.1 5 4.4 9 7.8 5 4.4 
Hungary (N=104)  14  13.5 21 20.2 20 19.2 13 12.5 17 16.4 
Switzerland (N=185)  49  26.5 58 31.4 32 17.3 23 12.4  8  4.3 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=130)  7 5.4  12 9.2 2 1.5 0  0 0  0 
Denmark (N=115)  1  0.9  0 0  0 0  0 0  0 0 
Hungary (N=104)  8 7.7 8 7.7 2 1.9 1 1.0 0  0 
Switzerland (N=185)  8 4.3 5 2.7 2 1.1 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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Appendix Table MDR18.  Frequency distribution of completely susceptible isolates and resistant isolates to from one to nine antimicrobials, in E. coli 
from fattening pigs in MSs and one non-MS reporting isolate-based data, 2012 
Country 
Susceptible to all  Resistant to 1 AMB  Resistant to 2 AMB  Resistant to 3 AMB  Resistant to 4 AMB 
n  % n % n % n % n % 
Austria (N=140)  53 37.9 21 15.0 32 22.9 18 12.9  6  4.3 
Denmark (N=152)  63 41.5 25 16.5 15  9.9 14  9.2 17 11.2 
Hungary (N=68)  16 23.5 11 16.2  7 10.3 12 17.7 10 14.7 
Switzerland (N=185)  80 43.2 19 10.3 22 11.9 28 15.1 21 11.4 
 
Country 
Resistant to 5 AMB  Resistant to 6 AMB  Resistant to 7 AMB  Resistant to 8 AMB  Resistant to 9 AMB 
n % n % n % n % n % 
Austria (N=140)  6 4.3 4 2.9 0  0 0  0 0  0 
Denmark (N=152)  16  10.5 2 1.3 0  0 0  0 0  0 
Hungary (N=68)  7  10.3 4 5.9 1 1.5 0  0 0  0 
Switzerland (N=185)  13 7.0 2 1.1 0  0 0  0 0  0 
N: total number of isolates tested for susceptibility against the whole common set of antimicrobial substances. 
n: number of resistant isolates per category of susceptibility or multiple resistance. 
%: percentage of resistant isolates per category of susceptibility or multiple resistance. 
AMB: antimicrobial substance(s). 
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APPENDIX 4.  Multi-resistance patterns 
Appendix  Table  MDRP1.    Multi-resistance patterns of interest in Salmonella spp. from meat from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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         R        R  R     65  25.3  16.3 8  14 0  43 
         R        R  R  R  43  16.7  10.8 0 2 0  41 
         R     R  R  R  R  26  10.1  6.5 0 0 0  26 
         R     R  R  R     18  7.0  4.5 6 2 0  10 
R     R  R        R  R  R  16  6.2  4.0 0  14 0 2 
R  R     R        R  R     10  3.9  2.5 0 8 2 0 
R        R  R  R  R  R     8  3.1  2.0 0 0 1 7 
         R     R        R  7  2.7  1.8 0 5 2 0 
R        R     R  R  R     7  2.7  1.8 1 0 0 6 
R        R        R     R  6  2.3  1.5 0 6 0 0 
R                 R     R  5  1.9  1.3 0 1 2 2 
R     R           R        5  1.9  1.3 0 1 4 0 
      R  R     R  R  R     5  1.9  1.3 0 0 0 5 
R        R     R  R  R  R  5  1.9  1.3 0 0 0 5 
      R  R     R  R  R  R  4  1.6  1.0 0 0 0 4 
      R  R        R  R  R  3  1.2  0.8 0 0 0 3 
R  R              R  R     3  1.2  0.8 0 3 0 0 
R     R  R     R  R  R  R  2  0.8  0.5 0 1 0 1 
         R  R     R  R  R  2  0.8  0.5 0 0 0 2 
R        R        R  R  R  2  0.8  0.5 0 0 0 2 
R        R  R     R     R  2  0.8  0.5 0 0 2 0 
R  R  R  R        R  R  R  2  0.8  0.5 0 0 0 2 
         R  R  R  R  R     1  0.4  0.3 0 1 0 0 
R  R    R  R  R     1  0.4  0.3 0 0 1 0 
R              R  R  R     1  0.4  0.3 0 0 0 1 
Table continued overleaf. 
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Appendix Table MDRP1 (continued). Multi-resistance patterns of interest in Salmonella spp. from 
meat from broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=399) 
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      R  R           R  R  1  0.4  0.3 0 0 0 1 
R                 R  R     1  0.4  0.3 1 0 0 0 
R                 R  R  R  1  0.4  0.3 0 0 1 0 
R        R     R  R     R  1  0.4  0.3 0 0 1 0 
R        R  R  R  R     R  1  0.4  0.3 0 1 0 0 
R     R  R  R     R  R     1  0.4  0.3 0 0 0 1 
R     R  R  R  R  R  R  R  1  0.4  0.3 0 1 0 0 
R  R     R                 1  0.4  0.3 0 1 0 0 
Total  257  100  64.4  16  61  16  164 
MS: Member State;  Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP2.  Multi-resistance patterns of interest in Salmonella spp. from meat from pigs 
in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=538) 
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group % n  n n n n n n 
R          R  R  R    106  38.7  19.7 5  14  0 37 19 19 12 
          R  R  R    38  13.9  7.1 1  2  2 3 5 8  17 
R          R  R  R  R  18  6.6  3.3 2  0  0 7 2 4 3 
R    R      R  R  R    18  6.6  3.3 3  0  0 5 2 2 6 
R    R      R  R  R  R  16  5.8  3.0 0  1  0 4 5 5 1 
R          R  R      12  4.4  2.2 1  7  0 3 0 0 1 
R    R      R  R      6  2.2  1.1 0  0  1 5 0 0 0 
R    R  R    R  R  R    6  2.2  1.1 1  0  0 5 0 0 0 
      R      R  R    5  1.8  0.9 0  0  0 0 0 0 5 
R            R    R  5  1.8  0.9 0  0  0 0 0 0 5 
R    R    R  R        5  1.8  0.9 0  0  0 0 0 0 5 
    R      R  R  R  R  3  1.1  0.6 0  0  0 1 2 0 0 
R      R    R  R  R    3  1.1  0.6 0  0  0 2 0 0 1 
R    R  R      R  R  R  3  1.1  0.6 0  0  0 0 0 0 3 
      R    R  R  R    2  0.7  0.4 1  0  0 0 0 0 1 
R          R    R    2  0.7  0.4 0  0  0 1 0 0 1 
R        R  R  R  R    2  0.7  0.4 0  0  0 1 0 0 1 
R    R  R    R  R  R  R  2  0.7  0.4 0  0  0 0 1 1 0 
R            R  R  R  2  0.7  0.4 0  0  0 0 0 2 0 
R        R  R  R  R  R  2  0.7  0.4 0  0  0 0 2 0 0 
R    R          R    2  0.7  0.4 0  0  0 0 0 0 2 
R    R        R  R  R  2  0.7  0.4 0  0  0 0 0 0 2 
            R  R  R  1  0.4  0.2 0  0  0 1 0 0 0 
          R  R    R  1  0.4  0.2 0  0  0 0 0 1 0 
          R  R  R  R  1  0.4  0.2 0  0  0 0 1 0 0 
    R    R  R  R  R    1  0.4  0.2 0  0  0 0 0 1 0 
Table continued overleaf. 
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Appendix Table MDRP2 (continued). Multi-resistance patterns of interest in Salmonella spp. from 
meat from pigs in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=538) 
C
z
e
c
h
 
R
e
p
u
b
l
i
c
 
(
N
=
3
3
)
 
D
e
n
m
a
r
k
 
(
N
=
4
1
)
 
E
s
t
o
n
i
a
 
(
N
=
2
2
)
 
G
e
r
m
a
n
y
 
(
N
=
1
6
3
)
 
I
r
e
l
a
n
d
 
(
N
=
6
9
)
 
I
t
a
l
y
 
(
N
=
8
5
)
 
R
o
m
a
n
i
a
 
(
N
=
1
2
5
)
 
A
m
p
 
C
t
x
 
C
h
l
 
C
i
p
 
G
e
n
 
S
t
r
 
S
u
 
T
e
t
 
T
m
p
 
n %  MS 
group % n  n n n n n n 
R              R  R  1  0.4  0.2 0  0  0 0 0 0 1 
R            R  R    1  0.4  0.2 0  0  0 0 0 0 1 
R          R  R    R  1  0.4  0.2 0  0  0 1 0 0 0 
R    R        R      1  0.4  0.2 0  0  0 1 0 0 0 
R    R        R    R  1  0.4  0.2 0  0  0 0 1 0 0 
R    R        R  R    1  0.4  0.2 0  0  0 1 0 0 0 
R    R    R  R  R  R  R  1  0.4  0.2 0  0  0 0 1 0 0 
R  R          R  R  R  1  0.4  0.2 0  0  0 0 0 0 1 
R  R  R      R  R      1  0.4  0.2 0  0  0 1 0 0 0 
R  R  R  R      R  R    1  0.4  0.2 0  0  0 0 0 0 1 
Total  274  100  50.9  14  24  3  79  41  43  70 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP3.  Multi-resistance patterns of interest in Salmonella spp. from broilers in MSs 
reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,633) 
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group % n  n  n n n n n n  n 
      R      R  R    200  26.4  12.2  16 35  0  86 0 0  63 0  0 
      R    R  R  R    83  11.0  5.1  5 19  0  28 0 0  31 0  0 
      R      R  R  R  47  6.2  2.9  0  0  0 0 0 2  45 0  0 
R      R  R  R  R  R    47  6.2  2.9  0  4  0 0 0 0  43 0  0 
R    R  R      R      30  4.0  1.8  0  0  0 0 0 0  30 0  0 
R      R  R    R  R    28  3.7  1.7  0  1  0 1 0 0  26 0  0 
      R    R  R  R  R  26  3.4  1.6  0  0  0 0 0 0  26 0  0 
R      R      R  R    24  3.2  1.5  0  5  0 5 0 2  12 0  0 
R      R      R  R  R  18  2.4  1.1  0  0  0 0 0 1  16 1  0 
R      R      R      16  2.1  1.0  0  0  0 0 0 0  16 0  0 
R      R    R  R  R    15  2.0  0.9  0  3  0 2 0 0  10 0  0 
R      R    R    R    12  1.6  0.7  2  0  0 0 0 5 5 0  0 
R  R    R      R  R  R  11  1.5  0.7  0  0  0 0 0  10 1 0  0 
      R    R    R    10  1.3  0.6  0  0  0 1 0 2 6 1  0 
R          R  R  R    10  1.3  0.6  0  0  6 0 0 1 1 2  0 
   R  R    R  R  R  R  9  1.2  0.6  0  0  0 0 0 0 9 0  0 
R          R  R      8  1.1  0.5  0  0  0 0 0 0 8 0  0 
R      R    R  R  R  R  8  1.1  0.5  0  0  0 0 0 2 6 0  0 
R  R  R  R  R  R  R  R  R  8  1.1  0.5  0  0  0 0 0 0 8 0  0 
R      R        R    7  0.9  0.4  0  0  0 1 0 2 4 0  0 
R    R  R  R  R  R  R  R  6  0.8  0.4  0  0  0 0 0 2 4 0  0 
R            R  R  R  5  0.7  0.3  0  0  1 0 2 1 1 0  0 
R      R    R        5  0.7  0.3  0  0  0 0 0 1 4 0  0 
R      R  R  R  R  R  R  5  0.7  0.3  0  0  0 0 0 1 4 0  0 
R    R  R      R  R    5  0.7  0.3  0  0  0 0 0 0 5 0  0 
R    R  R    R  R  R  R  5  0.7  0.3  0  0  0 0 0 0 5 0  0 
Table continued overleaf.   
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Appendix Table MDRP3 (continued).  Multi-resistance patterns of interest in Salmonella spp. from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,633) 
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n %  MS 
group % n  n  n n n n n n  n 
R  R    R      R  R    5  0.7  0.3  0  0  0 0 0 0 5 0  0 
R  R    R  R  R  R  R    5  0.7  0.3  0  0  0 0 0 0 5 0  0 
R  R  R  R    R  R    R  5  0.7  0.3  0  0  0 0 0 0 5 0  0 
        R  R  R      4  0.5  0.2  0  0  0 0 0 0 3 0  1 
R      R  R    R      4  0.5  0.2  0  0  0 0 0 0 4 0  0 
R  R  R  R  R    R      4  0.5  0.2  0  0  0 0 0 0 4 0  0 
R      R  R  R  R      3  0.4  0.2  0  0  0 0 0 0 1 2  0 
R  R    R            3  0.4  0.2  0  0  0 0 0 1 2 0  0 
R      R          R  3  0.4  0.2  0  0  0 0 0 0 3 0  0 
R      R  R  R        3  0.4  0.2  0  0  0 0 0 0 3 0  0 
      R  R  R  R  R    2  0.3  0.1  0  0  0 0 0 1 1 0  0 
      R  R    R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
      R  R  R  R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
    R  R      R  R    2  0.3  0.1  0  0  0 2 0 0 0 0  0 
    R  R      R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R            R    R  2  0.3  0.1  0  0  0 0 0 2 0 0  0 
R      R  R    R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R    R      R  R  R    2  0.3  0.1  0  0  0 0 0 2 0 0  0 
R    R  R            2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R    R  R      R    R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R    R  R      R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R    R  R    R  R  R    2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R    R  R  R    R  R    2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R  R  R  R    R  R  R    2  0.3  0.1  0  0  0 0 0 0 2 0  0 
R  R  R  R    R  R  R  R  2  0.3  0.1  0  0  0 0 0 0 2 0  0 
            R  R  R  1  0.1  0.1  0  0  0 0 1 0 0 0  0 
          R  R    R  1  0.1  0.1  0  0  0 0 0 0 0 0  1 
          R  R  R    1  0.1  0.1  0  0  0 0 0 1 0 0  0 
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Appendix Table MDRP3 (continued).  Multi-resistance patterns of interest in Salmonella spp. from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,633) 
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n %  MS 
group % n  n  n n n n n n  n 
         R           R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
         R     R  R        1  0.1  0.1  0  0  0 1 0 0 0 0  0 
         R  R        R    1  0.1  0.1  0  0  0 1 0 0 0 0  0 
         R  R     R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
         R  R     R  R    1  0.1  0.1  0  0  0 0 0 0 0 1  0 
         R  R  R  R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
      R           R  R    1  0.1  0.1  0  0  0 0 0 1 0 0  0 
      R  R     R  R     R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
      R  R  R  R  R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R              R     R    1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R              R     R R  1  0.1  0.1  0  0  0 0 0 0 0 1  0 
R           R  R           1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R           R  R     R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R           R  R  R  R    1  0.1  0.1  0  0  0 0 0 1 0 0  0 
R        R           R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R        R  R  R     R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R        R  R  R  R     R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R     R           R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R     R  R  R        R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R     R  R  R     R  R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R     R  R  R  R     R    1  0.1  0.1  0  0  0 0 0 0 0 1  0 
Table continued overleaf. 
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Appendix Table MDRP3 (continued).  Multi-resistance patterns of interest in Salmonella spp. from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,633) 
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group % n  n  n n n n n n  n 
R     R  R  R  R  R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R     R  R  R  R  R  R    1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R                 R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R              R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R           R        R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R        R  R  R  R    1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R     R        R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R     R     R     R    1  0.1  0.1  0  0  0 0 0 0 0 1  0 
R  R     R     R  R  R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R     R  R     R  R    1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R     R  R     R  R R  1  0.1  0.1  0  0  0 0 0 1 0 0  0 
R  R     R  R  R  R        1  0.1  0.1  0  0  0 0 0 1 0 0  0 
R  R     R  R  R  R     R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R  R  R        R        1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R  R  R        R  R R  1  0.1  0.1  0  0  0 0 0 0 1 0  0 
R  R  R  R  R  R  R  R    1  0.1  0.1  0  0  0 0 0 0 1 0  0 
Total  757  100  46.4  23  67  7  128  3  43  474  10  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP4.  Multi-resistance patterns of interest in Salmonella spp. from laying hens in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=667) 
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group %  n n n n n n  n 
         R        R  R    20  17.7  3.0  3 0 8 0 9 0 0 
R        R           R    11  9.7  1.6  0 0 3 6 2 0 0 
         R        R  R R  11  9.7  1.6  3 0 0 0 8 0 0 
R        R     R     R    8  7.1  1.2  0 0 0 0 8 0 0 
R              R  R  R    7  6.1  1.0  0 0 0 4 0 2 0 
R        R     R  R  R    5  4.4  0.8  0 0 0 2 2 1 0 
         R     R  R  R    5  4.4  0.8  0 0 1 0 4 0 0 
R        R  R     R  R    5  4.4  0.8  0 0 0 0 5 0 0 
R        R  R  R  R  R    4  3.5  0.6  0 0 2 0 2 0 0 
R        R        R  R    4  3.5  0.6  0 0 0 0 4 0 0 
R     R        R  R  R    3  2.6  0.4  2 0 1 0 0 0 0 
         R     R     R    3  2.6  0.4  0 0 0 0 3 0 0 
R     R           R  R    3  2.6  0.4  0 0 0 3 0 0 0 
R     R  R        R  R    3  2.6  0.4  0 0 0 0 3 0 0 
               R  R  R    2  1.8  0.3  0 0 0 1 0 0 1 
R        R     R  R  R R  2  1.8  0.3  0 0 1 1 0 0 0 
R        R        R        2  1.8  0.3  0 0 0 0 2 0 0 
R     R  R        R  R R  2  1.8  0.3  0 0 0 2 0 0 0 
R  R     R                 2  1.8  0.3  0 0 0 2 0 0 0 
                  R  R R  1  0.9  0.2  0 0 0 0 0 1 0 
            R  R  R  R    1  0.9  0.2  1 0 0 0 0 0 0 
         R  R     R  R    1  0.9  0.2  0 0 0 0 1 0 0 
         R  R  R  R  R    1  0.9  0.2  0 0 0 0 0 1 0 
R                 R     R  1  0.9  0.2  0 0 0 1 0 0 0 
R              R  R  R R  1  0.9  0.2  0 0 0 0 0 1 0 
R        R        R     R  1  0.9  0.2  0 0 0 1 0 0 0 
R        R        R  R R  1  0.9  0.2  0 0 0 0 0 1 0 
R        R  R  R     R R  1  0.9  0.2  0 0 0 0 1 0 0 
R     R        R  R  R R  1  0.9  0.2  0 1 0 0 0 0 0 
R     R  R     R  R  R    1  0.9  0.2  0 0 0 0 1 0 0 
R     R  R  R  R  R  R R  5  4.4  0.8  0 0 0 0 0 1 0 
Total  113  100  16.9  9  1  16  23  55  8  1 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP5.  Multi-resistance patterns of interest in Salmonella spp. from turkeys in MSs 
reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=557) 
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group %  n  n  n n n n n 
R     R  R        R  R  R  69  18.6  12.4  0  0 0 0 0 0  69 
R        R        R  R  R  41  11.1  7.4  0  0 2 0 0 0  39 
R        R           R     39  10.5  7.0  0  2 0  37 0 0 0 
R        R  R  R  R  R     30  8.1  5.4  0  6 0  21 0 1 2 
R              R  R  R     20  5.4  3.6  0  0  17 0 0 2 1 
         R        R  R     19  5.1  3.4  1  0 3  15 0 0 0 
R        R     R     R     19  5.1  3.4  0  1 0 0 0 1  17 
R        R  R     R  R     18  4.9  3.2  0  2 1  15 0 0 0 
R                 R  R  R  15  4.1  2.7  0  0 2 0 0  11 2 
R        R  R  R  R        13  3.5  2.3  3  0  10 0 0 0 0 
R     R  R     R  R  R  R  13  3.5  2.3  0  0 0 0 0 0  13 
R           R  R     R     8  2.2  1.4  0  0 5 0 0 3 0 
         R     R     R     6  1.6  1.1  0  0 0 0 0 5 1 
         R     R  R  R     5  1.4  0.9  1  0 1 3 0 0 0 
R     R           R        5  1.4  0.9  0  0 1 0 0 0 4 
R        R     R  R     R  5  1.4  0.9  5  0 0 0 0 0 0 
               R  R  R     3  0.8  0.5  0  0 0 0 2 1 0 
R           R  R  R  R     3  0.8  0.5  0  0 0 0 0 3 0 
R        R  R     R        3  0.8  0.5  0  0 3 0 0 0 0 
R     R  R     R  R  R     3  0.8  0.5  0  0 0 0 0 0 3 
R        R     R  R  R     2  0.5  0.4  0  0 1 1 0 0 0 
      R        R  R  R  R  2  0.5  0.4  0  0 0 0 0 2 0 
R              R  R     R  2  0.5  0.4  0  0 2 0 0 0 0 
R        R        R  R     2  0.5  0.4  0  0 0 2 0 0 0 
R        R  R  R     R     2  0.5  0.4  0  0 0 0 0 2 0 
R     R        R  R        2  0.5  0.4  0  0 0 0 0 0 2 
R        R     R  R        2  0.5  0.4  0  0 1 0 0 1 0 
Table continued overleaf. 
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Appendix Table MDRP5 (continued).  Multi-resistance patterns of interest in Salmonella spp. from 
turkeys in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=557) 
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R     R  R  R  R  R  R  R  2  0.5  0.4  0  0 0 0 0 2 0 
                  R  R  R  1  0.3  0.2  0  0 1 0 0 0 0 
         R     R     R  R  1  0.3  0.2  0  0 0 0 0 1 0 
         R     R  R  R  R  1  0.3  0.2  0  0 0 1 0 0 0 
R              R  R  R  R  1  0.3  0.2  0  0 0 0 0 1 0 
R        R        R     R  1  0.3  0.2  0  0 0 1 0 0 0 
R        R     R     R  R  1  0.3  0.2  0  0 0 0 0 0 1 
R        R     R  R  R  R  1  0.3  0.2  0  0 0 0 0 1 0 
R        R  R     R  R  R  1  0.3  0.2  0  0 0 0 0 0 1 
R     R           R  R     1  0.3  0.2  0  0 0 0 0 0 1 
R     R           R  R  R  1  0.3  0.2  0  0 0 0 0 0 1 
R     R        R  R  R     1  0.3  0.2  0  0 1 0 0 0 0 
R     R        R  R  R  R  1  0.3  0.2  0  0 0 0 0 0 1 
R     R  R        R  R     1  0.3  0.2  0  0 0 0 0 0 1 
R  R     R  R     R  R  R  1  0.3  0.2  0  0 0 0 0 0 1 
R  R  R           R  R     1  0.3  0.2  0  0 0 0 0 1 0 
R  R  R  R     R  R  R  R  1  0.3  0.2  0  0 0 0 0 1 0 
R  R  R  R  R  R  R  R  R  1  0.3  0.2  0  0 0 0 0 0 1 
Total  370  100  66.4  10  11  51  96  2  39  161 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP6.  Multi-resistance  patterns  in  Salmonella spp. from fattening pigs in MSs 
reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,150) 
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R              R  R  R     280  40.6  24.3 60  0  198 8 4 2 8 
R              R  R  R  R  90  13.0  7.8 4  0  81 1 0 1 3 
R     R        R  R  R     75  10.9  6.5 9  0  60 3 3 0 0 
R     R        R  R  R  R  29  4.2  2.5 2  0  25 0 1 0 1 
R              R  R        24  3.5  2.1 13  0 7 4 0 0 0 
R     R  R     R  R  R  R  17  2.5  1.5 3  1  10 1 0 1 1 
R                 R  R  R  17  2.5  1.5 0  0  14 0 3 0 0 
               R  R  R     12  1.7  1.0 3  1 3 0 2 3 0 
R        R     R  R  R     11  1.6  1.0 7  0 3 1 0 0 0 
R     R     R  R  R  R     11  1.6  1.0 1  0 9 0 0 1 0 
R     R     R  R  R  R  R  11  1.6  1.0 0  0  11 0 0 0 0 
R        R     R  R  R  R  10  1.4  0.9 0  0 9 0 1 0 0 
         R        R  R     8  1.2  0.7 0  0 5 0 0 1 2 
R     R  R     R  R  R     8  1.2  0.7 0  0 2 6 0 0 0 
R     R        R  R     R  7  1.0  0.6 4  0 2 0 0 0 1 
R              R  R     R  7  1.0  0.6 0  0 6 1 0 0 0 
R           R  R  R  R     6  0.9  0.5 3  0 2 0 0 1 0 
                  R  R  R  6  0.9  0.5 1  0 5 0 0 0 0 
               R  R     R  4  0.6  0.3 2  0 2 0 0 0 0 
               R  R  R  R  4  0.6  0.3 1  3 0 0 0 0 0 
R                 R     R  4  0.6  0.3 0  0 4 0 0 0 0 
R  R     R     R  R     R  3  0.4  0.3 2  0 1 0 0 0 0 
R                 R  R     3  0.4  0.3 2  0 1 0 0 0 0 
R              R     R     3  0.4  0.3 1  0 2 0 0 0 0 
R  R              R     R  3  0.4  0.3 1  0 2 0 0 0 0 
R     R           R  R  R  3  0.4  0.3 0  0 3 0 0 0 0 
R     R  R  R  R  R  R  R  3  0.4  0.3 0  0 3 0 0 0 0 
Table continued overleaf. 
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Appendix Table MDRP6 (continued).  Multi-resistance patterns of interest in Salmonella spp. from 
fattening pigs in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=1,150) 
D
e
n
m
a
r
k
 
(
N
=
3
7
4
)
 
E
s
t
o
n
i
a
 
(
N
=
1
4
)
 
G
e
r
m
a
n
y
 
(
N
=
6
2
7
)
 
H
u
n
g
a
r
y
 
(
N
=
3
8
)
 
I
r
e
l
a
n
d
 
(
N
=
2
4
)
 
I
t
a
l
y
 
(
N
=
2
5
)
 
S
p
a
i
n
 
(
N
=
4
8
)
 
A
m
p
 
C
t
x
 
C
h
l
 
C
i
p
 
G
e
n
 
S
t
r
 
S
u
 
T
e
t
 
T
m
p
 
n %  MS 
group %  n n n n n n n 
R  R           R  R  R     2  0.3  0.2 0  0  1  0 0 0 1 
R           R  R  R  R  R  2  0.3  0.2 2  0  0  0 0 0 0 
R     R           R  R     2  0.3  0.2 2  0  0  0 0 0 0 
            R  R  R        1  0.1  0.1 1  0  0  0 0 0 0 
         R        R     R  1  0.1  0.1 1  0  0  0 0 0 0 
         R     R     R     1  0.1  0.1 1  0  0  0 0 0 0 
         R     R  R  R     1  0.1  0.1 0  0  0  0 1 0 0 
      R           R  R  R  1  0.1  0.1 0  0  0  0 0 0 1 
      R        R  R        1  0.1  0.1 0  0  0  1 0 0 0 
      R        R  R  R     1  0.1  0.1 0  0  0  0 0 0 1 
      R        R  R  R  R  1  0.1  0.1 1  0  0  0 0 0 0 
      R     R  R     R     1  0.1  0.1 0  0  1  0 0 0 0 
R           R     R  R     1  0.1  0.1 0  0  1  0 0 0 0 
R           R     R  R  R  1  0.1  0.1 0  0  0  0 0 0 1 
R           R  R  R        1  0.1  0.1 0  0  1  0 0 0 0 
R        R           R     1  0.1  0.1 0  0  0  0 0 0 1 
R        R        R        1  0.1  0.1 0  0  1  0 0 0 0 
R        R     R     R     1  0.1  0.1 0  0  1  0 0 0 0 
R        R  R  R     R     1  0.1  0.1 0  0  0  1 0 0 0 
R     R           R        1  0.1  0.1 0  0  1  0 0 0 0 
R     R        R           1  0.1  0.1 0  0  0  0 0 1 0 
R     R     R  R  R     R  1  0.1  0.1 0  0  0  0 0 0 1 
R     R  R        R  R     1  0.1  0.1 0  0  1  0 0 0 0 
R  R              R        1  0.1  0.1 0  0  0  0 0 0 1 
R  R           R  R  R  R  1  0.1  0.1 0  0  0  0 0 0 1 
R  R     R     R  R  R     1  0.1  0.1 0  0  1  0 0 0 0 
R  R     R     R  R  R  R  1  0.1  0.1 0  0  1  0 0 0 0 
R  R  R  R  R  R  R  R  R  1  0.1  0.1 0  0  0  0 0 0 1 
Total  690  100  60.0  127  5  480  27  15  12  25 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP7.  Multi-resistance patterns of interest in Salmonella spp. from cattle in MSs 
reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=205) 
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R     R        R  R  R     25  33.8  12.2  4 0 2  15 2 0  2 
R              R  R  R     16  21.6  7.8  2 0 5 5 2 2  0 
               R  R  R     5  6.8  2.4  3 0 0 0 0 2  0 
      R  R     R  R        3  4.1  1.5  3 0 0 0 0 0  0 
R     R        R  R  R  R  2  2.7  1.0  0 0 0 1 0 1  0 
         R        R  R  R  2  2.7  1.0  0 0 2 0 0 0  0 
      R  R        R        2  2.7  1.0  2 0 0 0 0 0  0 
R     R           R  R  R  2  2.7  1.0  0 0 0 0 0 2  0 
         R     R        R  1  1.4  0.5  0 0 1 0 0 0  0 
         R     R     R     1  1.4  0.5  0 0 1 0 0 0  0 
         R     R  R     R  1  1.4  0.5  0 0 1 0 0 0  0 
      R        R  R        1  1.4  0.5  0 0 1 0 0 0  0 
      R  R  R  R     R     1  1.4  0.5  0 0 0 0 1 0  0 
R                 R  R     1  1.4  0.5  1 0 0 0 0 0  0 
R              R  R        1  1.4  0.5  0 0 0 0 0 0  1 
R              R  R     R  1  1.4  0.5  0 1 0 0 0 0  0 
R              R  R  R  R  1  1.4  0.5  0 1 0 0 0 0  0 
R        R        R        1  1.4  0.5  1 0 0 0 0 0  0 
R        R     R  R  R  R  1  1.4  0.5  1 0 0 0 0 0  0 
R        R  R     R  R  R  1  1.4  0.5  0 0 0 0 1 0  0 
R     R     R  R  R  R  R  1  1.4  0.5  0 0 1 0 0 0  0 
R     R  R     R  R        1  1.4  0.5  1 0 0 0 0 0  0 
R     R  R     R  R     R  1  1.4  0.5  1 0 0 0 0 0  0 
R     R  R     R  R  R  R  1  1.4  0.5  1 0 0 0 0 0  0 
R  R     R     R  R  R  R  1  1.4  0.5  1 0 0 0 0 0  0 
Total  74  100  36.1  21  2  14  21  6  7  3 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP8.  Multi-resistance patterns of interest in Salmonella Enteritidis from broilers 
in MS reporting isolate-based data, 2012 
Multi-resistance pattern  MS  
(N=10) 
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         R        R  R     2  40.0  20.0 2 
R        R        R        1  20.0  10.0 1 
R     R           R        1  20.0  10.0 1 
R     R  R  R  R  R  R  R  1  20.0  10.0 1 
Total  5  100  50.0  5 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP9.   Multi-resistance patterns of interest in Salmonella Enteritidis from laying 
hens in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=109) 
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         R        R  R     4  33.3  3.7 0 4 
         R        R  R  R  4  33.3  3.7 0 4 
R        R        R        1  8.3  0.9 0 1 
R        R        R  R     1  8.3  0.9 0 1 
R        R        R  R  R  1  8.3  0.9 1 0 
R        R  R     R  R     1  8.3  0.9 0 1 
Total  12  100  11.0  1  11 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP10.    Multi-resistance patterns of interest in Salmonella Typhimurium from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=8) 
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R              R  R  R     4  57.1  50.0 1 0 3 
R     R        R  R  R     2  28.6  25.0 0 2 0 
R     R  R  R  R  R  R  R  1  14.5  12.5 0 1 0 
Total  7  100  87.5  1  3  3 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimetoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP11.    Multi-resistance patterns of interest in Salmonella Typhimurium from 
laying hens in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=38) 
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R     R           R  R     3  42.9  7.9 0 0 3 
R              R  R  R     1  14.3  2.6 0 0 1 
R        R     R  R  R     1  14.3  2.6 0 1 0 
R        R     R  R  R  R  1  14.3  2.6 0 0 1 
R     R        R  R  R  R  1  14.3  2.6 1 0 0 
Total  7  100  18.4  1  1  5 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimetoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP12.    Multi-resistance patterns of interest in Salmonella Typhimurium from 
fattening pigs in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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group %  n n n n n n n 
R     R        R  R  R     73  26.5  19.5  9 0  58 2 3 0 1 
R              R  R  R  R  62  22.5  16.6  0 0  62 0 0 0 0 
R              R  R  R     45  16.4  12.0  7 0  33 3 1 1 0 
R     R        R  R  R  R  16  5.8  4.3  0 0  15 0 1 0 0 
R     R  R     R  R  R  R  9  3.3  2.4  0 0 6 0 3 0 0 
R                 R  R  R  9  3.3  2.4  0 0 9 0 0 0 0 
               R  R  R     9  3.3  2.4  2 6 0 0 1 0 0 
R              R  R        8  2.9  2.1  6 0 1 1 0 0 0 
R     R  R     R  R  R     7  2.5  1.9  0 0 6 1 0 0 0 
R     R     R  R  R  R     7  2.5  1.9  1 0 6 0 0 0 0 
R     R     R  R  R  R  R  5  1.8  1.3  0 0 4 0 1 0 0 
R     R        R  R     R  4  1.5  1.1  0 0 4 0 0 0 0 
R        R     R  R  R  R  3  1.1  0.8  0 0 3 0 0 0 0 
               R  R     R  2  0.7  0.5  1 0 1 0 0 0 0 
R     R           R  R     2  0.7  0.5  1 0 1 0 0 0 0 
R              R  R     R  2  0.7  0.5  0 0 2 0 0 0 0 
R           R  R  R  R     2  0.7  0.5  0 0 2 0 0 0 0 
                  R  R  R  1  0.4  0.3  0 0 1 0 0 0 0 
               R  R  R  R  1  0.4  0.3  0 0 1 0 0 0 0 
      R     R  R     R     1  0.4  0.3  0 0 1 0 0 0 0 
R                 R  R     1  0.4  0.3  0 0 1 0 0 0 0 
R           R  R  R  R  R  1  0.4  0.3  0 0 1 0 0 0 0 
R        R        R        1  0.4  0.3  0 0 1 0 0 0 0 
R     R  R        R  R     1  0.4  0.3  0 0 0 0 0 1 0 
R  R              R        1  0.4  0.3  0 0 1 0 0 0 0 
R  R           R  R  R  R  1  0.4  0.3  0 0 1 0 0 0 0 
R  R     R     R  R  R     1  0.4  0.3  0 0 0 0 0 1 0 
Total  275  100  73.5  27  6  221  7  10  3  1 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP13.    Multi-resistance patterns of interest in Salmonella Typhimurium from 
cattle in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R     R        R  R  R     25  64.1  21.4 4 0 2  15 2 0 2 
R              R  R  R     3  7.7  2.6 2 0 0 0 0 1 0 
               R  R  R     3  7.7  2.6 3 0 0 0 0 0 0 
R                 R  R     1  2.6  0.9 1 0 0 0 0 0 0 
R              R  R        1  2.6  0.9 0 0 0 0 0 0 1 
R              R  R     R  1  2.6  0.9 0 1 0 0 0 0 0 
R              R  R  R  R  1  2.6  0.9 0 1 0 0 0 0 0 
R        R     R  R  R  R  1  2.6  0.9 1 0 0 0 0 0 0 
R     R        R  R  R  R  1  2.6  0.9 0 0 0 1 0 0 0 
R     R     R  R  R  R  R  1  2.6  0.9 0 0 1 0 0 0 0 
R     R  R     R  R  R  R  1  2.6  0.9 1 0 0 0 0 0 0 
Total  39  100  33.3  12  2  3  16  2  1  3 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP14.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from turkey meat in MS reporting isolate-based data, 2012 
Multi-resistance pattern  MS 
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R        R     R  R  R     12  63.2  54.5 12 
R              R  R  R     7  36.8  31.8 7 
Total  19  100  86.4  19 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP15.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from pig meat in MSs and one non-MS reporting isolate-based data, 2012 
Multi-resistance pattern 
Group of 
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countries 
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R              R  R  R     55  66.3  56.1  4  13 20 14  4 
               R  R  R     6  7.2  6.1  1  1 0 4 0 
R     R        R  R        5  6.0  5.1  0  0 5 0 0 
R              R  R        4  4.8  4.1  1  2 1 0 0 
R     R        R  R  R  R  3  3.6  3.1  0  1 1 1 0 
      R        R  R  R  R  2  2.4  2.0  0  0 1 1 0 
R     R        R  R  R     2  2.4  2.0  0  0 1 0 1 
R           R  R  R  R  R  2  2.4  2.0  0  0 0 2 0 
R              R  R  R  R  1  1.2  1.0  0  0 1 0 0 
R           R  R  R  R     1  1.2  1.0  0  0 1 0 0 
R        R     R  R  R     1  1.2  1.0  0  0 1 0 0 
R     R           R        1  1.2  1.0  0  0 1 0 0 
Total  83  100  84.7  6  17  33  22  5 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP16.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from bovine animals meat in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=4) 
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R              R  R  R     2  50.0  50.0 2  0 
               R  R  R     1  25.0  25.0 0  1 
      R        R  R  R  R  1  25.0  25.0 0  1 
Total  4  100  100  2  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimetoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP17.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R              R  R  R     5  71.4  62.5  3  2 
R              R     R  R  1  14.3  12.5  0  1 
R     R  R  R  R     R     1  14.3  12.5  0  1 
Total  7  100  87.5  3  4 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant;  
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP18.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from laying hens in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R              R  R  R     6  60.0  54.5 1 3 2 0 
R        R     R  R  R     2  20.0  18.2 0 1 1 0 
               R  R  R     1  10.0  9.1 0 0 0 1 
R              R  R  R  R  1  10.0  9.1 0 0 1 0 
Total  10  100  90.9  1  4  4  1 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant;  
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP19.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from turkeys in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=28) 
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R              R  R  R     17  85.0  60.7 15 0 1 1 
R        R     R  R  R     1  5.0  3.6 1  0  0  0 
R        R  R  R  R  R     1  5.0  3.6 0  1  0  0 
R     R        R  R  R     1  5.0  3.6 1  0  0  0 
Total  20  100  71.4  17  1  1  1 
MS: Member State;.Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim  
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant;  
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST).   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix  Table  MDRP20.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from fattening pigs in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=279) 
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R              R  R  R     192  74.4  68.8  18  163 3 1 7 
R              R  R  R  R  11  4.3  3.9 1  10 0 0 0 
R     R        R  R  R  R  10  3.9  3.6 0 9 0 0 1 
R        R     R  R  R     10  3.9  3.6 0  10 0 0 0 
R              R  R        7  2.7  2.5 2 5 0 0 0 
R     R     R  R  R  R     4  1.6  1.4 0 3 0 1 0 
R           R  R  R  R     3  1.2  1.1 2 0 0 0 1 
R              R     R     3  1.2  1.1 0 3 0 0 0 
R     R     R  R  R  R  R  3  1.2  1.1 0 3 0 0 0 
R     R  R     R  R  R  R  3  1.2  1.1 0 3 0 0 0 
         R        R  R     2  0.8  0.7 0 2 0 0 0 
               R  R  R     1  0.4  0.4 0 0 1 0 0 
      R        R  R  R  R  1  0.4  0.4 0 0 0 0 1 
R           R     R  R     1  0.4  0.4 0 0 0 0 1 
R        R     R  R  R  R  1  0.4  0.4 0 1 0 0 0 
R     R           R  R  R  1  0.4  0.4 0 1 0 0 0 
R     R        R  R  R     1  0.4  0.4 0 1 0 0 0 
R     R  R  R  R  R  R  R  1  0.4  0.4 0 0 0 0 1 
R  R           R  R  R     1  0.4  0.4 0 1 0 0 0 
R  R     R     R  R  R  R  1  0.4  0.4 0 0 0 0 1 
R  R  R  R  R  R  R  R  R  1  0.4  0.4 0 1 0 0 0 
Total  258  100  92.5  23  216  4  2  13 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP21.    Multi-resistance patterns of interest in monophasic Salmonella 
Typhimurium from cattle in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R              R  R  R     13  92.9  86.7 5 5 2 1 
      R        R  R        1  7.1  6.7 1 0 0 0 
Total  14  100  93.3  6  5  2  1 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP22.  Multi-resistance patterns of interest in Salmonella Kentucky from broiler 
meat in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=65) 
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R        R  R  R  R  R     6  50.0  9.2 1  5 
R     R           R        4  33.3  6.2 4  0 
R                 R     R  1  8.3  1.5 1  0 
R                 R  R  R  1  8.3  1.5 1  0 
Total  12  100  18.5  7  5 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates; 
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP23.  Multi-resistance patterns of interest in Salmonella Kentucky from broilers 
in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R        R  R  R  R  R     45  57.0  37.5  4 0 0 0  41 0 
R        R  R     R  R     17  21.5  14.2  1 1 0 0  15 0 
R  R     R  R  R  R  R     4  5.1  3.3  0 0 0 0 4 0 
R        R  R  R  R        2  2.5  1.7  0 0 0 0 0 2 
R  R  R  R  R  R  R  R  R  2  2.5  1.7  0 0 0 0 2 0 
         R  R     R  R     1  1.3  0.8  0 0 0 0 0 1 
R                 R  R  R  1  1.3  0.8  0 0 1 0 0 0 
R        R           R     1  1.3  0.8  0 0 0 1 0 0 
R        R        R  R     1  1.3  0.8  0 0 0 0 1 0 
R        R  R     R        1  1.3  0.8  0 0 0 0 1 0 
R        R  R  R  R  R  R  1  1.3  0.8  0 0 0 0 1 0 
R     R  R  R  R  R  R     1  1.3  0.8  0 0 0 0 1 0 
R  R     R                 1  1.3  0.8  0 0 0 1 0 0 
R  R  R  R  R  R  R  R     1  1.3  0.8  0 0 0 0 1 0 
Total  79  100  65.8  5  1  1  2  67  3 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim; N: total number of isolates tested for susceptibility against the whole common 
antimicrobial set for Salmonella and multi-resistant; n:  number  of  multi-resistant  isolates; R: minimum inhibitory concentration (MIC) 
above epidemiological cut-off values (ECOFFs) from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP24.  Multi-resistance patterns of interest in Salmonella Kentucky from laying 
hens in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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R        R           R     6  35.3  20.7 0 6 0 0 
R        R  R  R  R  R     3  17.7  10.3 2 0 1 0 
R  R     R                 2  11.8  6.9 0 2 0 0 
         R  R  R  R  R     1  5.9  3.4 0 0 0 1 
R        R        R     R  1  5.9  3.4 0 1 0 0 
R        R     R  R  R     1  5.9  3.4 0 1 0 0 
R        R  R     R  R     1  5.9  3.4 0 0 1 0 
R     R  R        R  R  R  1  5.9  3.4 0 1 0 0 
R     R  R  R  R  R  R  R  1  5.9  3.4 0 0 0 1 
Total  17  100  58.6  2  11  2  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim; N: total number of isolates tested for susceptibility against the whole common 
antimicrobial set for Salmonella and multi-resistant; n:  number  of  multi-resistant  isolates; R: minimum inhibitory concentration (MIC) 
above epidemiological cut-off values (ECOFFs) from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP25.  Multi-resistance patterns of interest in Salmonella Derby from pig meat in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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               R  R  R     16  64.0  20.0 1 1 7 7 
R              R  R  R  R  3  12.0  3.8 1 0 1 1 
                  R  R  R  1  4.0  1.3 1 0 0 0 
               R  R     R  1  4.0  1.3 0 0 1 0 
               R  R  R  R  1  4.0  1.3 0 1 0 0 
      R     R  R  R  R     1  4.0  1.3 0 0 1 0 
R              R     R     1  4.0  1.3 0 0 0 1 
R              R  R  R     1  4.0  1.3 0 0 1 0 
Total  25  100  31.3  3  2  11  9 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP26.    Multi-resistance patterns of interest in Salmonella Derby from bovine 
animals meat in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=8) 
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               R  R  R     1  33.3  12.5 0 1 0 
      R        R  R  R     1  33.3  12.5 1 0 0 
R     R           R  R  R  1  33.3  12.5 0 1 0 
Total  3  100  37.5  1  2  0 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP27.  Multi-resistance patterns of interest in Salmonella Derby from broilers in 
MS reporting isolate-based data, 2012 
Multi-resistance pattern  MS  
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R              R  R        1  50.0  50.0 1 
R  R     R        R        1  50.0  50.0 1 
Total  2  100  100  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP28.  Multi-resistance patterns of interest in Salmonella Derby from turkeys in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=124) 
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R     R  R        R  R  R  62  50.0  50.0 0  0  62  0 
R        R        R  R  R  39  31.5  31.5 0  0  39  0 
R     R  R     R  R  R  R  10  8.1  8.1 0  0  10  0 
               R  R  R     3  2.4  2.4 2  0  0  1 
R                 R  R  R  3  2.4  2.4 0  1  2  0 
R        R     R     R     1  0.8  0.8 0  0  1  0 
R        R  R     R  R  R  1  0.8  0.8 0  0  1  0 
R     R           R  R  R  1  0.8  0.8 0  0  1  0 
R     R        R  R  R  R  1  0.8  0.8 0  0  1  0 
R     R  R        R  R     1  0.8  0.8 0  0  1  0 
R     R  R  R  R  R  R  R  1  0.8  0.8 0  1  0  0 
R  R  R  R     R  R  R  R  1  0.8  0.8 0  1  0  0 
Total  124  100  100  2  3  118  1 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP29.    Multi-resistance patterns of interest in Salmonella Derby from fattening 
pigs in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=170) 
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               R  R  R     5  16.7  2.9  0 3 0 2 0 
R                 R  R  R  4  13.3  2.4  2 1 1 0 0 
R  R     R     R  R     R  4  13.3  2.4  0 4 0 0 0 
R              R  R  R  R  3  10.0  1.8  1 2 0 0 0 
               R  R     R  2  6.7  1.2  1 1 0 0 0 
R              R  R  R     2  6.7  1.2  1 0 0 1 0 
R                 R  R     2  6.7  1.2  2 0 0 0 0 
                  R  R  R  1  3.3  0.6  1 0 0 0 0 
      R           R  R  R  1  3.3  0.6  0 0 0 0 1 
      R        R  R  R     1  3.3  0.6  0 1 0 0 0 
R              R  R     R  1  3.3  0.6  1 0 0 0 0 
R           R  R  R        1  3.3  0.6  0 1 0 0 0 
R     R           R        1  3.3  0.6  1 0 0 0 0 
R     R        R  R     R  1  3.3  0.6  1 0 0 0 0 
R  R           R  R  R     1  3.3  0.6  0 0 0 0 1 
Total  30  100  17.6  11  13  1  3  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP30.  Multi-resistance patterns of interest in Salmonella Derby from cattle in MS 
reporting isolate-based data, 2012 
Multi-resistance pattern  MS 
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               R  R  R     2  100  100 2 
Total  2  100  100  2 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP31.    Multi-resistance patterns of interest in Salmonella Infantis from broiler 
meat in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=162) 
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         R        R  R     50  33.3  30.9  4  0 13  3 30 
         R        R  R  R  43  28.7  26.5  0  0 2 0  41 
         R     R  R  R  R  26  17.3  16.0  0  0 0 0  26 
         R     R  R  R     14  9.3  8.6  5  1 2 0 6 
   R     R        R  R  R  3  2.0  1.9  0  0 0 0 3 
         R  R     R  R  R  2  1.3  1.2  0  0 0 0 2 
R     R  R        R  R  R  2  1.3  1.2  0  0 0 0 2 
         R     R  R        1  0.7  0.6  0  1 0 0 0 
      R  R           R  R  1  0.7  0.6  0  0 0 0 1 
      R  R        R  R  R  1  0.7  0.6  0  0 0 0 1 
      R  R     R  R  R     1  0.7  0.6  0  0 0 0 1 
      R  R     R  R  R  R  1  0.7  0.6  0  0 0 0 1 
R                 R  R     1  0.7  0.6  1  0 0 0 0 
R        R        R  R  R  1  0.7  0.6  0  0 0 0 1 
R        R     R  R  R  R  1  0.7  0.6  0  0 0 0 1 
R     R  R     R  R  R  R  1  0.7  0.6  0  0 0 0 1 
R  R  R  R        R  R  R  1  0.7  0.6  0  0 0 0 1 
Total  150  100  92.6  10  2  17  3  118 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP32.  Multi-resistance patterns of interest in Salmonella Infantis from pig meat in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=23) 
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R                 R     R  5  38.5  21.7  0 0 0 5 
         R     R  R  R     2  15.4  8.7  1 0 0 1 
R              R  R  R  R  2  15.4  8.7  2 0 0 0 
         R        R  R     1  7.7  4.3  0 0 0 1 
R              R     R     1  7.7  4.3  0 1 0 0 
R     R           R  R     1  7.7  4.3  0 1 0 0 
R     R     R  R  R  R  R  1  7.7  4.3  0 0 1 0 
Total  13  100  56.5  3  2  1  7 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table MDRP33.  Multi-resistance patterns of interest in Salmonella Infantis from broilers in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=529) 
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         R        R  R     180  40.4  34.0 16  25 86  0 53 
         R     R  R  R     78  17.5  14.7 5  16 28  0 29 
         R        R  R  R  41  9.2  7.8 0  0 0 2  39 
         R     R  R  R  R  26  5.8  4.9 0  0 0 0  26 
R        R        R  R     18  4.0  3.4 0  5 5 2 6 
R        R     R  R  R     12  2.7  2.3 0  3 2 0 7 
R        R        R  R  R  12  2.7  2.3 0  0 0 0  12 
      R  R     R  R  R  R  9  2.0  1.7 0  0 0 0 9 
   R     R     R  R  R     8  1.8  1.5 0  0 0 0 8 
R        R     R  R  R  R  7  1.6  1.3 0  0 0 1 6 
R  R     R        R  R  R  7  1.6  1.3 0  0 0 7 0 
R        R  R     R  R     3  0.7  0.6 0  0 0 0 3 
R     R  R        R  R     3  0.7  0.6 0  0 0 0 3 
R  R     R        R  R     3  0.7  0.6 0  0 0 0 3 
         R  R     R  R  R  2  0.5  0.4 0  0 0 0 2 
      R  R        R  R     2  0.5  0.4 0  0 2 0 0 
R        R  R     R  R  R  2  0.5  0.4 0  0 0 0 2 
R        R  R  R  R  R  R  2  0.5  0.4 0  0 0 0 2 
R     R  R     R  R  R     2  0.5  0.4 0  0 0 0 2 
R     R  R     R  R  R  R  2  0.5  0.4 0  0 0 0 2 
R  R     R                 2  0.5  0.4 0  0 0 0 2 
R  R  R  R     R  R  R  R  2  0.5  0.4 0  0 0 0 2 
R  R  R  R  R  R  R  R  R  2  0.5  0.4 0  0 0 0 2 
         R           R  R  1  0.2  0.2 0  0 0 0 1 
         R     R     R     1  0.2  0.2 0  0 1 0 0 
         R     R  R        1  0.2  0.2 0  0 1 0 0 
         R  R        R     1  0.2  0.2 0  0 1 0 0 
Table continued overleaf. 
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Appendix Table MDRP33 (continued). Multi-resistance patterns of interest in Salmonella Infantis from 
broilers in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
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         R  R  R  R  R     1  0.2  0.2 0  0 0 0 1 
         R  R  R  R  R  R  1  0.2  0.2 0  0 0 0 1 
      R  R        R  R  R  1  0.2  0.2 0  0 0 0 1 
   R     R        R  R     1  0.2  0.2 0  0 0 0 1 
   R     R  R  R  R  R  R  1  0.2  0.2 0  0 0 0 1 
R        R     R           1  0.2  0.2 0  0 0 0 1 
R        R     R     R     1  0.2  0.2 0  0 0 1 0 
R        R  R  R  R  R     1  0.2  0.2 0  0 0 0 1 
R     R  R        R     R  1  0.2  0.2 0  0 0 0 1 
R     R  R        R  R  R  1  0.2  0.2 0  0 0 0 1 
R     R  R  R  R  R  R  R  1  0.2  0.2 0  0 0 0 1 
R  R     R     R  R  R  R  1  0.2  0.2 0  0 0 0 1 
R  R     R  R     R  R     1  0.2  0.2 0  0 0 0 1 
R  R     R  R     R  R  R  1  0.2  0.2 0  0 0 1 0 
R  R     R  R  R  R  R     1  0.2  0.2 0  0 0 0 1 
R  R  R  R     R  R  R      1  0.2  0.2 0  0 0 0 1 
Total  445  100  84.1  21  49  126  14  235 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix  Table  MDRP34.    Multi-resistance patterns of interest in Salmonella Infantis from laying 
hens in MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=36) 
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         R        R  R     16  55.2  44.4 3  0  8  5 
         R     R  R  R     5  17.2  13.9 0  0  1  4 
         R        R  R  R  2  6.9  5.6 0  0  0  2 
R     R  R        R  R     2  6.9  5.6 0  0  0  2 
R              R     R     1  3.5  2.8 0  1  0  0 
R        R        R  R     1  3.5  2.8 0  0  0  1 
R        R     R  R  R     1  3.5  2.8 0  0  0  1 
R     R  R     R  R  R     1  3.5  2.8 0  0  0  1 
Total  29  100  80.6  3  1  9  16 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix Table MDRP35.  Multi-resistance patterns of interest in Salmonella Infantis from turkeys in 
MSs reporting isolate-based data, 2012 
Multi-resistance pattern  MS group 
(N=27) 
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         R        R  R     19  76.0  70.4 1 3  15 
         R     R  R  R     5  20.0  18.5 1 1 3 
R        R        R  R     1  4.0  3.7 0 0 1 
Total  25  100  92.6  2  4  19 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP36.  Multi-resistance patterns of interest in Salmonella Infantis from fattening 
pigs in MSs reporting isolate-based data, 2012 
Resistance pattern  MS group 
(N=18) 
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         R        R  R     6  50.0  33.3 0 6 
R              R  R  R  R  2  16.7  11.1 2 0 
R  R              R     R  2  16.7  11.1 2 0 
                  R  R  R  1  8.3  5.6 1 0 
         R     R  R  R     1  8.3  5.6 0 1 
Total  12  100  66.7  5  7 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for Salmonella and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
Appendix  Table  MDRP37.    Multi-resistance patterns of interest in Escherichia  coli from broilers in 
MSs and one non-MS reporting isolate-based data, 2012 
R      R        R    13  7.8  2.4 0  0 5 8 
R      R    R  R  R  R  11  6.6  2.1 6  0 2 3 
      R    R  R  R    9  5.4  1.7 7  0 1 1 
      R    R  R    R  9  5.4  1.7 8  0 1 0 
R            R  R  R  8  4.8  1.5 0  3 1 4 
      R    R    R    6  3.6  1.1 1  0 2 3 
R            R    R  6  3.6  1.1 3  2 1 0 
R          R    R    6  3.6  1.1 1  3 0 2 
R      R    R  R  R    5  3.0  0.9 3  1 1 0 
R    R  R    R  R  R  R  5  3.0  0.9 2  0 1 2 
            R  R  R  5  3.0  0.9 1  0 0 4 
R      R      R    R  5  3.0  0.9 3  0 2 0 
R      R      R  R  R  5  3.0  0.9 0  0 1 4 
      R      R  R  R  4  2.4  0.8 2  0 1 1 
R          R  R  R  R  4  2.4  0.8 1  0 1 2 
R      R      R      4  2.4  0.8 1  0 0 3 
R  R    R            4  2.4  0.8 0  0 3 1 
      R      R  R    3  1.8  0.6 1  0 1 1 
R          R  R    R  3  1.8  0.6 0  2 1 0 
R          R  R  R    3  1.8  0.6 0  0 1 2 
R    R  R      R  R  R  3  1.8  0.6 1  0 2 0 
          R  R    R  3  1.8  0.6 0  3 0 0 
Table continued overleaf.   
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Appendix Table MDRP37 (continued). Multi-resistance patterns of interest in Escherichia coli from 
broilers in MSs and one non-MS reporting isolate-based data, 2012 
      R    R  R      2  1.2  0.4 1  0 0  1 
R      R      R  R    2  1.2  0.4 1  0 1  0 
R    R  R    R  R  R    2  1.2  0.4 1  0 1  0 
R  R    R      R  R  R  2  1.2  0.4 0  0 1  1 
          R  R  R  R  2  1.2  0.4 0  0 2  0 
R      R    R    R    2  1.2  0.4 0  0 2  0 
R  R    R      R  R    2  1.2  0.4 0  0 0  2 
      R      R    R  1  0.6  0.2 1  0 0  0 
      R    R  R  R  R  1  0.6  0.2 0  0 1  0 
    R  R    R  R      1  0.6  0.2 1  0 0  0 
    R  R    R  R    R  1  0.6  0.2 1  0 0  0 
    R  R    R  R  R    1  0.6  0.2 1  0 0  0 
    R  R    R  R  R  R  1  0.6  0.2 1  0 0  0 
    R  R  R    R      1  0.6  0.2 0  0 1  0 
R            R  R    1  0.6  0.2 0  1 0  0 
R          R      R  1  0.6  0.2 1  0 0  0 
R      R          R  1  0.6  0.2 0  0 1  0 
R      R        R  R  1  0.6  0.2 0  0 1  0 
R      R    R        1  0.6  0.2 1  0 0  0 
R      R    R  R      1  0.6  0.2 0  0 1  0 
R      R    R  R    R  1  0.6  0.2 0  0 1  0 
R      R  R  R  R    R  1  0.6  0.2 0  0 0  1 
R    R  R        R  R  1  0.6  0.2 0  0 1  0 
R    R  R      R    R  1  0.6  0.2 0  0 1  0 
R    R  R    R  R      1  0.6  0.2 0  0 1  0 
R    R  R  R    R    R  1  0.6  0.2 1  0 0  0 
R    R  R  R  R  R  R  R  1  0.6  0.2 0  0 1  0 
R  R          R      1  0.6  0.2 1  0 0  0 
R  R        R      R  1  0.6  0.2 0  0 1  0 
R  R        R  R  R    1  0.6  0.2 1  0 0  0 
R  R    R    R  R    R  1  0.6  0.2 0  0 1  0 
R  R    R    R  R  R  R  1  0.6  0.2 0  0 1  0 
R  R  R      R  R  R    1  0.6  0.2 1  0 0  0 
R  R  R  R      R    R  1  0.6  0.2 0  0 1  0 
R  R  R  R      R  R    1  0.6  0.2 1  0 0  0 
Total  166  100  31.1  56  15  49  46 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). 
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Appendix Table MDRP38.  Multi-resistance patterns of interest in Escherichia coli from fattening pigs 
in MSs and one non-MS reporting isolate-based data, 2012 
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               R  R  R     29  16.0  5.3  13  4  2  10 
R              R  R  R  R  29  16.0  5.3  3  16  2  8 
R              R  R     R  16  8.8  2.9  2  8  0  6 
               R  R  R  R  13  7.2  2.4  2  2  1  8 
R              R  R        13  7.2  2.4  1  8  0  4 
R              R  R  R     7  3.9  1.3  1  3  1  2 
R              R     R     6  3.3  1.1  1  0  4  1 
R                 R  R  R  5  2.8  0.9  0  1  3  1 
R        R     R  R  R  R  5  2.8  0.9  3  1  1  0 
               R  R     R  5  2.8  0.9  0  1  0  4 
                  R  R  R  4  2.2  0.7  1  1  0  2 
R        R           R     4  2.2  0.7  1  0  3  0 
R     R           R  R  R  4  2.2  0.7  0  0  3  1 
R     R        R  R  R  R  4  2.2  0.7  1  0  3  0 
R     R        R  R  R     3  1.7  0.6  1  0  1  1 
      R           R  R  R  3  1.7  0.6  0  1  0  2 
      R        R  R  R  R  3  1.7  0.6  1  0  0  2 
         R     R  R     R  2  1.1  0.4  0  0  2  0 
R              R        R  2  1.1  0.4  0  0  0  2 
               R     R  R  1  0.6  0.2  0  0  0  1 
         R     R     R     1  0.6  0.2  1  0  0  0 
         R     R     R  R  1  0.6  0.2  1  0  0  0 
         R     R  R  R     1  0.6  0.2  0  0  1  0 
      R        R  R        1  0.6  0.2  0  0  1  0 
      R        R  R  R     1  0.6  0.2  0  1  0  0 
      R  R           R     1  0.6  0.2  0  0  0  1 
R                 R     R  1  0.6  0.2  0  0  0  1 
R              R     R  R  1  0.6  0.2  0  0  0  1 
R           R  R           1  0.6  0.2  0  0  0  1 
R           R  R  R  R     1  0.6  0.2  0  0  1  0 
R        R     R     R     1  0.6  0.2  0  0  1  0 
R        R     R  R  R     1  0.6  0.2  1  0  0  0 
R        R  R  R  R     R  1  0.6  0.2  0  0  0  1 
R        R  R  R  R  R  R  1  0.6  0.2  0  0  1  0 
R     R              R     1  0.6  0.2  0  0  1  0 
Table continued overleaf. 
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Appendix Table MDRP38 (continued). Multi-resistance patterns of interest in Escherichia coli from 
fattening pigs in MSs and one non-MS reporting isolate-based data, 2012 
Multi-resistance pattern 
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countries 
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R     R              R  R  1  0.6  0.2  0  0  0  1 
R     R           R  R     1  0.6  0.2  0  0  1  0 
R     R        R     R     1  0.6  0.2  0  1  0  0 
R     R        R  R     R  1  0.6  0.2  0  0  0  1 
R     R     R  R  R     R  1  0.6  0.2  0  1  0  0 
R  R                 R     1  0.6  0.2  0  0  1  0 
R  R           R  R  R  R  1  0.6  0.2  0  0  0  1 
R  R     R                 1  0.6  0.2  0  0  0  1 
Total  181  100  33.2  34  49  34  64 
MS: Member State; Amp: ampicillin; Ctx: cefotaxime; Chl: chloramphenicol; Cip: ciprofloxacin; Gen: gentamicin; Str: streptomycin; Su: 
sulfonamides; Tet: tetracyclines; Tmp: trimethoprim. 
N:   total number of isolates tested for susceptibility against the whole common antimicrobial set for E. coli and multi-resistant; 
n:   number of multi-resistant isolates;  
R:    minimum inhibitory concentration (MIC) above epidemiological cut-off values (ECOFFs) from the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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APPENDIX 5.  High-level resistance to ciprofloxacin 
Appendix Table HLCR1.  High-level ciprofloxacin resistance in Salmonella serovars from broiler meat in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Czech Republic (N=47)  16 (34.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Estonia (N=3)  2 (66.7 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=94)  66 (70.2 %)  1 (1.1 %)  0 (0 %)  0 (0 %)  NA  NA 
Ireland (N=70)  8 (11.4 %)  1 (1.4 %)  1 (1.4 %)  1 (1.4 %)  AmpCipGenNalStrSuTet (1)  S. Kentucky 
Italy (N=8)  4 (50.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Romania (N=188)  168 (89.4%)  14 (7.4 %)  3 (1.6 %)  1 (0.5 %)  CipNalSuTetTmp(1)  S. Infantis 
Total (6 MSs) (N=410)  264 (64.4 %)  16 (3.9 %)  4 (1.0 %)  2 (0.5 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of resistant isolates; NA: not applicable. 
1:   European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2:   EUCAST clinical breakpoint. 
3:   High breakpoint. 
4:   Very high breakpoint. 
  EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table HLCR2.  High-level ciprofloxacin resistance in Salmonella serovars from turkey meat in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Czech Republic (N=10)  5 (50.0 %)  1 (10.0 %)  1 (10.0 %)  1 (10.0 %)  AmpCipGenNalSuTet (1)  S. Kentucky 
Estonia (N=2)  1 (50.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=126)  80 (63.5 %)  10 (7.9 %)  7 (5.6 %)  7 (5.6 %) 
AmpCipGenNalSuTet (5)  Other serovars 
AmpCipNal (1)  Other serovars 
AmpCipGenNalStrSuTet (1)  Other serovars 
Ireland (N=1)  1 (100 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=6)  2 (33.3 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (5 MSs) (N=145)  89 (61.4 %)  11 (7.6 %)  8 (5.5 %)  8 (5.5 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of resistant isolates; NA: not applicable. 
1:   European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2:   EUCAST clinical breakpoint. 
3:   High breakpoint. 
4:   Very high breakpoint. 
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Appendix Table HLCR3.  High-level ciprofloxacin resistance in Salmonella serovars from pig meat in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Czech Republic (N=33)  2 (6.1 %)  1 (3.0 %)  1 (3.0 %)  1 (3.0 %)  CipNalStrSuTet (1)  S. Infantis 
Denmark (N=41)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Estonia (N=22)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=163)  10 (6.1 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Ireland (N=69)  1 (1.4 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=85)  1 (1.2 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Romania (N=125)  13 (10.4 %)  1(0.8 %)  1 (0.8 %)  1 (0.8 %)  AmpChlCipSuTetTmp(1)  S. Typhimurium 
Total (7 MSs) (N=538)  27 (5.0 %)  2 (0.4 %)  2 (0.4 %)  2 (0.4 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of resistant isolates; NA: not applicable. 
1:   European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2:   EUCAST clinical breakpoint. 
3:   High breakpoint. 
4:   Very high breakpoint. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  324
Appendix Table HLCR4.  High-level ciprofloxacin resistance in Salmonella serovars from broilers in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates 
resistant at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Austria (N=113)  25 (22.1 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Czech Republic (N=351)  73 (20.8 %)  14 (4.0 %)  14 (4.0 %)  5 (1.4 %) 
AmpCipGenNalStrSuTet (4)  S. Kentucky 
AmpCipGenNalSuTet (1)  S. Kentucky 
Denmark (N=24)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=8)  2 (25.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Hungary (N=175)  158 (90.3 %)  5 (2.9 %)  4 (2.3 %)  2 (1.1 %) 
AmpCipGenNalSuTet (1)  S. Kentucky 
AmpCipNalSuTet (1)  S. Infantis 
Ireland (N=38)  1 (2.6 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=105)  34 (32.4 %)  1 (1.0 %)  1 (1.0 %)  0 (0 %)  NA  NA 
Spain (N=29)  19 (65.5 %)  6 (20.7 %)  5 (17.2 %)  4 (13.8 %) 
AmpCipGenNalStrSu (2)  S. Kentucky 
CipGenNalSuTet (1)  S. Kentucky 
AmpCipNal (1)  S. Kentucky 
Sweden (N=1)   0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
 
Table continued overleaf. 
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Appendix Table HLCR4 (continued). High-level ciprofloxacin resistance in Salmonella serovars from broilers in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella 
serovars 
n (%)  n (%)  n (%)  n (%) 
Romania (N=781)  572 (73.2 %)  138 (17.7%)  106 (13.6 %)  86 (11.0 %) 
AmpCipGenNalStrSuTet (39)  S. Kentucky 
AmpCipGenNalSuTet (13)  S. Kentucky 
AmpCtxCipGenNalStrSuTet (4)  S. Kentucky 
AmpCtxChlCipGenNalStrSuTetTmp (2)  S. Kentucky 
AmpCipNal (1)  S. Kentucky 
AmpCipNalSuTet (1)  S. Kentucky 
AmpCipGenNalSu (1)  S. Kentucky 
AmpCipGenNalStrSuTetTmp(1)  S. Kentucky 
AmpChlCipGenNalStrSuTet (1)  S. Kentucky 
AmpCtxCmCipGenNalStrSuTet (1)  S. Kentucky 
AmpCip (1)  S. Agona 
AmpCtxCmCipGenNalStrSuTetTmp (1)  S. Agona 
CipGenNalSuTetTmp (2)  S. Infantis 
AmpCipGenNalSuTet (2)  S. Infantis 
AmpCipGenNalSuTetTmp (2)  S. Infantis 
AmpCipGenNalStrSuTetTmp (2)  S. Infantis 
AmpCipSuTetTmp (1)  S. Infantis 
AmpChlCipNalStrSuTet (1)  S. Infantis 
AmpCtxCmCipGenNalStrSuTetTmp(1)  S. Infantis 
AmpChlCipSu (1)  S. Liverpool 
AmpChlCipSuTmp (1)  S. Liverpool 
AmpCipGenNalSuTet (3)  S. Tennessee 
AmpCipTet (1)  S. Tennessee 
AmpCipGenNalStrSuTetTmp(1)  S. Tennessee 
AmpCipNalSuTet (1)  S. Livingstone 
CipNalSuTet (1)  S. Rissen 
United Kingdom (N=17)   1 (5.9 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (11 MSs) (N=1,641)  885 (54.2 %)  164 (10.0 %)  130 (8.0 %)  97(5.9 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of resistant isolates; NA: not applicable. 
1:   European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2:   EUCAST clinical breakpoint. 
3:   High breakpoint. 
4:   Very high breakpoint. 
   EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
 
EFSA Journal 2014;12(3):3590  326
Appendix Table HLCR5.  High-level ciprofloxacin resistance in Salmonella serovars from laying hens in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella 
serovars 
n (%)  n (%)  n (%)  n (%) 
Austria (N=63)  7 (11.1 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Czech Republic (N=8)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Denmark(N=4)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Finland (N=5)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=51)  1 (2 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Hungary (N=86)  22 (25.6 %)  3 (3.5 %)  3 (3.5 %)  3 (3.5 %) 
AmpCipGenNalStrSuTet (2)  S. Kentucky 
AmpCipNalStrSuTetTmp (1)  S. Saintpaul 
Italy (N=161)  29 (18.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Romania (N=145)  67 (46.2 %)  13 (9.0 %)  10 (6.9%)  9 (6.2 %) 
Cip (2)  S. Kentucky 
AmpCipGenNalSuTet (1)  S. Kentucky 
AmpCipGenNalStrSuTet (1)  S. Kentucky 
CipNalTmp (1)  S. Thompson 
AmpCipGenNalStrSuTet (1)  S. Hadar 
AmpCipNalSu (1)  S. Albany 
Cip (1)  S. Corvallis 
AmpCipGenNalSuTet (1)  S. Corvallis 
Spain (N=150)  21 (14.0 %)  3 (2.0 %)  2 (1.3 %)  2 (1.3 %) 
CipGenNalStrSuTet (1)  S. Kentucky 
AmpChlCipGenNalStrSuTetTmp (1)  S. Kentucky 
Sweden (N=2)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
United Kingdom (N=11)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (11 MSs) (N=686)  147 (21.4 %)  19 (2.8 %)  15 (2.2 %)  14 (2 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of the resistant isolates; NA: Not applicable. 
1: European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2: EUCAST clinical breakpoint. 
3: High breakpoint. 
4: Very high breakpoint. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Appendix Table HLCR6.  High-level ciprofloxacin resistance in Salmonella serovars from turkeys in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
> 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Austria (N=38)  30 (78.9 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Belgium (N=2)  1 (50.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Czech Republic (N=27)  22 (81.5 %)  9 (33.3 %)  9 (33.3 %)  9 (33.3 %) 
AmpCipGenNalStrSuTet (6)  S. Kentucky 
AmpCipGenNalSuTet (2)  S. Kentucky 
AmpCipNal (1)  S. Kentucky 
Finland (N=1)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=87)  28 (32.2 %)  3 (3.4 %)  1 (1.1 %)  1 (1.1 %)  AmpCipGenNalSuTet (1)  Other serovars 
Hungary (N=174)  159 (91.4 %)  38 (21.8 %)  37 (21.3 %)  35 (20.1 %) 
AmpCipGenNalStrSuTet (18)  S. Kentucky 
AmpCipGenNalSuTet (14)  S. Kentucky 
AmpCipNal (1)  S. Kentucky 
AmpCipGenNalSuTet (1)  S. Stanley 
AmpCipGenNalStrSuTet (1)  S. Stanley 
Ireland (N=14)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=48)  18 (37.5 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Spain (N=169)  152 (89.9 %)  2 (1.2 %)  2 (1.2 %)  2 (1.2 %)  AmpCipGenNalStrSuTet (2)  S. Kentucky 
United Kingdom (N=7)  1 (14.3 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (10 MSs) (N=567)  411 (72.5 %)  52 (9.2 %)  49 (8.6 %)  47 (8.3 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of the resistant isolates; NA: Not applicable. 
1: European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2: EUCAST clinical breakpoint. 
3: High breakpoint. 
4: Very high breakpoint. 
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Appendix Table HLCR7.  High-level ciprofloxacin resistance in Salmonella serovars from fattening pigs in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant 
at  
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Denmark (N=374)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Estonia (N=14)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Finland (N=2)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=627)  47 (7.5 %)  1 (0.2 %)  0 (0 %)  0 (0 %)  NA  NA 
Hungary(N= 38)  9 (23.7 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Ireland (N=24)  4 (16.7 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=25)  3 (12.0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Spain (N=48)  10 (20.8 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Sweden (N=3)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (9 MSs) (N=1,155)  73 (6.3 %)  1 (0.1 %)  0 (0 %)  0 (0 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of the resistant isolates; NA: Not applicable. 
1: European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2: EUCAST clinical breakpoint. 
3: High breakpoint. 
4: Very high breakpoint. 
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Appendix Table HLCR8.  High-level ciprofloxacin resistance in Salmonella serovars from cattle in MSs reporting isolate-based data, 2012 
Country 
Isolates resistant 
at 
> 0.06 mg/L
1 Cip 
Isolates resistant 
at  
> 1 mg/L
2 Cip  
Isolates resistant at 
> 2 mg/L
3 Cip 
Isolates resistant 
at 
 > 4 mg/L
4 Cip  
Resistance patterns of isolates 
resistant at  
> 4 mg/L Cip 
Salmonella serovars 
n (%)  n (%)  n (%)  n (%) 
Belgium (N=42)  12 (28.6 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Estonia (N=7)  1 (14.3 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Finland (N=19)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Germany (N=68)  6 (8.8 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Ireland (N=36)  2 (5.6 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Italy (N=14)  2 (14.3 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Spain (N=9)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Sweden (N=17)  0 (0 %)  0 (0 %)  0 (0 %)  0 (0 %)  NA  NA 
Total (8 MSs) (N=212)  23 (10.8 %)  0 (0 %)  0 (0 %)  0 (0 %)   
MS: Member State; Cip: ciprofloxacin; N: Total number isolates for which relevant data are available; n: number of the resistant isolates; NA: Not applicable. 
1: European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cut-off values (ECOFFs). 
2: EUCAST clinical breakpoint. 
3: High breakpoint. 
4: Very high breakpoint. 
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APPENDIX 6. Level 3 Tables 
Level 3 Tables, containing information on reported MIC distributions and data on the number of resistant 
isolates, are available on the EFSA website. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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APPENDIX 7. List of abbreviations, Antimicrobial substances, Member States and other 
reporting countries, definitions 
List of abbreviations  
Abbreviation  Definition 
%  Percentage of resistant isolates per category of susceptibility or multiple resistance 
% f  Percentage frequency of isolates tested 
% Res  Percentage of resistant isolates 
-    No data reported 
AHVLA  Animal Health and Veterinary Laboratories Agency 
AMB Antimicrobial  substance 
AMR Antimicrobial  resistance 
AST  Antimicrobial susceptibility testing 
BIOHAZ  EFSA Panel on Biological Hazards 
BSAC  British Society for Antimicrobial Chemotherapy 
CA-SFM  French Society for Microbiology 
CC Clonal  complex 
CLSI Clinical  and  Laboratory Standards Institute 
CBP Clinical  breakpoints 
CTX-M Cefotaximase 
DIN  Deutsches Institut für Normung 
DNA desoxyribonucleic  acid 
DTU  Technical University of Denmark  
EARS-Net European  Antimicrobial  Resistance Surveillance Network 
EC European  Commission 
ECDC  European Centre for Disease Prevention and Control 
ECOFF  epidemiological cut-off value 
EEA  European Economic Area 
EFSA   European Food Safety Authority 
EMA  European Medicines Agency 
ESBL  Extended Spectrum Beta-Lactamase 
ETEC Enterotoxigenic  E. coli 
EU European  Union 
EUCAST  European Committee on Antimicrobial Susceptibility Testing 
EU-RL  European Union Reference Laboratory 
FWD  Food- and Waterborne Diseases and Zoonoses  
HACCP  Hazard Analysis and Critical Control Point 
HPA  Health Protection Agency (UK) 
I Intermediate 
IZD  Inhibition Zone Diameter 
LA-MRSA  Livestock- associated methicillin-resistant Staphylococcus aureus 
MDR  Multiple Drug Resistance 
MIC Minimum  Inhibitory Concentration 
MLST  Nulti-locus Sequence Typing 
MRSA Methicillin-resistant  Staphylococcus aureus 
MSSA Methicillin-susceptible  Staphylococcus aureus 
MS Member  State 
NA Not  applicable 
NCP  National Control Programme 
NRL  National Reference Laboratory 
R Resistant 
res1–res9  Resistance to one antimicrobial substance/resistance to nine antimicrobial substances 
of the common set for Salmonella 
S Susceptible 
SGI  Salmonella genomic island 
spp. species 
ST Sequence  type 
TESSy  The European Surveillance System EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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VTEC Vero(cyto)toxigenic  E. coli 
WHO World  Health  Organization 
 
 
Antimicrobial substances 
Abbreviation  Antimicrobials 
Amp Ampicillin   
Caz Ceftazidime 
Chl Chloramphenicol 
Cip Ciprofloxacin 
Ctx Cefotaxime 
Ery Erythromycin 
Gen Gentamicin 
Nal  Nalidixic acid  
Su Sulfonamides 
Str Streptomycin 
Tet Tetracycline 
Tmp Trimethoprim 
 EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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Member States of the European Union and other reporting countries in 2012 
Member States of the European Union, 2012 
Member State  Country abbreviations 
Austria  AT 
Belgium  BE 
Bulgaria  BG 
Cyprus  CY 
Czech Republic  CZ* 
Denmark  DK 
Estonia  EE 
Finland  FI 
France  FR 
Germany  DE 
Greece  GR 
Hungary  HU 
Ireland  IE 
Italy  IT 
Latvia  LV 
Lithuania  LT 
Luxembourg  LU 
Malta  MT 
Netherlands  NL* 
Poland  PL 
Portugal  PT 
Romania  RO 
Slovakia  SK 
Slovenia  SI 
Spain  ES 
Sweden  SE 
United Kingdom  UK* 
* In text, referred to as the Czech Republic, the Netherlands and the United Kingdom 
 
Non-Member States reporting, 2012 
Country  Country abbreviations 
Iceland  IS 
Norway  NO 
Switzerland  CH EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
from humans, animals and food 2012
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Definitions 
Term  Definition and description 
‘Antimicrobial resistant isolate’.  In the case of quantitative data, an isolate was defined as ‘resistant’ to a 
selected antimicrobial when its minimum inhibitory concentration (MIC) 
value (in mg/L) was above the cut-off value or the disc diffusion diameter (in 
mm) was below the cut-off value. The cut-off values, used to interpret MIC 
distributions (mg/L) for bacteria from animals and food, are shown in Table 
MM11. 
In the case of qualitative data, an isolate was regarded resistant when the 
country reported it as resistant using its own cut-off value or break point. 
‘Level of antimicrobial resistance’:  The percentage of resistant isolates among the tested isolates. 
‘Reporting MS group’:  Member States (MSs) that provided data and were included in the relevant 
table for antimicrobial resistance data for the bacteria–food/animal 
category–antimicrobial combination. 
Terms used to describe the 
antimicrobial resistance levels 
 
Rare:  < 0.1 % 
Very low:  0.1 % to 1 % 
Low:  >1 % to 10 % 
Moderate:  >10 % to 20 % 
High:  >20 % to 50 % 
Very high:  >50 % to 70 % 
Extremely high:  >70 % 
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APPENDIX 8. List of institutions contributing to antimicrobial resistance monitoring in 
animals and food 
List of institutions contributing to antimicrobial resistance monitoring in animals and food 
Member State  Institution 
Austria 
•  Federal Ministry for Health 
•  Austrian Agency for Health and Food Safety (AGES) 
Belgium 
•  Veterinary and Agrochemical Research Centre (CODA-CERVA), Uccle 
•  Institute of Public Health, Brussels 
•  Federal Agency for the Safety of the Food Chain, Brussels 
Bulgaria 
•  National Diagnostic and Research Veterinary Institute, Sofia 
•  Bulgarian Food Safety Agency, Sofia 
Cyprus 
• Veterinary  Services, Nicosia 
•  Ministry of Agriculture, Nicosia 
Czech Republic 
•  State Veterinary Institute, Prague and Olomouc 
•  State Veterinary Administration of the Czech Republic, Prague 
Denmark 
•  National Food Institute, Technical University of Denmark 
•  Danish Veterinary and Food Administration 
Estonia 
•  Estonian Veterinary and Food Laboratory, Tartu 
•  Veterinary and Food Board, Tallinn 
Finland  •  EVIRA, Finnish Food Safety Authority, Helsinki 
France 
•  ANSES, French Agency for Food, Environmental Occupational Health and Safety: 
Fougères Laboratory, Maisons-Alfort Laboratory, Ploufragan/Plouzané Laboratory 
•  Ministère de l´agriculture, de l’alimentation, de la pêche, de la ruralité et de l’aménagement 
du terriroire, Direction Générale de l’Alimentation, Paris 
Germany  •  Federal Institute for Risk Assessment (BfR), Berlin 
Greece 
• Veterinary  Laboratory,  Chalkis 
•  Ministry of Rural Development and Food, Athens 
Hungary 
•  Central Agricultural Office, Veterinary Diagnostical Directorate, Budapest 
•  Ministry of Rural Agriculture, Budapest 
Ireland 
•  Central Veterinary Research Laboratory, Celbridge 
•  Food Safety Authority of Ireland, Dublin 
Italy 
•  Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana, Rome 
•  Ministry of Health, Rome 
Latvia 
•  Institute of Food Safety, Animal Health and Enviroment "BIOR", Animal Disease Diagnostic 
Laboratory, Riga 
•  Food and Veterinary Service of Latvia, Riga 
Lithuania 
•  National Food and Veterinary Risk Assessment Institute, Vilnius 
•  State Food and Veterinary Service, Vilnius 
Luxembourg  •  Laboratoire de Médecine Vétérinaire, Luxembourg 
Malta  •  Ministry for Resources and Rural Affairs 
Table continued overleaf. EU summary report on antimicrobial resistance in zoonotic and indicator bacteria
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List of institutions contributing to antimicrobial resistance monitoring in animals and food 
(continued) 
Member State  Institution 
Netherlands 
•  Central Veterinary Institute, part of Wageningen UR (CVI), Lelystad 
•  National Institute of Public Health and the Environment (RIVM), Bilthoven 
•  Ministry of Agriculture, Nature and Food Quality 
•  Animal Health Service, Deventer 
Poland 
•  National Veterinary Research Institute, Pulawy 
•  General Veterinary Inspectorate, WARSAW 
Portugal 
•  Laboratório Nacional de Investigação Veterinária, Lisbon  
•  Direcção Geral de Veterinária, Lisbon 
Romania 
•  Institute for Diagnostic and Animal Heath, Bucharest 
•  Institute for Hygiene and Veterinary Public Heath, Bucharest 
•  National Sanitary Veterinary and Food Safety Authority, Bucharest 
Slovakia 
•  State Veterinary and Food Institute, Dolny Kubin and Bratislava 
•  State Veterinary and Food Administration of the Slovak Republic 
Slovenia 
•  National Veterinary Institute, Veterinary Faculty, Ljubljana 
•  Ministry for Agriculture and Environment, Veterinary Administration, Ljubljana 
Spain 
•  Laboratorio Central de Sanidad Animal de Santa Fe, Granada 
•  Laboratorio Central de Veterinaria de Algete, Madrid 
•  VISAVET Health Surveillance Center, Complutense University, Madrid 
•  Ministerio de Agricultura, Alimentación y Medio Ambiente 
•  Agencia Española de Seguridad Alimentaria y Nutrición 
Sweden 
•  National Veterinary Institute (SVA), Department of Animal Health and Antimicrobial 
Strategies, Uppsala 
•  National Food Administration, Uppsala 
United Kingdom  •  Animal Health and Veterinary Laboratories Agency (AHVLA)  
 
Other reporting 
country  Institution 
Norway  •  Norwegian Veterinary Institute 
Switzerland 
•  ZOBA–Centre for Zoonoses, Bacterial Animal Diseases and Antimicrobial Resistance–
Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern 
•  Swiss Federal Veterinary Office 
 